AU2002301331B2 - Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection - Google Patents

Description

AUSTRALIA

Patents Act 1990

GENSET

COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection The following statement is a full description of this invention including the best method of performing it known to us:- CHLAMYDIA TRACHOMATIS GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF

INFECTION

This is a divisional of AU 12545/99, the contents of which are incorporated in their entirety herein.

The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia trachomatis, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia trachomatis genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia trachomatis infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or treatment of bacterial, in particular Chlamydia trachomatis, infections.

The genus Chlamydia is composed of four species: Chlamydia psittaci, Chlamydia pecorum, Chlamydia pneumoniae and Chlamydia trachomatis.

Chlamydia psittaci comprises numerous species, whose hosts are terrestrial vertebrate animals as well as birds and occasionally humans; Chlamydia pecorum is a pathogen of ruminants; Chlamydia pneumoniae is responsible for pneumopathies, for sinusitis and for arterial impairments in humans; Chlamydia trachomatis (Ct) is responsible for a large number of human diseases: eye diseases: conventional trachoma, nonendemic trachoma, paratrachoma, inclusion conjunctivitis in neonates and in adults; genital diseases: nongonococcal uretritis, epididymitis, cervicitis, salpingitis, perihepatitis and bartholinitis as well as pneumopathy in breastfeeding infants; systemic diseases: venereal lymphogranulomatosis (LGV).

These diseases affect a very large number of women and men [more than 600 million individuals are trachoma carriers and there are more than 90 million cases of genital Chlamydia infections] worldwide. Accordingly, basic and applied research which makes it possible to understand the physiopathology linked to this bacterium is very important for public health. (Raulston JE., 1995; Hackstadt T. et al., 1996).

Eye impairments due to Chlamydia trachomatis cause trachoma and inclusion conjunctivitis. Trachoma is a chronic conjunctivitis. It is the major cause of curable eye diseases leading to blindness. It is estimated that 20 million cases of loss of sight are due to it worldwide.

Moreover, inclusion conjunctivitis is an eye inflammation which is caused by Chlamydia trachomatis and is transmitted by the venereal route. Inclusion conjunctivitis affects adults and neonates exposed to genital secretions.

Two types of eye disease caused by agents of the species Chlamydia trachomatis can be distinguished, The conventional trachomatous disease is found in endemic regions; transmission occurs from eye to eye and through the hands, or it can be passed on by flies. In nonendemic regions, transmission occurs through the genital apparatus; it usually only causes conjunctivitis, most often without associated keratitis; it is rare for a pannus or for scars similar to those in trachoma to develop.

This conjunctival impairment is called paratrachoma to differentiate it from the conventional endemic trachoma which is transmitted by the ocular route. The seriousness and the number of cases of trachoma have decreased over the last forty years. This is related to the improvement in hygiene and living conditions. However, trachoma remains the principal cause of avoidable blindness in Africa, in the Middle East and in some regions of Asia. The transmission of the endemic disease occurs in particular through close personal contact, in regions where a secondary exposure exists in a repeated form. Often, the infection is also latent. In some industrialized countries, such as the United States, a mild form of trachoma still exists in some ethnic groups. Sometimes, a tardive trachoma may be found following an immunosuppressive treatment. The eye impairments caused by Chlamydia trachomatis, such as inclusion conjunctivitis and paratrachoma, are also a complication due to a common venereal infection. These infections are not very frequent; they occur most often in young adults. The eye impairments in neonates are produced during the passage through the maternal genital routes during childbirth. Theoretically, endemic trachoma and inclusion conjunctivitis in adults appear in the form of conjunctivitis, the latter being characterized by the presence of lymphoid follicles. In regions where the endemic disease is serious, the disease often starts before the age of 2 years and reinfection is frequent. Superficial neovascularization is added, in this case, to leukocytic infiltration. The conjunctival scars will then cause trichiasis and entropion. The eroded cornea will become a carrier of a corneal ulcer of bacterial origin. The scar on the cornea causes blindness. Impairment of the lachrymal glands gives a picture of dryness of the cornea. Xerosis becomes complicated with secondary bacterial ulcer. In regions where trachoma is endemic, the infectious process disappears towards the age of fifteen. The scars then progress to blindness, which affects almost exclusively adults. In regions where exposure is lower, the infectious process is, in this case, less rapid and adults are carriers of a chronic disease.

Positive diagnosis of trachoma can be most often established by clinical observation: lymphoid follicles are visible on the upper tarsal conjuctiva; conjunctival scar is typical. Vascular pannus exists. In endemic regions, clinical diagnosis is often sufficient. However, isolated cases of inclusion conjunctivitis must be the subject of a differential diagnosis, in particular to distinguish viral conjunctivitis.

Public health measures against the endemic form of the disease provide for mass treatments with tetracycline or erythromycin collyria of all children. The treatment may also provide for surgical correction of the lesions. The other conjunctival impairments respond well to general treatments with tetracyclines or erythromycin. The prevention of trachomatous disease by health measures and by improving living standards is sufficient. Furthermore, to avoid the spread of trachoma, antibiotic collyria may be used, The role of Chlamydia trachomatis in a number of genital impairments has been demonstrated over the last three decades. Chlamydia trachomatis is responsible in this case for a pathology which may be superposed on the impairments observed with Neisseria gonorrhoeae. The pathologies for which Chlamydia trachomatis may be responsible at the genital level are acquired by the venereal route and are a major source of sexually transmitted diseases.

The epidemiology of Chlamydia trachomatis genital infections shows each year more than 4 million new cases in the United States, and more than 3 million new cases in Europe. Like the other venereal infections, Chlamydia trachomatis affects young subjects. There is a direct relationship between the number of sexual partners and the frequency of the disease. For example, the frequency of Chlamydia trachomatis appears to be five to ten times higher than that of Neisseria gonorrhoeae in pregnant women. The Chlamydia trachomatis infection is probably more discreet than its Neisseria gonorrhoeae homologue. This relative clinical silence, estimated in women at 50% or even 70% of infections, explains why the total morbidity of Chlamydia trachomatis conditions is high. Diagnosis must therefore be requested in patients who are sometimes asymptomatic carriers of infection.

Chlamydia trachomatis is responsible for nearly 30% of nongonococcal urethritis, or NGU. Chlamydia trachomatis urethritis may be discreet, the disease then progresses to a certain form of chronicity. The diagnosis will, like for the other clinical forms of the disease, be called into play later.

Chlamydia trachomatis is a cause of epididymitis in humans during a period of sexual activity. The bacterium may be found in the urethra, urine, sperm or even a sample collected by aspiration from the epididymis. It is in particular found in humans under 35 years of age. A discharge from the urethra which is associated with the disease suggests the diagnosis of a Chlamydia condition or sometimes a gonococcal condition.

Untreated Reiter's syndrome, if accompanied by urethritis, evokes a Chlamydia trachomatis condition.

Chlamydia trachomatis affects 30% to 40% of women who are clinically carriers of a gonorrhoea (or have had contact), 10% to 20% of women having a venereal origin, 5% of women consulting having no particular origin.

The cervix is often normal during a Chlamydia trachomatis infection. However, a hypertrophic cervical erythema will cause such an infection to be suspected. Chlamydia trachomatis is responsible for an endocervicitis whereas viral impairments result in exocervicitis. A nongonococcal endocervicitis requires treating the patient and partners with tetracyclines.

Chlamydia trachomatis is responsible for a large number of acute salpingites. The picture is often complicated by an acute peritonitis or even a perihepatitis.

In case of pregnancy, the risk is first that of infection of the neonate at birth.

However, the risk of postpartum complications exists (endometritis or salpingitis).

The reference method for the diagnosis of Chiamydia trachomatis is the isolation of the bacterium on cell culture. For all infections, the sample collection should make it possible to obtain a suitable sample with the aid of a swab. This sample should be transported to a laboratory under excellent conditions; in particular, the cold chain must absolutely be maintained. The placing in cell culture on mouse fibroblasts will be carried out by people having specific skills. The distinction of Chlamydia trachomatis with labelled antibodies and the observation of cell cultures under a microscope will take place two days after placing in culture. Provided these imperatives are observed, cell culture is a reliable technique. However, the constraints linked to this technique are many: not only must the laboratory be equipped for the cell culture, but, furthermore, highly competent staff must take care of this type of diagnosis.

Techniques for identifying genetic material can obviously be used for the detection of Chlamydia trachomaris. Among these techniques, enzymatic gene amplification or PCR is favoured by those skilled in the art. The technique indeed makes it possible to identify Chlamydia trachomatis with a very high sensitivity and complete specificity. Initially used in specialist laboratories, PCR is now performed in numerous medical laboratories. This diagnostic approach is important because it allows detection of the bacteria even in samples which have been transported under poor conditions.

The treatment of Chlamydia urethritis with antibiotics such as tetracycline or quinolones is very effective. The duration of treatment varies between 7 and 14 days. The treatment of pregnant women poses the problem of contraindications to tetracycline.

s0 Neonatal infections caused by Chlamydia trachomatis are explained by the frequency of these bacteria in the cervix. In some studies, 5% to 13% of impairments are observed in the cervix in asymptornatic pregnant women. The neonates risk, in this case, developing an inclusion conjunctivitis. Not only can Chlamydia trachomatis be isolated from the children's eyes, but also persistently from the rhinopharynx and also from the rectum. Pneumopathies and otitis media are also found, a result of contamination at childbirth.

Differential diagnosis of inclusion conjunctivitis in neonates is required with gonococcal ophthalmia; while the duration of incubation is from one to three days in the case of a gonococcal ophthalmia, neonatal inclusion conjunctivitis has an acute beginning with discharge and formation of membranes or even of conjunctival scars.

Treatment consists of oral erythromycin at the dose of 40 to 50 mg per kg of weight, for two to three weeks. In a nonendemic trachoma region, this disease never progresses to chronicity.

Finally, mention should be made of infantile pneumopathy. The syndrome is well defined; it is found in children affected by Chlamydia trachomatis. Less than ten children are affected by Chlamydia trachomatis pneumopathies per thousand births. The syndrome is, in this case, always found at an early age (less than four months).

Venereal lymphogranulomatosis is an infection which is transmitted through sexual contact and is due to Chlamydia trachomatis strains L1, L2 and L3. In humans, a passing primary genital lesion is followed by an often suppurative and multiple regional lymphadenopathy. This disease is a general disease which is accompanied by fever and a rise in the number of white blood cells. If it progresses to chronicity, the disease then becomes complicated with genital elephantiasis, stricture or even fistula of the genital apparatus, of the penis, of the urethra and of the rectum.

The three Chlamydia trachomatis strains LI, L2 and L3 are responsible for venereal lymphogranulomatosis. These Chlamydia strains are more virulent than the strains responsible for trachoma and STD. It is very important to note that venereal lymphogranulomatosis is a systemic disease which affects primarily the lymphatic tissue. Generally transmitted by the sexual route, Chlamydia trachomatis L may also cause contamination through direct contact or even during poor laboratory handling. In spite of these variable modes of transmission, the age for the highest incidence of these diseases corresponds to that for greater sexual activity. Venereal lymphogranulomatosis is still endemic in South America, in Africa and sometimes in Asia. For a long time, the prevalence of venereal lymphogranulomatosis was difficult to establish because of the difficulty of performing diagnosis with certitude. It should also be noted that men are affected more often than women. In low endemic regions, it is difficult to recognize the reservoir of microbes. This situation is explained by the fact that the isolation of the strains causing venereal lymphogranulomatoses from asymptomatic subjects is rarely successful.

Clinical impairment by venereal lymphogranulomatosis manifests itself by the appearance of a small ulcer 3 to 21 days after the exposure of small nonpainful vesicles. In both men and women, the lesion is most often silent. Since this impairment disappears within a few days and causes no functional discomfort and leaves no visible scar, the disease is often recognized late. The venereal lymphogranulomatosis strains may be found in the urethra or the endocervix in patients with inguinal adenopathies; these regions are then considered as the initial site of infection. The characteristic feature of the venereal lymphogranulomatosis strains is that from the initial site of infection, Chlamydia exhibits a diffusion drained by the lymphatic ducts. The disease is then complicated by a ganglionic impairment of the region draining the site of inoculatioa. By way of example, anorectal infection causes deep adenopathies. These adneopathies are marked by the appearance of a periadenitis which forms a fluctuating and suppurative ganglionic mass. Fistulae will appear during the decline of the disease. As general signs are present at this stage of the disease, it is often confused with a malignant lymphoma. The other general complications are rarely observed.

Clinical examinations have been able to lead biologists to isolate Chlamydia from the cerebrospinal fluid or from the blood. It should also be noted that in a number of cases venereal lymphogranulomatosis is complicated by a chronic oedema: this is genital elephantiasis.

The diagnosis of venereal lymphogranulomatosis requires the isolation of the Chlamydia strains involved in the disease. However, isolation on cell cultures is rarely used, but immunological reactions may be used.

The treatment of venereal lymphogranulomatosis in its initial phase is identical to the treatment of other Chlamydia infections. In the chronic phases, antibiotics have little effect on the progress of the disease, but they are however useful in case of superinfection. Although the recommended therapeutic arsenal is identical, it is advisable to prolong the treatment for a period of at least four weeks. In addition to this treatment, reconstructive surgery may be useful in cases of urethral, penile or rectal strictures, as well as for the treatment of fistulae.

In conclusion, a short and effective treatment, without recurrences, and a welltolerated treatment of Chlamydia trachomatis infections therefore remains desirable.

An even greater need up until now relates to a diagnosis which is specific to each of the strains, which is sensitive, which can be carried out conveniently and rapidly, and which allows early detection of the infection.

No vaccine is currently available against Chlamydia trachomatis. The role of the immune defense in the physiology and pathology of the disease should probably be understood in order to develop satisfactory vaccines.

More detailed information relating to the biology of these strains, their interactions with their hosts, the associated phenomena of infectivity and those of escaping the immune defenses of the host in particular, and finally their involvement in the development of the these associated pathologies, will allow a better understanding of these mechanisms. In the light of the preceding text which shows in particular the limitations of the means of controlling Chlamydia trachomatis infection, it is therefore at present essential, on the one hand, to develop molecular tools, in particular from a better genetic knowledge of Chlamydia trachomatis, but also to develop new preventive and therapeutic treatments, new diagnostic methods and new vaccine strategies which are specific, effective and tolerated. This is precisely the object of the present invention.

The subject of the present invention is the nucleotide sequence having the sequence SEQ ID No. 1 of the Chlamydia trachomatis LGV2 genome. However, the invention is not limited to SEQ ID No. I, but encompasses genomes and nucleotides encoding polypeptides of strain variants, polymorphisms, allelic variants, and mutants.

Thus, the subject of the present invention encompasses nucleotide sequences characterized in that they are chosen from: a) the nucleotide sequence of SEQ ID No. 1, a nucleotide sequence exhibiting at least 99.9% identity with the sequence SEQ ID No. 1, the nucleotide sequence of the genomic DNA contained within ECACC Deposit No. 98112618, the nucleotide sequence of a clone insert within ECACC Deposit No. 98112617 (these being provisional deposit numbers); b) a nucleotide sequence homologous to the sequence SEQ ID No. I; c) a polynucleotide sequence that hybridizes to the nucleotide sequence of a) under conditions of high or intermediate stringency as described below: By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCI (pH 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 jtg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65 0

C,

the preferred hybridization temperature, in prehybridization mixture containing 100 pg/ml denatured salmon sperm DNA and 5-20 X 106 cpm of 3P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCI and 0.05 M Na citrate. Subsequently, filter washes can be done at 37C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1X SSC at 50 0 C for min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS, or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68 0 C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which may be used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, pp. 9.47- 9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. are incorporated herein in their entirety.

(ii) By way of example and not limitation, procedures using conditions of intermediate stringency are as follows: Filters containing DNA are prehybridized, and then hybridized at a temperature of 60°C in the presence of a 5 x SSC buffer and labeled probe. Subsequently, filters washes are performed in a solution containing 2x SSC at 50 0 C and the hybridized probes are detectable by autoradiography. Other conditions of intermediate stringency which may be used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

are incorporated herein in their entirety.

d) a nucleotide sequence complementary to the sequence SEQ ID No. 1 or complementary to a nucleotide sequence as defined in b) or and a nucleotide sequence of their corresponding RNA; e) a nucleotide sequence of a representative fragment of the sequence SEQ ID No. 1, or of a representative fragment of the nucleotide sequence as defined in c) or d); f) a nucleotide sequence comprising a sequence as defined in d) or e); g) a nucleotide sequence capable of being obtained from a nucleotide sequence as defined in e) or and h) a modified nucleotide sequence of a nucleotide sequence as defined in d), f) or g).

Sequence of the genome, or genomic sequence of Chlamydia trachomatis is understood to mean the sequence of the chromosome of Chlamydia trachomatis, in contrast with the plasmid sequence of Chlamydia trachomatis.

Nucleotide sequence, polynucleotide or nucleic acid are understood to mean, according to the present invention, either a double-stranded DNA, a single-stranded DNA or products of transcription of the said DNAs.

It should be understood that the present invention does not relate to the genomic nucleotide sequences of Chlamydia trachomatis taken in their natural environment, that is to say in the natural state. They are sequences which may have been isolated, purified or partially purified, by separation methods such as, for example, ion-exchange chromatography, molecular size exclusion chromatography or affinity chromatography, or alternatively fractionation techniques based on solubility in various solvents, or by genetic engineering methods such as amplification, cloning or subcloning, it being possible for the sequences of the invention to be carried by vectors.

The nucleotide sequence SEQ ID No. 1 was obtained by sequencing the Chlamydia trachomatis LGV2 genome by the method of directed sequencing after fluorescent automated sequencing of the inserts of clones and assembling of these sequences of nucleotide fragments (inserts) by means of softwares (cf. Examples). In spite of the high precision of the sequence SEQ ID No. 1, it is possible that it does not perfectly, 100% represent the nucleotide sequence of the Chlamydia trachomatis LGV2 genome and that a few rare sequencing errors or uncertainties still remain in the sequence SEQ ID No. 1. In the present invention, the presence of an uncertainty for an amino acid is designated by <Xaa and that for a nucleotide is designated by <cN> in the sequence listing below. These few rare errors or uncertainties could be easily detected and corrected by persons skilled in the art using the entire chromosome and/or its representative fragments according to the invention and standard amplification, cloning and sequencing methods, it being possible for the sequences obtained to be easily compared, in particular by means of a computer software and using computer-readable media for recording the sequences according to the invention as described, for example, below. After correcting these possible rare errors or uncertainties, the corrected nucleotide sequence obtained would still exhibit at least 99.9% identity with the sequence SEQ ID No. 1. Such rare sequencing uncertainties are not present within the DNA contained within ECACC Deposit No.

98112617 or 98112618 (provisional numbers) and whatever rare sequence uncertainties that exist within SEQ ID No. 1 can routinely be corrected utilizing the DNA of the ECACC Deposits.

Homologous nucleotide sequence for the purposes of the present invention is understood to mean a nucleotide sequence having a percentage identity with the bases of the nucleotide sequence SEQ ID No. 1 of at least 80%, preferably 90% and 95%, this percentage being purely statistical and it being possible for the differences between the two nucleotide sequences to be distributed randomly and over their entire length. The said homologous sequences exhibiting a percentage identity with the bases of the nucleotide sequence SEQIDNo. 1 of at least preferably 90% and 95%, may comprise, for example, the sequences corresponding to the genomic sequence or to the sequences of its representative fragments of a bacterium belonging to the Chlamydia family, including the species Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia pecorum mentioned above, as well as the sequences corresponding to the genomic sequence or to the sequences of its representative fragments of a bacterium belonging to the variants of the species Chlamydia trachomatis. In the present invention, the terms family and genus are mutually interchangeable, the terms variant, serotype, strain and subspecies are also mutually interchangeable.

These homologous sequences may thus correspond to variations linked to mutations within the same species or between species and may correspond in particular to truncations, substitutions, deletions and/or additions of at least one nucleotide. The said homologous sequences may also correspond to variations linked to the degeneracy of the genetic code or to a bias in the genetic code which is specific to the family, to the species or to the variant and which are likely to be present in Chlamydia.

Protein and/or nucleic acid sequence homologies may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-2448; Altschul et at, 1990, J. Mol. Biol. 215(3):403-410; Thompson etaL, 1994, Nucleic Acids Res. 22(2):4673-4680; Higgins et al., 1996, Methods Enzymol. 266:383-402; Altschul et aL, 1990, J. Mol. Biol. 215(3):403- 410; Altschul et al., 1993, Nature Genetics 3:266-272).

In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") which is well known in the art (see, Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268; Altschul et al., 1990, J. Mol. Biol. 215:403-410; Altschul et al., 1993, Nature Genetics 3:266-272; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402). In particular, five specific BLAST programs are used to perform the following task: (1)BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database; (2)BLASTN compares a nucleotide query sequence against a nucleotide sequence database; (3)BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database; (4)TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database.

High-scoring segment pairs are preferably identified aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992, Science 256:1443-1445; Henikoff and Henikoff, 1993, Proteins 17:49-61). Less preferably, the PAM or PAM250 matrices may also be used (see, Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation) The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268).

Nucleotide sequence complementary to a sequence of the invention is understood to mean any DNA whose nucleotides are complementary to those of the sequence of the invention, and whose orientation is reversed (antiparallel sequence).

The present invention further comprises fragments of the sequences of a) through h) above. Representative fragments of the sequences according to the invention will be understood to mean any nucleotide fragment having at least 8 successive nucleotides, preferably at least 12 successive nucleotides, and still more preferably at least 15 or at least 20 successive nucleotides of the sequence from which it is derived. It is understood that such fragments refer only to portions of SEQ ID No. I that are not currently listed in a publicly available database.

Among these representative fragments, those capable of hybridizing under stringent conditions with a nucleotide sequence according to the invention are preferred. Hybridization under stringent conditions means that the temperature and ionic strength conditions are chosen such that they allow hybridization to be maintained between two complementary DNA fragments.

By way of illustration, high stringency conditions for the hybridization step for the purposes of defining the nucleotide fragments described above, are advantageously the following.

The hybridization is carried out at a preferred temperature of 65C in the presence of SSC buffer, 1 x SSC corresponding to 0.15 M NaCi and 0.05 M Na citrate. The washing steps may be, for example, the following: 2xSSC, 0.1% SDS at room temperature followed by three washes with I x SSC, 0.1% SDS; x SSC, 0.1% SDS; 0.1 x SSC, 0.1% SDS at 68"C for 15 minutes.

Intermediate stringency conditions, using, for example, a temperature of 60°C in the presence of a 5 x SSC buffer, or of low stringency, for example a temperature of 50°C in the presence of a 5 x SSC buffer, respectively require a lower overall complementarity for the hybridization between the two sequences.

The stringent hybridization conditions described above for a polynucleotide of about 300 bases in size will be adapted by persons skilled in the art for larger- or smaller-sized oligonucleotides, according to the teaching of Sambrook et al., 1989.

Among the representative fragments according to the invention, those which can be used as primer or probe in methods which make it possible to obtain homologous sequences or their representative fragments according to the invention, or to reconstitute a genomic fragment found to be incomplete in the sequence SEQ ID No. 1 or carrying an error or an uncertainty, are also preferred, these methods, such as the polymerase chain reaction (PCR), cloning and sequencing of nucleic acid being well known to persons skilled in the art. These homologous nucleotide sequences corresponding to mutations or to inter- or intra-species variations, as well as the complete genomic sequence or one of its representative fragments capable of being reconstituted, of course form part of the invention.

Among the said representative fragments, those which can be used as primer or probe in methods allowing diagnosis of the presence of Chlamydia trachomatis or one of its associated microorganisms as defined below are also preferred.

The representative fragments capable of modulating, regulating, inhibiting or inducing the expression of a gene of Chlamydia trachomatis or one of its associated microorganisms, and/or capable of modulating the replication cycle of Chlamydia trachomatis or one of its associated microorganisms in the host cell and/or organism, are also preferred. Replication cycle is intended to designate invasion, multiplication, intracellular localization, in particular retention in the vacuole and inhibition of the process of fusion to the lysosome, and propagation of Chlamydia trachomatis or one of its associated microorganisms from host cells to host cells.

Among the said representative fragments, those corresponding to nucleotide sequences corresponding to open reading frames, called ORF sequences (ORF for open reading frame), and encoding polypeptides, such as for example, but without being limited thereto, the ORF sequences which will be later described, are finally preferred.

The representative fragments according to the invention may be obtained, for example, by specific amplification, such as PCR, or after digestion, with appropriate restriction enzymes, of nucleotide sequences according to the invention; these methods are in particular described in the manual by Sambrook et al., 1989. The said representative fragments may also be obtained by chemical synthesis when they are not too large in size and according to methods well known to persons skilled in the art. For example, such fragments can be obtained by isolating fragments of the genomic DNA of ECACC Deposit No. 98112618 or a clone insert present at this ECACC Deposit No. 98112617 (provisional numbers).

The representative fragments according to the invention may be used, for example, as primer, to reconstitute some of the said representative fragments, in particular those in which a portion of the sequence is likely to be missing or imperfect, by methods well known to persons skilled in the art such as amplification, cloning or sequencing techniques.

Modified nucleotide sequence will be understood to mean any nucleotide sequence obtained by mutagenesis according to techniques well known to persons skilled in the art, and exhibiting modifications in relation to the normal sequences, for example mutations in the regulatory and/or promoter sequences for the expression of a polypeptide, in particular leading to a modification of the level of expression of the said polypeptide or to a modulation of the replicative cycle.

Modified nucleotide sequence will also be understood to mean any nucleotide sequence encoding a modified polypeptide as defined below.

The subject of the present invention also includes Chlamydia trachomatis nucleotide sequences characterized in that they are chosen from a nucleotide sequence of an open reading frame (ORF), that is, the ORF2 to ORF1197 sequences.

The ORF2 to ORF1197 nucleotide sequences are defined in Tables 1 and 2, infra, represented below by their position on the sequence SEQ ID No. 1. For example, the ORFI0 sequence is defined by the nucleotide sequence between the nucleotides at position 9828 and 10430 on the sequence SEQ ID No. 1, ends included. ORF2 to ORF 197 have been identified via homology analyses as well as via analyses of potential ORF start sites, as discussed in the examples below. It is to be understood that each identified ORF of the invention comprises a nucleotide sequence that spans the contiguous nucleotide sequence from the codon immediately 3' to the stop codon of the preceding ORF and through the 5' codon to the next stop codon of SEQ ID No.:l inframe to the ORF nucleotide sequence. Table 2, infra, lists the beginning, end and potential start site of each of ORFs 2-1197. In one embodiment, the ORF comprises the contiguous nucleotide sequence spanning from the potential ORF start site downstream (that is, to the ORF stop codon (or the ORF codon immediately adjacent to and upstream of the ORF stop codon). ORF2 to ORF1197 encode the polypeptides of SEQ ID No. 2 to SEQ ID No. 1197.

Upon introduction of minor frameshifts, certain individual ORFs can comprise larger <combined ORFs. A list of such putative <combined> ORFs is shown in Table 3, below. For example, a combined ORF can comprise ORF 1076 and ORF 1073, including intervening in-frame, nucleotide sequences. The order of ORFs to within each <combined> ORF is as listed. It is to be understood that when ORF2 to ORF1197 are referred to herein, such reference is also meant to include <combined> ORFs. Polypeptide sequences encoded by such <combined> ORFs are also part of the present invention.

Table 3 ORF 1076, ORF 1073; ORF 3, ORF 2; ORF 23, ORF 22, ORF 21; ORF 1141, ORF 477, ORF 478, ORF 479; ORF 487, ORF 486, ORF 485, ORF 484, ORF 483, ORF 482, ORF 481; ORF 488, ORF 489; ORF 573, ORF 572, ORF 571; ORF 817, ORF 818; ORF 819, ORF 820; ORF 1037, ORF 1038; ORF 1071, ORF 1070; ORF 17, ORF 1077; ORF 1185, ORF 933, ORF 934; ORF 1060, ORF 1059; ORF 155, ORF 156; ORF 679, ORF 680; ORF 879, ORF 878; ORF 1028; ORF 1029, and representative fragments.

Table I also depicts the results of homology searches that compared the sequences of the polypeptides encoded by each of the ORFs to sequences present in public published databases. It is understood that in one embodiment, those polypeptides listed in Table 1 as exhibiting'greater than about 95% identity to a polypeptide present in a publicly disclosed database are not considered part of the present invention; likewise in this embodiment, those nucleotide sequences encoding such polypeptides are not considered part of the invention. In another embodiment, it is understood that those polypeptides listed in Table 1 as exhibiting greater than about 99% identity to a polypeptide present in a publicly disclosed database are not considered part of the invention; likewise, in this embodiment, those nucleotide sequences encoding such polypeptides are not considered part of the invention.

The invention also relates to the nucleotide sequences characterized in that they comprise a nucleotide sequence chosen from: a) an ORF2 to ORF1197 a <combined> ORF nucleotide sequence, the nucleotide sequence of the genomic DNA contained within ECACC Deposit No. 98112618 or the nucleotide sequence of a clone insert in ECACC Deposit No. 98112617 according to the invention; b) a homologous nucleotide sequence exhibiting at least 80% identity across an entire ORF2 to ORF1197 nucleotide sequence according to the invention or as defined in a); c) a polynucleotide sequence that hybridizes to ORF2 to ORF1197 under conditions of high or intermediate stringency as described below: By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65 0 C in buffer composed of 6X SSC, 50 mM Tris-HCI (pH 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 gg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 gg/ml denatured salmon sperm DNA and 5-20 X 106 cpm of "P-labeled probe. Alternatively, the hybridization step can be performed at 65*C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCI and 0.05 M Na citrate. Subsequently, filter washes can be done at 37 0 C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1X SSC at 50C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS, or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68 0 C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which may be used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. are incorporated herein in their entirety.

Preferably, such sequences encode a homolog of a polypeptide encoded by one of ORF2 to ORFI 197.

In one embodiment, such sequences encode a Chlamydia trachomatis polypeptide.

(ii) By way of example and not limitation, procedures using conditions of intermediate stringency are as follows: Filters containing DNA are prehybridized, and then hybridized at a temperature of 60 0 C in the presence of a 5 x SSC buffer and labeled probe. Subsequently, filters washes are performed in a solution containing 2x SSC at 50 0 C and the hybridized probes are detectable by autoradiography. Other conditions of intermediate stringency which may be used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

are incorporated herein in their entirety. Preferably, such sequences encode a homolog of a polypeptide encoded by one of ORF2 to ORF1197 In one embodiment, such sequences encode a Chlamydia trachomatis polypeptide.

d) a complementary or RNA nucleotide sequence corresponding to an ORF2 to ORF1197 sequence according to the invention or as defined in b) or c); e) a nucleotide sequence of a representative fragment of an ORF2 to ORF1197 sequence according to the invention or of a sequence as defined in c) or d); f) a nucleotide sequence capable of being obtained from an ORF2 to ORF1197 sequence according to the invention or as defined in d) or and g) a modified nucleotide sequence of an ORF2 to ORF1197 sequence according to the invention or as defined in e) or f).

As regards the homology with the ORF2 to ORFl197 nucleotide sequences, the homologous sequences exhibiting a percentage identity with the bases of one of the ORF2 to ORF1197 nucleotide sequences of at least 80%, preferably 90% and 95%, are preferred. Such homologous sequences are identified routinely via, for example, the algorithms described above and in the examples below. The said homologous sequences correspond to the homologous sequences as defined above and may comprise, for example, the sequences corresponding to the ORF sequences of a bacterium belonging to the Chlamydia family, including the species Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia pecorum mentioned above, as well as the sequences corresponding to the ORF sequences of a bacterium belonging to the variants of the species Chlamydia trachomatis.

These homologous sequences may likewise correspond to variations linked to mutations within the same species or between species and may correspond in particular to truncations, substitutions, deletions and/or additions of at least one nucleotide. The said homologous sequences may also correspond to variations linked to the degeneracy of the genetic code or to a bias in the genetic code which is specific to the family, to the species or to the variant and which are likely to be present in Chlamydia.

The invention comprises the polypeptides encoded by a nucleotide sequence according to the invention, preferably by a representative fragment of the sequence SEQ ID No. 1 and corresponding to an ORF sequence, in particular the Chlamydia trachomatis polypeptides, characterized in that they are chosen from the sequences SEQ ID No. 2 to SEQ ID No. 1197, and representative fragments thereof. However, the invention is not limited to polypeptides encoded by ORFs in SEQ ID No. 1 and its corresponding ORF sequences, but encompasses polypeptides of strain variants, polymorphisms, allelic variants, and mutants.

Thus, the invention also comprises the polypeptides characterized in that they comprise a polypeptide chosen from: a) a polypeptide encoded by a polynucleotide sequence in SEQ ID No. I any polypeptide encoded by a polynucleotide sequence corresponding to ORF2 to ORF1197) and/or representative fragments thereof according to the invention; b) a polypeptide homologous to a polypeptide according to the invention, or as defined in a); c) a polypeptide encoded by a polynucleotide sequence that hybridizes to SEQ ID No. 1 or ORF2 to ORF1197 under high or intermediate stringency as described below: By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65*C in buffer composed of 6X SSC, 50 mM Tris-HCI (pH 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 jgg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 g/ml denatured salmon sperm DNA and 5-20 X 106 cpm of 3 2 P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCI and 0.05 M Na citrate. Subsequently, filter washes can be done at 37 0 C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1X SSC at 50°C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS, or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68 0 C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which may be used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. are incorporated herein in their entirety.

Preferably, such sequences encode a homolog of a polypeptide encoded by one of ORF2 to ORF 197 In one embodiment, such sequences encode a Chlamydia trachomatis polypeptide.

(ii) By way of example and not limitation, procedures using conditions of intermediate stringency are as follows: Filters containing DNA are prehybridized, and then hybridized at a temperature of 60°C in the presence of a 5 x SSC buffer and labeled probe. Subsequently, filters washes are performed in a solution containing 2x SSC at 50°C and the hybridized probes are detectable by autoradiography. Other conditions of intermediate stringency which may be used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

are incorporated herein in their entirety. Preferably, such sequences encode a homolog of a polypeptide encoded by one of ORF2 to ORF1197 In one embodiment, such sequences encode a Chlamydia trachomatis polypeptide.

d) a fragment of at least 5 amino acids of a polypeptide according to the invention, or as defined in b) or c); e) a biologically active fragment of a polypeptide according to the invention, or as defined in c) or and f) a modified polypeptide of a polypeptide according to the invention, as defined in a), d) or e).

In the present description, the terms polypeptide, peptide and protein are interchangeable.

It should be understood that the invention does not relate to the polypeptides in natural form, that is to say that they are not taken in their natural environment but that they may have been isolated or obtained by purification from natural sources, or alternatively obtained by genetic recombination, or else by chemical synthesis and that they may, in this case, comprise nonnatural amino acids, as will be described below.

Homologous polypeptide will be understood to designate the polypeptides exhibiting, in relation to the natural polypeptide, certain modifications such as in particular a deletion, addition or substitution of at least one amino acid, a truncation, an extension, a chimeric fusion, and/or a mutation, or polypeptides exhibiting post-translational modifications. Among the homologous polypeptides, those whose amino acid sequence exhibits at least 80%, preferably 90%, homology or identity with the amino acid sequences of the polypeptides according to the invention are preferred. In the case of a substitution, one or more consecutive or nonconsecutive amino acids are replaced by <equivalentP amino acids. The expression <equivalent amino acid is intended here to designate any amino acid capable of being substituted for one of the amino acids in the basic structure without, however, essentially modifying the biological activities of the corresponding peptides and as will be defined later.

Protein and/or nucleic acid sequence homologies may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-2448; Altschul et al, 1990, J. Mol. Biol. 215(3):403-410; Thompson et al., 1994, Nucleic Acids Res,. 22(2):4673-4680; Higgins et al., 1996, Methods Enzymol. 266:383-402; Altschul et al., 1990, J. Mol. Biol. 215(3):403- 410; Altschul et al., 1993, Nature Genetics 3:266-272).

In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") which is well know in the art (see, Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268; Altschul et al., 1990, J. Mol. Biol. 215:403-410; Altschul et al., 1993, Nature Genetics 3:266-272; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402). In particular, five specific BLAST programs are used to perform the following task: (1)BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database; (2)BLASTN compares a nucleotide query sequence against a nucleotide sequence database; (3)BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database; (4)TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database.

High-scoring segment pairs are preferably identified aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992, Science 256:1443-1445; Henikoff and Henikoff, 1993, Proteins 17:49-61). Less preferably, the PAM or PAM250 matrices may also be used (see, Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation) The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268).

Equivalent amino acids may be determined either based on their structural homology with the amino acids for which they are substituted, or on results of comparative tests "of biological activity between the various polypeptides which may be carried out.

By way of example, there may be mentioned the possibilities of substitutions which may be carried out without resulting in a substantial modification of the biological activity of the corresponding modified polypeptides; the replacements, for example, of leucine with valine or isoleucine, of aspartic acid with glutamic acid, of glutamine with asparagine, of arginine with lysine, and the like, the reverse substitutions naturally being feasible under the same conditions.

The homologous polypeptides also correspond to the polypeptides encoded by the homologous nucleotide sequences as defined above and thus comprise in the present definition the mutated polypeptides or polypeptides corresponding to inter- or intra-species variations which may exist in Chlamydia, and which correspond in particular to truncations, substitutions, deletions and/or additions of at least one amino acid residue.

Biologically active fragment of a polypeptide according to the invention will be understood to designate in particular a polypeptide fragment, as defined below, exhibiting at least one of the characteristics of the polypeptides according to the invention, in particular in that it is: capable of eliciting an immune response directed against Chlamydia trachomatis; and/or capable of being recognized by an antibody specific for a polypeptide according to the invention; and/or capable of binding to a polypeptide or to a nucleotide sequence of Chlamydia trachomatis; and/or capable of modulating, regulating, inducing or inhibiting the expression of a gene of Chlamydia trachomatis or one of its associated microorganisms, and/or capable of modulating the replication cycle of Chlamydia trachomatis or one of its associated microorganisms in the host cell and/or organism; and/or capable of generally exerting an even partial physiological activity, such as for example a structural activity (cellular envelope, ribosome), an enzymatic (metabolic) activity, a transport activity, an activity in the secretion or in the virulence.

A representative polypeptide fragment according to the invention is understood to designate a polypeptide comprising a minimum of 5 amino acids, preferably 10 amino acids or preferably 15 amino acids. It is to be understood that such fragments refer only to portions of polypeptides encoded by ORF2 or ORF1197 that are not currently listed in a publicly available database.

The polypeptide fragments according to the invention may correspond to isolated or purified fragments which are naturally present in Chlamydia trachomatis or which are secreted by Chlamydia trachomatis, or may correspond to fragments capable of being obtained by cleaving the said polypeptide with a proteolytic enzyme, such as trypsin or chymotrypsin or collagenase, or with a chemical reagent, such as cyanogen bromide (CNBr) or alternatively by placing the said polypeptide in a highly acidic environment, for example at pH 2.5. Such polypeptide fragments may be equally well prepared by chemical synthesis, using hosts transformed with an expression vector according to the invention containing a nucleic acid allowing the expression of the said fragments, placed under the control of appropriate elements for regulation and/or expression.

<Modified polypeptide> of a polypeptide according to the invention is understood to designate a polypeptide obtained by genetic recombination or by chemical synthesis as will be described below, exhibiting at least one modification in relation to the normal sequence. These modifications may in particular affect amino acids responsible for a specificity or for the efficiency of the activity, or responsible for the structural conformation, for the charge or for the hydrophobicity, and for the capacity for multimerization and for membrane insertion of the polypeptide according to the invention. It is thus possible to create polypeptides with an equivalent, an increased or a reduced activity, and with an equivalent, a narrower or a broader specificity. Among the modified polypeptides, there may be mentioned the polypeptides in which up to 5 amino acids may be modified, truncated at the N- or C-terminal end, or alternatively deleted, or else added.

As is indicated, the modifications of the polypeptide may have in particular the objective: -of making it capable of modulating, regulating, inhibiting or inducing the expression of a gene of Chlamydia, in particular of Chlamydia trachomatis and its variants, or one of its associated microorganisms, and/or capable of modulating the replication cycle of Chlamydia, in particular of Chlamydia trachomatis and its variants, or one of its associated microorganisms, in the host cell and/or organism, of allowing its use in methods of biosynthesis or of biodegradation, or its incorporation into vaccine compositions, of modifying its bioavailability as a compound for therapeutic use.

The said modified polypeptides may also be used on any cell or microorganism for which the said modified polypeptides will be capable of modulating, regulating, inhibiting or inducing gene expression, or of modulating the growth or the replication cycle of the said cell or of the said microorganism. The methods allowing demonstration of the said modulations on eukaryotic or prokaryotic cells are well known to persons skilled in the art. The said cells or microorganisms will be chosen, in particular, from tumour cells or infectious microorganisms and the said modified polypeptides may be used for the prevention or treatment of pathologies linked to the presence of the said cells or of the said microorganisms. It is also clearly understood that the nucleotide sequences encoding the said modified polypeptides may be used for the said modulations, for example by the intermediacy of vectors according to the invention and which are described below, so as to prevent or to treat the said pathologies.

The above modified polypeptides may be obtained using combinatory chemistry, in which it is possible to systematically vary portions of the polypeptide before testing them on models, cell cultures or microorganisms for example, so as to select the compounds which are the most active or which exhibit the desired properties.

Chemical synthesis also has the advantage of being able to use: nonnatural amino acids, or nonpeptide bonds.

Accordingly, in order to extend the life of the polypeptides according to the invention, it may be advantageous to use nonnatural amino acids, for example in the D form, or alternatively amino acid analogues, in particular sulphur-containing forms for example.

Finally, the structure of the polypeptides according to the invention, its homologous or modified forms, as well as the corresponding fragments may be integrated into chemical structures of the polypeptide type and the like. Accordingly, it may be advantageous to provide at the N- and C-terminal ends compounds which are not recognized by proteases.

Also forming part of the invention are the nucleotide sequences encoding a polypeptide according to the invention. Described below are ORF nucleotide sequences encoding polypeptides exhibiting particularly preferable characteristics. For each group of preferred ORFs described below, it is to be understood that in addition to the individual ORFs listed, in instances wherein such ORFs are present as part of <<combined> ORFs, the 4<combined> ORFs are also to be included within the preferred group.

More particularly, the subject of the invention is nucleotide sequences, characterized in that they encode a polypeptide of the cellular envelope, preferably of the outer cellular envelope of Chlamydia trachomatis or one of its representative fragments, such as for example the predominant proteins of the outer membrane, the adhesion proteins or the proteins entering into the composition of the Chlamydia wall. Among these sequences, the sequences comprising a nucleotide sequence chosen from the following sequences are most preferred: ORF3; ORF19; ORF51; ORF189; ORF212; ORF213; ORF324; ORF477; ORF478; ORF479; ORF481; ORF482; ORF483; ORF484; ORF486; ORF488; ORF489; ORF490; ORF572; ORF573; ORF742; ORF817; ORF818; ORF820; ORF1035; ORF1036; ORF1037; ORFI038; ORF1070; ORF1071; ORF1073 and one of their representative fragments.

The structure of the cytoplasmic membranes and of the wall of bacteria is dependent on the associated proteins. The structure of the cytoplasmic membrane makes it impermeable to water, to water-soluble substances and to small-sized molecules (ions, small inorganic molecules, peptides or proteins). To enter into or to interfere with a cell or a bacterium, a ligand must establish a special relationship with a protein anchored in the cytoplasmic membrane (the receptor). These proteins which are anchored on the membrane play an important role in metabolism since they control the exchanges in the bacterium. These exchanges apply to molecules of interest for the bacterium (small molecules such as sugars and small peptides) as well as undesirable molecules for the bacterium such as antibiotics or heavy metals.

The double lipid layer structure of the membrane requires the proteins which are inserted therein to have hydrophobic domains of about twenty amino acids forming an alpha helix.

Predominantly hydrophobic and potentially transmembrane regions may be predicted from the primary sequence of the proteins, itself deduced from the nucleotide sequence. The presence of one or more putative transmembrane domains raises the possibility for a protein to be associated with the cytoplasmic membrane and to be able to play an important metabolic role therein or alternatively for the protein thus exposed to be able to exhibit potentially protective epitopes.

If the proteins inserted into the membrane exhibit several transmembrane domains capable of interacting with one another via electrostatic bonds, it then becomes possible for these proteins to form pores which go across the membrane which becomes permeable for a number of substances. It should be noted that proteins which do not have transmembrane domains may also be anchored by the intermediacy of fatty acids in the cytoplasmic membrane, it being possible for the breaking of the bond between the protein and its anchor in some cases to be responsible for the release of the peptide outside the bacterium.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis transmembrane polypeptide or one of its representative fragments, having between 1 and 3 transmembrane domains and in that they comprise a nucleotide sequence chosen from the following sequences: ORF2; ORF3; ORF5; ORF8; ORF9; ORF10; ORFll; ORF12; ORF17; ORF21; ORF26; ORF27; ORF28; ORF29; ORF30; ORF3I; ORF33; ORF35; ORF37; ORF39; ORF40; ORF41; ORF42; ORF43; ORF44; ORF45; ORF46; ORF47; ORF48; ORF49; ORF52; ORF53; ORF55; ORF56; ORF58; ORF65; ORF66; ORF68; ORF70; ORF74; ORF75; ORF76; ORF78; ORF79; ORF81; ORF82; ORF83; ORF86; ORF91; ORF92; ORF94; ORF97; ORF100; ORF102; ORF103; ORF105; ORF106; ORF107; ORF109; ORF110; ORFIII; ORF112; ORF113; ORF114; ORF115; ORF116; ORF117; ORF120; ORF122; ORF123; ORF130; ORF134; ORF135; ORF137; ORFl40; ORFI41; ORF143; ORF144; ORF145; ORF147; ORFL48; ORF149; ORFS50; ORF151; ORF155; ORF156; ORF162; ORF163; ORF164; ORF165; ORF166; ORF167; ORF168; ORF169; ORF170; ORFI71; 0RF173;, 0RF175; 0RF176; 0RF177; ORFi8i; 0RF183; ORFlS4; ORF1S6;, 0RP187; 0kF1 .88; ORF19Q; ORFI91; 0RF192; 0RE194; 0RF195; 0RF196; 0RF197; 0RF198; 0RF199; ORF2Oi;' 0RF202; 0RF204; ORF2OE; 0RF207; 0RF209; 0RF212; 0RF213; 0RF217; 0RF2 19; ORF22Q; 0RF22 1; 0RF222; 0RF223; 0R1F224; 0RF225;, 0RF227; 0RF228; ORF23 1; 0RF232; 0RF234; 0RF236; 0RF237; 0RF243; 0RF244; 0RF245; 0RF247; 0RF248; 0RF249; 0R1F252; 0RF254; 0RF257; 0RF260; 0RF261; 0RF263; 0RF265; 0RF266; 0RF267; 0RF270; ORF27 1; 0RF272; 0RF274; 0RF276; ORF277; 0RF278; 0RF279; ORiF2S2; 0RF283; 0RF284; 0RF285; 0RF287: 0RF289; 0RF290; 0RF291; 0RE294; 0RF298; 0RF305; 0RF306; ORF3IO;, ORF31I1; 0RF313; ORF3-15; 0RF316; 0RF319; 0RF320; 0RF322; 0RF323; 0RF325; 0RF326; 0RF327; 0RF328; 0RF330; 0RF331; 0RF332; 0RF333; 0RF334; 0RF335; 0RF336; 0RF338; 0RF339; 0RF340;- 0RF341; 0RF344; 0RF345; 0RF348; 0RF349; 0RF350; 0RF351; 0RF352; 0RF353; 0RF356; 0RF357; 0RF358; ORFJ6I; 0RF362; 0RF366; 0RF367; 0RF368; 0RF370; 0R2372; 0RE373; 0RF375; 0RF377; 0RF378; 0RF379; ORF3SO; 0RF382; 0RF383; 0RF384; 0RF385; 0RF387; 0RF389; 0RF390; 0RF391; 0RE393; 0RF396; 0RF398; 0RF399; 0RF403; 0RF404; 0RF406; 0RF407; 0RF413; 0RF414; 0RF417; ORF41S; 0RF420; 0RF42 1; 0RF424; 0RF426; 0RF427; 0RF428; 0RF430; 0RF433; 0RF434; 0RF435; 0RF436; 0RF437; 0RE440;, 0RF443; 0RF446; 0RF448; 0RF450; ORF451; 0R1P454; 0RF455; 0R1F457; ORF4SS; 0RF459; 0RF463; OR.F464; 0RF466; 0RF467; 0RF468; 0RF469; 0RF470; 0RF473; 0RF474; 0RF475; 0RF476; 0RF477; 0RF479; 0RF480; ORF4S1; 0RF483; 0RF484; 0RF485; 0RF486; 0RF487; 0RF488; 0RF491; 0RF493; 0RF496; 0RF497; 0RF498; ORESCO; ORF50O1; ORF5OJ; 0RF504;, ORF5OS; 0RF512; 0RF513; 0RF514; 0RF519; 0RF521; 0RF523; 0RF524; 0RF526; 0RF527; 0RF529; 0RF530; 0RF53 1; 0RF532; 0RF534; 0RF536; 0RF537; 0RF538; 0RF540; 0RF54 1; 0RF542; 0RF543; 0RF544; 0RF545; 0RF546; 0RF547; 0RF55 1; 0RF552; 0RF553; 0RF555; 0RF558; 0RF559; 0RF560; 0RF561; OR.F562; 0RF566; 0RF567; ORF5ES; 0RF569; ORF57 1; 0RF572; 0RF574; ORFS7S; 0RF576; 0RF580; 0RE582; 0RF585; ORLF5S7; 0RF589; 0RF592; 0RF593; 0RF595; 0RF596; 0RF597; 0RF599; ORF6OI; 0RF602; 0RF603; 0RF604; ORF6OS; 0RF609; ORF6 ORF6J1; 0RF615; 0RF616; 0RF617; 0RF618; 0RF621; 0RF622; 0RF623; 0R.F624; 0RF625; 0RF628; 0RF632; 0RF633; 0RF634; 0RF635; 0RF637; 0RF638; 0RF640; 0RE641; 0RF643; 0RF646; 0RF648; 0RF649; ORF65 1; 0RF652; 0RF653; 0RF654; 0RF655; 0RF658; 0RF664; 0RF665; 0RF666; 0RF668; 0RF669; ORF67O; 0RF671; 0RF672; 0RF673; 0RF674; 0RF676; 0RF677; 0RF678; 0RF680; 0R.F682; 0RF683; 0RF684; 0RP686; ORF6S8; 0RF689; 0RF690; 0RF691; 0RF692; 0RF693; 0RF695; 0RF696; 0RF698; ORF7OI; 0RF703; 0RF704; OR.F705; 0RF706; 0RF707; 0RF709; ORF7IO; ORF711; ORF7II; 0RF713; 0RF714; 0RF715; ORF7I7; ORF7 18; 0RF720;, 0RF721; ORF722; 0RF724;, 0RF726; 0RF728; 0RF729;, 0RF730; 0RF731; 0RF732; 0RF733; 0RF734; 0RF737; 0RF738; 0RF739; 0RF740; 0RF742; 0RF743; 0RF744; 0RF745; 0RF746; OR3748; ORF750; ORF751; ORF752; ORF753; ORF754; ORF755; 0RF757; 0RF758; 0RF759; ORF760; 0RF764; ORF766; ORF768; ORF769; ORF771; CRF772; 0RF773; ORF774; ORF775; ORF776; 0RF777; ORF778; ORF779; 0RF780; ORF781; ORF782; ORF783; ORF786; 0RF787; ORF788; ORF789; ORF790; OR3793; ORF798; ORF800; ORF802; ORF803; OR3806; ORF808; 0RF809; ORF81; CRF811; ORF813; ORF814; OR3817; ORF820; ORF822; ORF824; ORF825; 0RF827; ORF828; ORF829; ORF830; ORF833; ORF834; CRF835; OR3837; ORF838; ORF839; ORF840; CRF841; CRF842; ORF843; 0RF845; ORF848; ORF849; ORF850; 0RF851; ORF852; ORF854; CRF855; CRF856; CRFS57; CRF859; ORF860; ORF862; ORF863; 0RF864; ORF866; ORF869; 0RF872; OR3873; ORF874; ORF878; ORF879; CR3880; ORFS81; ORF883; ORF884; ORF885; 0RF886; ORF887; ORF892; ORF893; ORF894; ORF895; ORF897; ORF899; ORF900; ORF901; ORF904; 0RF906; ORF909; ORF910; ORF912; ORF914; ORF917; ORF920; 0RF921; ORF922; CRF923; ORF924; ORF925; ORF926; ORF927; ORF930; ORF933; ORF934; ORF935; ORF936; ORF937; ORF940; 0RF941; ORF942; ORF943; 0RF944; CR3945; ORF947; ORF948; ORF951; ORF952; ORF953; ORF954; ORF955; ORF956; CRF957; ORF958; ORF960; ORF961; ORF962; ORF963; ORF964; ORF966; 0RF967; ORF969; CR3970; ORF971; CR3973; 0RF974; OR3979; ORF980; ORF981; ORF982; ORF984; ORF988; ORF989; ORF990; ORF991; 0RF995; ORF996; ORF999; ORF001; ORF1003; ORF1004; ORF1005; OR31006; ORF1007; ORF1009; ORF1010; ORF1011; CR31012; ORF1013; ORF1014; ORF1016; ORF1017; ORF1018; ORF1020; ORF1021; ORF1025; OR31026; ORF1027; ORF1029; ORF1030; ORF1031; ORF1035; ORF1036; ORF1037; OR31038; ORF1039; ORF1040; ORF1044; ORF1045; ORF1047; ORF1048; ORF1050; ORF1051; ORF1052; ORF1053; ORF1055; ORF1056; ORF1057; ORF1058; ORF1061; ORF1062; ORF1063; ORF1064; ORF1065; ORF1066; ORF1068; ORF1069; ORF1072; ORF1074; 0R31076 and one of their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chiamydia trachomazis transmembrane polypeptide or one of its representative fragments, having between 4 and 6 transmembrane domains and in that they comprise a nucleotide sequence chosen from the following sequences: CRF7; ORF14; ORF16; ORF32; ORF34; ORF36; ORF38; ORF50; ORF57; ORF59; ORF61; ORF62; ORF63; ORF64; ORF67; CRF69; ORF72; OR377; ORF80; ORF84; ORF87; ORF93; ORF99; ORF108; ORF119; ORF125; ORF126; ORF129; ORF131; ORF136; ORF139; ORF146; ORF152; ORF154; ORF160; ORF161; ORF172; ORF179; ORF182; ORF185; ORF200; ORF203; ORF205; ORF239; ORF242; ORF250; ORF253; ORF256; ORF259; ORF262; ORF268; ORF275; ORF281; ORF286; ORF288; CRF292; ORF295; ORF296; CRF297; CRF299; ORF300; ORF308; ORF314; ORF317; OR3318; ORF324; ORF342; ORF343; ORF355; ORF360; ORF374; ORF376; ORF386; ORF388; ORF392; CR3394; ORF395; ORF402; ORF405; ORF411; ORF415; ORF416; 0RF422; 0RF460; 0RF502; 0RF549; 0RF607; 0RF656; 0RF725; ORFSO1; ORE939; 0RF423; ORFE46 1; ORF5 05; ORES 54; 0RF612; 0RF659; 0RF747;,

ORESO);

ORFS 82; 0RF975; 0RF429; 0RF465; ORES 06; 0RE557; 0RF6 13; 0RE661; 0RF749; ORF82 1; ORFS8; ORF4 32; 0RF47 1; ORES 09; ORES 63; OR.F620; ORF6 85; 0RF756; 0RF823; ORFS 89; ORF44 1; 0RF472; ORES 16; ORFS7O; 0RF626; 0RF687; 0RF765; 0RF826; ORFS9S; 0RF442; 0RF422; ORES 17; 0RF573; 0RE629; ORF6 99; 0RF767; 0RF847; 0RF902; ORF444; 0RE489; ORES2O; ORES8 1; 0RF630; ORF700; 0RF794; 0RF853; 0RF903; 0RF449; 0RF492; ORFS2S; 0RF590; 0RF639; 0RE708; 0RF796; 0RF861; ORF91I1; 0RE452; 0RE494; 0RE533; 0RF591; 0RF644; ORF7 16; 0RF797; 0RF870; ORF9 16; 0RF456; 0RE495; 0RF539; OR.P600; 0RF647; 0RF719; ORF799; 0RE871; ORF931I;- 0RE976; 0RE978; 0RF983; 0RF986; 0RF987; 0RF992; 0RE993; ORF1000; ORF1002; OREJOOS; 0RE1019; 0RE1022; CR91032; 0RE1034; CR91046; 0RE1054; ORFIO6O; ORE107 1 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chiamydia trachomatis trausreembrane polypeptide or one of its representative fragments. having at least 7 transmembrane domains and in that they comprise a nucleotide sequence chosen from the following sequences: CRF4; ORF6; ORF13; 0RE20; CR951; CR971; ORFSS; ORFiSS; 0RE229; 0RF369; CR9490; CR9579; 0RF727; ORE865; ORF159; CR9174; CR9233; 0RF371; ORES 10; CR96 14; CRF741; ORES 67; 0RF235; CRF397; ORES 11; ORF63 1; 0RF763; ORFS6S; CR9180; CR9240; 0RE401; ORES 18; CRF636; 0RF791; 0RF877; ORE 189; 0RF246; CR9409; CR9535; CR9650; CR97 92; CR989 1; CR92 10; CR925 1; CR94 12; 0RE548; 0RE662; ORES 15; 0RF896; ORFi 118;- ORF2 11; CRF255; CR94 19; CR9550; 0RF667; ORES 16; 0RF907; ORFl2S; CR92 14; 0RF273; 0RF439; 0RF564; 0RF679; ORES 32; CR9908; 0RF132; CR92 15; CR93 54; CR9453; ORES 65; CR9681; CRF846; CR918;, ORE 133; CR9226; 0RF364; CR9462; CR9578; 0RE702; 0RF858; CR919; 0RF932; CR9959; 0RF977; CRF994; CRF998; CR91024; 0RF1028; 0RF1042; CR11067; CR9 1070; ORE 1073 and one of their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chiarnydia trachornaris surface exposed polypeptide (S&,an outer membrane protein) or one of its representative fragments, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORE 2, ORE 3, ORE 21, ORE 22, ORE 23, ORE 53, ORE 77, ORE 187, ORE 203, ORE 383, ORE 477, CRF 478, ORE 479, ORF 48 1, ORE 482, ORE 483, ORE 484, ORE 485, ORE 486, ORE 487, ORE 488, ORF 489, ORE 490, ORE 571, ORE 572, ORE 573, ORE 593, ORE 670, ORE 693, ORE 742, ORF 749, ORE 80 1, ORE 817. ORE 818, ORE 8 19, ORE 820, ORE 85 1, ORE 902, ORE 923, ORE 1035, CRF 1036, ORE 1037, ORE 1038, ORE 1069, ORE 1070, ORE 107 1, ORE 1073, ORE 1076, ORF 1095, ORF 1096, ORF 1141, ORF 1181, and their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis lipoprotein or one of its representative fragments, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORF 29, ORF 42, ORF 66, ORF 72, ORF 76, ORF 78, ORF 148, ORF 154, ORF 180, ORF 182, ORF 184, ORF 187, ORF 200, ORF 242, ORF 245, ORF 250, ORF 253, ORF 272, ORF 274, ORF 275, ORF 308, ORF 350, ORF 362, ORF 383, ORF 394, ORF 396, ORF 399, ORF 422, ORF 488, ORF 535, ORF 568, ORF 573, ORF 578, ORF 593, ORF 607, ORF 625, ORF 662, ORF 669, ORF 688, ORF 690, ORF 716, ORF 773, ORF 778, ORF 781, ORF 783, ORF 788, ORF 817, ORF 848, ORF 851, ORF 853, ORF 857, ORF 875, ORF 877, ORF 886, ORF 898, ORF 902, ORF 923, ORF 938, ORF 976, ORF 978, ORF 990, ORF 1005, ORF 1021, ORF 1035, ORF 1069, ORF 1083, ORF 1088, ORF 1089, ORF 1091, ORF 1092, ORF 1095, ORF 1096, ORF 1100, ORF 1105, ORF 1108, ORF 1117, ORF 1120, ORF 1121, ORF 1124, ORF 1128, ORF 1133, ORF 1135, ORF 1139, ORF 1140, ORF 1157, ORF 1159, ORF 1163, ORF 1165, ORF 1167, ORF 1168, ORF 1169, ORF 1171, ORF 1173, ORF 1174, ORF 1177, ORF 1180, ORF 1181, ORF 1186, ORF 1194, ORF 1197, and their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide involved in lipopolysaccharide (LPS) biosynthesis, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORF 17, ORF 201, ORF 691, ORF 807, ORF 936, ORF 983, ORF 1019, ORF 1077 and one of their representative fragments.

Preferably the invention relates to additional LPS-related nucleotide sequences according to the invention, characterized in that they encode: a Chlamydia trachomatis KDO (3-deoxy-D-manno-octulosonic acid)-related polypeptide or one of its representative fragments, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORF 41, ORF 242, ORF 269, ORF 772, and one of their representative fragments; a Chlamydia trachomatis phosphomannomutase-related polypeptide or one of its representative fragments, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequence: ORF 139, and one of its representative fragments; a Chlamydia trachomatis phosphoglucomutase-related polypeptide or one of its representative fragments, said nuclectide sequences comprising a nucleotide sequence chosen from the following sequence: ORF 567, and one of its representative fragments; and a Chlamydia trachomaris lipid A component-related polypeptide or one of its representative fragments, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORF 4, ORF 933, ORF 934, ORF 935, ORF 1185, and one of their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis Type II or other, non-Type In secreted polypeptides or one of its representative fragments, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORF 180, ORF 181, ORF 207, ORF 208, ORF 372, ORF 391, ORF 399, ORF 477, ORF 486, ORF 749, ORF 758, ORF 819, ORF 878, ORF 888, ORF 896, ORF 897, ORF 900, ORF 902, ORF 923, ORF 1015, ORF 1018, ORF 1059, ORF 1060, ORF 1069, ORF 1071, ORF 1073, ORF 1076, ORF 1189, and their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide containing RGD (Arg-Gly-Asp) attachment sites or one of its representative fragments: RGD-containing proteins that are outer membrane proteins, are more likely to play a role in cell attachment. ORFs that encoded a protein containing an RGD sequence and also were classified as outer membrane proteins are ORF 488, ORF 489, ORF 571, ORF 572, ORF 573 or ORF 716, and its representative fragments.

The outer membrane of Chlamydia is made of cysteine-rich proteins that form a network of both intra and inter molecular disulfide links. This contributes to the integrity of the membrane since Chlamydia lacks the peptidoglycan layer that other gram-negative bacteria have.

Cysteine-rich proteins that have the RGD sequence are also considered to be potential vaccine candidates. Cysteine-rich proteins were defined as proteins that had more than 3.0% cysteine in their primary amino acid sequence, above the mean genomic ORF cysteine content. The corresponding ORF is: ORF 1144 and one of its representative fragments.

The outer membrane of Chlamydia may also contain small proteins that have cysteines in their N- and C-terminus that may contribute to the network formed by disulfide linkages.

These proteins may be anchored in the outer membrane via their N-terminus and may have their Cterminus exposed, which then can interact with the host cells. Alternatively, these proteins may be anchored in the outer membrane via both N-and C-terminus and may have regions in the middle that may be exposed which can in turn interact with the host cells. ORFs encoding polypeptides that contain cysteines in their first 30 amino acids and also contain an RGD sequence are: ORF 101, ORF 122, ORF 308, ORF 488, ORF 489, ORF 571, ORF 572, ORF 573, ORF 651, ORF 679, ORF 680, ORF 705, ORF 716, ORF 763, ORF 870, ORF 878, ORF 879, ORF 995, ORF 1028, ORF 1029, ORF 1176, and one of their representative fragments.

RGD-containing ORFs homologous to RGD-containing ORFs from Chlamydia pneumoniae are: ORF 28, ORF 101, ORF 125, ORF 155, ORF 156, ORF 286, ORF 571, ORF 572, ORF 573, ORF 763, ORF 870, and one of their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis cell wall anchored surface polypeptide or one of its representative fragments, said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORF 662, ORF 681, ORF 1182, ORF 1192, and their representative fragments.

Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they encode Chlamydia trachomatis polypeptides not found in Chlamydia pneumoniae (Blastp said nucleotide sequences comprising a nucleotide sequence chosen from the following sequences: ORF 2, ORF 18, ORF 60, ORF 66, ORF 67, ORF 68, ORF 69, ORF 70, ORF 81, ORF 89, ORF 107, ORF 108, ORF 109, ORF 134, ORF 147, ORF 191, ORF 194, ORF 216, ORF 217, ORF 218, ORF 219, ORF 220, ORF 221, ORF 222, ORF 223, ORF 224, ORF 225, ORF 228, ORF 235, ORF 257, ORF 276, ORF 277, ORF 278, ORF 279, ORF 280, ORF 281, ORF 282, ORF 283, ORF 284, ORF 285, ORF 289, ORF 291, ORF 298, ORF 313, ORF 314, ORF 315, ORF 316, ORF 334, ORF 335, ORF 336, ORF 337, ORF 338, ORF 339, ORF 340, ORF 381, ORF 393, ORF 413, ORF 418, ORF 419, ORF 420, ORF 421, ORF 422, ORF 423, ORF 436, ORF 460, ORF 475, ORF 476, ORF 480, ORF 485, ORF 487, ORF 491, ORF 492, ORF 493, ORF 494, ORF 496, ORF 500, ORF 504, ORF 514, ORF 527, ORF 559, ORF 569, ORF 570, ORF 575, ORF 580, ORF 582, ORF 593, ORF 598, ORF 632, ORF 640, ORF 651, ORF 671, ORF 690, ORF 694, ORF 698, ORF 710, ORF 722, ORF 723, ORF 724, ORF 770, ORF 771, ORF 782, ORF 783, ORF 784, ORF 790, ORF 795, ORF 798, ORF 805, ORF 810, ORF 817, ORF 829, ORF 830, ORF 864, ORF 866, ORF 876, ORF 887, ORF 892, ORF 899, ORF 913, ORF 921, ORF 933, ORF 938, ORF 949, ORF 956, ORP 1010, ORF 1017, ORF 1018, ORF 1027, ORF 1030, ORF 1037, ORF 1038, ORF 1047, ORF 1072, ORF 1074, ORF 1075, ORF 1078, ORF 1079, ORF 1081, ORF 1083, ORF 1084, ORF 1087, ORF 1088, ORF 1089, ORF 1091, ORF 1092, ORF 1094, ORF 1095, ORF 1096, ORF 1098, ORF 1104, ORF 1105, ORF 1106, ORF 1108, ORF 1110, ORF 1114, ORF 1115, ORF 1116, ORF 1117, ORF 1119, ORF 1128, ORF 1132, ORF 1133, ORF 1135, ORF 1136, ORF 1139, ORF 1140, ORF 1141, ORF 1142, ORF 1144, ORF 1148, ORF 1151, ORF 1155, ORF 1157, ORF 1159, ORF 1161, ORF 1162, ORF 1165, ORF 1166, ORF 1167, ORF 1168, ORF 1169, ORF 1171, ORF 1172, ORF 1173, ORF 1174, ORF 1175, ORF 1176, ORF 1177, ORF 1178, ORF 1180, ORF 1181, ORF 1183, ORF 1184, ORF 1186, ORF 1187, ORF 1188, ORF 1192, ORF 1194, ORF 1197, and their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invencion, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the intermediate metabolism, in particular in the metabolism of sugars and/or of cofactors, such as for example triose phosphate isomerase or pyruvate kinase, and in that they comprise a nucleotide sequence chosen from the following sequences: ORFIO; ORF44; ORF45; ORF46; ORF47; ORF93; ORFl01; ORF102; ORF03; ORF106; ORF107; ORF120; ORFI21; ORF130; ORF135; ORF140; ORF143; ORF144; ORF145; ORF158; ORF159; ORF160; ORFI61; ORF192, ORF193; ORF196; ORF197; ORF198; ORF199; ORF227; ORF229; ORF236; ORF236; ORF239; ORF243; ORF245; ORF264; ORF265; ORF297; ORF331; ORF333; ORF359; ORF360; ORF374; ORF404; ORF405; ORF405; ORF410; ORF415; ORF415; ORF416; ORF417; ORF432; ORF460; ORF461; ORF462; ORF495; ORF513; ORF515; ORF566; ORF566; ORF566; ORF589; ORF613; ORF645; ORF646; ORF647; ORF652; ORF653; ORF654; ORF672; ORF673; ORF674; ORF682; ORF684; ORF692; ORF700; ORF725; ORF801; ORF802; ORF835; ORF836; ORF837; ORF860; ORF861; ORF862; ORF863; ORF869; ORF869; ORF925; ORF964; ORF983 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the intermediate metabolism of nucleotides or nucleic acids, such as for example CTP synthetase or GMP synthetase, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF142; ORF142; ORF169; ORF256; ORF268; ORF325; ORF352; ORF366; ORF435; ORF444; ORF528; ORF529; ORF530; ORF548; ORF549; ORF601; ORF602; ORF617; ORF619; ORF644; ORF745; ORF971; ORF972; ORF1023 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of nucleic acids, such as for example DNA polymerases or DNA topoisomerases, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF12; ORF82; ORF96; ORF97; ORF98; ORF99; ORF100; ORF105; ORF118; ORF136; ORF137; ORF163; ORF190; ORF204; ORF259; ORF260; ORF262; ORF290; ORF300; ORF301; ORF302; ORF387; ORF427; ORF434; ORF441; ORF444; ORF471; ORF595; ORF596; ORF597; ORF599; ORF600; ORF605; ORF612; ORF624; ORF625; ORF650; ORF657; ORF658; ORF702; ORF703; ORF704; ORF708; ORF719; ORF766; ORF767; ORF775; ORF779; ORF787; ORF788; ORF794; ORF841; ORF842; ORF883; ORF884; ORF907; ORF918; ORF924; ORF928; ORF929; ORF962; ORF962; ORF963; ORF969; ORF970; ORF975; ORF979; ORF995; ORF1031; ORF1032 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of amino acids or polypeptides, such as for example serine hydroxymethyl transferase or the proteins which load amino acids onto transfer RNAs, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF27; ORF41; ORF55; ORF56; ORF57; ORF59; ORF62; ORF63; ORF64; ORF65; ORF119; ORF132; ORF240; ORF241; ORF277; ORF278; ORF279; ORF382; ORF406; ORF428; ORF442; ORF446; ORF447; ORF453; ORF454; ORF541; ORF542; ORF591; ORF608; ORF609; ORF61O; ORF618; ORF648; ORF649; ORF660; ORF661; ORF677; ORF717; ORF765; ORF797; ORF871; ORF875; ORF920; ORF922; ORF937; ORF998; ORF1020; ORF1021; ORF1034; ORF1044; ORF1046; ORF1 049 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of polypeptides, such as for example protein kinases or proteases, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF21; ORF22; ORF23; .ORF24; ORF25; ORF26; ORF75; ORF84; ORF86; ORF92; ORF133; ORF151; ORF152; ORF157; ORF179; ORF209; ORF307; ORF326; ORF343; ORF344; ORF345; ORF371; ORF429; ORF519; ORF557; ORF586; ORF587; ORF630; ORF656; ORF706; ORF707; ORF730; ORF751; ORF752; ORF786; ORF847; ORF885; ORF923; ORF978; ORF1039; ORF1048 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of fatty acids, such as for example succinyl-CoA-synthesizing proteins or phosphatidylserine synthetase, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF4; ORFl5; ORFl6; ORFI41; ORF173; ORF205; ORF205; ORF206; ORF207; ORF208; ORF312; ORF355; ORF415; ORFSS0; ORF558; ORF560; ORF561; ORF574; ORF574; ORF577; ORF578; ORF590; ORF614; ORF772; ORF808; ORF809; ORF904; ORF905; ORF905; ORF933; ORF934; ORF934; ORF936 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the synthesis of the wall, such as for example KDO transferase, and the proteins responsible for the attachment of certain sugars onto the exposed proteins, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF87; ORF196; ORF242; ORF269; ORF628; ORF629; ORF634; ORF635; ORF637; ORF638; ORF1019 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the transcription, translation and/or maturation process, such as for example initiation factors, RNA polymerases or certain chaperone proteins, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF112; ORF113; ORF332; ORF212; ORF213; ORF350; ORF362; ORF363; ORF364; ORF407; ORF451; ORF546; ORF643; ORF744; ORF746; ORF833; ORF868; ORF981; ORF982; ORF1003; ORF101 1; ORF1042 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis ribosomal polypeptide or one of its representative fragments, such as for example the ribosomal proteins L21, L27 and S10, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF114; ORF115; ORF116; ORF328; ORF361; ORF375; ORF445; ORF543; ORF584; ORF585; ORF743; ORF813; ORF941; ORF942; ORF944; ORF946; ORF947; ORF948; ORF950; ORF951; ORF952; ORF953; ORF954; ORF955; ORF955; ORF957; ORF958; ORF960; ORF961; ORF1040; ORF1041; ORF1043; ORF1063; ORF1064 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chlamydia trachomatis transport polypeptide or one of its representative fragments, such as for example the proteins for transporting amino acids, sugars and certain oligopeptides, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF6; ORF50; ORF51; ORF80; ORF125; ORF126; ORF128; ORF129; ORF215; ORF246; ORF248; ORF249; ORF251; ORF252; ORF253; ORF255; ORF271; ORF275; ORF293; ORF309; ORF323; ORF324; ORF398; ORF401; ORF449; ORF511; ORF512; ORF564; ORF565; ORF667; ORF679; ORF680; ORF711; ORF712; ORF713; ORF714; ORF715; ORF730; ORF731; ORF736; ORF737; ORF738; ORF870; ORF908; ORF919; ORF977; ORF987; ORF988; ORF992; ORF993; ORF994; ORF1028; ORF1029 and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to the invention, characterized in that they encode a Chiwnydia trachomatis polypeptide or one of its representative fragments which is involved in the virulence process, such as for example the proteins analogous to the Escherichia coli vacB protein, and in that they comprise a nucleotide sequence chosen from the following sequences: ORF2O; ORF8 15; ORES 16; ORFS9S; 0RF1059; ORF1O6O and one of their representative fragments.

Preferably, the invention also relates to the nucleotide sequences according to theinvention, characterized in that they encode a Chiamydia trachomazis polypeptide or one of its representative fragments which is involved in the secretary system and/or which is secreted, such as for example proteins homologous to proteins in the secretory system of certain bacteria such as the Salmonellae or the Yersiniae, and in that they comprise a nucleotide sequence chosen from the following sequences: 0RF758; ORFSSS; 0RF889; ORFS9O; ORFS91; 0RF896; 0RF897; ORF898 and one of their representative fragments.

Preferably, the invention also relates to nucleotide sequences according to the invention, characterized in that they encode a polypeptide specific to Chlamydiae or one of its representative fragments, and in that they comprise a nucleotide sequence chosen from the following sequences: 0RF22; 0RF29; ORF3I; 0RF32; 0RF34; 0RF35; 0RF39; ORF4O; 0RE43; 0RF48; 0RF49; ORESO; 0RF52; 0RF53; 0RF54; 0RF72; 0RF77; 0RF78; ORFS7; ORF9O; 0RLF95; ORFIOS; ORFIIO; ORFI l; 0RF122; 0RF123; 0RF124; 0RF127; ORF13S; 0RF144; 0RF146; 0RF153; ORFiSS; 0RF164, 0RF166; 0RF175; ORFIS2; 0RF184; ORFlS6; ORF1S7; ORF1S88; 0RF202; ORF21I0; 0RF247; 0RF258; 0RF266; 0RF267; 0RF270; 0RF273; 0RF274; 0RF295; OR.F296; 0R1F305; 0RF306; OR.F309; QRF3 IS; ORF3 19; 0RF322; CR5326; 0RF342; 0RF357; 0RF376; 0RF379; ORF3SO; 0RF388; 0RF390; ORF400; 0RF431; 0RF433; 0RF438; 0RF443; 0RF456; ORF4SY; 0RP458; 0RF464; 0RF468;, 0RF470; 0RF473; ORF4S6; 0RF489; 0RF497; ORF5O1; 0RF503; 0RF504; ORFSOS; ORFS12; 0RF521; 0RF522; 0RF523; 0RF524; 0RF533;' 0RF535: 0RF536; 0RF537; 0RF538; 0RF539; 0RF540; 0RF554; 0RF563; 0RF572; 0RF579; 0RF595; 0RE603; 0RF604; 0RF606; 0RF607; 0RF615; 0RF616; 0RF622; 0RF64 1; 0RF642; 0RF659; 0RF668; 0RF670; 0RF693; 0RF695; 0RF696; 0RF699; 0RF703; 0RF704; 0RF716; 0RF726; 0RF728; 0RF739; 0RF742; 0RF747; 0RF750; ORF75I; 0RF755; 0RF757; 0RF759; 0RF761; 0RF762; 0RF763; 0RF764; 0RF773; ORE/SO; ORF7Sl; 0RF789; ORFSOO; ORFSO3; ORF804; ORE8iS; ORFS2O; 0RF822; 0RF823; 0RF824; ORFS27; 0RF828; 0RF839; 0RE849; ORESSO; 0RF852; ORFS5S; 0RF856; 0RF857; ORESSS; 0RF859; ORFS6O; QRF86 1; 0RF862; 0RF863; 0RF865; ORFS6S; 0RF869; ORFS7O; ORFS7I; 0RF872; 0RF873; ORFSY4; ORFS7S; 0RF877; 0RF878; ORESSO; QRFSS2; ORF884; ORFSS6; 0RF893; ORF9Oi; 0RF906; ORF912; ORF915; ORF916; ORF917; ORF926; ORF929; ORF933; ORF965; ORF967; ORF968; ORF984; ORF986; ORF989; ORF990; ORF996; ORF997; ORF1001; ORF1002; ORF1013; ORF1016; ORF1031; ORF1033; ORF1035; ORF1049; ORF105I; ORF1052; ORF1054 ORF1056; ORF1057; ORF1058; ORF1062; ORF1070; ORF1071; ORF1073 and one of their representative fragments.

Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. In one embodiment, the polypeptides and fusion polypeptides immunoreact with seropositive serum of an individual infected with Chlamydia trachomatis. For example, described below, are polypeptide sequences exhibiting particularly preferable characteristics. For each group of preferred polypeptides described below, it is to be understood that in addition to the individual polypeptides listed, in instances wherein such polypeptides are encoded as part of <combined> ORFs, such <combined> polypeptides are also to be included within the preferred group.

The subject of the invention is also a polypeptide according to the invention, characterized in that it is a polypeptide of the cellular envelope, preferably of the outer cellular envelope, of Chlamydia trachomatis or one of its representative fragments. According to the invention, the said polypeptide is preferably chosen from the polypeptides having the following sequences: SEQ ID No. 3; SEQ ID No. 19; SEQ ID No. 51; SEQ ID No. 189; SEQ ID No. 212; SEQ ID No. 213; SEQ ID No. 324; SEQ ID No. 477; SEQ ID No. 478; SEQ ID No. 479; SEQ ID No. 481; SEQ ID No. 482; SEQ ID No. 483; SEQ ID No. 484; SEQ ID No. 486; SEQ ID No. 488; SEQ ID No. 489; SEQ ID No. 490; SEQ ID No. 572; SEQ ID No. 573; SEQ ID No. 742; SEQ ID No. 817; SEQ ID No. 818; SEQ ID No. 820; SEQ ID No. 1035; SEQ ID No. 1036; SEQ ID No. 1037; SEQ ID No. 1038; SEQ ID No. 1070; SEQ ID No. 1071; SEQ ID No. 1073 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis transmembrane polypeptide or one of its representative fragments, having between 1 and 3 transmembrane domains, and in that it is chosen from the polypeptides having the following sequences: 33 SEQ ID No. 2; SEQ ID No. 3; SEQ ID No. 5; SEQ ID No. 8; SEQ ID No. 9; SEQ ID No. SEQ ID No. 11; SEQ ID No. 12; SEQ ID No. 17; SEQ ID No. 21; SEQ ID No. 26; SEQ ID No. 27; SEQ ID No. 28; SEQ ID No. 29; SEQ ID No. 30; SEQ ID No. 31; SEQ ID No. 33; SEQ ID No. SEQ ID No. 37; SEQ ID No. 39; SEQ ID No. 40; SEQ ID No. 41; SEQ ID No. 42; SEQ ID No. 43; SEQ ID No. 44; SEQ ID No. 45; SEQ ID No. 46; SEQ ID No. 47; SEQ ID No. 48; SEQ ID No. 49; SEQ ID No. 52; SEQ ID No. 53; SEQ ID No. 55; SEQ ID No. 56; SEQ ID No. 58; SEQ ID No. SEQ ID No. 66; SEQ ID No. 68; SEQ ID No. 70; SEQ ID No. 74; SEQ ID No. 75; SEQ ID No. 76; SEQ ID No. 78; SEQ ID No. 79; SEQ ID No. 81; SEQ ID No. 82; SEQ ID No. 83; SEQ ID No. 86; SEQ ID No. 91; SEQ ID No. 92; SEQ ID No. 94; SEQ ID No. 97; SEQ ID No. 100; SEQ ID No. 102; SEQ ID No. 103; SEQ ID No. 110; SEQ ID No. 115; SEQ ID No. 123; SEQ ID No. 140; SEQ ID No. 147; SEQ ID No. 155; SEQ ID No. 165; SEQ ID No. 170; SEQ ID No. 177; SEQ ID No. 187; SEQ ID No. 194; SEQ ID No. 199; SEQ ID No. 207; SEQ ID No. 219; SEQ ID No. 224; SEQ ID No. 232; SEQ ID No. 244; SEQ ID No. 252; SEQ ID No. 263; SEQ ID No. 271; SEQ ID No. 278; SEQ ID No. 285; SEQ ID No. 294; SEQ ID No. 311; SEQ ID No. 320; SEQ ID No. 327; SEQ ID No. 333; SEQ ID No. 339; SEQ ID No. 348; SEQ ID No. 353; SEQ ID No. 362; SEQ ID No. 105; SEQ ID No. 111; SEQ ID No. 116; SEQ ID No. 130; SEQ ID No. 141; SEQ ID No. 148; SEQ ID No. 156; SEQ ID No. 166; SEQ ID No. 171; SEQ ID No. 181; SEQ ID No. 188; SEQ ID No. 195; SEQ ID No. 201; SEQ ID No. 209; SEQ ID No. 220; SEQ ID No. 225; SEQ ID No. 234; SEQ ID No. 245; SEQ ID No. 254; SEQ ID No. 265; SEQ ID No. 272; SEQ ID No. 279; SEQ ID No. 287; SEQ ID No. 298; SEQ ID No. 313; SEQ ID No. 322; SEQ ID No. 328; SEQ ID No. 334; SEQ ID No. 340; SEQ ID No. 349; SEQ ID No. 356; SEQ ID No. 366; SEQ ID No. 106; SEQ ID No. 112; SEQ ID No. 117; SEQ ID No. 134; SEQ ID No. 143; SEQ ID No. 149; SEQ ID No. 162; SEQ ID No. 167; SEQ ID No. 173; SEQ ID No. 183; SEQ ID No. 190; SEQ ID No. 196; SEQ ID No. 202; SEQ ID No. 212; SEQ ID No. 221; SEQ ID No. 227; SEQ ID No. 236; SEQ ID No. 247; SEQ ID No. 257; SEQ ID No. 266; SEQ ID No. 274; SEQ ID No. 282; SEQ ID No. 289; SEQ ID No. 305; SEQ ID No. 315; SEQ ID No. 323; SEQ ID No. 330; SEQ ID No. 335; SEQ ID No. 341; SEQ ID No. 350; SEQ ID No. 357; SEQ ID No. 367; SEQ ID No. 107; SEQ ID No. 113; SEQ ID No. 120; SEQ ID No. 135; SEQ ID No. 144; SEQ ID No. 150; SEQ ID No. 163; SEQ ID No. 168; SEQ ID No. 175; SEQ ID No. 184; SEQ ID No. 191; SEQ ID No. 197; SEQ ID No. 204; SEQ ID No. 213; SEQ ID No. 222; SEQ ID No. 228; SEQ ID No. 237; SEQ ID No. 248; SEQ ID No. 260; SEQ ID No. 267; SEQ ID No. 276; SEQ ID No. 283; SEQ ID No. 290; SEQ ID No. 306; SEQ ID No. 316; SEQ ID No. 325; SEQ ID No. 331; SEQ ID No. 336; SEQ ID No. 344; SEQ ID No. 351; SEQ ID No. 358; SEQ ID No. 368; SEQ ID No. 109; SEQ ID No. 114; SEQ ID No. 122; SEQ ID No. 137; SEQ ID No. 145; SEQ ID No. 151; SEQ ID No..164; SEQ ID No. 169; SEQ ID No. 176; SEQ ID No. 186; SEQ ID No. 192; SEQ ID No. 198; SEQ ID No. 206; SEQ ID No. 217; SEQ ID No. 223; SEQ ID No. 231; SEQ ID No. 243; SEQ ID No. 249; SEQ ID No. 261; SEQ ID No. 270; SEQ ID No. 277; SEQ ID No. 284; SEQ ID No. 291; SEQ ID No. 310; SEQ ID No. 319; SEQ ID No. 326; SEQ ID No. 332; SEQ ID No. 338; SEQ ID No. 345; SEQ ID No. 352; SEQ ID No. 361; SEQ ID No. 370; SEQ ID No. 372; SEQ ID No. 379; SEQ ID No. 385; SEQ ID No. 393; SEQ ID No. 404; SEQ ID No. 417; SEQ ID No. 426; SEQ ID No. 434; SEQ ID No. 443; SEQ ID No. 454; SEQ ID No. 463; SEQ ID No. 469; SEQ ID No. 476; SEQ ID No. 483; SEQ ID No. 488; SEQ ID No. 498; SEQ ID No. 508; SEQ ID No. 521; SEQ ID No. 529; SEQ ID No. 536; SEQ ID No. 542; SEQ ID No. 547; SEQ ID No. 558; SEQ ID No. 566; SEQ ID No. 572; SEQ ID No. 582; SEQ ID No. 593; SEQ ID No. 601; SEQ ID No. 609; SEQ ID No. 617; SEQ ID No. 624; SEQ ID No. 634; SEQ ID No. 641; SEQ ID No. 65 1; SEQ ID No. 658; SEQ ID No. 373; SEQ ID No. 380; SEQ ID No. 387; SEQ ID No. 396; SEQ ID No. 406; SEQ ID No. 418; SEQ ID No. 427; SEQ ID No. 435; SEQ ID No. 446; SEQ ID No. 455; SEQ ID No. 464; SEQ ID No. 470; SEQ ID No. 477; SEQ ID No. 484; SEQ ID No. 491; SEQ ID No. 500; SEQ ID No. 512; SEQ ID No. 523; SEQ ID No. 530; SEQ ID No. 537; SEQ ID No. 543; SEQ ID No. 551; SEQ ID No. 559; SEQ ID No. 567; SEQ ID No. 574; SEQ ID No. 585; SEQ ID No. 595; SEQ ID No. 602; SEQ ID No. 610; SEQ ID No. 618; SEQ ID No. 625; SEQ ID No. 635; SEQ ID No. 643; SEQ ID No. 652; SEQ ID No. 664; SEQ ID No. 375; SEQ ID No. 382; SEQ ID No. 389; SEQ ID No. 398; SEQ ID No. 407; SEQ ID No. 420; SEQ ID No. 428; SEQ ID No. 436; SEQ ID No. 448; SEQ ID No. 457; SEQ ID No. 466; SEQ ID No. 473; SEQ ID No. 479; SEQ ID No. 485; SEQ ID No. 493; SEQ ID No. 501; SEQ ID No. 513; SEQ ID No. 524; SEQ ID No. 531; SEQ ID No. 538; SEQ ID No. 544; SEQ ID No. 552; SEQ ID No. 560; SEQ ID No. 568; SEQ ID No. 575; SEQ ID No. 587; SEQ ID No. 596; SEQ ID No. 603; SEQ ID No. 611; SEQ ID No. 621; SEQ ID No. 628; SEQ ID No. 637; SEQ ID No. 646; SEQ ID No. 653; SEQ ID No. 665; SEQ ID No. 377; SEQ ID No. 383; SEQ ID No. 390; SEQ ID No. 399; SEQ ID No. 413; SEQ ID No. 421; SEQ ID No. 430; SEQ ID No. 437; SEQ ID No. 450; SEQ ID No. 458; SEQ ID No. 467; SEQ ID No. 474; SEQ ID No. 480; SEQ ID No. 486; SEQ ID No. 496; SEQ ID No. 503; SEQ ID No. 514; SEQ ID No. 526; SEQ ID No. 532; SEQ ID No. 540; SEQ ID No. 545; SEQ ID No. 553; SEQ ID No. 561; SEQ ID No. 569; SEQ ID No. 576; SEQ ID No. 589; SEQ ID No. 597; SEQ ID No. 604; SEQ ID No. 615; SEQ ID No. 622; SEQ ID No. 632; SEQ ID No. 638; SEQ ID No. 648; SEQ ID No. 654; SEQ ID No. 666; SEQ ID No. 378; SEQ ID No. 384; SEQ ID No. 391; SEQ ID No. 403; SEQ ID No. 414; SEQ ID No. 424; SEQ ID No. 433; SEQ ID No. 440; SEQ ID No. 451; SEQ ID No. 459; SEQ ID No. 468; SEQ ID No. 475; SEQ ID No. 481; SEQ ID No. 487; SEQ ID No. 497; SEQ ID No. 504; SEQ ID No. 519; SEQ ID No. 527; SEQ ID No. 534; SEQ ID No. 541; SEQ ID No. 546; SEQ ID No. 555; SEQ ID No. 562; SEQ ID No. 571; SEQ ID No. 580; SEQ ID No. 592; SEQ ID No. 599; SEQ ID No. 608; SEQ ID No. 616; SEQ ID No. 623; SEQ ID No. 633; SEQ ID No. 640; SEQ ID No. 649; SEQ ID No. 655; SEQ ID No. 668; SEQ ID No. 669; SEQ ID No. 674; SEQ ID No. 682; SEQ ID No. 689; SEQ ID No. 695; SEQ ID No. 704; SEQ ID No. 710; SEQ ID No, 715; SEQ ID No. 722; SEQ ID No. 730; SEQ ID No. 737; SEQ ID No. 743; SEQ ID No. 750; SEQ ID No. 755; SEQ ID No. 764; SEQ ID No. 772; SEQ ID No. 777; SEQ ID No. 782; SEQ ID No. 789; SEQ ID No. 802; SEQ ID No. 810; SEQ ID No. 820; SEQ ID No. 828; SEQ ID No. 835; SEQ ID No. 841; SEQ ID No. 849; SEQ ID No. 855; SEQ ID No. 862; SEQ ID No. 872; SEQ ID No. 880; SEQ ID No. 886; SEQ ID No. 895; SEQ ID No. 904; SEQ ID No. 914; SEQ ID No. 923; SEQ ID No. 670; SEQ ID No. 676; SEQ ID No. 683; SEQ ID No. 690; SEQ ID No. 696; SEQ ID No. 705; SEQ ID No. 711; SEQ ID No. 717; SEQ ID No. 724; SEQ ID No. 731; SEQ ID No. 738; SEQ ID No. 744; SEQ ID No. 751; SEQ ID No. 757; SEQ ID No. 766; SEQ ID No. 773; SEQ ID No. 778; SEQ ID No. 783; SEQ ID No. 790; SEQ ID No. 803; SEQ ID No. 811; SEQ ID No. 822; SEQ ID No. 829; SEQ ID No. 837; SEQ ID No. 842; SEQ ID No. 850; SEQ ID No. 856; SEQ ID No. 863; SEQ ID No. 873; SEQ ID No. 881; SEQ ID No. 887; SEQ ID No. 897; SEQ ID No. 906; SEQ ID No. 917; SEQ ID No, 924; SEQ ID No. 671; SEQ ID No. 677; SEQ ID No. 684; SEQ ID No. 691; SEQ ID No, 698; SEQ ID No. 706; SEQ ID No. 712; SEQ ID No. 718; SEQ ID No. 726; SEQ ID No. 732; SEQ ID No. 739; SEQ ID No. 745; SEQ ID No. 752; SEQ ID No. 758; SEQ ID No. 768; SEQ ID No. 774; SEQ ID No. 779; SEQ ID No. 786; SEQ ID No. 793; SEQ ID No. 806; SEQ ID No. 813; SEQ ID No. 824; SEQ ID No. 830; SEQ ID No. 838; SEQ ID No. 843; SEQ ID No. 851; SEQ ID No. 857; SEQ ID No. 864; SEQ ID No. 874; SEQ ID No. 883; SEQ ID No. 892; SEQ ID No. 899; SEQ ID No. 909; SEQ ID No. 920; SEQ ID No. 925; SEQ ID No. 672; SEQ ID No. 678; SEQ ID No. 686; SEQ ID No. 692; SEQ ID No. 701; SEQ ID No. 707; SEQ ID No. 713; SEQ ID No. 720; SEQ ID No. 728; SEQ ID No. 733; SEQ ID No. 740; SEQ ID No. 746; SEQ ID No. 753; SEQ ID No. 759; SEQ ID No. 769; SEQ ID No. 775; SEQ ID No. 780; SEQ ID No. 787; SEQ ID No. 798; SEQ ID No. 808; SEQ ID No. 814; SEQ ID No. 825; SEQ ID No. 833; SEQ ID No. 839; SEQ ID No. 845; SEQ ID No. 852; SEQ ID No. 859; SEQ ID No. 866; SEQ ID No. 878; SEQ ID No. 884; SEQ ID No. 893; SEQ ID No. 900; SEQ ID No. 910; SEQ ID No. 921; SEQ ID No. 926; SEQ ID No. 673; SEQ ID No. 680; SEQ ID No. 688; SEQ ID No. 693; SEQ ID No. 703; SEQ ID No. 709; SEQ ID No. 714; SEQ ID No. 721; SEQ ID No. 729; SEQ ID No. 734; SEQ ID No. 742; SEQ ID No. 748; SEQ ID No. 754; SEQ ID No. 760; SEQ ID No. 771; SEQ ID No. 776; SEQ ID No, 781; SEQ ID No. 788; SEQ ID No. 800; SEQ ID No. 809; SEQ ID No. 817; SEQ ID No. 827; SEQ ID No. 834; SEQ ID No. 840; SEQ ID No. 848; SEQ ID No. 854; SEQ ID No. 860; SEQ ID No. 869; SEQ ID No. 879; SEQ ID No. 885; SEQ ID No. 894; SEQ ID No. 901; SEQ ID No. 912; SEQ ID No. 922; SEQ ID No. 927; SEQ ID No. 930; SEQ ID No. 937; SEQ ID No, 944; SEQ ID No. 952; SEQ ID No. 957; SEQ ID No. 963; SEQ ID No. 970; SEQ ID No. 980; SEQ ID No. 989; SEQ ID No. 999; SEQ ID No. 1006; SEQ ID No. 1012; SEQ ID No. 1018; SEQ ID No. 1027; SEQ ID No. 1036; SEQ ID No. 1044; SEQ ID No. 1051; SEQ ID No. 1057; SEQ ID No. 1064; SEQ ID No. 933; SEQ ID No. 940; SEQ ID No. 945; SEQ ID No. 953; SEQ ID No. 958; SEQ ID No. 964; SEQ ID No. 971; SEQ ID No. 981; SEQ ID No. 990; SEQ ID No. 1001; SEQ ID No. 1007; SEQ ID No. 1013; SEQ ID No. 1020; SEQ ID No. 1029; SEQ ID No. 1037; SEQ ID No. 1045; SEQ ID No. 1052; SEQ ID No. 1058; SEQ ID No. 1065; SEQ ID No. 934; SEQ ID No. 941; SEQ ID No. 947; SEQ ID No. 954; SEQ ID No. 960; SEQ ID No. 966; SEQ ID No. 973;.

SEQ ID No. 982; SEQ ID No. 991; SEQ ID No. 1003; SEQ ID No. 1009; SEQ ID No. 1014; SEQ ID No. 1021; SEQ ID No. 1030; SEQ ID No. 1038;.

SEQ ID No. 1047; SEQ ID No. 1053; SEQ ID No. 1061; SEQ ID No. 1066; SEQ ID No. 935; SEQ ID No. 942; SEQ ID No. 948; SEQ ID No. 955; SEQ ID No. 961; SEQ ID No. 967; SEQ ID No. 974; SEQ ID No. 984; SEQ ID No. 995; SEQ ID No. 1004; SEQ DD No. 1010; SEQ ID No. 1016; SEQ ID No. 1025; SEQ ID No. 1031; SEQ ID No. 1039; SEQ ID No. 1048; SEQ ID No. 1055; SEQ ID No. 1062; SEQ ID No. 1068; SEQ ID No. 936: SEQ ID No. 943; SEQ ID No. 951; SEQ ID No. 956; SEQ ID No. 962; SEQ ID No. 969; SEQ ID No. 979; SEQ ID No. 988; SEQ ID No. 996; SEQ ID No. 1005; SEQ ID No. 1011; SEQ ID No. 1017; SEQ ID No. 1026; SEQ ID No. 1035; SEQ ID No. 1040; SEQ ID No. 1050; SEQ ID No. 1056; SEQ ID No. 1063; SEQ ID No. 1069; SEQ ID No. 1072; SEQ ID No. 1074; SEQ ID No. 1076 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis transmembrane polypeptide or one of its representative fragments, having between 4 and 6 transmembrane domains, and in that it is chosen from the polypeptides having the following sequences: SEQIDNo. 7; SEQIDNo. 14; SEQIDNo. 16; SEQIDNo. 32; SEQIDNo. 34; SEQIDNo. 36; SEQ ID No. 38; SEQ ID No. 50; SEQ ID No. 57; SEQ ID No. 59; SEQ ID No. 61; SEQ ID No. 62; SEQ ID No. 63; SEQ ID No. 64; SEQ ID No. 67; SEQ ID No. 69; SEQ ID No. 72; SEQ ID No. 77; SEQ ID No. 80; SEQ ID No. 84; SEQ ID No. 87; SEQ ID No. 93; SEQ ID No. 95; SEQ ID No. 99; SEQ ID No. 108; SEQ ID No. 119; SEQ ID No. 125; SEQ ID No. 126; SEQ ID No. 129; SEQ ID No. 131; SEQ ID No. 136; SEQ ID No. 139; SEQ ID No. 146; SEQ ID No..152; SEQ IDNo. 154; SEQ ID No. 160; SEQ ID No. 161; SEQ ID No. 172; SEQ ID No. 179; SEQ ID No. 182; SEQ ID No. 185; SEQ ID No. 200; SEQ ID No. 203; SEQ ID No. 205; SEQ ID No. 239; SEQ ID No. 242; SEQ ID No. 250; SEQ ID No. 253; SEQ ID No. 256; SEQ ID No. 259; SEQ ID No. 262; SEQ ID No. 268; SEQ ID No. 275; SEQ ID No. 281; SEQ ID No. 286; SEQ ID No. 283; SEQ ID No. 292; SEQ ID No. 295; SEQ ID No. 296; SEQ ID No. 297; SEQ ID No. 317; SEQ ID No. 355; SEQ ID No. 388; SEQ ID No. 405; SEQ ID No. 423; SEQ ID No. 444; SEQ ID No. 461; SEQ ID No. 489; SEQ ID No. 505; SEQ ID No. 520; SEQ ID No. 554; SEQ ID No. 581; SEQ ID No. 612; SEQ ID No. 630; SEQ ID No. 659; SEQ ID No. 700; SEQ ID No. 747; SEQ ID No. 794; SEQ ID No. 807; SEQ ID No. 853; SEQ ID No. 882; SEQ ID No. 903; SEQ ID No. 975; SEQ ID No. 987; SEQ ID No. 1008; SEQ ID No. 1046; SEQ ID No. 299; SEQ ID No. 318; SEQ ID No. 360; SEQ ID No. 392; SEQ ID No. 411; SEQ ID No. 429; SEQ ID No. 449; SEQ ID No. 465; SEQ ID No. 492; SEQ ID No. 506; SEQ ID No. 525; SEQ ID No. 557; SEQ ID No. 590; SEQ ID No. 613; SEQ ID No. 639; SEQ ID No. 661; SEQ ID No. 708; SEQ ID No. 749; SEQ ID No. 796; SEQ ID No. 821; SEQ ID No. 861; SEQ ID No. 888; SEQ ID No. 911; SEQ ID No. 976; SEQ ID No. 992; SEQ ID No. 1019; SEQ IDNo. 1054; SEQ ID No. 300; SEQ ID No. 324; SEQ ID No. 374; SEQ ID No. 394; SEQ ID No. 415; SEQ ID No. 432; SEQ ID No. 452; SEQ ID No. 471; SEQ ID No. 494; SEQ ID No. 509; SEQ ID No. 533; SEQ ID No. 563; SEQ ID No. 591; SEQ ID No. 620; SEQ ID No. 644; SEQ ID No. 685; SEQ ID No. 716; SEQ ID No. 756; SEQ ID No. 797; SEQ ID No. 823; SEQ ID No. 870; SEQ ID No. 889; SEQ ID No. 916; SEQ ID No. 978; SEQ ID No. 993; SEQ ID No. 1022; SEQ ID No. 1060; SEQ ID No. 308; SEQ ID No. 342; SEQ ID No. 376; SEQ ID No. 395; SEQ ID No. 416; SEQ ID No. 441; SEQ ID No. 456; SEQ ID No. 472; SEQ ID No. 495; SEQ ID No. 516; SEQ ID No. 539; SEQ ID No. 570; SEQ ID No. 600; SEQ ID No. 626; SEQ ID No. 647; SEQ ID No. 687; SEQ ID No. 719; SEQ ID No. 765; SEQ ID No. 799; SEQ ID No. 826; SEQ ID No. 871; SEQ ID No. 898; SEQ ID No. 931; SEQ ID No. 983; SEQ ID No. 1000; SEQ ID No. 1032; SEQ ID No. 314; SEQ ID No. 343; SEQ ID No. 386; SEQ ID No. 402; SEQ ID No. 422; SEQ ID No. 442; SEQ ID No. 460; SEQ ID No. 482; SEQ ID No. 502; SEQ ID No. 517; SEQ ID No. 549; SEQ ID No. 573; SEQ ID No. 607; SEQ ID No. 629; SEQ ID No. 656; SEQ ID No. 699; SEQ ID No. 725; SEQ ID No. 767; SEQ ID No. 801; SEQ ID No. 847; SEQ ID No. 875; SEQ ID No. 902; SEQ ID No. 939; SEQ ID No. 986; SEQ ID No. 1002; SEQ ID No. 1034; SEQ ID No. 1071 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis transmembrane polypeptide or one of its representative fragments, having at least 7 transmembrane domains, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 4; SEQ ID No. 6; SEQ ID No. 13; SEQ ID No. 20; SEQ ID No. 51; SEQ ID No. 71; SEQ ID No. 88; SEQ ID No. 118; SEQ ID No. 128; SEQ ID No. 132; SEQ ID No. 133; SEQ ID No. 158; SEQ ID No. 159; SEQ ID No. 174; SEQID No. 180; SEQ ID No. 189; SEQ ID No. 210; SEQIDNo. 211;- SEQIDNo. 214; SEQ ID No. 215; SEQ ID No. 240; SEQ ID No. 354; SEQ ID No. 401; SEQ ID No. 453; SEQ ID No. 518; SEQ ID No. 565; SEQ ID No. 636; SEQ ID No. 681; SEQ ID No.791; SEQ ID No. 846; SEQ ID No. 877; SEQ ID No. 918; SEQ ID No. 994; SEQ ID No. 226; SEQ ID No. 246; SEQ ID No. 364; SEQ ID No. 409; SEQ ID No. 462; SEQ ID No. 535; SEQ ID No. 578; SEQ ID No. 650; SEQ ID No. 702; SEQ ID No. 792; SEQ ID No. 858; SEQ ID No. 891; SEQ ID No. 919; SEQ ID No. 998; SEQ ID No. 229; SEQ ID No. 251; SEQ ID No. 369; SEQ ID No. 412; SEQ ID No. 490; SEQ ID No. 548; SEQ ID No. 579; SEQ ID No. 662; SEQ ID No. 727; SEQ ID No. 815; SEQ ID No. 865; SEQ ID No. 896; SEQ ID No. 932; SEQ ID No. 1024; SEQ ID No. 233; SEQ ID No. 255; SEQ ID No. 371; SEQ ID No. 419; SEQ ID No. 510; SEQ ID No. 550; SEQ ID No. 614; SEQ ID No. 667; SEQ ID No. 741; SEQ ID No. 816; SEQ ID No. 867; SEQ ID No. 907; SEQ ID No. 959; SEQ ID No. 1028; SEQ ID No. 235; SEQ ID No. 273; SEQID No. 397; SEQ ID No. 439; SEQ ID No. 511; SEQ ID No. 564; SEQ ID No. 631; SEQ ID No. 679; SEQ ID No. 763; SEQ ID No. 832; SEQ ID No. 868; SEQ ID No. 908; SEQ ID No. 977; SEQ ID No. 1042; SEQ ID No. 1067; SEQ ID No. 1070; SEQ ID No. 1073 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis surface exposed polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 53, SEQ ID No. 77, SEQ ID No. 187, SEQ ID No. 203, SEQ ID No. 383, SEQ ID No. 477, SEQ ID No. 478, SEQ ID No. 479, SEQ ID No. 481, SEQ ID No. 482, SEQ ID No. 483, SEQ ID No. 484, SEQ ID No.

485, SEQ ID No. 486, SEQ ID No. 487, SEQ ID No. 488, SEQ ID No. 489, SEQ ID No. 490, SEQ ID No. 571. SEQ ID No. 572, SEQ ID No. 573, SEQ ID No. 593, SEQ ID No. 670, SEQ ID No. 693, SEQ ID No. 742, SEQ ID No. 749, SEQ ID No. 801, SEQ ID No. 817, SEQ ID No. 818, SEQ ID No.

819, SEQ ID No. 820, SEQ ID No. 851, SEQ ID No. 902, SEQ ID No. 923, SEQ ID No. 1035, SEQ ID No. 1036, SEQ ID No. 1037, SEQ ID No. 1038, SEQ ID No. 1069, SEQ ID No. 1070, SEQ ID No.

1071, SEQ ID No. 1073, SEQ ID No. 1076, SEQ ID No. 1095, SEQ ID No. 1096, SEQ ID No. 1141, SEQ ID No. 1181, and their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis lipoprotein or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 29, SEQ ID No. 42, SEQ ID No. 66, SEQ ID No. 72, SEQ ID No. 76, SEQ ID No. 78, SEQ ID No. 148, SEQ ID No. 154, SEQ ID No. 180, SEQ ID No. 182, SEQ ID No. 184, SEQ ID No.

187, SEQ ID No. 200, SEQ ID No. 242, SEQ ID No. 245, SEQ ID No. 250, SEQ ID No. 253, SEQ ID No. 272, SEQ ID No. 274, SEQ ID No. 275, SEQ ID No. 308, SEQ ID No. 350, SEQ ID No. 362, SEQ ID No. 383, SEQ ID No. 394, SEQ ID No. 396, SEQ ID No. 399, SEQ ID No. 422, SEQ ID No.

488, SEQ ID No. 535, SEQ ID No. 568, SEQ ID No. 573, SEQ ID No. 578, SEQ ID No. 593, SEQ ID No. 607, SEQ ID No. 625, SEQ ID No. 662, SEQ ID No. 669, SEQ ID No. 688, SEQ-ID No. 690, SEQ ID No. 716, SEQ ID No. 773, SEQ ID No. 778, SEQ ID No. 781, SEQ ID No. 783, SEQ ID No.

788, SEQ ID No. 817, SEQ ID No. 848, SEQ ID No. 851, SEQ ID No. 853, SEQ ID No. 857, SEQ ID No. 875, SEQ ID No. 877, SEQ ID No. 886, SEQ ID No. 898, SEQ ID No. 902, SEQ ID No. 923, SEQ ID No. 938, SEQ ID No. 976, SEQ ID No. 978, SEQ ID No. 990, SEQ ID No. 1005, SEQ ID No.

1021, SEQ ID No. 1035, SEQ ID No. 1069, SEQ ID No. 1083, SEQ ID No. 1088, SEQ ID No. 1089, SEQ ID No. 1091, SEQ ID No. 1092, SEQ ID No. 1095, SEQ ID No. 1096, SEQ ID No. 1100, SEQ ID No. 1105, SEQ ID No. 1108, SEQ ID No. 1117, SEQ ID No. 1120, SEQ ID No. 1121, SEQ ID No.

1124, SEQ ID No. 1128, SEQ ID No. 1133, SEQ ID No. 1135, SEQ ID No. 1139, SEQ ID No. 1140, SEQ ID No. 1157, SEQ ID No. 1159, SEQ ID No. 1163, SEQ ID No. 1165, SEQ ID No. 1167, SEQ ID No. 1168, SEQ ID No. 1169, SEQ ID No. 1171, SEQ ID No. 1173, SEQ ID No. 1174, SEQ ID No.

1177, SEQ ID No. 1180, SEQ ID No. 1181, SEQ ID No. 1186, SEQ ID No. 1194, SEQ ID No. 1197, and their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis polypeptide involved in lipopolysaccharide (LPS) biosynthesis, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 17, SEQ ID No.

201, SEQ ID No. 691, SEQ ID No. 807, SEQ ID No. 936, SEQ ID No. 983, SEQ ID No. 1019, SEQ ID No. 1077, and their representative fragments.

Preferably, the invention relates to additional LPS-related polypeptides according to the invention, in that it is: a Chlamydia trachomatis KDO (3-deoxy-D-manno-octylosonic acid)-related polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 41, SEQ ID No. 242, SEQ ID No. 269, SEQ ID No. 772, and one of their representative fragments; a Chlamydia trachomatis phosphomannomutase-related polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequence: SEQ ID No. 139, and its representative fragments; a Chlamydia trachomatis phosphoglucomutase-related polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequence: SEQ ID No. 567 and its representative fragments; and a Chlamydia trachomatis lipid A component-related polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 4, SEQ ID No. 933, SEQ ID No. 934, SEQ ID No. 935, SEQ ID No. 1185, and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments that contains an ROD sequence and is also an outer membrane protein, and in that it is chosen from the polypeptides having the following sequences: SEQ. ID No. 488, SEQ ID No. 489, SEQ ID No. 571, SEQ ID No. 572, SEQ No. 573, SEQ ID No. 716 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments that is cysteine-rich and contains RGD sequence, and in that it is chosen from the polypeptides having the following sequence: SEQ ID No. 144 and one of its representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis outer membrane polypeptide that contains cysteines in their first 30 amino acids and also contain an RGD sequence, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 101, SEQ ID No. 122, SEQ ID No. 308, SEQ ID No. 488, SEQ ID No. 489, SEQ ID No. 571, SEQ ID No. 572, SEQ ID No. 573, SEQ ID No. 651, SEQ ID No. 679, SEQ ID No. 680, SEQ ID No. 705, SEQ ID No. 716, SEQ ID No. 763, SEQ ID No. 870, SEQ ID No.

878, SEQ ID No. 879, SEQ ID No. 995, SEQ ID No. 1028, SEQ ID No. 1029, SEQ ID No. 1176, and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments that contains RGD sequences homologous to Chlamydia pneumoniae polypeptides containing RGD sequences, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 28, SEQ ID No.

101, SEQ ID No. 125, SEQ ID No. 155, SEQ ID No. 156, SEQ ID No. 286, SEQ ID No. 571, SEQ ID No. 572, SEQ ID No. 573, SEQ ID No. 763, SEQ ID No. 870, and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis Type I or non-Type fl secreted polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 180, SEQ ID No. 181, SEQ ID No. 207, SEQ ID No. 208, SEQ ID No. 372, SEQ ID No.

391, SEQ ID No. 399, SEQ ID No. 477, SEQ ID No. 486, SEQ ID No. 749, SEQ ID No. 758, SEQ ID No. 819, SEQ ID No. 878, SEQ ID No. 888, SEQ ID No. 896, SEQ ID No. 897, SEQ ID No. 900, SEQ ID No. 902, SEQ ID No. 923, SEQ ID No. 1015, SEQ ID No. 1018, SEQ ID No. 1059, SEQ ID No. 1060, SEQ ID No. 1069, SEQ ID No. 1071, SEQ ID No. 1073, SEQ ID No. 1076, SEQ ID No.

1189, and their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis cell wall anchored surface polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 662, SEQ ID No. 681, SEQ ID No. 1182, SEQ ID No. 1192, and their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments not found in Chlamydia pneumoniae (Blastp P>e' 0 and in that it is chosen from the polypeptides having the following sequences: SEQ ID No.2, SEQ ID No. 18, SEQ ID No. 60, SEQ ID No. 66, SEQ ID No. 67, SEQ ID No.68, SEQ ID No. 69, SEQ ID No. 70, SEQ ID No. 81, SEQ ID No. 89, SEQ ID No. 107, SEQ ID No.108, SEQ ID No. 109, SEQ ID No.134, SEQ ID No. 147, SEQ IDNo.191, SEQ ID No. 194, SEQ ID No. 216, SEQ ID No. 217, SEQ ID No. 218, SEQ ID No. 219, SEQ ID No. 220, SEQ ID No. 221, SEQ ID No. 222, SEQ ID No. 222, SEQ ID No. 223, SEQ ID No. 224, SEQ ID No. 225, SEQ ID No.

228, SEQ ID No. 235, SEQ ID No.257, SEQ ID No. 276, SEQ ID No. 277, SEQ ID No. 278, SEQ ID No. 279, SEQ ID No. 280, SEQ ID No. 281, SEQ ID No. 282, SEQ ID No.283, SEQ ID No. 284, SEQ ID No. 285, SEQ ID No. 289, SEQ ID No.291, SEQ ID No. 298, SEQ ID No. 284, SEQ ID No.

313, SEQ ID No. 314, SEQ ID No. 315, SEQ ID No. 316, SEQ ID No. 334, SEQ ID No. 335, SEQ ID No. 336, SEQ ID No. 337, SEQ ID No. 338, SEQ ID No. 339, SEQ ID No. 340, SEQ ID No. 381, SEQ ID No. 393, SEQ ID No. 413, SEQ ID No. 418, SEQ ID No. 419, SEQ ID No. 419, SEQ ID No.

420, SEQ ID No. 421, SEQ ID No. 422, SEQ ID No. 423, SEQ ID No. 436, SEQ ID No. 460, SEQ ID No. 475, SEQ ID No. 476, SEQ ID No. 480, SEQ ID No. 485, SEQ ID No. 487, SEQ ID No.491, SEQ ID No. 492, SEQ ID No. 493, SEQ ID No. 494, SEQ ID No. 496, SEQ ID No. 500, SEQ ID No.504, SEQ ID No. 514, SEQ ID No. 527, SEQ ID No. 559, SEQ ID No.569, SEQ ID No. 570, SEQ ID No.

575, SEQ ID No. 580, SEQ ID No. 582, SEQ ID No. 593, SEQ ID No. 598, SEQ ID No.632, SEQ ID No.640, SEQ ID No.651, SEQ ID No.671, SEQ ID No. 690, SEQ ID No. 694, ID No. 698, SEQ ID No. 710, SEQ ID No. 722, SEQ ID No. 723, SEQ ID No. 724, SEQ ID No. 770, SEQ ID No. 771, SEQ ID No.782, SEQ ID No. 783, SEQ ID No. 784, SEQ ID No. 790, SEQ ID No. 795, SEQ ID No.

798, SEQ ID No. 805, SEQ ID No. 810, SEQ ID No. 817, SEQ ID No. 829, SEQ ID No. 830, SEQ ID No. 864, SEQ ID No. 866, SEQ ID No. 876, SEQ ID No. 887, SEQ ID No. 892, SEQ ID No. 899, SEQ ID No. 913, SEQ ID No. 921, SEQ ID No. 933, SEQ ID No. 938, SEQ ID No. 949, SEQ ID No.

956, SEQ ID No. 1010, SEQ ID No. 1017, SEQ ID No. 1018, SEQ ID No. 1027, SEQ ID No. 1030, SEQ ID No. 1037, SEQ ID No. 1038, SEQ ID No. 1047, SEQ ID No. 1072, SEQ ID No. 1074, SEQ ID No. 1075, SEQ ID No. 1078, SEQ ID No. 1079, SEQ ID No. 1081, SEQ ID No. 1083, SEQ ID No.

1084, SEQ ID No. 1087, SEQ ID No. 1088, SEQ ID No. 1089, SEQ ID No. 1091, SEQ ID No. 1092, SEQ ID No. 1094, SEQ ID No. 1095, SEQ ID No. 1096, SEQ ID No. 1098, SEQ ID No. 1104, SEQ IDNo. 1105, SEQIDNo. 1106, SEQ IDNo. 1108, SEQIDNo. 1110, SEQ IDNo. 1114, SEQIDNo.

1115, SEQ ID No. 1116, SEQ ID No. 1117, SEQ ID No. 1119, SEQ ID No. 1128, SEQ ID No. 1132, SEQ ID No. 1133, SEQ ID No. 1135, SEQ ID No. 1136, SEQ ID No. 1139, SEQ ID No. 1140, SEQ ID No. 1141, SEQ ID No. 1142, SEQ ID No. 1144, SEQ IDNo. 1148, SEQ ID No. 1151,-SEQ ID No.

1155, SEQ ID No. 1157, SEQ ID No. 1159, SEQ ID No. 1161, SEQ ID No. 1162, SEQ ID No. 1165, SEQID No. 1166, SEQ ID No. 1167, SEQ ID No. 1168, SEQ ID No. 1169, SEQ ID No. 1171, SEQ ID No. 1172, SEQ ID No. 1173, SEQ ID No. 1174, SEQ ID No. 1175, SEQ ID No. 1176, SEQ ID No.

1177, SEQ ID No. 1178, SEQ ID No. 1180, SEQ ID No. 1181, SEQ ID No. 1183, SEQ ID No. 1184, SEQ ID No. 1186, SEQ ID No. 1187, SEQ ID No. 1188, SEQ ID No. 1192, SEQ ID No. 1194, SEQ ID No. 1197, and their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the intermediate metabolism, in particular in the metabolism of sugars and/or of cofactors, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 10; SEQ ID No. 44; SEQ ID No. 45; SEQ ID No. 46; SEQ ID No. 47; SEQ ID No. 93; SEQ ID No. 101; SEQ ID No. 120; SEQ ID No. 143; SEQ ID No. 160; SEQ ID No. 197; SEQ ID No. 236; SEQ ID No. 264; SEQ ID No. 359; SEQ ID No. 405; SEQ ID No. 417; SEQIDNo. 495; SEQ ID No. 566; SEQ ID No. 647; SEQ ID No. 673; SEQ ID No. 700; SEQ ID No. 836; SEQ ID No. 863; SEQ ID No. 102; SEQ ID No. 121; SEQ ID No. 144; SEQ ID No. 161; SEQ ID No, 198; SEQ ID No. 236; SEQ ID No. 265; SEQ ID No. 360; SEQ ID No. 410; SEQ ID No. 432; SEQ ID No. 513; SEQ ID No. 589; SEQ ID No. 652; SEQ ID No. 674; SEQ ID No. 725; SEQ ID No. 837; SEQ ID No. 869; SEQ ID No. 103; SEQ ID No. 130; SEQ ID No. 145; SEQ ID No. 192; SEQ ID No. 199; SEQ ID No. 239; SEQ ID No. 297; SEQ ID No. 374; SEQ ID No. 415; SEQ ID No. 460; SEQ ID No. 515; SEQ ID No. 613; SEQ ID No. 653; SEQ ID No. 682; SEQ ID No. 801; SEQ ID No. 860; SEQ ID No. 869; SEQ ID No. 106; SEQ ID No. 135; SEQ ID No. 158; SEQ ID No. 193; SEQ ID No. 227; SEQ ID No. 243; SEQ ID No. 331; SEQ ID No. 404; SEQ ID No. 415; SEQ ID No. 461; SEQ ID No. 566; SEQ ID No. 645; SEQ ID No. 654; SEQ ID No. 684; SEQ ID No. 802; SEQ ID No. 861; SEQ ID No. 925; SEQ ID No. 107; SEQ ID No. 140; SEQ ID No. 159; SEQ ID No. 196; SEQ ID No. 229; SEQ ID No. 245; SEQ ID No. 333; SEQ ID No. 405; SEQ ID No. 416; SEQ ID No. 462; SEQ ID No. 566; SEQ ID No. 646; SEQ ID No. 672; SEQ ID No. 692; SEQ ID No. 835; SEQ ID No. 862; SEQ ID No. 964; SEQ ID No. 983 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the intermediate metabolism of nucleotides or nucleic acids, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 142; SEQ ID No. 142; SEQ ID No. 169; SEQ ID No. 256; SEQ ID No. 268; SEQ ID No. 325; SEQ ID No. 352; SEQ ID No. 366; SEQ ID No. 435; SEQ ID No. 444; SEQ ID No. 528; SEQ ID No. 529; SEQ ID No. 530; SEQ ID No. 548; SEQ ID No. 549; SEQ ID No. 601; SEQ ID No. 602; SEQ ID No. 617; SEQ ID No. 619; SEQ ID No. 644; SEQ ID No. 745; SEQ ID No. 971; SEQ ID No. 972; SEQ ID No. 1023 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of nucleic acids, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 5; SEQ ID No. 12; SEQ ID No. 82; SEQ ID No. 96; SEQ ID No. 97; SEQ ID No. 98; SEQ ID No. 99; SEQ ID No. 137; SEQ ID No. 260; SEQ ID No. 302; SEQ ID No. 444; SEQ ID No. 599; SEQ ID No. 625; SEQ ID No. 703; SEQ ID No. 767; SEQ ID No. 794; SEQ ID No. 907; SEQ ID No. 962; SEQ ID No. 100; SEQ ID No. 163; SEQ ID No. 262; SEQ ID No. 387; SEQ ID No. 471; SEQ ID No. 600; SEQ ID No. 650; SEQ ID No. 704; SEQ ID No. 775; SEQ ID No. 841; SEQ ID No. 918; SEQ ID No. 962; SEQ ID No. 105; SEQ ID No. 190; SEQ ID No. 290; SEQ ID No. 427; SEQ ID No. 595; SEQ ID No. 605; SEQ ID No. 657; SEQ ID No. 708; SEQ ID No. 779; SEQ ID No. 842; SEQ ID No. 924; SEQ ID No. 963; SEQ ID No. 118; SEQ ID No. 204; SEQ ID No. 300; SEQ ID No. 434; SEQ ID No. 596; SEQ ID No. 612; SEQ ID No. 658; SEQ ID No. 719; SEQ ID No. 787; SEQ ID No. 883; SEQ ID No. 928; SEQ ID No. 969; SEQ ID No. 136; SEQ ID No. 259; SEQ ID No. 301; SEQ ID No. 441; SEQ ID No. 597; SEQ ID No. 624; SEQ ID No. 702; SEQ ID No. 766; SEQ ID No. 788; SEQ ID No. 884; SEQ ID No. 929; SEQ ID No. 970; SEQ ID No, 975; SEQ ID No. 979; SEQ ID No. 995; SEQ ID No. 1031; SEQ ID No. 1032 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of amino acids or polypeptides, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 27; SEQ ID No. 41; SEQ ID No. 55; SEQ ID No. 56; SEQ ID No. 57; SEQ ID No. 59; SEQ ID No. 62; SEQ ID No. 63; SEQ ID No. 64; SEQ ID No. 65; SEQ ID No. 119; SEQ ID No. 132; SEQ ID No. 240; SEQ ID No. 241; SEQ ID No. 277; SEQ ID No. 278; SEQ ID No. 279; SEQ ID No. 382; SEQ ID No. 406; SEQ ID No. 428; SEQ ID No. 442; SEQ ID No. 446; SEQ ID No. 447; SEQ ID No. 453; SEQ ID No. 454; SEQ ID No. 541; SEQ ID No. 542; SEQ ID No. 591; SEQ ID No. 608; SEQ ID No. 609; SEQ ID No. 610; SEQ ID No. 618; SEQ ID No. 648; SEQ ID No. 649; SEQ ID No. 660; SEQ ID No. 661; SEQ ID No. 677; SEQ ID No. 717; SEQ ID No. 765; SEQ ID No. 797; SEQ ID No. 871; SEQ TD No. 875; SEQ ID No. 920; SEQ ID No. 922; SEQ ID No. 937; SEQ ID No. 998; SEQ ID No. 1020; SEQ ID No. 1021; SEQ ID No. 1034; SEQ ID No, 1044; SEQ ID No. 1046; SEQ ID No. 1049 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of polypeptides, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 21; SEQ ID No. 22; SEQ ID No. 23; SEQ ID No. 24; SEQ ID No. 25; SEQ ID No. 26; SEQ ID No. 75; SEQ ID No. 84; SEQ ID No. 86; SEQ ID No. 92; SEQ ID No. 133; SEQ ID No. 151; SEQ ID No. 152; SEQ ID No. 157; SEQ ID No. 179; SEQ ID No. 209; SEQ ID No. 307; SEQ ID No. 326; SEQ ID No. 343; SEQ ID No. 344; SEQ ID No. 345; SEQ ID No. 371; SEQ ID No. 429; SEQ ID No. 519; SEQ ID No. 557; SEQ ID No. 586; SEQ ID No. 587; SEQ ID No. 630; SEQ ID No. 656; SEQ ID No. 706; SEQ ID No. 707; SEQ ID No; 730; SEQ ID No. 751; SEQ ID No. 752; SEQ ID No. 786; SEQ ID No. 847; SEQ ID No. 885; SEQ ID No. 923; SEQ ID No. 978; SEQ ID No. 1039; SEQ ID No. 1048 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the metabolism of fatty acids, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 4; SEQ ID No. 15; SEQ ID No. 16; SEQ ID No. 141; SEQ ID No. 173; SEQ ID No. 205; SEQ ID No. 205; SEQ ID No. 206; SEQ ID No. 207; SEQ ID No. 208; SEQ ID No. 312; SEQ ID No. 355; SEQ ID No. 415; SEQ ID No. 550; SEQ ID No. 558; SEQ ID No. 560; SEQ ID No. 561; SEQ ID No. 574; SEQ ID No. 574; SEQ ID No. 577; SEQ ID No. 578; SEQ ID No. 590; SEQ ID No. 614; SEQ ID No. 772; SEQ ID No. 808; SEQ ID No. 809; SEQ ID No. 904; SEQ ID No. 905; SEQ ID No. 905; SEQ ID No. 933; SEQ ID No. 934; SEQ ID No. 934; SEQ ID No. 936 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the synthesis of the wall, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 87; SEQ ID No. 196; SEQ ID No. 242; SEQ ID No. 269; SEQ ID No. 628; SEQ ID No. 629; SEQ ID No. 634; SEQ ID No. 635; SEQ ID No. 637; SEQ ID No. 638; SEQ ID No. 1019 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the transcription, translation and/or maturation process, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 112; SEQ ID No. 113; SEQ ID No. 332; SEQ ID No. 212; SEQ ID No. 213; SEQ ID No. 350; SEQ ID No. 362; SEQ ID No. 363; SEQ ID No. 364; SEQ ID No. 407; SEQ ID No. 451; SEQ ID No. 546; SEQ ID No. 643; SEQ ID No. 744; SEQ ID No. 746; SEQIDNo. 833; SEQ ID No. 868; SEQ ID No. 981; SEQ ID No. 982; SEQ ID No. 1003; SEQ ID No. 1011; SEQ ID No. 1042 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis ribosomal polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQIDNo. 114; SEQ IDNo. 115; SEQ ID No. 116; SEQ IDNo. 328; SEQ IDNo. 361; SEQ ID No. 375; SEQ ID No. 445; SEQ ID No. 543; SEQ ID No. 584; SEQ ID No. 585; SEQ ID No. 743; SEQ ID No. 813; SEQ ID No, 941; SEQ ID No. 942; SEQ ID No. 944; SEQ ID No. 946; SEQ ID No. 947; SEQ ID No. 948; SEQ ID No. 950; SEQ ID No. 951; SEQ ID No. 952; SEQ ID No. 953; SEQ ID No. 954; SEQ ID No. 955; SEQ ID No. 955; SEQ ID No. 957; SEQ ID No. 958; SEQ ID No. 960; SEQ ID No. 961; SEQ ID No. 1040; SEQIDNo. 1041; SEQ IDNo. 1043; SEQIDNo. 1063; SEQIDNo. 1064 and one of their fragments.

Preferably, the invention also relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis transport polypeptide or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 6; SEQ ID No. 50; SEQ ID No. 51; SEQ ID No. 80; SEQ ID No. 125; SEQ ID No. 126; SEQ ID No. 128; SEQ ID No. 129; SEQ ID No. 215; SEQ ID No. 246; SEQ ID No. 248; SEQ ID No. 249; SEQ ID No. 251; SEQ ID No. 252; SEQ ID No. 253; SEQ ID No. 255; SEQ ID No. 271; SEQ ID No. 275; SEQ ID No. 293; SEQ ID No. 309; SEQ ID No. 323; SEQ ID No. 324; SEQ ID No. 398; SEQ ID No. 401; SEQ ID No. 449; SEQ ID No. 511; SEQ ID No. 512; SEQ ID No. 564; SEQ ID No. 565; SEQ ID No. 667; SEQ ID No. 679; SEQ ID No. 680; SEQ ID No. 711; SEQ ID No. 712; SEQ ID No. 713; SEQ ID No. 714; SEQ ID No. 715; SEQ ID No. 730; SEQ ID No. 731; SEQ ID No. 736; SEQ ID No. 737; SEQ ID No. 738; SEQ ID No. 870; SEQ ID No. 908; SEQ ID No. 919; SEQ ID No. 977; SEQ ID No. 987; SEQ ID No. 988; SEQ ID No. 992; SEQ ID No. 993; SEQ ID No. 994; SEQ ID No. 1028; SEQ ID No. 1029 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the virulence process, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 20; SEQ ID No. 815; SEQ ID No. 816; SEQ ID No. 898; SEQ ID No. 1059; SEQ ID No. 1060 and one of their representative fragments.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a Chlamydia trachomatis polypeptide or one of its representative fragments which is involved in the secretory system and/or which is secreted, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 758; SEQ ID No. 888; SEQ ID No. 889; SEQ ID No. 890; SEQ ID No. 891; SEQ ID No. 896; SEQ ID No. 897; SEQ ID No. 898 and one of their representative fragments.

The secreted polypeptides, including the Type III and other, non-Type III secreted polypeptides, of the present invention, as well as the corresponding nucleotide sequences, may be detected by techniques known to persons skilled in the art, such as for example the techniques using cloning combined with vectors allowing the expression of the said polypeptides fused to export markers such as the luc gene for luciferase or the PhoA gene for alkaline phosphatase.

Preferably, the invention relates to a polypeptide according to the invention, characterized in that it is a polypeptide specific to Chlamydiae or one of its representative fragments, and in that it is chosen from the polypeptides having the following sequences: SEQ ID No. 22; SEQ ID No. 29; SEQ ID No. 31; SEQ ID No. 32; SEQ ID No. 34; SEQ ID No. SEQ ID No. 39; SEQ ID No. 40; SEQ ID No. 43; SEQ ID No. 48; SEQ ID No. 49; SEQ ID No. SEQ ID No. 52; SEQ ID No. 53; SEQ ID No. 54; SEQ ID No. 72; SEQ ID No. 77; SEQ ID No. 78; SEQ ID No. 87; SEQ ID No. 111; SEQ ID No. 138; SEQ ID No. 164; SEQ ID No. 186; SEQ ID No. 247; SEQ ID No. 273; SEQ ID No. 306; SEQ ID No. 326; SEQ ID No. 380; SEQIDNo. 433; SEQ ID No. 90; SEQ ID No. 122; SEQ ID No. 144; SEQ ID No. 166; SEQ ID No. 187; SEQ ID No. 258; SEQ ID No. 274; SEQ ID No. 309; SEQ ID No. 342; SEQ ID No. 388; SEQ ID No. 438; SEQ ID No. 95; SEQ ID No. 123; SEQ ID No. 146; SEQ ID No. 175; SEQ ID No. 188; SEQ ID No. 266; SEQ ID No. 295; SEQ ID No. 318; SEQ ID No. 357; SEQ ID No. 390; SEQ ID No. 443; SEQ ID No. 108; SEQ ID No. 124; SEQ ID No. 153; SEQ ID No. 182; SEQ ID No. 202; SEQ ID No. 267; SEQ ID No. 296; SEQ ID No. 319; SEQ ID No. 376; SEQ ID No. 400; SEQ ID No. 456; SEQ ID No. 110; SEQ ID No. 127; SEQ ID No. 155; SEQ ID No. 184; SEQ ID No. 210; SEQ ID No. 270; SEQ ID No. 305; SEQ ID No. 322; SEQ ID No. 379; SEQ ID No. 431; SEQ ID No. 457; SEQ ID No. 458; SEQ ID No. 486; SEQ ID No. 504; SEQ ID No. 523; SEQ ID No. 537; SEQ ID No. 563; SEQ ID No. 604; SEQ ID No. 622; SEQ ID No. 670; SEQ ID No. 703; SEQ ID No. 739; SEQ ID No. 755; SEQID No. 763; SEQ ID No, 789; SEQ ID No. 820; SEQ ID No. 828; SEQ ID No. 852; SEQ ID No. 859; SEQ ID No. 865; SEQ ID No. 872; SEQ ID No. 878; SEQ ID No. 893; SEQ ID No. 915; SEQ ID No. 933; SEQ ID No. 986; SEQ ID No. 1001; SEQ ID No. 1033; SEQ ID No. 1054; SEQ ID No. 464; SEQ ID No. 489; SEQ ID No. 508; SEQ ID No. 524; SEQ ID No. 538; SEQ ID No. 572; SEQ ID No. 606; SEQ ID No. 641; SEQ ID No. 693; SEQ ID No. 704; SEQ ID No. 742; SEQ ID No. 757; SEQ ID No. 764; SEQ ID No. 800; SEQ ID No. 822; SEQ ID No. 839; SEQ ID No. 855; SEQ ID No. 860; SEQ ID No. 868; SEQ ID No. 873; SEQ ID No. 880; SEQ ID No. 901; SEQ ID No. 916; SEQ ID No. 965; SEQ ID No. 989; SEQ ID No. 1002; SEQ ID No. 1035; SEQ ID No. 1056; SEQ ID No. 468; SEQ ID No. 497; SEQ ID No. 512; SEQ ID No. 533; SEQ ID No. 539; SEQ ID No. 579; SEQ ID No. 607; SEQ ID No. 642; SEQ ID No. 695; SEQ ID No. 716; SEQ ED No. 747; SEQ ID No. 759; SEQ ID No. 773; SEQ ID No. 803; SEQ ID No. 823; SEQ ID No. 849; SEQ ID No. 856; SEQ ID No. 861; SEQ ID No. 869; SEQ ID No. 874; SEQ ID No. 882; SEQ ID No. 906; SEQ ID No. 917; SEQ ID No. 967; SEQ ID No. 990; SEQ ID No. 1013; SEQ ID No. 1049; SEQ ID No. 1057; SEQ ID No. 470; SEQ ID No. 501; SEQ ID No. 521; SEQ ID No. 535; SEQ ID No. 540; SEQ ID No. 595; SEQ ID No. 615; SEQ ID No. 659; SEQ ID No. 696; SEQ ID No. 726; SEQ ID No. 750; SEQ ID No. 761; SEQ ID No. 780; SEQ ID No. 804; SEQ ED No. 824; SEQ ID No. 850; SEQ ID No. 857; SEQ ID No. 862; SEQ ID No. 870; SEQ ID No. 875; SEQ ID No. 884; SEQ ID No. 910; SEQ ID No. 926; SEQ ID No. 968; SEQ ID No. 996; SEQ ID No. 1016; SEQ ID No. 1051; SEQ ID No. 1058; SEQ ID No. 473; SEQ ID No. 503; SEQTD No. 522; SEQ ID No. 536; SEQ ID No. 554; SEQ ID No. 603; SEQ ID No. 616; SEQ ID No. 668; SEQ ID No. 699; SEQ ID No. 728; SEQ ID No. 751; SEQ ID No. 762; SEQ ED No. 781; SEQ ED No. 818; SEQ ED No. 827; SEQ ID No. 851; SEQ ID No. 858; SEQ ID No. 863; SEQ ID No. 871; SEQ ID No. 877; SEQ ID No. 886; SEQ ID No. 912; SEQ ID No. 929; SEQ ID No. 984; SEQ ID No. 997; SEQ ID No. 1031; SEQ ID No. 1052; SEQ ID No. 1062; SEQ ID No. 1070; SEQ ID No. 1071; SEQ ID No. 1073 and one of their representative fragments.

In general, in the present invention, the functional group to which a polypeptide of the invention belongs, as well as its corresponding nucleotide sequence, may be determined either by comparative analogy with sequences already known, or by the use of standard techniques of biochemistry, of cytology combined with the techniques of genetic engineering such as immunoaffinity, localization by immunolabelling. differential extraction, measurement of enzymatic activity, study of the activity inducing or repressing expression or the study of expression in E. coli.

It is clearly understood, on the one hand, that, in the present invention, the nucleotide sequences (ORF) and the amino acid sequences (SEQ ID No. 2 to SEQ ID No. 1197 which are listed by functional group, are not exhaustive within the group considered. Moreover, it is'also clearly understood that, in the present invention, a nucleotide sequence (ORF) or an amino acid sequence mentioned within a given functional group may also be part of another group taking into account, for example, the interrelationship between the groups listed. Accordingly, and as an example of this interrelationship, an exported and/or secreted polypeptide as well as its coding nucleotide sequence may also be involved in the Chlamydia trachomatis virulence process by modifying the defense mechanism of the infected host cell, or a transmembrane polypeptide or its coding nucleotide sequence is also part of the polypeptides or coding nucleotide sequences of the cellular envelope.

The subject of the present invention is also the nucleotide and/or polypeptide sequences according to the invention, characterized in that the said sequences are recorded on a medium, called recording medium, whose type and nature facilitate the reading, the analysis and the exploitation of the said sequences. These media may of course also contain other information extracted from the present invention, such as in particular the analogies with already known sequences, such as those mentioned in Table 1 of the present description, and/or may contain, in addition, information relating to the nucleotide and/or polypeptide sequences of other microorganisms so as to facilitate the comparative analysis and the exploitation of the results obtained.

Among these recording media, computer-readable media, such as magnetic, optical, electrical and hybrid media such as, for example, floppy disks, CD-ROMs or recording cassettes, are preferred in particular.

The invention also relates to nucleotide sequences which can be used as primer or probe, characterized in that the said sequences are chosen from the nucleotide sequences according to the invention.

The invention relates, in addition, to the use of a nucleotide sequence according to the invention, as primer or probe, for the detection and/or amplification of nucleic acid sequences.

The nucleotide sequences according to the invention may thus be used to amplify nucIeotide sequences, in particular by the PCR technique (polymerase chain reaction) (Erlich, 1989; Innis et al., 1990; Rolfs et al., 1991, and White et al., 1997).

These oligodeoxyribonucleotide or oligoribonucleotide primers correspond to representative nucleotide fragments, and are advantageously at least 8 nucleotides, preferably at least 12 nucleotides, 15 nucleotides and still more preferably at least 20 nucleotides long.

Other techniques for amplifying the target nucleic acid may be advantageously used as alternatives to PCR.

The nucleotide sequences of the invention, in particular the primers according to the invention, may also be used in other methods for amplifying a target nucleic acid, such as: the TAS (Transcription-based Amplification System) technique described by Kwoh et al. in 1989; the 3SR (Self-Sustained Sequence Replication) technique described by Guatelli et al. in 1990; the NASBA (Nucleic Acid Sequence Based Amplification) technique described by Kievitis etal. in 1991; the SDA (Strand Displacement Amplification) technique (Walker et aI., 1992); the TMA (Transcription Mediated Amplification) technique.

The polynucleotides of the invention may also be used in techniques for amplifying or for modifying the nucleic acid serving as probe, such as: the LCR (Ligase Chain Reaction) technique described by Landegren et al. in 1988 and perfected by Barany et al. in 1991, which uses a thermostable ligase; the RCR (Repair Chain Reaction) technique described by Segev in 1992; the CPR (Cycling Probe Reaction) technique described by Duck et al. in 1990; the Q-beta-replicase amplification technique described by Miele et al. in 1983 and perfected in particular by Chu et al. in 1986, Lizardi et al. in 1988, and then by Burg et al. as well as by Stone et al. in 1996.

The invention also relates to the nucleotide sequences of fragments which can be obtained by amplification with the aid of at least one primer according to the invention. The present invention encompasses both hybridization probes and primers. In general, the complementary probes should be of the length sufficient to form a stable hybrid complex with the target sequences. Primers, while complementary to the target sequences need not form stable hybridization complexes with the target sequences alone. Rather, primers form stable complexes with the target sequences in the presence of polymerase to permit extension of the primer.

In the case where the target polynucleotide to be detected is possibly an RNA, for example an mRNA, it will be possible to use, prior to the use of an amplification reaction with the aid of at least one primer according to the invention or to the use of a method of detection with the aid of at least one probe of the invention, a reverse transcriptase-type enzyme so as to obtain a cDNA from the RNA contained in the biological sample. The cDNA obtained will then serve as target for the primer(s) or the probe(s) used in the amplification or detection method according to the invention.

The detection probe will be chosen so that it hybridizes with the target sequence or the amplicon generated from the target sequence. Such a detection probe will advantageously have as sequence a sequence of at least 12 nucleotides, 15 nucleotides, in particular of at least 20 nucleotides, and preferably at least 100 nucleotides.

The invention also comprises the nucleotide sequences which can be used as probe or primer according to the invention, characterized in that they are labelled with a radioactive compounc or with a nonradioactive compound.

The nonlabelled nucleotide sequences may be used directly as probes or primers: however, the sequences are generally labelled with a radioactive element (32p, 3S, 3.H, 1 2 or with a nonradioactive molecule (biotin, acetylaminofluorene, digoxigenin, fluorescein) so as to obtain probes which can be used in numerous applications.

Examples of nonradioactive labelling of nucleotide sequences are described, foi example, in French patent No. 78,10975 or by Urdea et al. or by Sanchez-Pescador et al. in 1988.

In the latter case, one of the labelling methods described in patents FR-2 422 956 and FR-2 518 755 may also be used.

The invention also relates to the nucleotide sequences of fragments which can be obtained by hybridization with the aid of at least one probe according to the invention.

The hybridization technique may be performed in various ways (Matthews et al., 1988). The most common method consists in immobilizing the nucleic acid extracted from C trachomatis cells on a support (such as nitrocellulose, nylon, polystyrene) and in incubating, under well-defined conditions, the target nucleic acid immobilized with the probe. After hybridization, the excess probe is removed and the hybrid molecules formed are detected by the appropriate method (measurement of the radioactivity, of the fluorescence or of the enzymatic activity linked to the probe).

The invention also comprises the nucleotide sequences according to the invention, characterized in that they are covalently or noncovalently immobilized on a support.

According to another advantageous embodiment of the nucleic sequences according to the invention, the latter may be used immobilized on a support and may thus serve to capture, through specific hybridization, the target nucleic acid obtained from the biological sample to be tested. If necessary, the solid support is separated from the sample and the hybridization complex formed between the so-called capture probe and the target nucleic acid is then detected by means of a second probe, called detection probe, labelled with an easily detectable element.

The nucleotide sequences according to the invention may also be used in new analytical systems, DNA chips, which allow sequencing, the study of mutations and of the expression of genes, and which are currently of interest given their very small size and their high capacity in terms of number of analyses.

The principle of the operation of these chips is based on molecular probes, most often oligonucleotides, which are attached onto a miniaturized surface, generally of the order of a few square centimetres. During an analysis, a sample containing fragments of a target nucleic acid to be analysed, for example DNA or RNA labelled, for example, after amplification, is deposited onto the DNA chip in which the support has been coated beforehand with probes. Bringing the labelled target sequences into contact with the probes leads to the formation, through hybridization, of a duplex according to the rule of pairing defined by J.D. Watson and F. Crick. After a washing step, analysis of the surface of the chip allows the effective hybridizations to be located by means of the signals emitted by the labels tagging the target. A hybridization fingerprint results from this analysis which, by appropriate computer processing, will make it possible to determine information such as the presence of specific fragments in the sample, the determination of sequences and the presence of mutations.

The chip consists of a multitude of molecular probes, precisely organized or arrayed [0 on a solid support whose surface is miniaturized. It is at the centre of a system where other elements (imaging system, microcomputer) allow the acquisition and interpretation of a hybridization fingerprint.

The hybridization supports are provided in the form of flat or porous surfaces (pierced with wells) composed of various materials. The choice of a support is determined by its physicochemical properties, or more precisely, by the relationship between the latter and the conditions under which the support will be placed during the synthesis or the attachment of the probes or during the use of the chip. It is therefore necessary, before considering the use of a particular support Matson et al., 1994), to consider characteristics such as its stability to pH, its physical strength, its reactivity and its chemical stability as well as its capacity to nonspecifically bind nucleic acids. Materials such as glass, silicon and polymers are commonly used. Their surface is, in a first step, called <functionalization>, made reactive towards the groups which it is desired to attach thereon. After the functionalization, so-called spacer molecules are grafted onto the activated surface.

Used as intermediates between the surface and the probe, these molecules of variable size render unimportant the surface properties of the supports, which often prove to be problematic for the synthesis or the attachment of the probes and for the hybridization.

Among the hybridization supports, there may be mentioned glass which is used, for example, in the method of in situ synthesis of oligonucleotides by photochemical addressing developed by the company Affymetrix Sheldon, 1993), the glass surface being activated by silane. Genosensor Consortium Merel, 1994) also uses glass slides carrying wells 3 mm apart, this support being activated with epoxysilane.

Polymers or silicon may also be mentioned among these hybridization supports. For example, the Andrein Mirzabekov team has developed a chip consisting of polyacrylamide squares polymerized on a silanized glass surface Yershov et al., 1996). Several teams use silicon, in particular the IFOS laboratory of Ecole Centrale of Lyon which uses a silicon semiconductor substrate which is p-doped by introducing it into its crystalline structure atoms whose valency is different from that of silicon. Various types of metals, in particular gold and platinum, may also be used as support (Genosensor Consortium Beattie et al., 1993)).

The probes according to the invention may be synthesized directly in-situ on the supports of the DNA chips. This in situ synthesis may be carried out by photochemical addressing (developed by the company Affymax (Amsterdam, Holland) and exploited industrially by its subsidiary Affymetrix (United States)) or based on the VLSIPS (very large scale immobilized polymer synthesis) technology Fodor etal., 1991) which is based on a method of photochemically directed combinatory synthesis and the principle of which combines solid-phase chemistry, the use of photolabile protecting groups and photolithography.

The probes according to the invention may be attached to the DNA chips in various ways such as electrochemical addressing, automated addressing or the use of probe printers Livache et al., 1994; G. Yershov et al., 1996; J. Derisi et al,, 1996, and S. Borman, 1996).

The revealing of the hybridization between the probes of the invention, deposited or synthesized in situ on the supports of the DNA chips, and the sample to be analysed, may be determined, for example, by measurement of fluorescent signals, by radioactive counting or by electronic detection.

The use of fluorescent molecules such as fluorescein constitutes the most common method of labelling the samples. It allows direct or indirect revealing of the hybridization and allows the use of various fluorochromes.

Affymetrix currently provides an apparatus or a scanner designed to read its Gene Chip? chips. It makes it possible to detect the hybridizations by scanning the surface of the chip in confocal microscopy Lipshutz et al., 1995). Other methods of detecting fluorescent signals have been tested: coupling of an epifluorescence microscope and a CCD camera Yershov et al., 1996), the use of an optical fibre collecting system Sheldon, 1993). A conventional method consists in carrying out an end labelling, with phosphorus 32, of the target sequences, by means of an appropriate apparatus, the Phosphorimager (marketed by Molecular Dynamics). The electronic detection is based on the principle that the hybridization of two nucleic acid molecules is accompanied by physical phenomena which can be quantified under certain conditions (system developed by Ecole Centrale of Lyon and called GEN-FET (GEN field effect transistor)). Genosensor Consortium and the company Beckman Instruments who are developing an electronic chip or Permittivity Chips? may also be mentioned Beattie et al., 1993).

The nucleotide sequences according to the invention may thus be used in DNA chips to carry out the analysis of mutations. This analysis is based on the production of chips capable of analysing each base of a nucleotide sequence according to the invention. It is possible, in particular to this end, to use the microsequencing techniques on a DNA chip. The mutations are detected by extending immobilized primers which hybridize to the template of sequences analysed, just at the position adjacent to that of the mutated nucleotide to be detected. A single-stranded template, RNA or DNA, of the sequences to be analysed will be advantageously prepared according to eonventional methods, from products amplified according to PCR-rype techniques. The templates of singlestranded DNA, or of RNA thus obtained are then deposited on the DNA chip, under conditions allowing their specific hybridization to the immobilized primers. A thermnostable polymerase, for example Tth or T7 DNA polymerase, specifically extends the 3' end of the immobilized primer with a labelled nucleotide analogue complementary to the nucleotide at the position of the variable site, For example a thermal cycling is performed in the presence of fluorescent di deoxyribonucleoti des.

The experimental conditions will be adapted in particular to the chips used, to the immobilized primers, to the polymerases used and to the labelling system chosen. One advantage of microsequencing, compared with techniques based on the hybridization of probes, is that it makes it possible to identify all the variable nucleotides with optimal discrimination under homogeneous reaction conditions; used on DNA chips, it allows optimal resolution and specificity for the routine and industrial detection of mutations in multiplex.

The nucleotide sequences according to the invention may also be used in DNA chips to carry out the analysis of the expression of the Chiamydia trachomatis genes. This analysis of the expression of Chiamydia trachomaz'is genes is based on the use of chips where probes of the invention, chosen for their specificity to characterize a given gene, are present Lockhart et al., 1996; D.D. Shoemaker et al., 1996). For the methods of analysis of gene expression using the DNA chips, reference may, for example, be made to the methods described by D.J. Lockhart et al. (1996) and Sosnowsky et (1997) for the synthesis of probes in situ or for the addressing and the attachment of previously synthesized probes. The target sequences to be analysed are labelled and in general fragmented into sequences of about 50 to 100 nucleotides before being hybridized onto the chip. After washing as described, for example, by DI. Lockhart et al. (1996) and application of different electric fields (Sosnowsky et 1997), the labelled compounds are detected and quantified, the hybridizations being carried out at least in duplicate. Comparative analyses of the signal intensities obtained with respect to the same probe for different samples and/or for different probes with the same sample, determine the differential expression of RNA or of DNA derived from the sample.

The nucleotide sequences according to the invention may, in addition, be used in DNA chips where other nucleotide probes specific for other microorganisms are also present, and may allow the carrying out of a serial test allowing rapid identification of the presence of a microorganism in a sample.

Accordingly, the subject of the invention is also the nucleotide sequences according to the invention, characterized in that they are immobilized on a support of a DNA chip.

The DNA chips, characterized in that they contain at least one nucleotide sequence according to the invention, immobilized on the support of the said chip, also form- part of the invention.

The said chips will preferably contain several probes or nucleotide sequences of the invention of different length and/or corresponding to different genes so as to identify, with greater certainty, the specificity of the target sequences or the desired mutation in the sample to be analysed.

Accordingly, the analyses carried out by means of primers and/or probes according to the invention, immobilized on supports such as DNA chips, will make it possible, for example, to identify, in samples, mutations linked to variations such as intraspecies variations. These variations may be correlated or associated with pathologies specific to the variant identified and will make it possible to select the appropriate treatment.

The invention thus comprises a DNA chip according to the invention, characterized in that it contains, in addition, at least one nucleotide sequence of a microorganism different from Chlamydia trachomatis, immobilized on the support of the said chip; preferably, the different microorganism will be chosen from an associated microorganism, a bacterium of the Chlamydia family, and a variant of the species Chlamydia trachomatis.

Another subject of the present invention is a vector for the cloning and/or the expression of a sequence, characterized in that it contains a nucleotide sequence according to the invention.

Among the said vectors according to the invention, the vectors containing a nucleotide sequence encoding a polypeptide of the cellular, preferably outer, envelope of Chlamydia trachomatis or one of its representative fragments, are preferred.

In a specific embodiment, the vectors contain a nucleotide sequence encoding a Chlamydia trachomatis secreted polypeptide or one of its representative fragments or encoding a transport polypeptide, a surface exposed polypeptide, a lipoprotein or one of its representative fragments, a polypeptide involved in lipopolysaccharide (LPS) biosynthesis, a Type I or non-Type III secreted polypeptide, a polypeptide containing RGD attachment sites, a cell wall anchored surface polypeptide, a polypeptide not found in Chlamydia pneumoniae, a ribosomal polypeptide or a polypeptide involved in secretion, transcription, translation, maturation of proteins, a polypeptide involved in the synthesis of the wall, a polypeptide involved in the virulence, a polypeptide involved in the intermediate metabolism, in particular in the metabolism of sugars and/or of cofactors, a polypeptide involved in the metabolism of nucleotides, of amino acids, of nucleic acids or of fatty acids of Chlamydia trachomatis or one of their representative fragments, or a polypeptide specific to Chlamydiae, are also preferred.

According to the invention, the vectors comprise the elements necessary to allow the expression and/or the secretion of the said nucleotide sequences in a given host cell, and also form part of the invention.

The vector should, in this case, comprise a promoter, signals for initiation and for termination of translation, as well as appropriate regions for regulation of transcription. It should be capable of being stably maintained in the host cell and may optionally possess particular signals specifying the secretion of the translated protein. These different elements are chosen according to the host cell used. To this effect, the nucleotide sequences according to the invention may be inserted into autonomously-replicating vectors within the chosen host, or integrative vectors in the chosen host.

Any of the standard methods known to those skilled in the art for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination).

Expression of a polypeptide, peptide or derivative, or analogs thereof encoded by a polynucleotide sequence in SEQ ID No. 1 or ORFs contained within SEQ ID No. 1 may be regulated by a second nucleic acid sequence so that the protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a protein or peptide may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control expression include, but are not limited to, the CMV promoter, the SV40 early promoter region (Bemoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the P-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A.

75:3727-3731), or the tac promoter (DeBoer, er al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; plant expression vectors comprising the nopaline synthetase promoter region (Herrera-Estrella et al., 1983, Nature 303:209-213) or the cauliflower mosaic virus 35S RNA promoter (Gardner, et al., 1981, Nucl.

Acids Res. 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 2:425- 515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol.

Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al,, 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al,, 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

The vectors according to the invention are, for example, vectors of plasmid or viral origin. In a specific embodiment, a vector is used that comprises a promoter operably linked to a protein or peptide-encoding nucleic acid sequence in SEQ ID No. 1, or ORFs contained within SEQ ID No. 1, one or more origins of replication, and, optionally, one or more selectable markers an antibiotic resistance gene). Expression vectors comprise regulatory sequences that control gene expression, including gene expression in a desired host cell. Preferred vectors for the expression of the polypeptides of the invention include the pET-type plasmid vectors (Promega) or pBAD plasmid vectors (Invitrogen). Furthermore, the vectors according to the invention are useful for transforming host cells so as to clone or express the nucleotide sequences of the invention.

Expression can also be achieved using targeted homologous recombination to activate Chlamydia trachomatis genes present in the cloned genomic DNA. A heterologous regulatory element may be inserted into a stable cell line or cloned microorganism, such that it is operatively linked with an endogenous Chlamydia trachomatis gene present in the cloned genome, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art (See, eg., Chappel, U.S. Patent No. 4,215,051 and Skoultchi, WO 91/06667 each of which is incorporated herein in its entirety).

Expression vector/host cell systems containing inserts of polynucleotide sequences in SEQ ID No. I or ORFs within SEQ ID No. 1, which encode polypeptides, peptides or derivatives, or analogs thereof, can be identified by three general approaches: nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and expression of inserted sequences. In the first approach, the presence of a polynucleotide sequence inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted polynucleotide sequence. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a polynucleotide sequence in the vector. For example, if the polynucleotide sequence in SEQ ID No. 1 or ORFs within SEQ ID No. 1 is inserted within the marker gene sequence of the vector, recombinants containing the insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product of the polynucleotide sequence expressed by the recombinant.

Such assays can be based, for example, on the physical or functional properties of the expressed polypeptide in in vitro assay systems, binding with antibody, promotion of cell proliferation.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. The clones identified may be introduced into an appropriate host cell by standard methods, such as for example lipofection, electroporation, and heat shock. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity.

The invention also encompasses the host cells transformed by a vector according to the invention. These cells may be obtained by introducing into host cells a nucleotide sequence inserted into a vector as defined above, and then culturing the said cells under conditions allowing the replication and/or the expression of the transfected nucleotide sequence.

The host cell may be chosen from eukaryotic or prokaryotic systems, such as for example bacterial cells (Olins and Lee, 1993), but also yeast cells (Buckholz, 1993), as well as animal cells, in particular cultures of mammalian cells (Edwards and Aruffo, 1993), and in particular Chinese hamster ovary (CHO) cells, but also insect cells in which methods using baculoviruses for example may be used (Luckow, 1993).

Furthermore, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired.

Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered polypeptide may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification glycosylation, phosphorylation) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

A preferred host cell for the expression of the proteins of the inventioh consists of prokaryotic cells, such as Gram negative bacteria.

A further preferred host cell according to the invention is a bacterium belonging to the Chlamydia family, more preferably belonging to the species Chlamydia trachomatis or chosen from a microorganism associated with the species Chlamydia trachomatis, In other specific embodiments, the polypeptides, peptides or derivatives, or analogs thereof may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

Alternatively, such a chimeric product may be made by protein synthetic techniques, by use of a peptide synthesizer.

Genomic sequences can be cloned and expressed as translational gene products peptides, polypeptides, and proteins) or transcriptional gene products antisense and ribozymes).

The invention further relates to the intracellular production of an antisense nucleic acid sequence of SEQ ID No. 1 by transcription from an exogenous sequence. For example, a vector can be introduced in vivo such that it is taken up by a cell, within which cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding an antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art.

Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the CMV promoter, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3 N long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), etc.

In a specific embodiment, the antisense oligonucleotide comprises catalytic RNA, or a ribozyme (see, PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al., 1990, Science 247:1222-1225). In another embodiment, the oligonucleotide is a methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analog (Inoue et al., 1987, FEBS Lett. 215:327-330).

In another embodiment, the antisense nucleic acids of the invention -comprise a sequence complementary to at least a portion of an RNA transcript of a polynucleotide sequence in SEQ ID No. 1. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acid sequence, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA transcribed from SEQ ID No. I may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

15 The invention also relates to the animals, except humans, comprising one of the above-described transformed cells according to the invention.

The production of transgenic animals according to the invention overexpressing one or more of the Chlamydia trachomatis genes will be preferably carried out on rats, mice or rabbits according to methods well known to persons skilled in the art such as viral or nonviral transfections.

The transgenic animals overexpressing one or more of the said genes may be obtained by transfection of multiple copies of the said genes under the control of a powerful promoter of a ubiquitous nature, or which is selective for one type of tissue. The transgenic animals may also be obtained by homologous recombination on embryonic stem cells, transfer of these stem cells to embryos, selection of the chimeras affected at the level of the reproductive lines, and growth of the said chimeras.

The transformed cells as well as the transgenic animals according to the invention can be used in methods of preparing the recombinant polypeptide.

It is now possible to produce recombinant polypeptides in a relatively large quantity by genetic engineering using the cells transformed with expression vectors according to the invention or using transgenic animals according to the invention.

The methods of preparing a polypeptide of the invention in recombinant form, characterized in that they use a vector and/or a cell transformed with a vector according to the invention and/or a transgenic animal comprising one of the said transformed cells according to the invention, are themselves included in the present invention.

Among the said methods of preparing a polypeptide of the invention in recombinant form, the methods of preparation using a vector, and/or a cell transformed with the said vector and/or a transgenic animal comprising one of the said transformed cells, containing a nucleotide sequence encoding a polypeptide of the cellular envelope of Chlamydia trachomatis or one of its representative fragments, more preferably encoding a polypeptide of the outer cellular envelope of Chlamydia trachomatis or one of its fragment, are preferred.

Among the said methods of preparing a polypeptide of the invention in recombinant form, the methods of preparation using a vector, and/or a cell transformed with the said vector and/or a transgenic animal comprising one of the said transformed cells, containing a nucleotide sequence encoding a Chlamydia trachomatis secreted polypeptide or one of its representative fragments, or encoding a transport polypeptide, a surface exposed polypeptide, a lipoprotein or one of its representative fragments, a polypeptide involved in lipopolysaccharide biosynthesis, a Type II or other secreted polypeptide, a polypeptide containing RGD attachment sites, a cell wall anchored surface polypeptide, a polypeptide not found in Chlamydia pneumoniae, a ribosomal polypeptide or a polypeptide involved in secretion, transcription, translation, maturation of proteins, a polypeptide involved in the synthesis of the wall, a polypeptide involved in the virulence, a polypeptide involved in the intermediate metabolism, in particular in the metabolism of sugars and/or of cofactors, a polypeptide involved in the metabolism of nucleotides, of amino acids, of nucleic acids or of fatty acids of Chlamydia trachomatis or one of their representative fragments, or a polypeptide specific to Chlamydiae, are also preferred.

The recombinant polypeptides obtained as indicated above may be provided either in glycosylated or nonglycosylated form and may or may not have the natural tertiary structure.

A preferred variant consists in producing a recombinant polypeptide fused to a <carrier> protein (chimeric protein). The advantage of this system is that it allows a stabilization and a reduction in proteolysis of the recombinant product, an increase in solubility during renaturation in vitro and/or a simplification of purification when the fusion partner has affinity for a specific ligand.

More particularly, the invention relates to a method of preparing a polypeptide of the invention comprising the following steps: a) culture of the transformed cells under conditions allowing the expression of a recombinant polypeptide having a nucleic acid sequence according to the invention; b) where appropriate, recovery of the said recombinant polypeptide.

When the method of preparing a polypeptide of the invention uses a transgenic animal according to the invention, the recombinant polypeptide is then extracted from the said animal.

The subject of the invention is also a polypeptide capable of being obtained by a method of the invention as described above.

The invention also comprises a method of preparing a synthetic polypeptide, characterized in that it uses an amino acid sequence of polypeptides according to the invention.

The invention also relates to a synthetic polypeptide obtained by a method according to the invention.

Polypeptides according to the invention may also be prepared by conventional techniques in the field of peptide synthesis under conditions suitable to produce the polypeptides encoded by the polynucleotide of the invention. This synthesis may be carried out in and recovered from a homogeneous solution or on a solid phase.

For example, the synthesis technique in a homogeneous solution described by Houbenweyl in 1974 may be used.

This method of synthesis consists in successively condensing, in pairs, the successive amino acids in the required order, or in condensing amino acids and fragments previously formed and already containing several amino acids in the appropriate order, or alternatively several fragments thus previously prepared, it being understood that care will have been taken to protect beforehand all the reactive functional groups carried by these amino acids or fragments, with the exception of the amine functional groups of one and the carboxyl functional groups of the other or vice versa, which should normally take part in the formation of the peptide bonds, in particular after activation of the carboxyl functional group, according to methods well known in peptide synthesis.

According to another preferred technique of the invention, the one described by Merrifield is used.

To manufacture a peptide chain according to the Merrifield method, a highly porous polymer resin is used, onto which the first C-terminal amino acid of the chain is attached. This amino acid is attached onto a resin via its carboxyl group and its amine functional group is protected. The amino acids which will constitute the peptide chain are thus attached, one after another, onto the amine group, each time deprotected beforehand, of the portion of the peptide chain already formed, and which is attached to the resin. When the entire peptide chain desired is formed, the protecting groups are removed from the various amino acids constituting the peptide chain and the peptide is detached from the resin with the aid of an acid.

The invention relates, in addition, to hybrid (fusion) polypeptides having at least one polypeptide or one of its representative fragments according to the invention, and a sequence of a polypeptide capable of eliciting an immune response in humans or animals.

Advantageously, the antigenic determinant is such that it is capable of eliciting a humoral and/or cellular response.

An antigenic determinant may be identified by screening expression libraries of the Chlamydia trachomatis genome with antibodies contained in the serum of patients infected with a bacterium belonging to the species Chlamydia trachomatis. An antigenic determinant may comprise a polypeptide or one of its fragments according to the invention, in glycosylated form, used in order to obtain immunogenic compositions capable of inducing the synthesis of antibodies directed against multiple epitopes. The said polypeptides or their glycosylated fragments also form- part of the invention.

These hybrid molecules may consist, in part, of a carrier molecule for polypeptides or for their representative fragments according to the invention, combined with a portion which may be immunogenic, in particular an epitope of the diphtheria toxin, the tetanus toxin, a hepatitis B virus surface antigen (patent FR 79 21811), the poliomyelitis virus VPI antigen or any other viral or bacterial toxin or antigen.

The methods of synthesizing the hybrid molecules include the methods used in genetic engineering to construct hybrid nucleotide sequences encoding the desired polypeptide sequences. Reference may be advantageously made, for example, to the technique for producing genes encoding fusion proteins described by Minton in 1984.

The said hybrid nucleotide sequences encoding a hybrid polypeptide as well as the hybrid polypeptides according to the invention, characterized in that they are recombinant polypeptides obtained by the expression of the said hybrid nucleotide sequences, also form part of the invention.

The invention also comprises the vectors characterized in that they contain one of the said hybrid nucleotide sequences. The host cells transformed by the said vectors, the transgenic animals comprising one of the said transformed cells as well as the methods of preparing recombinant polypeptides using the said vectors, the said transformed cells and/or the said transgenic animals of course also form part of the invention.

The polypeptides according to the invention, the antibodies according to the invention described below and the nucleotide sequences according to the invention may advantageously be used in in vitro and/or in vivo methods for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis, in a biological sample (biological tissue or fluid) which is likely to contain them. These methods, depending on the specificity of the polypeptides, of the antibodies and of the nucleotide sequences according to the invention which will be used, may in particular detect and/or identify the bacterial variants belonging to the species Chlamydia trachomatis as well as the associated microorganisms capable of being detected by the polypeptides, the antibodies and the nucleotide sequences according to the invention which will be chosen. It may, for example, be advantageous to choose a polypeptide, an antibody or a nucleotide sequence according to the invention, which is capable of detecting any bacterium of the Chlamydia family by choosing a polypeptide, an antibody and/or a nucleotide sequence according to the invention which is specific to the family or, on the contrary, it will be most particularly advantageous to target a variant of the species Chlamydia trachomatis, which is responsible, for example, for the induction or the worsening of pathologies specific to the targeted variant, by choosing a polypeptide, an antibody and/or z nucleotide sequence according to the invention which is specific to the said variant.

The polypeptides according to the invention may advantageously be used in a method for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis or to an associated microorganism, in a biological sample (biological tissue or fluid) which is likely to contain them, characterized in that it comprises the following steps: a) bringing this biological sample into contact with a polypeptide or one of its representative fragments according to the invention (under conditions allowing an immunological reaction between the said polypeptide and the antibodies which may be present in the biological sample); b) detecting the antigen-antibody complexes which may be formed.

Preferably, the biological sample consists of a fluid, for example a human or animal serum, blood or biopsies.

Any conventional procedure may be used to carry out such a detection of the antigenantibody complexes which may be formed.

By way of example, a preferred method uses immunoenzymatic procedures based on the ELISA technique, immunofluorescence procedures or radioimmunological procedures (RIA), and the like.

Accordingly, the invention also relates to the polypeptides according to the invention, labelled with the aid of a suitable label such as a label of the enzymatic, fluorescent or radioactive type.

Such methods comprise, for example, the following steps: deposition of defined quantities of a polypeptide composition according to the invention into the wells of a microtitre plate, introduction, into the said wells, of increasing dilutions of serum, or of a different biological sample as defined above, which has to be analysed, incubation of the microplate, introduction, into the wells of the microtitre plate, of labelled antibodies directed against human or animal immunoglobulins, these antibodies having been labelled with the aid of an enzyme selected from those which are capable of hydrolyzing a substrate, thereby modifying the absorption of the radiation of the latter, at least at a defined wavelength, for example at 550 nm, detection, by comparison with a control, of the quantity of substrate hydrolyzed.

The invention also relates to a kit or set for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis or to an associated microorganism, characterized in that it comprises the following components: a polypeptide according to the invention, where appropriate, the reagents for constituting the medium appropriate for the immunological or specific reaction, the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction between the polypeptide(s) of the invention and the antibodies which may be present in the biological sample, it being possible for these reagents also to carry a label, or to be capable of being recognized in turn by a labelled reagent, more particularly in the case where the polypeptide according to the invention is not labelled, where appropriate, a reference biological sample (negative control) free of antibodies recognized by a polypeptide according to the invention, where appropriate, a reference biological sample (positive control) containing a predetermined quantity of antibodies recognized by a polypeptide according to the invention.

According to the invention, the polypeptides, peptides, fusion proteins or other derivatives, or analogs thereof encoded by a polynucleotide sequence in SEQ ID No. 1, may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen. Such antibodies may include, but are not limited to, polyclonal and monoclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. In a specific embodiment, the antibody to a polypeptide, peptide or other derivative, or analog thereof encoded by a polynucleotide sequence in SEQ ID No. 1 is a bispecific antibody (see generally, e.g. Fanger and Drakeman, 1995, Drug News and Perspectives 8: 133-137). Such a bispecific antibody is genetically engineered to recognize both an epitope and one of a variety of "trigger" molecules, e.g. Fc receptors on myeloid cells, and CD3 and CD2 on T cells, that have been identified as being able to cause a cytotoxic T-cell to destroy a particular target. Such bispecific antibodies can be prepared either by chemical conjugation, hybridoma, or recombinant molecular biology techniques known to the skilled artisan.

Various procedures known in the art may be used for the production of polyclonal antibodies to a polypeptide, peptide or other derivative, or analog thereof encoded by a polynucleotide sequence in SEQ ID No. 1. For the production of antibody, various host animals can be immunized by injection with a polypeptide, or peptide or other derivative, or analog thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants, depending on the host species, may be used to increase the immunological response, including but not limited to Stimulon T QS-21 (Aquila Biopharmaceuticals, Inc., Framingham, MA), MPL T (3-O-deacylated monophosphoryl lipid A; RIBI ImmunoChem Research, Inc., Hamilton, MT), aluminum phosphate, IL-12 (Genetics Institute, Cambridge, MA), Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions keyhole limpet hemocyanins, dinitrophenol, BCG (bacille Calmette-Guerin), and corynebacteriurr parvum. Alternatively, polyclonal antibodies may be prepared by purifying, on an affinity column onto which a polypeptide according to the invention has been previously attached, the antibodies contained in the serum of patients infected with a bacterium belonging to the species Chlamydic trachomatis.

For preparation of monoclonal antibodies directed toward a polypeptide, peptide or other derivative, or analog, any technique which provides for the production of antibody molecules b) continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al, 1983, Immunology Today 4:72), and the EBVhybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclona Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing technology described in PCT/US90/02545. In another embodiment of the invention, transgenic non-human animals can be used for the production of human antibodies utilizing technology described in WO 98/24893 and WO 96/33735. According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al, 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of <chimeric antibodies>, (Morrison et al., 1984, PROC.

NATL. ACAD. SCI. U.S.A. 81:6851-6855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for a polypeptide, peptide or other derivative, or analog together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies Patent 4,946,778) can be adapted to produce polypeptide or peptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al, 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for polypeptides, derivatives, or analogs.

Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, the Fab fragments which can b generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.

In addition, techniques have been developed for the production of chimerized (See, eg Boss, M. et al., U.S. Patent No. 4,816,397; and Cabilly, S. et al., U.S. Patent No. 5,585,089 each o which is incorporated herein by reference in its entirety) humanized antibodies (See, Queen, U.S Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) An immunoglobuli light or heavy chain variable region consists of a "framework" region interrupted by thre hypervariable regions, referred to as complementarily determining regions (CDRs). The extent of th, framework region and CDRs have been precisely defined (See, "Sequences of Proteins o Immunological Interest", Kabat, E. et al., U.S. Department of Health and Human Services (1983)).

Briefly, humanized antibodies are antibody molecules from non-human species having one or morn CDRs from the non-human species and a framework from a human immunoglobulin molecule.

The antibodies of the invention may also be labelled in the same manner as describec above for the nucleic probes of the invention such as an enzymatic, fluorescent or radioactive type labelling.

The invention relates, in addition, to a method for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis or to an associated microorganism in a biological sample, characterized in that it comprises the following steps: a) bringing the biological sample (biological tissue or fluid) into contact with a mono- or polyclonal antibody according to the invention (under conditions allowing an immunological reaction between the said antibodies and the polypeptides of the bacterium belonging to the species Chlamydia trachomatis or to an associated microorganism which may be present in the biological sample, that is, under conditions suitable for the formation of immune complexes); b) detecting the antigen-antibody complex which may be formed.

Also falling within the scope of the invention is a kit or set for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis or to an associated microorganism, characterized in that it comprises the following components: a polyclonal or monoclonal antibody according to the invention, labelled where appropriate; where appropriate, a reagent for constituting the medium appropriate for carrying out the immunological reaction; a reagent allowing the detection of the antigen-antibody complexes produced by the immunological reaction, it being possible for this reagent also to carry a label, or to be capable of being recognized in turn by a labelled reagent, more particularly in the case where the said monoclonal or polyclonal antibody is not labelled; where appropriate, reagents for carrying out the lysis of the cells in the sample tested.

The principle of the DNA chip which was explained above may also be used tc produce protein <<chips> on which the support has been coated with a polypeptide or an antibod 3 according to the invention, or arrays thereof, in place of the DNA. These protein <chips* make i possible, for example, to analyse the biomolecular interactions (BIA) induced by the affinity capture of target analytes onto a support coated, for example, with proteins, by surface plasma resonance (SPR). Reference may be made, for example, to the techniques for coupling proteins onto a solid support which are described in EP 524 800 or to the methods describing the use of biosensor-type protein chips such as the BIAcore-type technique (Pharmacia) (Arlinghaus et al., 1997, Krone et al..

1997, Chatelier et al., 1995). These polypeptides or antibodies according to the invention, capable of specifically binding antibodies or polypeptides derived from the sample to be analysed, may thus be used in protein chips for the detection and/or the identification of proteins in samples. The said protein chips may in particular be used for infectious diagnosis and may preferably contain, per chip several polypeptides and/or antibodies of the invention of different specificity, and/or polypeptides and/or antibodies capable of recognizing microorganisms different from Chlamydia trachomatis.

Accordingly, the subject of the present invention is also the polypeptides and the antibodies according to the invention, characterized in that they are immobilized on a support, in particular of a protein chip.

The protein chips, characterized in that they contain at least one polypeptide or one antibody according to the invention immobilized on the support of the said chip, also form part of the invention.

The invention comprises, in addition, a protein chip according to the invention, characterized in that it contains, in addition, at least one polypeptide of a microorganism different from Chlamydia trachomatis or at least one antibody directed against a compound of a microorganism different from Chlamydia trachomatis, immobilized on the support of the said chip.

The invention also relates to a kit or set for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis or to an associated microorganism, or for the detection and/or the identification of a microorganism characterized in that it comprises a protein chip according to the invention.

The subject of the present invention is also a method for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis or to an associated microorganism in a biological sample, characterized in that it uses a nucleotide sequence according to the invention.

More particularly, the invention relates to a method for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis or to an associated microorganism in a biological sample, characterized in that it comprises the following steps: a) where appropriate, isolation of the DNA from the biological sample to be analysed, ol optionally production of a cDNA from the RNA in the biological sample; b) specific amplification of the DNA of bacteria belonging to the species Chlamydia trachomatii or to an associated microorganism with the aid of at least one primer according to the invention; c) detection of the amplification products.

These may be detected, for example, by the molecular hybridization technique using a nucleic probe according to the invention. This probe will be advantageously labelled with a nonradioactive (cold probe) or radioactive element.

For the purposes of the present invention, <<DNA in the biological sample> or <<DNA contained in the biological sample> will be understood to mean either the DNA present in the biological sample considered, or optionally the cDNA obtained after the action of a reverse transcriptase-type enzyme on the RNA present in the said biological sample.

Another aim of the present invention consists in a method according to the invention, characterized in that it comprises the following steps: a) bringing a nucleotide probe according to the invention into contact with a biological sample, the DNA contained in the biological sample having, where appropriate, been previously made accessible to hybridization, under conditions allowing the hybridization of the probe to complementary base pairs of the DNA of a bacterium belonging to the species Chlamydia trachomatis or to an associated microorganism; b) detecting the hybridization complex formed between the nucleotide probe and the DNA in the biological sample.

The present invention also relates to a method according to the invention, characterized in that it comprises the following steps: a) bringing a nucleotide probe immobilized on a support according to the invention into contact with a biological sample, the DNA in the sample having, where appropriate, been previously made accessible to hybridization, under conditions allowing the hybridization of the probe to the DNA of a bacterium belonging to the species Chlamydia trachomatis or to an associated microorganism; b) bringing the hybrid formed between the nucleotide probe immobilized on a support and the DNA contained in the biological sample, where appropriate after removal of the DNA in the biological sample which has not hybridized with the probe, into contact with a labelled nucleotide probe according to the invention; c) detecting the new hybrid formed in step b).

According to an advantageous embodiment of the method for the detection and/or the identification defined above, it is characterized in that, prior to step the DNA in the biological sample is primer-extended and/or amplified beforehand with the aid of at least one primer according to the invention.

The invention relates, in addition, to a kit or set for the detection and/or th identification of bacteria belonging to the species Chlamydia trachomatis or to an associate microorganism, characterized in that it comprises the following components: a) a nucleotide probe according to the invention; b) where appropriate, the reagents necessary for carrying out a hybridization reaction; c) where appropriate, at least one primer according to the invention as well as the reagents (eg polymerase and/or deoxynucleotide triphosphates) necessary for a DNA amplification reaction.

The invention also relates to a kit or set for the detection and/or the identification c bacteria belonging to the species Chlamydia trachomatis or to an associated mnicroorganisn characterized in that it comprises the following components: a) a nucleotide probe, called capture probe, according to the invention; b) an oligonucleotide probe, called detection probe, according to the invention; c) where appropriate, at least one primer according to the invention as well as the reagents (e.g polymerase and/or deoxynucleotide triphosphates) necessary for a DNA amplification reaction.

The invention also relates to a kit or set for the detection and/or the identification c bacteria belonging to the species Chlamydia trachomatis or to an associated microorganisnr characterized in that it comprises the following components: a) at least one primer according to the invention; b) where appropriate, the reagents necessary for carrying out a DNA amplification reaction; c) where appropriate, a component which makes it possible to check the sequence of th amplified fragment, more particularly an oligonucleotide probe according to the invention.

The invention relates, in addition, to a kit or set for the detection and/or th identification of bacteria belonging to the species Chlamydia trachomatis or to an associatet microorganism, or for the detection and/or the identification of a microorganism characterized in tha it comprises a DNA chip according to the invention, I The invention also relates to a method or to a kit or set according to the invention fc the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis characterized in that the said primer and/or the said probe according to the invention are chosen fron the nucleotide sequences specific to the species Chlamydia trachomatis, in that the said polypeptide' according to the invention are chosen from the polypeptides specific to the species Chlamydi trachomatis and in that the said antibodies according to the invention are chosen from the antibodie, directed against the polypeptides according to the invention chosen from the polypeptides specific tc the species Chlamydia trachomatis.

Preferably, the said method or the said kit or set above according to the invention, for the detection and/or the identification of bacteria belonging to the species Chlamydia trachomatis i: characterized in that the said primer and/or the said probe or the said polypeptides are chosen from the nucleotide sequences or polypeptides according to the invention which have been identified as being specific to the species Chlamydia trachomatris and in that the said antibodies according to the invention are chosen from the antibodies directed against the polypeptides according to the inventior chosen from the polypeptides identified as being specific to the species Chlamydia trachomatis.

The invention relates, in addition, to a method or a kit or set according to the invention for the diagnosis of predispositions to, or of a condition caused by, genital diseases which are induced or worsened by a Chlamydia trachomatis infection.

The invention also relates to a method or a kit or set according to the invention for the diagnosis of predispositions to, or of conditions caused by, eye diseases induced or worsened by E Chlamydia trachomatis infection.

The invention also relates to a method or a kit or set according to the invention for the diagnosis of predispositions to, or of conditions caused by, systemic diseases, in particular of the lymphatic system, which are induced or worsened by a Chlamydia trachomatis infection.

According to another aspect, the subject of the invention is the use of polypeptides according to the invention, of cells transformed with a vector according to the invention and/or of transformed animals according to the invention, for the biosynthesis or the biodegradation of organic or inorganic compounds.

As has been mentioned above, the nucleotide sequences of the invention were identified by homology with sequences known to encode, for example, polypeptides or fragments of enzymatic polypeptides involved in the biosynthesis or the biodegradation of organic or inorganic molecules.

It is thus possible to use the said polypeptides of.the invention in a similar manner for the biosynthesis or the biodegradation of organic or inorganic compounds of industrial or therapeutic interest (called compounds of interest).

Among these polypeptides, there may be mentioned in particular the enzymes involved in metabolism, such as the proteolytic enzymes, amino transferases, glucose metabolism, or the enzymes which may be used in the biosynthesis of sugars, amino acids, fatty acids, polypeptides, nucleotides, nucleic acids or any other organic or inorganic compound or in the biodegradation of organic or inorganic compounds.

Among these polypeptides, there may be mentioned, in addition, the mutated or modified enzymes corresponding to mutated or modified polypeptides according to the invention which may also be used for the biosynthesis or the biodegradation of organic or inorganic compounds at the industrial level, such as, for example, the production of compounds of interest, the reprocessing of manufacturing residues applied to the food industries, to the papermaking industry or to th, chemical and pharmaceutical industries.

The methods of biosynthesis or biodegradation of organic or inorgani& compounds characterized in that they use a polypeptide or one of its representative fragments according to the invention, transformed cells according to the invention and/or a transformed animal according to th, invention, also form part of the invention.

The invention relates, in addition, to the use of a nucleotide sequence according to th, invention, of a polypeptide according to the invention, of an antibody according to the invention, of; cell according to the invention, and/or of a transformed animal according to the invention, for tht selection of an organic or inorganic compound capable of modulating, regulating, inducing o inhibiting the expression of genes, and/or of modifying the cellular replication of eukaryotic o prokaryotic cells or capable of inducing, inhibiting or worsening the pathologies linked to an infectior by Chlamydia trachomatis or one of its associated microorganisms.

The invention also comprises screening assays that comprise method of selectinj compounds capable of binding to a polypeptide, fusion polypeptide, or one of its representative fragments according to the invention, capable of binding to a nucleotide sequence according to th( invention, or capable of recognizing an antibody according to the invention, and/or capable oj modulating, regulating, inducing or inhibiting the expression of genes, and/or of modifying the growtl or the cellular replication of eukaryotic or prokaryotic cells, or capable of inducing, inhibiting o; worsening, in an animal or human organism, the pathologies linked to an infection by Chlamydic trachomatis or one of its associated microorganisms, characterized in that it comprises the following steps: a) bringing the said compound into contact with the said polypeptide, the saic nucleotide sequence, with a transformed cell according to the invention and/or administering the said compound to a transformed animal according to the invention; b) determining the capacity of the said compound to bind with the said polypeptide or the said nucleotide sequence, or to modulate, regulate, induce or inhibit the expressior of genes, or to modulate growth or cellular replication, or to induce, inhibit or worsen in the said transformed animal, the pathologies linked to an infection by Chlamydia trachomatis or one of its associated microorganisms.

The transformed cells and/or animals according to the invention may advantageously serve as a model and may be used in methods for studying, identifying and/or selecting compounds capable of being responsible for pathologies induced or worsened by Chlamydia trachomatis, or capable of preventing and/or of treating these pathologies such as, for example, genital, eye or systemic diseases, especially of the lymphatic system. In particular, the transformed host cells, in particular bacteria of the Chiamnydia family whose transformation with a viector according to the invention may, for example, increase or inhibit its infectivity, or modulate the pathologies usually induced or worsened by the infection, may be used to infect animals in which the onset 6f pathologies will be monitored. These nontransformed animals, infected for example with transformed Chlaniydia bacteria, may serve as a study model. In the same manner, the transformed animals according to the invention may, for example, exhibit predispositions to genital and/or eye and/or systemic diseases, e specially of the lymphatic system, and thus be used in methods for selecting compounds capable of preventing and/or of treating the said diseases. The said methods using the said transformed cells and/or transformed animals form part of the invention.

The compounds capable of being selected may be organic compounds such as polypeptides or carbohydrates or any other organic or inorganic compounds already known, or nev, organic compounds produced using molecular modelling techniques and obtained by chemical or biochemical synthesis, these techniques being known to persons skilled in the art.

The said selected compounds may be used to modulate the growth and/or the cellular replication of Chiamydia trachomatis or any other associated microorganism and thus to control infection by these microorganisms. The said compounds according to the invention may also be used to modulate the growth and/or the cellular replication of all eukaryatic or prokaryotic cells, in particular rumour cells and infectious microorganisms, for which the said compounds will prove active, the methods which make it possible to determine the said modulations being well known to persons skilled in the art.

Compound capable of modulating the growth of a microorganism is understood to designate any compound which makes it possible to act, to modify, to limit and/cr to reduce the development, the growth, the rate of proliferation and/or the viability of the said microorganism.

This modulation may be achieved, for example, by an agent capable of binding to a protein and thus of inhibiting or of potentiating its biological activity, or capable of binding to a membrane protein of the outer surface of a microorganism and of blocking the penetration of the said microorganism into the host cell or of promoting the action of the immune system of the infected organism directed against the said microorganism. This modulation may also be achieved by an agent capable of binding to a nucleotide sequence of a DNA or RNA of a microorganism and of blocking, for example, the expression of a polypeptide whose biological or structural activity is necessary for the growth or for the reproduction of the said microorganism.

Associated microorganism is understood to designate in the present invention any microorganism whose gene expression may be modulated, regulated, induced or inhibited, or whose growth or cellular replication may also be modulated by a compound of the invention. Associated microorganism is also understood to designate in the present invention any microorganism containing nucleotide sequences or polypeptides according to the invention. These microorganisms may, in som cases, contain polypeptides or nucleotide sequences identical or homologous to those of the inventior may also be detected and/or identified by the detection and/or identification methods orf kit accordin.

to the invention and may also serve as a target for the compounds of the invention.

The invention relates to the compounds capable of being selected by a method o selection according to the invention.

The invention also relates to a pharmaceutical composition comprising a compounr chosen from the following compounds: a nucleotide sequence according to the invention; a polypeptide or fusion polypeptide according to the invention; a vector according to the invention; an antibody according to the invention; and a compound capable of being selected by a method of selection according to the invention, optionall' in combination with a pharmaceutically acceptable vehicle or carrier.

An effective quantity is understood to designate a sufficient quantity of the saic compound or antibody, or of a polypeptide of the invention, which makes it possible to modulate tht growth of Chlamydia trachomatis or of an associated microorganism.

The invention also relates to a pharmaceutical composition according to the inventior for the prevention or the treatment of an infection by a bacterium belonging to the species Chlamydic trachomatis or by an associated microorganism.

The invention relates, in addition, to an immunogenic and/or vaccine composition.

characterized in that it comprises one or more polypeptides according to the invention and/or one oi more hybrid polypeptides according to the invention.

The invention also comprises the use of a transformed cell according to the invention, for the preparation of a vaccine composition.

The invention also relates to a vaccine composition, characterized in that it contains a nucleotide sequence according to the invention, a vector according to the invention and/or a transformed cell according to the invention.

The invention also relates to the vaccine compositions according to the invention, for the prevention or the treatment of an infection by a bacterium belonging to the species Chlamydia trachomatis or by an associated microorganism.

The invention also relates to the use of DNA encoding polypeptides of Chlamydia trachomatis, in particular antigenic determinants, to be formulated as vaccine compositions. In accordance with this aspect of the invention, the DNA of interest is engineered into an expression vector under the control of regulatory elements, which will promote expression of the DNA, i.e., promoter or enhancer elements. In one preferred embodiment, the promoter element may be cellspecific and permit substantial transcription of the DNA only in predetermined cells. The DNA may be introduced directly into the host either as naked DNA Patent No. 5, 6 7 9 ,647-incorporated herein by reference in their entirety) or formulated in compositions with other agents which may facilitate uptake of the DNA including viral vectors, adenovirus vectors, or agents which facilitate immunization, such as bupivicaine and other local anesthetics Patent 5,593,972 incorporated herein by reference in their entirety), saponins Patent 5,739,118 incorporated herein by reference in their entirety) and cationic polyamines (published international application WO 96/10038 incorporated herein by reference in their entirety).

The DNA sequence encoding the antigenic polypeptide and regulatory element may be inserted into a stable cell line or cloned microorganism, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art, and described in Chappel, U.S. Patent No. 4,215,051; Skoultchi, WO 91/06667 each of which is incorporated herein by reference in its entirety.

Such cell lines and microorganisms may be formulated for vaccine purposes. In yet another embodiment, the DNA sequence encoding the antigenic polypeptide and regulatory element may be delivered to a mammalian host and introduced into the host genome via homologous recombination (See, Chappel, U.S. Patent No. 4,215,051; Skoultchi, WO 91/06667 each of which is incorporated herein by reference in its entirety.

Preferably, the immunogenic and/or vaccine compositions according to the invention intended for the prevention and/or the treatment of an infection by Chlamydia trachomatis or by an associated microorganism will be chosen from the immunogenic and/or vaccine compositions comprising a polypeptide or one of its representative fragments corresponding to a protein, or one of its representative fragments, of the cellular envelope of Chlamydia trachomatis. The vaccine compositions comprising nucleotide sequences will also preferably comprise nucleotide sequences encoding a polypeptide or one of its fragments corresponding to a protein, or one of its representative fragments, of the cellular envelope of Chlamydia trachomatis.

Among these preferred immunogenic and/or vaccine compositions, the most preferred are those comprising a polypeptide or one of its representative fragments, or a nucleotide sequence or one of its representative fragments whose sequences are chosen from the nucleotide or amino acid sequences identified in this functional group and listed above.

The polypeptides of the invention or their representative fragments entering into the immunogenic compositions according to the invention may be selected by techniques known to persons skilled in the art, such as for example on the capacity of the said polypeptides to stimulate T cells, which results, for example, in their proliferation or the secretion of interleukins, and which leads to the production of antibodies directed against the said polypeptides.

In mice, in which a weight dose of the vaccine composition comparable to the dose used in humans is administered, the antibody reaction is tested by collecting serum followed by a study of the formation of a complex between the antibodies present in the serum and the antigen of the vaccine composition, according to the customary techniques.

According to the invention, the said vaccine compositions will be preferably in combination with a pharmaceutically acceptable vehicle and, where appropriate, with one or more appropriate immunity adjuvants.

Various types of vaccines are currently available for protecting humans against infectious diseases: attenuated live microorganisms bovis BCG for tuberculosis), inactivated microorganisms (influenza virus), acellular extracts (Bordetella pertussis for whooping cough), recombinant proteins (hepatitis B virus surface antigen), polysaccharides (pneumococci). Experiments are underway on vaccines prepared from synthetic peptides or from genetically modified microorganisms expressing heterologous antigens. Even more recently, recombinant plasmid DNAs carrying genes encoding protective antigens were proposed as an alternative vaccine strategy. This type of vaccination is carried out with a particular plasmid derived from an E. coli plasmid which does not replicate in vivo and which encodes only the vaccinal protein. Animals were immunized by simply injecting the naked plasmid DNA into the muscle. This technique leads to the expression of the vaccine protein in situ and to a cell-type (CTL) and a humoral type (antibody) immune response.

This double induction of the immune response is one of the main advantages of the technique of vaccination with naked DNA.

The vaccine compositions of the present invention can be evaluated in in vitro and in vivo animal models prior to host, human, administration. For example, in vitro neutralization assays such as those described by Peterson et al. (1988) can be utilized. The assay described by Peterson et al. (1988) is suitable for testing vaccine compositions directed toward either Chlamydia trachomatis or Chlamydia pneumoniae.

Briefly, hyper-immune antisera is diluted in PBS containing 5% guinea pig serum, as a complement source. Chlamydiae (104 IFU; inclusion forming units) are added to the antisera dilutions. The antigen-antibody mixtures are incubated at 37 0 C for 45 minutes and inoculated into duplicate confluent Hep-2 or HeLa cell monolayers contained in glass vials 15 by 45 mm), which have been washed twice with PBS prior to inoculation. The monolayer cells are infected by centrifugation at 1000X g for 1 hour followed by stationary incubation at 37* for 1 hour. Infected monolayers are incubated for 48 or 72 hours, fixed and stained with a Chlamydiae specific antibody, such as anti-MOMP for C. trachomatis, etc. Inclusion-bearing cells are counted in ten fields at a magnification of 200X. Neutralization titer is assigned based on the dilution that gives inhibition as compared to control monolayers/IFU.

The efficacy of vaccine compositions can be determined in vivo by challenging animal models of Chlamydia trachomatis infection, guinea pigs or mice, with the vaccine compositions. For example, in vivo vaccine composition challenge studies in the guinea pig model of Chlamydia trachomatis infection can be performed. Briefly, female guinea pigs weighing 450 to 500 g are housed in an enviommentally controlled room with a 12 hour light-dark cycle and immunized with vaccine compositions via a variety of immunization routes. Post-vaccination, guinea pigs are infected in the genital tract with the agent of guinea pig inclusion conjunctivitis (GPIC), which has been grown in HeLa or McCoy cells (Rank et al. (1988)). Each animal receives approximately 1.4x10 inclusion forming units (IFU) contained in 0.05 ml of sucrose-phosphate-glutamate buffer, pH 7.4 (Schacter, J. (1980)). The course of infection monitored by determining the percentage of inclusion-bearing cells by indirect immunofluorescence with GPIC specific antisera, or by Giemsastained smear from a scraping from the genital tract (Rank et al. (1988)). Antibody titers in the serum is determined by an enzyme-linked immunosorbent assay.

Alternatively, in vivo vaccine composition challenge studies can be performed in the murine model of Chlamydia trachomatis (Morrison et al., 1995). Briefly, female mice 7 to 12 weeks of age receive 2.5 mg of depoprovera subcutaneously at 10 and 3 days before vaginal infection. Postvaccination, mice are infected in the genital tract with 1,500 inclusion-forming units of Chlamydia trachomatis contained in 5ml of sucrose-phosphate-glutamate buffer, pH. 7.4. The course of infection is monitored by determining the percentage of inclusion-bearing cells by indirect immunofluorence with Chlamydia trachomatis specific antisera, or by a Giemsa-stained smear from a scraping from the genital tract of an infected mouse. The presence of antibody titers in the serum of a mouse is determined by an enzyme-linked immunosorbent assay.

The vaccine compositions comprising nucleotide sequences or vectors into which the said sequences are inserted are in particular described in International Application No. WO 90/11092 and also in International Application No. WO 95/11307.

The nucleotide sequence constituting the vaccine composition according to the invention may be injected into the host after having been coupled to compounds which promote the penetration of this polynucleotide inside the cell or its transport up to the cell nucleus. The resulting conjugates may be encapsulated into polymeric microparticles, as described in International Application No. WO 94/27238 (Medisorb Technologies International).

According to another embodiment of the vaccine composition according to the invention, the nucleotide sequence, preferably a DNA, is complexed with the DEAE-dextran (Pagano et al., 1967) or with nuclear proteins (Kaneda et al., 1989), with lipids (Felgner et al., 1987) or encapsulated into liposomes (Fraley et al., 1980) or alternatively introduced in the form of a gel facilitating its transfection into the cells (Midoux et al., 1993, Pastore et al., 1994). The polynucleotide or the vector according to the invention may also be in suspension in a buffer solution or may be combined with liposomes.

Advantageously, such a vaccine will be prepared in accordance with the technique described by Tacson et al. or Huygen et al. in 1996 or alternatively in accordance with the technique described by Davis et al. in International Application No. WO 95/11307.

Such a vaccine may also be prepared in the form of a composition containing a vector according to the invention, placed under the control of regulatory elements allowing its expression in humans or animals. It is possible, for example, to use, as vector for the in vivo expression of the polypeptide antigen of interest, the plasmid pcDNA3 or the plasmid pcDNAI/neo, both marketed by Invitrogen (R D Systems, Abingdon, United Kingdom). It is also possible to use the plasmid V1lns.tPA, described by Shiver et al. in 1995. Such a vaccine will advantageously comprise, in addition to the recombinant vector, a saline solution, for example a sodium chloride solution.

The immunogenic compositions of the invention can be utilized as part of methods of immunization, wherein such methods comprise administering to a host, a human host, an immunizing amount of the immunogenic compositions of the invention. In a preferred embodiment, the method of immunizing is a method of immunizing against Chlamydia trachomatis.

A pharmaceutically acceptable vehicle is understood to designate a compound or a combination of compounds entering into a pharmaceutical or vaccine composition which does not cause side effects and which makes it possible, for example, to facilitate the administration of the active compound, to increase its life and/or its efficacy in the body, to increase its solubility in solution or alternatively to enhance its preservation. These pharmaceutically acceptable vehicles are well known and will be adapted by persons skilled in the art according to the nature and the mode of administration of the active compound chosen.

As regards the vaccine formulations, these may comprise appropriate immunity adjuvants which are known to persons skilled in the art, such as, for example, aluminium hydroxide, a representative of the family of muramyl peptides such as one of the peptide derivatives of N-acetylmuramyl, a bacterial lysate, or alternatively incomplete Freund's adjuvant, Stimulon t QS-21 (Aquila Biopharmaceuticals, Inc., Framinham, MA), MPL T (3-0-deacylated monophosphoryl lipid A; RIBI ImmunoChem Research, Inc., Hamilton, MT), aluminum phosphate, IL-12 (Genetics Institute, Cambridge, MA).

Preferably, these compounds will be administered by the systemic route, in particular by the intravenous route, by the intranasal, intramuscular, intradermal or subcutaneous route, or by the oral route. More preferably, the vaccine composition comprising polypeptides according to the invention will be administered several times, spread out over time, by the intradermal or subcutaneous route.

Their optimum modes of administration, dosages and galenic forms may be determined according to criteria which are generally taken into account in establishing a treatment adapted to a patient, such as for example the patient's age or body weight, the seriousness of his general condition, tolerance of the treatment and the side effects observed.

The invention comprises the use of a composition according to the invention for the treatment or the prevention of genital diseases which are induced or worsened by Chlamydia trachomatis.

Finally, The invention comprises the use of a composition according to the invention for the treatment or the prevention of eye diseases which are induced or worsened by the presence of Chlamydia trachomatis.

Finally, the invention comprises the use of a composition according to the invention for the treatment or the prevention of systemic diseases, especially of the lymphatic system, which are induced or worsened by the presence of Chlamydia trachomatis.

In another aspect, the present invention provides an isolated polynucleotide having a nucleotide sequence of a Chlamydia trachomatis genome, comprising: the nucleotide sequence of SEQ ID NO:1; or the nucleotide sequence contained in a clone insert in ECACC Deposit No. 98112617.

The present invention further provides an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: a nucleotide sequence chosen from ORF 52, ORF 75, ORF 116, ORF 212, ORF 305, ORF 349, ORF 369, ORF 508, ORF 653, ORF 693, ORF 758, ORF 781, ORF 867, ORF 875, ORF 901, ORF 902, ORF 904, ORF 923, ORF 971 and ORF 1009; a nucleotide sequence exhibiting at least 80% identity to any one of ORF 52, ORF 75, ORF 116, ORF 212, ORF 305, ORF 349, ORF 369, ORF 508, ORF 653, ORF 693, ORF 758, ORF 781, ORF 867, ORF 875, ORF 901, ORF 902, ORF 904, ORF 923, ORF 971 and ORF 1009; 81A a nucleotide sequence exhibiting greater than 97% identity to any one of ORF 52, ORF 75, ORF 116, ORF 212, ORF 305, ORF 349, ORF 369, ORF 508, ORF 653, ORF 693, ORF 758, ORF 781, ORF 867, ORF 875, ORF 901, ORF 902, ORF 904, ORF 923, ORF 971 and ORF 1009; a nucleotide sequence exhibiting at least 99.9% identity to any one of ORF 52, ORF 75, ORF 116, ORF 212, ORF 305, ORF 349, ORF 369, ORF 508, ORF 653, ORF 693, ORF 758, ORF 781, ORF 867, ORF 875, ORF 901, ORF 902, ORF 904, ORF 923, ORF 971 and ORF 1009; a nucleotide sequence which is greater than 20 bases in length and hybridizes to a nucleotide sequence according to under high stringency conditions; or a fragment of any one of to which is greater than 20 bases in length, wherein a polypeptide encoded by the nucleotide sequence is not found in Chlamydia pneumoniae.

In a further aspect, the present invention provides an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: a nucleotide sequence chosen from ORF 2, ORF 485, ORF 487, ORF 593, ORF 1037, ORF 1038, ORF 1095, ORF 1096, ORF 1141, and ORF 1181; a nucleotide sequence exhibiting at least 80% identity to any one of ORF 2, ORF 485, ORF 487, ORF 593, ORF 1095, ORF 1096, ORF 1141, and ORF 1181; a nucleotide sequence exhibiting greater than 97% identity to any one of ORF 1037 and ORF 1038; a nucleotide sequence exhibiting at least 99.9% identity to any one of ORF 2, ORF 485, ORF 487, ORF 593, ORF 1037, ORF 1038, ORF 1095, ORF 1096, ORF 1141, and ORF 1181; \0 82

O

O

c a nucleotide sequence which is greater than 20 bases in length O and hybridizes to a nucleotide sequence according to under

O

high stringency conditions; or a fragment of any one of to which is greater than 20 bases in length, wherein a polypeptide encoded by the nucleotide sequence is not found in Chlamydia pneumoniae.

SThe present invention further provides an isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: a nucleotide sequence of ORF 971; N a nucleotide sequence exhibiting at least 80% identity to ORF 971; a nucleotide sequence exhibiting greater than 97% identity to ORF 971; a nucleotide sequence exhibiting at least 99.9% identity to ORF 971; a nucleotide sequence which is greater than 20 bases in length and hybridizes to a nucleotide sequence according to under high stringency conditions; or a fragment of any one of to which is greater than 20 bases in length, wherein a polypeptide encoded by the nucleotide sequence is not found in Chlamydia pneumoniae.

In another aspect, the present invention provides a polynucleotide encoding a fusion polypeptide, comprising a nucleotide of the invention ligated in frame to a polynucleotide encoding a heterologous polypeptide.

In another aspect, the present invention provides a recombinant vector that contains a polynucleotide of the invention.

In another aspect, the present invention provides a recombinant vector that contains a polynucleotide of the invention operatively associated with a regulatory sequence that controls gene expression.

In another aspect, the present invention provides a genetically engineered host cell that contains a polynucleotide of the invention.

In another aspect, the present invention provides a genetically engineered host cell that contains a polynucleotide of the invention operatively associated with a regulatory sequence that controls gene expression in the host cell.

I 82A O In another aspect, the present invention provides a method for producing

O

a polypeptide, comprising: culturing the genetically engineered host cell of the invention under conditions suitable to produce the polypeptide encoded by the polynucleotide; and recovering the polypeptide from the culture.

In another aspect, the present invention provides a polypeptide encoded by a polynucleotide of the invention.

Preferably, the polypeptide immunoreacts with seropositive serum of an (C individual infected with Chlamydia trachomatis.

In another aspect, the present invention provides an antibody that immunospecifically binds to a polypeptide of the invention.

In another aspect, the present invention provides a method for the detection and/or identification of Chlamydia trachomatis in a biological sample, comprising: contacting the sample with a polynucleotide primer which hybridizes to a polynucleotide sequence according to claim 2 in the presence of a polymerase enzyme and nucleotides under conditions which permit primer extension; and detecting the presence of primer extension products in the sample in which the detection of primer extension products indicates the presence of Chlamydia trachomatis in the sample, wherein the primer does not hybridize with a polynucleotide sequence of the Chlamydia pneumoniae genome.

In another aspect, the present invention provides a method for the detection and/or identification of Chlamydia trachomatis in a biological sample, comprising: contacting the sample with a polynucleotide probe which hybridizes to a polynucleotide sequence according to the invention under conditions which permit hybridization of complementary base pairs; and detecting the presence of hybridization complexes in the sample in which the detection of hybridization complexes indicates the presence of Chlamydia trachomatis in the sample, wherein the probe does not hybridize with a polynucleotide sequence of the Chlamydia pneumoniae genome.

In another aspect, the present invention provides a method for the detection and/or identification of Chlamydia trachomatis in a biological sample, comprising: contacting the sample with an antibody of the invention under conditions suitable for the formation of immune complexes; and detecting the presence of immune complexes in the sample, in which the detection of immune complexes indicates the presence of Chlamydia trachomatis in the sample.

In another aspect, the present invention provides a method for the detection and/or identification of antibodies to Chlamydia trachomatis in a biological sample, comprising: contacting the sample with a polypeptide of the invention under conditions suitable for the formation of immune complexes; and detecting the presence of immune complexes in the sample, in which the detection of immune complexes indicates the presence of Chlamydia trachomatis in the sample.

In another aspect, the present invention provides a DNA chip containing an array of polynucleotides comprising at least one of the polynucleotide of the invention.

In another aspect, the present invention provides a protein chip containing an array of polypeptides comprising at least one of the polypeptide of the invention.

In another aspect, the present invention provides an immunogenic composition comprising a polypeptide of the invention and a pharmaceutically acceptable carrier.

In another aspect, the present invention provides a pharmaceutical composition comprising a polypeptide of the invention and a pharmaceutically acceptable carrier.

In another aspect, the present invention provides a method of immunizing against Chlamydia trachomatis, comprising: administering to a host an immunizing amount of an immunogenic composition of the invention.

In another aspect, the present invention provides a DNA immunogenic composition comprising an expression vector of the invention.

Preferably, the DNA composition directs the expression of a neutralizing epitope of Chlamydia trachomatis.

In another aspect, the present invention provides a screening assay, comprising: contacting a test compound with an isolated polynucleotide according to the invention; and detecting whether binding occurs.

In another aspect, the present invention provides a screening assay, comprising: contacting a test compound with a polypeptide of the invention; and detecting whether binding occurs.

In another aspect, the present invention provides a kit comprising a container containing an isolated polynucleotide according to the invention.

Preferably, the polynucleotide is a primer or a probe.

Preferably, the polynucleotide is a primer and the kit further comprises a container containing a polymerase.

Preferably, the kit further comprises a container containing deoxynucleotide triphosphates.

In another aspect, the present invention provides a kit comprising a container containing an antibody that immunospecifically binds to a polypeptide of the invention.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Other characteristics and advantages of the invention appear in the following examples and figures: Legend to the figures: Figure 1: Line for the production of Chlamydia trachomatis sequences Figure 2: Analysis of the sequences and assembling Figure 3: Finishing techniques Figure 3a): Assembly map Figure 3b): Determination and use of the orphan ends of the contigs

EXAMPLES

Cells The Chlamydia trachomatis LGV2 strain used is identified to have over 98% homology with the outer membrane protein sequences ompl (CHTMOMPA) and omp2 (CHTOMP2A) of the Chlamydia trachomatis serovar L2/434/Bu strain.

The Chlamydia trachomatis LGV2 strain is cultured on mouse fibroblasts (McCoy cells), obtained from the American Type Culture Collection, under the reference ATCC CRL-1696.

86 Culture of the cells The mouse fibroblasts are cultured in 75-ml cell culture flasks (Corning). The culture medium is Dulbecco's modified cell culture medium (Gibco BRL No. 04101965) supplemented with MEM amino acids (Gibco BRL No. 04301140) L (5 ml per 500 ml of medium) and 5% foetal calf serum (Gibco BRL No. 10270 batch 40G8260K) without antibiotics or antifungals.

The cell culture stock is maintained in the following manner. The cell cultures are examined under an inverted microscope. 24 hours after confluence, each cellular lawn is washed with PBS (Gibco BRL No. 04114190), rinsed and then placed for 5 min in an oven in the presence of 3 ml of trypsine (Gibco BRL No. 25200056). The cellular lawn is then detached and then resuspended in 120 ml of culture medium, the whole is stirred in order to make the cellular suspension homogeneous.

ml of this suspension are then distributed per cell culture flask. The flasks are kept in a CO 2 oven for 48 hours at a temperature of 370C. The cell stock is maintained so as to have available daily 16 flasks of subconfluent cells. It is these subconfluent cells which will be used so as to be infected with Chlamydia. 25-mi cell culture flasks are also used, these flasks are prepared in a similar manner but the volumes used for maintaining the cells are the following: I ml of trypsine, 28 ml of culture medium to resuspend the cells, 7 ml of culture medium are used per 25-ml flask.

Infection of the cells with Chlamydia Initially, the Chlamydiae are obtained frozen (at -70aC), in suspension in a volume of 1 millilitre. This preparation is slowly thawed, 500 pl are collected and brought into contact with subconfluent cells, which are obtained as indicated above, in a 25-mi cell culture flask, containing 1 ml of medium, so as to cover the cells. The flask is then centrifuged at 2000 rpm in a <<swing> rotor for microtitre plates, the centrifuge being maintained at a temperature of 35°C. After centrifugation, the two flasks are placed in an oven at 35 0 C for three hours. 6 ml of culture medium containing cycloheximide (1 pg/ml) are then added and the flask is stored at 35 0 C. After 48 hours, the level of infection is evaluated by direct immunofluorescence and by the cytopathogenic effect caused to the cells.

Direct immunofluorescence Starting with infected cells, which were obtained as indicated above, a cellular smear is deposited with a Pasteur pipette on a microscope slide. The cellular smear is fixed with acetone for minutes; after draining the acetone, the smear is covered with 30 p1 of murine monoclonal antibodies directed against MOMP (major outer membrane protein) of Chlamydia (Syva, Biomdrieux) labelled with fluorescein isothiocyanate. The whole is then incubated in a humid chamber at a temperature of 37°C. The slides are then rinsed with water, slightly dried, and then after depositing a drop of mounting medium, a coverslip is mounted before reading. The reading is carried out with the aid of a fluorescence microscope equipped with the required filters (excitation at 490 nm, emission at 520 nm).

Harvesting of the Chlamdia trachomatis After checking the infection by direct immunofluorescence, carried out as indicated above, the culture flasks are opened under a sterile cabinet, sterile glass beads with a diameter of the order of a millimeter are placed in the flask. The flask is closed and then vigorously stirred while being maintained horizontally, the cellular lawn at the bottom, so that the glass beads can have a mechanical action on the cellular lawn. Most of the cells are thus detached or broken: the effect of the stirring is observed under an optical microscope so as to ensure proper release of Chlamydiae.

Large-scale infection of the cell cultures The product of the Chlamydiae harvest (culture medium and cellular debris) is collected with a pipette, and distributed into three cell culture flasks containing subconfluent L cells, obtained as indicated above. The cells thus inoculated are placed under gentle stirring (swing) in an oven at 35 0 C. After one hour, the flasks are kept horizontally in an oven so that the culture medium I 5 covers the cells for 3 hours. 30 ml of culture medium containing actydione (I plg/ml) are then added to each of the flasks. The culture flasks are then stored at 35C for 48 hours. The cells thus infected are examined under an optical microscope after 24 hours, the cytopathogenic effect is evaluated by the appearance of cytoplasmic inclusions which are visible under an inverted optical microscope. After 48 hours, the vacuoles containing the Chlamydiae occupy the cytoplasm of the cell and push the cell nucleus sideways. At this stage, numerous cells are spontaneously destroyed and have left free elementary bodies in the culture medium. The Chlamydiae are harvested as described above and are either frozen at -80 0 C or used for another propagation.

Purification of the Chlamydiae The product of the Chlamydia harvests, stored at -80 0 C, is thawed on a water bath at room temperature. After thawing, each tube is vigorously stirred for one minute and immersed for one minute in an ultrasound tank (BRANSON 1200); the tubes are then stirred by inverting before being centrifuged for 5 min at 2000 rpm. The supernatant is carefully removed and kept at cold temperature (ice). The supematant is vigorously stirred and then filtered on nylon filters having pores of 5 microns in diameter on a support (Nalgene) allowing a delicate vacuum to be established under the nylon filter. For each filtration, three nylon filters are superposed; these filters are replaced after every 40 ml of filtrate. Two hundred milliliters of filtration product are kept at cold temperature, and then after stirring by inverting, are centrifuged at 10,000 rpm for 90 min, the supernatant is removed and the pellet is taken up in 10 ml of 10 mM Tris, vigorously vortexed and then centrifuged at 10,000 rpm for 90 min. The supernatant is removed and the pellet is taken up in a buffer (20 mM Tris pH 8.0, 50 mM KC1, 5 mM MgCl 2 to which 800 units of DNAse I (Boehringer) are added. The whole is kept at 37°C for one hour. One ml of 0.5 M EDTA is then added, and the whole is vortexed and frozen at -20 0

C.

Preparation of the DNA The Chlamydiae purified above are thawed and subjected to a proteinase K (Boehringer) digestion in a final volume of 10 ml. The digestion conditions are the following: 0.1 mg/ml proteinase K, 0.1 SDS at 55°C, stirring every 10 min. The product of digestion is then subjected to a double extraction with phenol-chloroform, two volumes of ethanol are added and the DNA is directly recovered with a Pasteur pipette having one end in the form of a hook. The DNA is dried on the edge of the tube and then resuspended in 500 pl of 2 mM Tris pH 7.5. The DNA is stored at 4'C for at least 24 hours before being used for the cloning.

Cloning of the DNA After precipitation, the DNA is quantified by measuring the optical density at 260 nm. Thirty pg of Chlamydia DNA are distributed into 10 tubes of 1.5 ml and diluted in 300 pl of water. Each of the tubes is subjected to 10 applications of ultrasound lasting for 0.5 sec in a sonicator (Unisonix XL2020). The contents of the 10 tubes are then grouped and concentrated by successive extractions with butanol (Sigma B1888) in the following manner: two volumes of butanol are added to the dilute DNA mixture. After stirring, the whole is centrifuged for five minutes at 2500 rpm and the butanol is removed. This operation is repeated until the volume of the aqueous phase is less than 1 ml. The DNA is then precipitated in the presence of ethanol and of 0.5 M sodium acetate pH 5.4, and then centrifuged for thirty minutes at 15,000 rpm at cold temperature The pellet is washed with 75% ethanol, centrifuged for five minutes at 15,000 rpm and dried at room temperature. A tenth of the preparation is analysed on a 0.8% agarose gel. Typically, the size of the DNA fragments thus prepared is between 200 and 8000 base pairs.

To allow the cloning of the DNA obtained, the ends are repaired. The DNA is distributed in an amount of 10 pg/tube, in the following reaction medium: 100 pl final volume, 1 H buffer (Biolabs 201L), 0.5 pl BSA 0.05 mg/ml, 0.1 mM dATP, 0.1 mM each of dGTP, dCTP or dTTP, 60,000 IU T4 DNA polymerase. The reaction is incubated for thirty minutes at 16°C. The contents of each of the tubes are then grouped before carrying out an extraction with phenolchloroform and then precipitating the aqueous phase as described above. After this step, the DNA thus prepared is phosphorylated. For that, the DNA is distributed into tubes in an amount of 10 pg per tube, and then in a final volume of 50 pl, the reaction is prepared in the following manner: 1 mM ATP, 1 x kinase buffer, 10 IU T4 polynucleotide kinase (Biolabs 201L). The preparation is incubated for thirty minutes at 37 0 C. The contents of the tubes are combined and a phenol-chloroform extraction and then a precipitation are carried out in order to precipitate the DNA. The latter is then suspended in I pl of water and then the DNA fragments are separated according to their size on a 0.8% agarose gel (I x TAE). The DNA is subjected to an electric field of 5 V/cm and then visualized on a UV table.

The fragments whose size varies between 1200 and 2000 base pairs are selected by cutting out the gel.

The gel fragment thus isolated is placed in a tube and then the DNA is purified with the Qiaex kit (20021 Qiagen), according to the procedure provided by the manufacturer.

Preparation of the vector 14 pg of the cloning vector pGEM-5Zf (Promiga P2241) are diluted in a final volume of 150 pl and are subjected to digestion with the restriction enzyme EcoRV 300 IU (Biolabs 195S) according to the protocol and with the reagents provided by the manufacturer. The whole is placed at 37"C for 150 min and then distributed in the wells of a 0.8% agarose gel subjected to an electric field of 5 V/cm. The linearized vector is visualized on a UV table, isolated by cutting out the gel and then purified by the Qiaex kit (Qiagen 20021) according to the manufacturer's recommendations. The purification products are grouped in a tube, the volume is measured and then half the volume of phenol is added and the whole is vigorously stirred for 1 min. Half the volume of chloroform-isoamyl alcohol 24:1 is added and vigorously stirred for 1 min. The whole is centrifuged at 15,000 rpm for min at 4°C, the aqueous phase is recovered and transferred into a tube. The DNA is precipitated in the presence of 0.3 M sodium acetate, pH 5.4 and 3 volumes of ethanol and placed at -20"C for 1 hour. The DNA is then centrifuged at 15,000 rpm for 30 min at 4°C, the supernatant is removed while preserving the pellet, washed twice with 70% ethanol. After drying at room temperature, the DNA is suspended in 25 pl of water.

Phosphorvlation of the vector 25 pl of the vector prepared in the preceding step are diluted in a final volume of 500 pl of the following reaction mixture: After repair, the DNA is subjected to a phenol-chloroform extraction and a precipitation, the pellet is then taken up in 10 pl of water, the DNA is quantified by measuring the optical density at 260 nm. The quantified DNA is ligated into the vector PGEm-5Zf(+) prepared by the restriction enzyme EcoRV and dephosphorylated (see preparation of the vector). The ligation is cairried out under three conditions which vary in the ratio between the number of vector molecules and the number of insert molecules. Typically, an equimolar ratio, a ratio of 1:3 and a ratio of 3:1 are used for the ligations which are, moreover, carried out under the following conditions: vector 25 ng, cut DNA, ligation buffer in a final volume of 20 pl with T4 DNA ligase (Amersham E70042X); the whole is then placed in a refrigerator overnight and then a phenolchloroform extraction and a precipitation are carried out in a conventional manner. The pellet is taken up in 5 pl of water.

Transformation of the bacteria Plating of the bacteria Petri dishes containing LB Agar medium containing ampicillin (50 pg/ml), Xgal (280 pg/ml) [5-bromo-4-chloro-indolyl-beta-D-galactopyranoside (Sigma B-4252)], IPTG (140 g/mrnl) [isopropyl-beta-D-thiogalactoside (Sigma 1-6758)] are used, 50 and 100 p1 of bacteria are plated for each of the ligations. The Petri dishes are placed upside down at 37°C for 15 to 16 hours in an oven.

The number of <recombinantv> positive clones is evaluated by counting the white colonies and the blue colonies which are thought to contain the vector alone.

Evaluation of the «<<recombinant> positive clones: Ninety-four white colonies and two blue colonies.are collected with the aid of sterile cones and are deposited at the bottom of the wells of plates designed for carrying out the amplification techniques. 30 pl of the following reaction mixture are added to each well: 1.7 mM MgCI 2 0.2 rmM each of dATP, dCTP, dGTP and dTTP, two synthetic oligonucleotides corresponding to sequences flanking the cloning site on either side and orienting the synthesis of the DNA in a convergent manner (0.5 pM RP and PU primers, 1 U TAQ polymerase (GibcoBRL 18038-026)).

The colonies thus prepared are subjected to a temperature of 94°C for 5 min and then to 30 thermal cycles composed of the following steps: 94°C for 40s, 50°C for 30 s, 72°C for 180 s.

The reaction is then kept for 7 min at 72°C and then kept at 4°C.

The amplification products are deposited on an agarose gel stained with ethidium bromide, subjected to electrophoresis, and then analysed on an ultraviolet table. The presence of an amplification fragment having a size greater than 500 base pairs indicates the presence of an insert. The bacterial clones are then prepared so as to study the sequence of their insert.

Sequencing To sequence the inserts of the clones obtained as above, these were amplified by PCR on bacteria cultures carried out overnight using the primers for the vectors flanking the inserts. The sequence of the ends of these inserts (on average 500 bases on each side) was determined by automated fluorescent sequencing on an ABI 377 sequencer, equipped with the ABI Prism DNA Sequencing Analysis software (version 2.1.2).

Analysis of the sequences The sequences obtained by sequencing in a high-yield line (Figure 1) are stored in a database; this part of the production is independent of any treatment of the sequences. The sequences are extracted from the database? avoiding all the regions of inadequate quality, that i to say the regions for which uncertainties are observed on the sequence at more than 95%. After extraction, the sequences are introduced into a processing line, the diagram of which is described in Figure 2. In a first path of this processing line, the sequences are assembled by the Gap4 software from R. Staden (Bonfield et al., 1995) (OS UNIX/SUN Solar-is); the results obtained by this software are kept in the form of two files which will be used for a subsequent processing. The first of these files provides information on the sequence of each of the contigs obtained. The second file represents all the clones participating in the composition of all the contigs as well as their positions on the respective contigs.

The second processing path uses a sequence assembler (TIGR-Asrng assembler UNIX/SUN Solaris); the results of this second processing path are kept in the form of a file in the TIGR-Asmg format which provides information on the relationship existing between the sequences selected for the assembly. This assembler is sometimes incapable of linking contigs whose ends overlap over several hundreds of base pairs.

The results obtained from these two assemblers are compared with the aid of the BLAST program, each of the contigs derived from one assembly path being compared with the contigs derived from the other path.

For the two processing paths, the strict assembly parameters are fixed homology, 30 superposition nucleotides). These'parameters avoid 3 to 5% of the clones derived from eukaryotic cells being confused with sequences obtained from the clones derived from Chiamydia trachomatis. The eukaryotic sequences are however preserved during the course of this project; the strategy introduced, which is described below, will be designed, inter alia, not to be impeded by these sequences derived from contaminating clones.

The results of these two assemblers are processed in a software developed for this project. This software operates on a Windows NT platform and receives, as data, the results derived from the STADEN software and/or the results derived from the TJOR-Asmg assembler, the software, results, after processing of the data, in the determination of an assembly map which gives the proximity relationship and the orientation of the contigs in relation to one another (Figure 3a). Using this assembly map, the software determines all the primers necessary for finishing the project. This treatment, which will be detailed below, has the advantage of distinguishing the isolated sequences derived from the contaminations, by the DNA eukaryotic cells, of the small-sized sequences clearly integrated into the project by the relationships which they establish with contigs. In order to allow, without any risk of error, the arrangement and the orientation of the contigs in relation to one another, a statistical evaluation of the accuracy of the names 4<naming> of sequence is made from the results of C<contigation>>. This evaluation makes it possible to give each of the clone plates, as well as each of the subsets of plates, a weight which is inversely proportional to probable error rate existing in the <<naingr of the sequences obtained from this plate or from a subset of this plate. In spite of a low error rate, errors may occur throughout the steps of production of the clones and of the sequences.

These steps are numerous, repetitive and although most of them are automated, others, like the deposition in the sequencers, are manual; it is then possible for the operator to make mistakes such as the inversion of two sequences. This type of error has a repercussion on the subsequent processing of the data, by resulting in relationships (between the contigs) which do not exist ini reality, then in attempts at directed sequencing between the contigs which will end in failure. It is because of this that the evaluation of the naming errors is of particular importance since it allows the establishment of a probabilistic assembly map from which it becomes possible to determine all the clones which will serve as template to obtain sequences separating two adjacent contigs. Table 2 of parent U.S, Application Serial No. 60/107077 filed November 4, 1998, French application 97-15041 filed November 28, 1997 and French application 97-16034 filed December 17, 1997, each of which is incorporated by reference herein in its entirety, gives the clones and the sequences of the primers initially used during the initial operations.

To avoid the step which consists in ordering and then preparing the clones by conventional microbiological means, outer and inner primers oriented towards the regions not yet sequenced axe defined by the software. The primers thus determined make it possible to prepare, by PCR, a template covering the nonsequenced region. It is the so-called outer primers (the ones most distant from the region to be sequenced) which are used to prepare this template. The template is then purified and a sequence is obtained on each of the two strands during 2 sequencing reactions which each use one of the 2 inner primers. In order to facilitate the use of this approach, the two outer primers and the two inner primers are prepared and then stored on the same position of 4 different 96-well plates. The two plates containing the outer primers are used to perform the PCRs which serve to prepare the templates. These templates will be purified on purification columns preserving the topography of the plates. Each of the sequences are obtained using primers situated on one and then on the other of the plates containing the inner primers. This distribution allows a very extensive automation of the process and results in a method which is simple to use for finishing the regions not yet sequenced. Table 3 of parent U.S. Application Serial No. 60/107077 filed November 4, 1998, French application 97-15041 filed November 28, 1997 and French application 97-16034 filed December 17, 1997, each of which is incorporated by reference herein in its entirety, gives the names and the sequences of the primers used for finishing Chiamydia :rachomaris.

Finally, a number of contigs exist in a configuration where one of their ends is not linked to any other contig end (Figure 3b) by a connecting clone relationship (a connecting clone is defined as a clone having one sequence end on a contig and the other end of its sequence on another contig; furthermore, this clone must be derived from a plate or a subset of plates with adequate naming quality). For the Chiamydia trachomatis project, this particular case occurred 37 times. Two adjacent PCR primers orienting the synthesis of the DNA towards the end of the consensus sequence are defined for each of the orphan ends of the consensus sequence. The primer which is closest to the end of the sequence is called the inner primer whereas the primer which is more distant from the end of the sequence is called the outer primer. 'The outer primers are used to explore the mutual relationship between the orphan ends of the different contigs. The presence of a single PCR product and the possibility of amplifying this product unambiguously using the inner primers evokes the tO probable relationship between the contigs on which the primers which allowed the amplification are situated. This relationship will be confirmed by sequencing and will allow the connection between the orphan ends of the consensus sequences. This strategy has made it possible to obtain a complete map of the Chiamydia trachomatis chromosome and then to finish the project.

Ouality controlf All the bases not determined with certainty in the chromosomal sequence were noted and the density of uncertainties was measured on the entire chromosome. The regions with a high density of uncertainties were noted and the PCR primers spanning these regions were drawn and are represented in Table 4 of parent U.S. Application Serial No. 60/107077 filed November 4, 1998, French application 97-15041 Filed November 28, 1997 and French application 97-16034 filed December 17, 1997 each of which is incorporated by reference herein in its entirety.

Data banks Local reorganizations of major public banks were used. The protein bank used consists of the nonredundant fusion of the Cenpepc bank (automated translation of GenBank, NCBI; Benson et al., 1996).

The entire BLAST software (public domain, Altschul et al., 1990) for searching for.

homologies between a sequence and protein or nucleic data banks was used. The significance levels used depend on the length and the complexity of the region tested as well as the size of the reference bank. They were adjusted and adapted to each analysis.

The results of the search for homologies between a sequence according to the invention and protein or nucleic data banks are presented and summarized in Table I below.

Table 1: List or codina chromaosame regions and homaoo ies between these regions and the sequence banks.

Legend to Table 1: Open reading frames are identified with the GenMark software version 2.3A (GenePro), the template used is Chlamydia trachomatis of order 4 on a length of 196 nucleotides with a window of 12 nucleotides and a minimum signal of 0.5. These redding frames are numbered in order of appearance on the chromosome, starting with ORF2 (ORF column). The positions of the beginning and of the end are then given in column 2 (position). When the position of the beginning is greater than the position of the end, this means that the region is encoded by the strand complementary to the sequence which was given in the sequence SEQ ID No. 1.

All the putative products were subjected to a search for homology on GENPEPT (release 103 for SEQ ID No. 2 to SEQ ID No. 1076 and release 108 for SEQ ID No. 1077 to SEQ ID No. 1197 with the BLASTp software (Altschul etal. 1990), with, as parameters, the default parameters with the exception of the expected value E set at 10 (for SEQ ID No. 2 to SEQ ID No.

1076) and P value set at e'o (for SEQ ID No. 1077 to SEQ ID No. 1197). Subsequently, only the identities greater than 30% column) were taken into account. The description of the most homologous sequence is given in the Homology column; the identifier for the latter sequence is given in the ID column and the animal species to which this sequence belongs is given in the Species column. The Homology score is evaluated by the sum of the blast scores for each region of homology and reported in the Score column. Table 1 also reflects data from additional ORF finder programs as defined below.

Materials and methods: transmembrane domains: The DAS software was used as recommended by the authors (Cserzo et al., 1997).

This method uses, to predict the transmembrane domains, templates derived from a sampling of selected proteins. All the regions for which a «Cutoff> greater than 1.5 was found by the program were taken into account.

Additional ORF Finder Programs For this analysis, two additional ORF finder programs were used to predict potential open reading frames of a minimum length of 74 amino acids; Glimmer (Salzberg, Delcher, A., Kasif, and W. White. 1998. Microbial gene identification using interpolated Markov models.

Nucleic Acids Res. 26:544-548.), and an in-house written program. The in-house program used a very simple search algorithm. The analysis required the that the genomic DNA sequence text be in the 5' to 3' direction, the genome is circular, and that TAA, TAG, and TGA are stop codons. The search parameters were as follows: A search for an ORF that started with a GTG codon was performed. If no GTG codons were found, then a search for an ATG codon was performed. However, if a GTG codon was found, then a search downstream for a ATG codon was performed. All start and stop nucleotide positions were recorded.

A search for an ORF that started with a TTG codon was performed. If no TTG codons were found, then a search for a ATG codon was performed. However, if a TTG codon was found, then a search downstream for a ATG codon was performed. All start and stop nucleotide positions were recorded.

The analysis described in steps 1 and 2 were repeated for the opposite strand of DNA sequence.

A search for ORFs that determined all ORF lengths using start and stop positions in the same reading frames was performed.

All ORFs whose DNA length was less than 225 nucleotides were eliminated from the search.

Surface Exposed Protein Search Criteria Potential cell surface vaccine targets are outer membrane proteins such as porins, lipoproteins, adhesions and other non-integral proteins. In Chlamydia psittaci, the major immunogens is a group of putative outer membrane proteins (POMPs) and no homologs have been found in Chlamydia trachomatis and Chlamydia trachomatis by traditional analysis (Longbottom, D., Russell, Dunbar, Jones, and A.J. Herring. 1998. Molecular Cloning and Characterization of the Genes Coding for the Highly Immunogenic Cluster of 90-Kilodalton Envelope Proteins from Chlamydia psittaci Subtype That Causes Abortion in Sheep. Infect Immun 66:1317- 1324.) However, utilizing the criteria described below, several ORFs encoding outer membrane proteins have been identified in Chlamydia trachomatis, all of which may represent vaccine candidates. Any ORF which met any one of the criteria described below were considered to encode a surface exposed protein.

Protein homology searches of the translated ORFs were done using the Blastp 2.0 tool (Altschul, Madden, Schaffer, Zhang, Zhang, Miller, and D.J. Lipman.

1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

Nucleic Acids Res. 25:3389-3402). An ORF was labeled surface exposed if the translated ORF had homology to a known, or hypothetical, or putative surface exposed protein with a P score less than e Most, if not all, proteins that are localized to the membrane of bacteria, via a secretory pathway, contain a signal peptide. The software program SignalP, was used to analyze the amino acid sequence of an ORF for such a signal peptide (Nielsen, Engelbrecht. Brunak, S., and G. von Heijne. 1997. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Engineering 10:1-6.) The first 60 N-terminal amino acids of each ORF were analyzed by SignalP using the Gram-negative software database. The output generates four separate values, maximum C, maximum Y, maximum S, and mean S. The S-score, or sighal region, is the probability of the position belonging to the signal peptide. The C-score, or cleavage site, is the probability of the position being the first in the mature protein. The Y-score is the geometric average of the C-score and a smoothed derivative of the S-score. A conclusion of either a Yes or No is given next to each score. If all four conclusions are Yes and the C-terminal amino acid is either a phenylalanine or a tyrosine the ORF was labelled outer membrane (Struyve, Moons, M., and J. Tommassen. 1991. Carboxy-terminal Phenylalanine is Essential for the Correct Assembly of a Bacterial Outer Membrane Protein. J. Mol. Biol. 218:141-148.) The program called Psort was used to determine the localization of a protein based on its signal sequence, recognition of transmembrane segments, and analysis of its amino acid composition (Nakai, and M. Kanehisa. 1991. Expert system for predicting protein localization sites in gram-negative bacteria. Proteins 11:95-110.) An ORF is considered to be an outer membrane protein if the output data predicts the ORF encoded protein as outer membrane with a certainty value of 0.5 or better and whose value is at least twice as large as the next predicted localized certainty value.

Finally, ORFs that were not predicted to be outer membrane or surface exposed, based on the above criteria, were further analyzed. The Blastp output data for these ORFs were searched using various general and specific keywords, suggestive of known cell surface exposed proteins. An ORF was labeled surface exposed if the keywords matched had a Blastp hit with a P score less than e'o 1 and there was no better data indicating otherwise. The following is a list of the searched keywords: Adhesion Adhesin Invasin Invasion Extension Omp Outer Surface Porin Outer Membrane Cell Surface Cell Wall Pilin Flagellar sheath Cir ChuA CopB ExeD FadL FecA FepA FhuA FmdC FomA FrpB GspD HemR HgbA Hgp HmbR HmuR HMW HrcC Hrp InvG LamB LbpA LcrQ Lmp MxiD MOMP PilE HpaA NolW NspA OpcP OpnP Opr OspA PhoE PldA Por PscC PulD PupA QuiX RafY ScrY SepC ShuA SomA SpiA Tbpl Yop YscC mip Tol Pilus BtuB Those ORFs that did not meet the minimum requirement for being an outer membrane protein based on the above search criteria but which were homologous to identified outer membrane ORFs in Chlamydia pneumoniae were included. The Chlamydia pneumoniae genome (French patent application No. 97-14673, filed 21 November 1997) was analyzed using the above search criteria and a number of outer membrane ORFs were identified. These Chlamydia pneumoniae ORFs were then tested against the Chlamydia trachomatis genome using Blastp. Any Chlamydia trachomatis ORF with a Blastp P value less than e"- 1 against a Chlamydia pneumoniae outer membrane was included in this section, if there was no better data indicating otherwise. A list of ORFs in the Chlamydia trachomatis genome encoding putative surface exposed proteins is set forth above in the specification.

Identification of Putative Lipoproteins in the Genome of Chlamvdia trachomatis Lipoproteins are the most abundant post-translationally modified bacterial secretory proteins (Pugsley, A. 1993. The complete general secretory pathway in Gram-negative bacteria.

Microbiol. Rev. 57:50-108). The characteristic features of lipoproteins are a thiol-linked diacylglyceride and an amine-linked monoacyl group on the cysteine that becomes the amino-terminal residue after signal peptide cleavage by Signal Peptidase II. (Pugsley, A. 1993. The complete general secretory pathway in Gram-negative bacteria. Microbiol. Rev. 57:50-108). The identification of putative lipoproteins from the genomic sequencing of Chlamydia trachomatis was done by examining the deduced amino acid sequence of identified ORFs for the presence of a signal peptide with a Signal Peptidase II cleavage site analogous to the consensus sequence for prolipoprotein modification and processing reactions (Hayashi, and H. C. Wu. 1992. Identification and characterization of lipid-modified proteins in bacteria, p. 261-285. In N. M. Hooper and A. J. Turner Lipid modification of proteins: A practical approach. Oxford University Press, New York; Sutcliffe, I. C. and R. R. B. Russell. 1995. Lipoproteins of Gram-positive bacteria. J. Bacteriol.

177:1123-1128).

The deduced amino acid sequences of Chlamydia trachomatis ORFs were initially screened for the most basic of lipoprotein characteristics, a cysteine in the first 30 amino acids of the deduced protein. ORFs with a standard start codon (ATG, GTG, or TTG) and having one or more of the following characteristics were selected for direct analysis of their first 30 amino acids: Significant Signal P value (at least two out-of-the four values are Yes) PSORT value indicating membrane passage (TM-inner membrane, Peri-periplasm, or OM-outer membrane) Identification of the word lipoprotein among the ORF Blastp data set.

A Blastp value of <e'1o with a putative lipoprotein from Chlamydia pneumoniae (French application No. 97-14673 filed 21 November 1997).

The first 30 amino acids encoded by each ORF in this set were analyzed for the characteristics commonly found in lipoprotein signal peptides (Pugsley, A. 1993. The complete general secretory pathway in Gram-negative bacteria. Microbiol. Rev. 57:50-108; Hayashi, and H.

C. Wu. 1992. Identification and characterization of lipid-modified proteins in bacteria, p. 261-285. In N. M. Hooper and A. J. Turner Lipid modification of proteins: A practical approach. Oxford University Press, New York; Sutcliffe, I. C. and R. R. B. Russell. 1995. Lipoproteins of Grampositive bacteria. J. Bacteriol. 177:1123-1128.) Putative lipoprotein signal peptides were required to have a cysteine between amino acid 10 and 30 and reach a minimum score of three based on the following criteria for lipoprotein signal peptides: Identification of specific amino acids in specific positions around the cysteine which are part of the consensus Signal Peptidase II cleavage site (Hayashi, and H. C. Wu. 1992.

Identification and characterization of lipid-modified proteins in bacteria, p. 261-285. In N. M. Hooper and A. J. Turner Lipid modification of proteins: A practical approach.

Oxford University Press, New York); Sutcliffe, I. C. and R. R. B. Russell. 1995.

Lipoproteins of Gram-positive bacteria. J. Bacteriol, 177:1123-1128). Since the identification of the cleavage site is the most important factor in identifying putative lipoproteins, each correctly positioned amino acid contributed toward reaching the minimum score of three.

A hydrophobic region rich in alanine and leucine prior to the cleavage site (Pugsley, A.

1993. The complete general secretory pathway in Gram-negative bacteria. Microbiol.

Rev. 57:50-108) contributed toward reaching the minimum score of three.

A short stretch of hydrophilic amino acids greater than or equal to 1, usually lysine or arginine, following the N-terminal methionine (Pugsley, A. 1993. The complete general secretory pathway in Gram-negative bacteria. Microbiol. Rev. 57:50-108) contributed toward reaching the minimum score of three.

A list of ORFs in the Chlamydia trachomatis genome encoding putative lipoproteins is set forth above in the specification.

LPS-Related ORFs of Chlamvdia trachomatis Lipopolysaccharide (LPS) is an important major surface antigen of Chlamydia cells.

Monoclonal antibodies (Mab) directed against LPS of Chlamydia pneumoniae have been identified that can neutralize the infectivity of Chlamydia pneumoniae both in vitro and in vivo (Peterson et al.

1988). Similar results are expected utilizing monoclonal antibodies against LPS of Chlamydia trachomatis. LPS is composed of lipid A and a core oligosaccharide portion and is phenotypically of the rough type (R-LPS) (Lukacova, Baumann, Brade, Mamat, Brade, H. 1994.

Lipopolysaccharide Smooth-Rough Phase Variation in Bacteria of the Genus Chlamydia. Infect.

Immun. June 62(6):2270-2276.) The lipid A component is composed of fatty acids which serve to anchor LPS in the outer membrane. The core component contains sugars and sugar derivatives such as a trisaccharide of 3-deoxy-D-manno-octulosonic acid (KDO) (Reeves, Hobbs, Valvano, Skurnik, Whitfield, Coplin, Kido, Klena, Maskell, Raetz, Rick, P.D. 1996. Bacterial Polysaccharide Synthesis and Gene Nomenclature pp. 10071-10078, Elsevier Science Ltd.). The KDO gene product is a multifunctional glycosyltransferase and represents a shared epitope among the Chlamydia. For a review of LPS biosynthesis see, Schnaitman, C.A., Klena, J.D. 1993. Genetics of Lipopolysaccharide Biosynthesis in Enteric Bacteria. Microbiol. Rev.

57:655-682.

A text search of the ORF Blastp results identified several genes that are involved in Chlamydial LPS production with a P score less than e" t O. The following key-terms were used in the text search: KDO, CPS (Capsular Polysaccharide Biosynthesis), capsule, LPS, rfa, rfb, rfc, rfe, rha, rhl, core, epimerase, isomerase, transferase, pyrophosphorylase, phosphatase, aldolase, heptose, manno, glucose, IpxB, fibronectin, fibrinogen, fucosyltransferase lic, lgt, pgm, tolC, rol, ChoP, phosphorylcholine, waaF, PGL-Tbl. A list of ORFs in the Chlamydia trachomatis genome encoding putative polypeptides involved in LPS biosynthesis is set forth above in the specification.

Type III And Other Secreted Products Type III secretion enables gram-negative bacteria to secrete and inject pathogenicity proteins into the cytosol of eukaryotic host cells (Hueck, C. 1998. Type II Protein Secretion Systems in Bacterial Pathogens of Animals and Plants. In Microbiology and Molecular Biology Reviews. 62:379-433.) These secreted factors often resemble eukaryotic signal transduction factors, thus enabling the bacterium to redirect host cell functions (Lee, 1997. Type II secretion systems: machines to deliver bacterial proteins into eukaryotic cells? Trends Microbiol. 5:148-156.) In an attempt to corrupt normal cellular functions, Chlamydial pathogenicity factors injetted into the host cytosol will nonetheless, as cytoplasmic constituents be processed and presented in the context of the Major Histocompatibility Complex (MHC class As such, these pathogenicity proteins represent MHC class I antigens and will play an important role in cellular immunity. Also included in this set are secreted non-type l products that may play a role as vaccine components.

A text search of the ORF Blastp results identified genes that are involved in Chlamydia trachomatis protein secretion with a P score less than e-' 1 The following key-terms were used in the text search in an effort to identify surface localized or secreted products: Yop, Lcr, Ypk, Exo, Per, Pop, Ipa, Vir, Ssp, Spt, Esp, Tir, Hrp, Mxi, hemolysin, toxin, IgA protease, cytolysin, tox, hap, secreted and Mip.

Chlamydia trachomatis ORFs that did not meet the above keyword search criteria, but have homologs in Chlamydia pneumoniae that do meet the search criteria are included herein.

The Chlamydia pneumoniae genome (French patent application No. 97-14673, filed 21 November 1997) was analyzed using the above search criteria and a number of ORFs were identified. These Chlamydia pneumoniae ORFs were tested against the Chlamydia trachomatis genome using Blastp.

Any Chlamydia trachomatis ORF with a Blastp P value against a Chlamydia pneumoniae homolog, identified using the above search criteria, was included. A list of ORFs in the Chlamydia trachomatis genome encoding putative secreted proteins is set forth above in the specification.

Chlamvdia trachomatis RGD Recognition Sequence Proteins that contain Arg-Gly-Asp (RGD) attachment site, together with integrins that serve as their receptor constitute a major recognition system for cell adhesion. The RGD sequence is the cell attachment site of a large number of adhesive extracellular matrix, blood, and cell surface proteins and nearly half of the known integrins recognize this sequence in their adhesion protein ligands. There are many RGD containing microbial proteins such as the penton protein of adenovirus, the coxsackie virus, the foot and mouth virus and pertactin, a 69 kDa (kilodalton) surface protein of Borderella pertussis, that serve as ligands through which these microbes bind to integrins on the cell surfaces and gain entry into the cell. The following provides evidence supporting the importance of RGD in microbial adhesion: a) The adenovirus penton base protein has a cell rounding activity and when penton base was expressed in E. coli, it caused cell rounding and cells adhered to polystyrene wells coated with the protein. Mutant analysis showed that both these properties required an RGD sequence. Virus mutants with amino acid substitutions in the RGD sequence, showed much less adherence to HeLa S3 cells, and also were delayed in virus reproduction (Bai, Harfe, and Freimuth, P. 1993.

Mutations That Alter an RGD Sequence in the Adenovirus Type 2 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells. J. Virol. 67:5198-5205).

b) It has been shown that attachment and entry of coxsackie virus A9 to GMK cells were dependent on an RGD motif in the capsid protein VP1. VP1 has also been shown to bind cavb integrin, which is a vitronectin receptor (Roivainen, Piirainen, Hovi, Virtanen, Riikonen, Heino, and Hyypia, T. 1994. Entry of Coxsackievirus A9 into Host Cells: Specific Interactions with av P Integrin, the Vitronectin Receptor Virology, 203:357-65).

c) During the course of whooping cough, Bordetella pertussis interacts with alveolar macrophages and other leukocytes on the respiratory epithelium. Whole bacteria adheres by means of two proteins, filamentous hemagglutinin (FHA) and pertussis toxin. FHA interacts with two classes of molecules on macrophages, galactose containing glycoconjugates and the integrin CR3.

The interaction between CR3 and FHA involves recognition of RGD sequence at the positions 1097- 1099 in FHA (Relman, Tuomanen, Falkow, Golenbock, D. Saukkonen, and Wright, S. D. Recognitition of a Bacterial Adhesin by an Integrin: Macrophage CR3 Binds Filamentous Hemagglutinin of Bordetella Pertussis." Cell, 61:1375-1382 (1990)).

d) Pertactin, a 69 kDa outer membrane protein of Bordetella pertussis, has been shown to promote attachment of Chinese hamster ovary cells (CHO). This attachment is mediated by recognition of RGD sequence in pertactin by integrins on CHO cells and can be inhibited by synthetic RGD containing peptide homologous to the one present in pertactin (Leininger, Roberts, M., Kenimer, J. Charles, I. Fairweather, Novotny, and Brennan, M. J. 1991. Pertactin, an Arg-Gly-Asp containing Bordetella pertussis surface protein that promotes adherence of mammalian cells Proc. Natl. Acad. Sci. USA, 88:345-349).

e) The RGD sequence is highly conserved in the VP1 protein of foot and mouth disease virus (FMDV). Attachment of FMDV to baby hamster kidney cells (BHK) has been shown to be mediated by VPI protein via the RGD sequence. Antibodies against the RGD sequence of VPI blocked attachment of virus to BHK cells (Fox, Parry, N. Barnett, P. McGinn, Rowland, D. J., and Brown, F. 1989. The Cell Attachment Site on Foot-and-Mouth Disease Virus Includes the Amino Acid Sequence RGD (Arginine-Glycine-Aspartic Acid) J. Gen. Virol., 70:625-637).

It has been demonstrated that bacterial adherence can be based on interaction of a bacterial adhesin RGD sequence with an integrin and that bacterial adhesins can have multiple binding site characteristic of eukaryotic extracellular matrix proteins. ROD recognition is one of the important mechanisms used by microbes to gain entry into eukaryotic cells.

The complete deduced protein sequence of the Chlamydia trachomatis'genome was searched for the presence of RGD sequence. There were a total of 38 ORFs that had one or more RGD sequences. Not all RGD containing proteins mediate cell attachment. It has been shown that RGD containing peptides that have proline immediately following the RGD sequence are inactive in cell attachment assays (Pierschbacher Ruoslahti. 1987. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem. 262:17294-98).

ORFs that had RGD, with proline as the amino acid following the RGD sequence were excluded from the list. Also, RGD sequence may not be available at the surface of the protein or may be present in a context that is not compatible with integrin binding. Since not all RGD-containing proteins are involved in cell attachment, several other criteria were used to refine the list of RGD-containing proteins. A list of ORFs in the Chlamydia trachomatis genome encoding polypeptides with RGD recognition sequence(s) is set forth above in the specification.

Non-Chlamvdia pneumoniae ORFs Chlamydia trachomatis ORFs were compared to the ORFs in the Chlamydia pneumoniae genome (French patent application No. 97-14673, filed 21 November 1997) using Blastp.

Any Chlamydia trachomatis ORF with a Blastp 4P value greater than e against Chlamydia pneumoniae ORFs are included in this section. A list of ORFs in the Chlamydia trachomatis genome which are not found in Chlamydia pneumoniae is set forth above in the specification.

Cell Wall Anchor Surface ORFs Many surface proteins are anchored to the cell wall of Gram-positive bacteria via the conserved LPXTG motif (Schneewind, Fowler, and Faull, K.F. 1995. Structure of the Cell Wall Anchor of Surface Proteins in Staphylococcus aureus. Science 268:103-106). A search of the proteins encoded by the Chlamydia trachomatis ORFs was done using the motif LPXTG. A list of ORFs in the Chlamydia trachomatis genome encoding polypeptides anchored to the cell wall is set forth above in the specification.

ECACC Deposits Samples of Chlamydia trachomatis were deposited with the European Collection of Cell Cultures (ECACC), Salisbury, Wiltshire SP4 OJG, UK on November 26, 1998 and assigned the provisional accession number 98112618. Cells can be grown, harvested and purified, and DNA can be prepared as discussed above. In order to enable recovery of specific fragments of the chromosome, one can run targeted PCR reactions, whose amplification products can then be sequenced and/or cloned into any suitable vector, according to standard procedures known to those skilled irl the art.

In addition, a pool of clones covering the Chlamydia trachomatis genome was deposited with the ECACC on November 26, 1998 and assigned provisional accession number 98-112617. The pool of clones contains a series of clones, which when taken together, cover the whole chromosome, with a redundancy of slightly more than ten. The total number of clones in the sample is 13,572.

Table 4 lists groups of oligonucleotides to be used to amplify each of ORFs 2-1 197 according to standard procedures known to those skilled in the art. Such oligonucleotides are listed as SEQ ID Nos. 1198 to 5981. For each ORE, the following is listed: one forward primer positioned 2,000 bp upstream of the beginning of the ORE; one forward primer positioned 200 bp upstream of the beginning of the ORF; one reverse primer positioned 2,000 bp downstream at the end of ORF, which is 2,000 bp upstream of the end site of the ORE on the complementary strand; and one reverse primer 200 bp downstream at the end of ORF, which is 200 bp upstream of the end site of the ORE on the complementary strand. The corresponding SEQ ID Nos. for the primers are listed in Table 4, where Pp is the proximal forward primer; Ed is the distal for-ward primer; Bp is the proximal reverse primer; and Bd is the distal reverse primer. The positions of the 5' ends of each of these primers on the nucleotide sequence of SEQ ID No. 1 are shown in Table The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

TABLE I ORF begin stop Homology ID Species Score 1% ORF2 501 208 putative ORF3 3276 505 putative 98 kDa outer U72499 Chlamydia psittaci 379 37 membrane protein ORF4 5068 3242 lipid A disaccharide U32786 Haemophilus influenzae 285 synthetase (lpxB) 6400 5126 poly(A) polymerase AE000123 Escherichia coli 552 46 ORF6 7977 6619 D-alanine permease (dagA) U32770 Haemophilus influenzae 265 36 ORF7 8582 8082 signalpeptidase II X78084 Staphylococcus carnosus 174 36 ORF8 8995 8591 YteA AF008220 Bacillus subtilis 157 43 ORF9 9440 8979 ORF 168 D28752 Synechococcus sp. 318 42 9828 10430 unknown Z80108 Mycobacterium 324 46 tuberculosis ORF11 10367 11254 hypothetical protein U67605 Methanococcus 152 38 (SP:P39587) jannaschii ORF12 11245 11916 rRNA methylase D90913 Synechocystis sp. 209 ORFP13 12068 13324 hypothetical U32691 Haemophilus influenzae 367 ORF14 13532 14413 neutral amino acid U75284 Oryctolagus cuniculus 410 39 transporter

BO.

14807 15019 dihydrolipoamide L38646 Saccharopolyspora 324 47 acetyltransferase erythraea ORF16 14932 15969 branched chain alpha-keto M97391 Bacillus subtilis 577 44 acid dehydrogenase E2 ORF17 15995 16501 ORF_o328 U18997 Escherichia coli 223 44 ORF18 16467 16138 putative ORF19 18190 17417 putative outer membrane U80956 Borrelia burgdorferi 86 36 protein 20521 18437 ORF-2 D11024 Shigella flexneri 642 37 ORF21 22202 20814 dnaK like protein (AA 1-660) X52175 Chlamnydia trachomatis 2214 99 ORF begin stop Homology ID Species Score 1% ORP22 22602 22153 OR?, 82 kDa protein L22180 Chlamydia trachomatis 558 89 ORF23 22804 22478 heat shock protein M62819 Chlamydia trachomatis 503 99 ORF24 23183 22824 GrpE-like protein L25105 Chlamydia trachomatis 580 98 23394 23110 GrpE-like protein L25105 Chlamydia trachomatis 373 87 ORF26 24569 23394 has homology to putative L25105 Chlamydia trachomatis 1999 99 heat shock proteins of Bacillus subtilis and Clostridium acetobutylicum; ORFA; putative ORF27 26383 24641 aminoacyl-tRNA synthetase L25105 Chlamydia trachomatis 3044 99 ORF28 26640 27710 ORFB; putative L25105 Chlamydia trachomatis 1298 99 ORF29 28780 27725 putative 29957 28740 hypothetical protein D64004 Synechocystis sp. 786 46 ORF31 30721 30032 putative ORF32 31281 30520 putative ORP33 31436 31780 putative L46591 Bartonella 126 bacilliformi a ORF34 33356 31800 putative 33901 33314 putative ORF36 34116 35027 Yer156cp U18917 Saccharomyces 175 32 cerevisiae ORF37 34988 35359 F21C3.3 Z71261 Caenorhabditis elegans 245 44 ORF38 35167 35919 putative ORF39 35923 36996 putative 37810 37013 putative ORF begin stop Homology ID Species Score I% ORF41 38207 39085 DAPH synthase-chorismate AF008220 Bacillus subtilis 529 48 mutase ORF42 39151 39927 arginine binding protein X67753 Escherichia coli 192 44 ORF43 39923 40756 putative ORF44 40760 42007 hypothetical protein Z98209 Mycobacterium 663 43 MTCY154.05c tuberculosis 42175 43116 phophoglucoisomerase-like L40822 Chlamydia trachomatis 681 protein ORF46 42999 43802 phophoglucoisomerase-like L40822 Chlamydia trachomatis 959 91 protein ORF47 44211 45227 NADP-malate dehydrogenase L40958 Flaveria bidentis 755 42 ORP48 46072 45275 putative ORF49 46340 45975 putative 46895 46506 putative ORF51 47955 46882 membrane protein (arcD) M33223 Pseudomonas aeruginosa 892 47 ORF52 48585 48178 putative ORP53 50072 48630 putative ORF54 50710 50099 putative 52439 50925 dehydroquinate L32794 Nicotiana tabacum 142 36 dehydratase/shikimate dehydrogenase ORF56 53484 52348 3-dehydroquinate synthase D90911 Synechocystis sp. 462 39 ORFS7 54536 53466 chorismate synthase X67516 Synechocystis sp. 801 56 ORF58 55086 54595 shikimate kinase II M13045 Escherichia coli 154 38 ORF59 56350 55031 5-enolpyruvylshikimate 3- U67500 Methanococcus 355 37 phosphate synthase jannaschii 55659 56084 putative ORF61 56847 58235 putative ORF62 58423 59181 dihydrodipicolinate U47017 Pseudomonas syringae 350 reductase pv. tabaci ORF63 59185 60195 aspartate-semialdehyde U67476 Methanococcus 590 44 dehydrogenase jannaschii ORF begin stop Homology ID Species Score I% ORF64 60188 61483 aspartokinase III U00006 Escherichia coli 312 41 61496 62353 dihydrodipicolinate AE000609 Helicobacter pylori 345 42 synthetase (dapA) ORF66 62500 63141 putative ORF67 63396 63983 hypothetical protein Y14084 Bacillus subtilis 148 42 ORF68 64628 64071 putative ORF69 64285 64656 putative ORF7D 64944 64609 putative ORF71 65347 67269 unknown D26185 Bacillus subtilis 733 44 ORF72 67656 68873 putative ORF73 68877 69233 KegA Z94752 Mycobacterium 156 38 tuberculosis ORF74 69212 69721 high level kasgamycin D26185 Bacillus subtilis 306 43 resistance 69958 70455 polypeptide deformylase Y10305 Calothrix PCC7601 272 43 ORF76 70701 71006 protein translocation U32727 Haemophilus influenzae 90 32 protein, low temperature (secG) ORF77 73191 71086 putative ORF78 74900 73497 putative ORF79 75463 74876 homologous to unidentified M96343 Bacillus subtilis 283 34 E. coli protein 77124 75502 0530; This 530 aa ORF is 33 AE000184 Escherichia coli 1447 42 pct identical (14 gaps) to 525 residues of an approx.

640 aa protein YHESHAEIN SW: P44808 ORFP81 77000 77299 putative ORF82 78095 77145 integrase-recombinase TU32750 Haemophilus influenzae 495, 38 protein (xerC) ORP83 79065 78154 hypothetical protein D64001 Synechocystis sp. 400 ORF84 81971 79878 LON protease homolog U88087 Arabidopsis thaliana 1927 48 82639 83271 putative If ORF begin stop Homology ID Species Score I% ORP86 83792 84850 DnaJ U58360 Salmonella typhimurium 822 42 ORF87 84876 86921 putative ORF88 88650 87313 putative ORFS9 87440 87805 putative 88400 88747 putative ORF91 88717 89265 putative ORF92 89355 89732 Hpr protein X12832 Bacillus subtilis 128 32 ORF93 89735 91447 PTS enzyme I 012340 Bacillus 671 34 stearothermophilus ORF94 91749 91435 ORF107 X17014 Bacillus subtilis 120 92392 91745 putative ORF96 93138 92344 dnaZX-like ORF put. DNA X06803 Bacillus subtilis 542 53 polymerase III ORF97 94134 93361 excinuclease ABC subunit A AE000583 Helicobacter pylori 326 36 (uvrA) ORF98 94637 94071 excinuclease ABC subunit A AE000583 Helicobacter pylori 487 (uvrA) ORF99 98299 94628 UvrA D49911 Thermus thermophilus 2090 44 ORF100 98715 98113 excinuclease ABC subunit A AE000583 Helicobacter pylori 319 42 (uvrA) ORF101 100228 98741 pyruvate kinase U83196 Chlamydia trachomatis 2411 97 ORF102 101347 100337 hypothetical protein D90903 Synechocystis sp. 494 37 ORF103 102210 101323 YqiE D84432 Bacillus subtilis 471 49 ORF104 102485 102210 putative ORF105 104315 102726 exonuclease VII, large U32723 Haemophilus influenzae 634 51 subunit (xseA) ORF106 105075 104254 triose phosphate isomerase L29475 Bacillus subtilis 558 48 ORF107 105259 105894 phosphoribosylanthranilate U18969 Arabidopsis thaliana 300 38 isomerase ORF108 107429 108460 putative ORF begin stop Homology ID Species Score 1% ORF109 108665 108955 putative ORF110 109459 109013 putative ORF111 110366 109704 putative ORF112 111330 112520 elongation factor Tu L22216 Chlamydia trachomatis 2007 100 ORF113 112915 113463 transcription U32754 Haemophilus influenzae 313 37 antitermination protein (nusG) ORF114 113566 113994 ribosomal protein L11 D13303 Bacillus subtilis 443 59 ORF115 114020 114604 ribosomal protein L1 Z11839 Thermotoga maritima 528 54 ORF116 114720 115253 ribosomal protein L10 Z11839 Thermotoga maritima 143 38 ORF117 115362 115676 rpll2 (AA 1-128) X53178 Synechocystis PCC6803 254 62 ORF118 116022 119795 DNA-directed RNA polymerase X64172 Staphylococcus aureus 2675 61 beta chain ORF119 119823 124010 DNA-directed RNA polymerase U32733 Haemophilus influenzae 3486 beta' chain (rpoC) ORF120 124065 124988 transaldolase L19437 Homo sapiens 677 ORF121 124873 125106 transaldolase U67611 Homo sapiens 121 44 ORF122 126261 125536 putative ORF123 126328 126930 putative ORF124 127138 127785 putative ORF125 127924 129714 Al isoform of vacuolar U22077 Gallus gallus 1062 ATPase subunit A ORF126 129720 131033 membrane ATPase X79516 Haloferax volcanii 790 48 ORF127 131018 131629 putative ORF128 131834 133156 Na+ -ATPase subunit I D17462 Enterococcus hirae 188 34 ORF129 133075 133584 v-type Na-ATPase X76913 Enterococcus hirae 110 38 ORF130 133625 133999 v-type Na-ATPase X76913 Enterococcus hirae 89 32 ORF131 133861 134508 putative ORF132 134638 137454 valyl-tRNA synthetase D64006 Synechocystis sp. 1763 51 ORF begin stop Homology ID Species Score I% ORF133 137442 140276 PknD Z95209 Mycobacterium 452 44 tuberculosis ORF134 140733 140335 putative ORF135 141799 141077 porphobilinogen deaminase U22968 Yersinia pestis 282 38 ORF136 143240 141780 unknown D26185 Bacillus subtilis 1113 53 ORF137 143829 143128 ORF3 D64116 Bacillus subtilis 356 39 ORF138 143923 144393 putative ORF139 144548 146326 unknown Z47210 Streptococcus 741 44 pneumoniae ORF140 146413 147078 manganese superoxide D12984 Caenorhabditis elegans 625 56 dismutase precursor ORF141 147140 148075 acetyl-CoA carboxylase beta AE000604 Helicobacter pylori 704 52 subunit (accD) ORF142 148115 148549 Dut Z96072 Mycobacterium 277 53 tuberculosis ORF143 148524 149027 enzyme IIANtr U18997 Escherichia coli 168 44 ORF144 149000 149305 putative ORF145 149187 149708 enzyme IIANtr U18997 Escherichia coli 169 43 ORF146 149712 150911 putative ORF147 152044 151004 putative ORF148 152664 151999 putative ORF149 152900 153352 hypothetical U32702 Haemophilus influenzae 292 47 ORF150 153389 153997 hypothetical protein in purB AE000213 Escherichia coli 555 49 region ORF151 155276 153984 ClpC adenosine U02604 Bacillus subtilis 986 triphosphatase ORF152 156544 155231 CIpC adenosine U02604 Bacillus subtilis 1535 53 triphosphatase ORF153 156806 157525 putative ORF154 157489 158955 Unknown Y08559 Bacillus subtilis 99 39 ORF155 159104 159961 putative ORF156 159916 161220 putative ORP begin stop Homology ID Species Score 1% ORF157 161183 161593 glycine cleavage protein U12980 Saccharomyces 175 homolog cerevisiae ORF158 162354 161623 unidentified protein of Na+- D49364 Vibrio alginolyticus 524 51 translocating NADH-quinone reductase ORF159 163013 162363 NADH:uniquinone Z37111 Vibrio alginolyticus 543 oxidoreductase ORF160 163941 162994 MADH:ubiquinone U32702 Haemophilus influenzae 287 54 oxidoreductase (GP:Z37111_4) ORP161 165505 164474 NADH:ubiquinone Z37111 Vibrio alginolyticus 449 oxidoreductase subunit B ORF162 166686 166093 H. pylori predicted coding AE000652 Helicobacter pylori 111 33 region HP1542 ORF163 168171 166729 pot. ORF 446 (aa 1-446) X02369 Bacillus subtilis 722 42 ORF164 169249 168848 putative ORF165 169586 170431 hypothetical protein D90906 Synechocystis sp. 462 48 ORF166 170780 171334 putative ORF167 171333 172376 penicillin-binding protein 2 M26645 Neisseria flavescens 210 47 ORF168 172309 172722 penicillin-binding protein 2 M26645 Neisseria flavescens 176 44 ORF169 173048 174496 murE gene product Z15056 Bacillus subtilis 789 43 ORF170 174399 174968 N-acetylmuramoyl-L-alanine AE000589 Helicobacter pylori 177 41 amidase (amiA) ORF171 175267 175710 integration host factor beta L35259 Pseudomonas aeruginosa 110 38 subunit ORF172 175714 177009 putative ORF173 177423 178115 carboxyltransferase alpha U59236 Synechococcus PCC7942 558 subunit ORF174 178084 180021 ATP dependent translocator U32691 Haemophilus influenzae 453 41 homolog (msbA) ORF175 180704 180048 putative ORF begin stop Homology ID Species Score 1% ORF176 181398 180631 H. pylori predicted coding AE000536 Helicobacter pylori 256 34 region HP0152 ORF177 182594 181398 contains similarity to DNA AP007270 Arabidopsis thaliana 173 polymerase III, alpha chain (SP:P47277) ORF178 182895 183656 putative Ptcl protein Y13937 Bacillus subtilis 371 53 ORF179 183665 184786 NifS2 AF008220 Bacillus subtilis 452 43 ORF180 186007 184796 similar to [SwissProt D90888 Escherichia coli 93 Accession Number P37908] ORF181 186848 186000 hypothetical U32728 Haemophilus influenzae 154 ORF182 187270 186749 putative ORF183 187426 187809 regulatory protein for beta- D90902 Synechocystis sp. 96 36 lactamase ORF184 189481 188798 putative ORF185 189693 190352 prolipoprotein AJ000977 Rhodobacter sphaeroides 99 38 diacylglyceryl transferase ORF186 190235 190510 putative ORF187 190785 191786 putative ORF188 191790 192464 putative ORF189 192392 193183 60 kDa inner-membrane AE000645 Helicobacter pylori 373 protein ORF190 193254 194630 DnaA D89066 Staphylococcus aureus 545 43 ORF191 195046 194690 putative ORF192 195184 197031 glycogen phosphorylase B U47025 Homo sapiens 1758 56 ORF193 197018 197635 glycogen phosphorylase (AA 1 X16931 Escherichia coli 580 53 790) ORF194 197762 198208 unknown X86470 Saccharomyces 148 42 cerevisiae ORF195 198963 197668 F23B12.5 Z77659 Caenorhabditis elegans 795 ORF begin stop Homology ID Species Score 1% ORF196 199957 198962 pyruvate dehydrogenase El U09137 Arabidopsis thaliana 856 48 beta subunit ORP197 200327 199941 pyruvate dehydrogenase El U38804 Porphyra purpurea 170 31 component, alpha subunit ORF198 200685 200266 pyruvate dehydrogenase U81808 Thiobacillus 302 complex El alpha subunit ferrooxidans ORF199 200962 200585 TPP-dependent acetoin L31844 Clostridium magnum 127 43 dehydrogenase alpha-subunit ORF200 201169 202377 putative ORF201 203441 202380 UDP-3-O-(3-hydroxymyristoyl] U70214 Escherichia coli 577 38 glucosamine Nacyltransferase ORF202 203998 203471 putative ORF203 206449 204059 OMP1 precursor U51683 Brucella abortus 83 31 ORF204 207425 206811 recombination protein D90916 Synechocystis sp. 334 ORF205 207506 208528 beta-ketoacyl-acyl carrier M77744 Escherichia coli 706 protein synthase III ORF206 208545 209471 malonyl-CoA:Acyl carrier U59433 Bacillus subtilis 522 48 protein transacylase ORF207 209471 210214 3-ketoacyl-acyl carrier U59433 Bacillus subtilis 616 51 protein reductase ORP208 210586 210816 acyl carrier protein (acpP) U32701 Haemophilus influenzae 220 57 ORF209 211332 210883 protein kinase type II J02934 Rattus norvegicus 150 31 regulatory subunit EC 2.7.1.37) ORF210 212978 211374 putative ORF211 214134 212875 unknown AF017105 Chlamydia psittaci 852 63 ORF212 214710 214168 inclusion membrane protein C AF017105 Chlamydia psittaci 231 43 ORF begin stop Homology ID Species Score I% ORF213 215143 214754 inclusion membrane protein B AF017105 Chlamydia psittaci 181 47 ORF214 216705 215236 sodium-dependent transporter AF017105 Chlamydia psittaci 1341 ORP215 217917 216892 amino acid transporter AF017105 Chlamydia psittaci 1027 ORF216 217088 217441 putative ORF217 218364 218702 putative ORF218 218695 219009 putative ORF219 219179 219748 putative ORF220 219891 220430 putative ORF221 220499 221074 putative ORF222 221137 221541 putative ORF223 221601 222092 putative ORF224 222472 223290 putative ORF225 223423 223818 LAGLI-DADG endonuclease U57090 Chlamydia trachomatis 619 99 ORF226 224278 225171 YqfU D84432 Bacillus subtilis 530 46 ORF227 225749 225174 phenylacrylic acid U67467 Methanococcus 334 52 decarboxylase jannaschii ORF228 225334 225549 Ydr537cp U43834 Saccharomyces 96 42 cerevisiae ORF229 226654 225749 4-hydroxybenzoate U61168 Bacillus firmus 321 36 octaprenyltransferase ORF230 227299 226769 putative ORF231 227646 227161 stationary-phase survival AE000602 Helicobacter pylori 274 48 protein (surE) ORF232 228457 227750 f311; This 311 aa ORF is 22 AE000232 Escherichia coli 246 36 pet identical (13 gaps) to 186 residues of an approx.

488 aa protein YACABACSU SW: P37563; pyul of D21139 ORF233 230001 228607 GadC AF005098 Lactococcus lactis 740 ORF begin stop Homology ID Species Score I% ORF234 231074 230151 f374; This 374 aa ORF is 30 AE000299 Escherichia coli 985 pct identical (9 gaps) to 102 residues of an approx.

512 aa protein PLICSALMU SW: P06177 ORF235 231348 233006 putative ORF236 233059 233829 orf2 D88555 Methanobacterium 351 52 thermoautotrophicum ORF237 233801 234265 hypothetical protein D90906 Synechocystis sp. 151 37 ORF238 234282 234854 ORF o211 U28377 Escherichia coli 105 54 ORF239 236300 235227 glutamate l-semialdehyde 2,1 X82072 Pseudomonas aeruginosa 650 52 aminomutase ORF240 236314 238209 leucine tRNA synthetase AF008220 Bacillus subtilis 1836 61 ORF241 238164 238769 leucine tRNA synthetase AF008220 Bacillus subtilis 410 46 ORF242 238769 240061 3-deoxy-D-manno-2- Z22659 Chlamydia trachomatis 2240 100 octulosonic acid (Kdo) transferase ORF243 242022 240313 pyrophosphate-dependent Z32850 Ricinus communis 1021 43 phosphofructokinase beta subunit ORF244 242846 241941 putative ORP245 244480 242798 pyrophosphate-dependent Z32850 Ricinus communis 1017 42 phosphofructokinase beta subunit ORF246 245897 244479 YflS D86417 Bacillus subtilis 951 42 ORF247 246877 245924 putative ORF248 247731 246985 ATP binding protein L18760 Lactococcus lactis 442 47 ORF249 248585 247743 sporulation protein M57689 Bacillus subtilis 532 38 ORF250 249420 248569 sporulation protein M57689 Bacillus subtilis 601 38 ORF251 250383 249766 sporulation protein M57689 Bacillus subtilis 464 47 ORPF252 251186 250545 oligopeptide permease AF000366 Borrelia burgdorferi 119 31 homolog AII ORF253 252111 251095 sporulation protein M57689 Bacillus subtilis 317 36 ORF begin stop Homology ID Species Score I% ORF254 253088 252066 P. haemolytica o- D88802 Bacillus subtilis 601 46 sialoglycoprotein endopeptidase; P36175 (660) transmembrane ORF255 255153 256718 Mg2+ transporter D90905 Synechocystis sp. 103 ORF256 256762 257844 tRNA guanine L33777 Zymomonas mobilis 482 44 tranaglycosylase ORF257 257911 258690 putative ORF258 258780 259187 putative ORF259 259193 261604 subunit B of DNA gyrase Y07916 Salmonella typhimurium 1925 58 ORF260 261622 264129 DNA gyrase L47978 Aeromonas salmonicida 1963 ORF261 264125 264742 unknown D26185 Bacillus subtilis 307 37 ORF262 264741 265628 replication protein (dnaX) U32802 Haemophilus influenzae 162 ORF263 266416 265631 putative isozyme of glucose- 014553 Anabaena sp. 218 47 6-P-dehydrogenase; developmentally regulated gene in heterocyst development ORF264 266938 266426 glucose 6-phosphate U83195 Chlamydia trachomatis 914 99 dehydrogenase ORF265 267961 266942 glucose 6-phosphate U83195 Chlamydia trachomatis 1770 99 dehydrogenase ORF266 268320 268066 ORF3 015192 Chlamydia trachomatis 403 100 ORF267 268510 268205 ORF3 U15192 Chlamydia trachomatis 320 91 ORF268 270116 268500 CTP synthetase 015192 Chlamydia trachomatis 2828 100 ORP begin stop Homology ID Species Score 1% ORF269 270892 270095 CMP-2-keto-3- U15192 Chlamydia trachomatis 1313 100 deoxyoctulosonic acid synthetase ORF270 271191 271613 putative ORF271 272219 272932 nitrate transporter X61625 Synechococcus sp. 300 34 ORF272 272884 273588 putative ORF273 274816 273596 putative ORF274 274821 275666 putative ORF275 277689 276103 ORF_f535 U28377 Escherichia coli 396 38 ORP276 278268 278816 putative ORF277 279771 279013 tryptophan synthase alpha M15826 Pseudomonas aeruginosa 357 37 subunit ORF278 280777 279767 tryptophan synthetase M91661 Coprinus cinereus 1042 62 ORF279 281603 281295 tryptophan repressor L26582 Enterobacter aerogenes 151 ORF280 282104 281787 putative ORF281 284335 282794 putative ORF282 284460 284795 putative ORF283 284817 285674 putative ORF284 285637 286137 putative ORF285 286357 286677 putative ORF286 286681 287898 hypothetical protein U88070 Chlamydia psittaci 99 ORF287 288127 289227 comE ORF1 D64002 Synechocystis sp. 90 46 ORF288 289744 290679 hypothetical protein U88070 Chlamydia psittaci 246 36 ORF289 290828 291535 putative ORF290 291514 292230 endonuclease U09868 Escherichia coli 160 37 ORF291 292326 293048 putative ORF292 293330 294853 putative ORF293 295684 295010 glutamine transport ATP- U67524 Methanococcus 407 38 binding protein Q jannaschii ORF294 296336 295692 H. influenzae predicted U32830 Haemophilus influenzae 134 37 coding region HI1555 ORF295 297238 296243 putative ORP begin stop Homology ID Species Score ORF296 297791 298735 putative ORF297 298905 300458 similar to putative U73857 Escherichia coli 82 oxygenase of S. fradiae ORF298 302152 300527 putative 0RF299 304917 302071 i ORF300 306157 304973 DNA ligase I. 1 I I M74792 i Thermus aquaticus thermophilus ORF301 1 306 I Ithezincphil us 1O4 I l11 I C ~uvrrr DNA LIGASE (EC 6.5.1.2)

(POLYDEOXYRIBONUCLEOTIDE

SYNTHASE D90870 Escherichia coli ORF302 1 306963 1 306436 I Mycoplasma pneumoniae, DNA ligase; similar to Swiss- Prot Accession Number P15042, from E. coli -f -F

J

1AE000047 ORF303 308773 306977 unknown Z84395 ORF304 ORF305 ORF306 ORF307 ORF308 ORF309 ORF310 309881 310720 311570 312451 313435 314340 315526 309276 309872 310716 311972 314364 314738 314741 putative putative putative Preprotein translocase SecA subunit.

sporulation protein putative orfX gene product Similar to Saccharomyces cerevisiae SUA5 protein serine esterase (Spirulina platensis, C1, Peptide, 207 aa] putative putative putative D90832 M57689 X58778 Mycoplasma pneumoniae Mycoba c teri urn tuberculosis Escherichia coli Bacillus subtilis Klebsiella pneumoniae 316 f 52 1 292 1 37 123 202 169 86 37 ORF311 316507 315665 ORF312 317284 316529 ORF313 317592 317338 ORF314 318470 317499 ORF315 317599 317874 Z38002 Bacillus subtilis 147 41 S70419 Spirulina platensis 167 58

I

I

I

ORF begin stop Homology ID Species Score 1% ORF316 318947 318477 putative ORF317 319342 320142 ORF2 L35036 Chlamydia psittaci 802 ORF318 320544 321497 putative ORF319 321485 321937 putative ORF320 321901 322362 putative ORF321 322301 323140 putative ORF322 323144 324913 putative- ORF323 325621 324977 YqiZ D84432 Bacillus subtilis 430 43 ORF324 326268 325621 integral membrane protein U97348 Lactobacillus fermentum 343 44 homolog ORF325 326469 327203 adenylate kinase AB000111 Synechococcus sp. 371 46 ORF326 327281 328150 putative ORF327 328605 328204 RpsI Z95389 Mycobacterium 315 tuberculosis ORF328 329066 328734 505 ribosomal subunit U18997 Escherichia coli 269 protein L13

O

RF329 329663 329292 YqhX D84432 Bacillus subtilis 297 56 ORF330 330666 329608 biotin carboxylase L14862 Anabaena sp. 1089 58 ORF331 331161 330670 YqhW D84432 Bacillus subtilis 208 52 ORF332 331731 331177 elongation factor P D64001 Synechocystis sp. 297 33 ORF333 332404 331721 putative CfxE protein Y13937 Bacillus subtilis 483 ORF334 332779 333021 putative ORF335 333005 333589 putative ORF336 334357 333806 putative ORF337 334089 334361 putative ORF338 335142 334729 putative- ORF339 335195 335602 putative ORF340 335673 335194 putative-- ORF341 336334 335903 putative ORF342 337378 336338 putative ORF343 339947 337347 ATP-dependent protease M29364 Escherichia coli 2005 53 ___binding subunit ORF begin stop Homology ID Species Score 1% ORP344 340507 341847 Pz-peptidase D88209 Bacillus licheniformis 508 39 ORF345 341783 342022 group B oligopeptidase PepB U49821 Streptococcus 140 48 agalactiae ORF346 342249 342470 hypA protein M31739 Chlamydia trachomatis 361 99 ORF347 342597 343370 heat shock protein L12004 Chlamydia trachomatis 1271 99 ORF348 343361 344032 hypB protein M31739 Chlamydia trachomatis 1051 100 ORF349 343956 344225 hypB protein M31739 Chlamydia trachomatis 344 100 ORF350 344357 345142 orf 3'of chaperonin homolog S40172 Chlamydia psittaci 344 63 hypB [Chlamydia psittaci, pigeon strain P-1041, Peptide Partial, 98 aal ORF351 345934 345161 o247; This 247 aa ORF is 51 AE000174 Escherichia coli 387 41 pet identical (0 gaps) to 117 residues of an approx.

160 aa protein YPH7_CHRVI SW: P45371 ORF352 347102 346080 mutY homolog U63329 Homo sapiens 492 46 ORF353 347113 347940 hypothetical 36.0 kD protein AE000209 Escherichia coli 397 44 in rne-rpmF intergenic region ORF354 350164 348146 putative ORF355 350423 351283 enoyl-acyl carrier protein S60064 Brassica napus 909 64 reductase [Brassica napus, Peptide, 385 aal ORF356 352207 351314 hypothetical protein D90914 Synechocystis sp. 113 42 ORF357 352727 352245 putative ORF begin stop Homology ID Species Score I% ORF358 353709 353305 FUNCTION UNKNOWN, SIMILAR AB001488 Bacillus subtilis 213 PRODUCT IN E. COLI AND MYCOPLASMA PNEUMONIAE.

ORF359 354218 353670 NADPH thioredoxin reductase Z23108 Arabidopsis thaliana 577 ORF360 354721 354140 Thioredoxin Reductase D45049 Neurospora crassa 417

(NADPH)

ORF361 354966 356672 30S ribosomal protein SI D90729 Escherichia coli 1305 44 ORF362 356700 357377 NusA U74759 Chlamydia trachomatis 948 100 ORF363 357326 358093 NusA U74759 Chlamydia trachomatis 1216 100 ORF364 358035 360743 U74759 Chlamydia trachomatis 3311 98 ORF365 360753 361121 ORF6 gene product Z18631 Bacillus subtilis 116 32 ORF366 361162 361884 tRNA pseudouridine 55 D90917 Synechocystis sp. 362 42 synthase ORF367 361826 362746 protein X M35367 Pseudomonas fluorescens 192 49 ORF368 363859 362816 hypothetical GTP-binding AE000219 Escherichia coli 978 52 protein in pth 3' region ORF369 364116 365195 cdsl gene product U88070 Chlamydia psittaci 1631 88 ORF370 365198 365587 cds2 gene product U88070 Chlamydia psittaci 516 93 ORF371 365479 367320 cds2 gene product U88070 Chlamydia psittaci 2817 87 ORF372 367341 368603 copN gene product U88070 Chlamydia psittaci 585 37 ORF373 368644 369081 Csecl gene product U88070 Chlamydia psittaci 528 67 ORF374 369088 370251 No definition line found U88070 Chlamydia psittaci 1362 62 ORF375 370769 371086 ribosomal protein L28 U32776 Haemophilus influenzae 182 46 1 (rpL28) ORF376 371203 372816 hypothetical protein U88070 Chlamydia psittaci 1926 68 ORF377 373119 373529 hypothetical protein U88070 Chlamydia psittaci 286 49 ORF378 373614 374204 hypothetical protein U88070 Chlamydia psittaci 379 48 ORF379 374736 374224 putative ORF begin stop Homology ID Species Score I% ORF380 376391 374703 putative ORF381 377062 376748 corresponds to a 97 amino L40838 Chlamydia trachomatis 490 98 acid long polypeptide ORF382 377853 378737 methylenetetrahydrofolate D64000 Synechocystis sp. 678 51 dehydrogenase ORF383 378626 379048 putative_ ORF384 379017 379403 hypothetical U32702 Haemophilus influenzae 137 ORF385 380009 379641 small protein D90914 Synechocystis sp. 216 51 ORF386 380187 381470 DNA polymerase III beta- U32780 Haemophilus influenzae 76 39 subunit (dnaN) ORF387 381473 382567 recombination protein D26185 Bacillus subtilis 477 ORF388 382704 383702 putative ORF389 383945 383655 hypothetical U70214 Escherichia coli 134 ORF390 385217 383949 putative ORF391 385507 385178 conserved hypothetical AE000606 Helicobacter pylori 185 secreted protein ORF392 386845 385706 hypothetical protein D64000 Synechocystis sp. 686 41 ORF393 386127 386627 putative ORF394 387372 386872 ORF1; putative M26130 Streptococcus 150 parasanguis ORF395 387823 387338 ytgD AF008220 Bacillus subtilis 168 42 ORF396 388250 387816 TroR U55214 Treponema pallidum 134 ORF397 389169 388237 putative protein of 299 U30821 Cyanophora paradoxa 164 31 amino acids ORF398 389955 389173 TroB U55214 Treponema pallidum 592 51 ORF399 390988 389945 YtgA AF008220 Bacillus subtilis 282 ORF400 391514 391810 putative ORF401 392410 393996 adenine nucleotide Z49227 Arabidopsis thaliana 1295 56 translocase ORF402 394170 395354 lepA gene product X91655 Bacillus subtilis 1235 ORF403 395309 395992 GTP-binding membrane protein AE000552 Hlelicobacter pylori 543 54 ORF begin stop Homology ID Species Score I% ORF404 396538 396059 phosphogluconate U30255 Homo sapiens 411 dehydrogenase ORP405 397507 396542 6-phosphogluconate AB006102 Candida albicans 908 51 dehydrogenase ORF406 398753 397401 tyrosyl-tRNA synthetase M13148 Bacillus caldotenax 844 ORF407 399688 398909 whiG-Stv gene product X68709 Streptoverticillium 463 41 griseocarneumn ORF408 400167 399778 FLHA gene product X63698 Bacillus subtilis 134 ORF409 401224 400034 flbP M73782 Caulobacter crescentus 355 39 ORP410 401776 402021 ferredoxin IV M59855 Rhodobacter capsulatus 98 54 ORF411 402126 403220 putative ORF412 403348 405180 GcpE D90908 Synechocystis sp. 995 49 ORF413 403788 403276 putative ORP414 405165 405920 YfiH U50134 Escherichia coli 166 43 ORF415 407049 405955 dihydrolipoamide M27141 Bacillus subtilis 833 61 transsuccinylase (odhB; EC 2.3.1.61) ORF416 409773 407056 alpha-ketoglutarate U41762 Rhodobacter capsulatus 1537 dehydrogenase ORF417 410532 411416 YqeR D84432 Bacillus subtilis 496 44 ORF418 411707 413410 putative ORF419 413433 412606 putative ORF420 413404 413952 putative ORF421 413841 415112 putative ORF422 414379 413978 putative ORF423 416664 415177 putative ORF424 417456 416740 unknown Z94752 Mycobacterium 172 36 41 3 .2 pa tuberculosis ORF425 418053 417721 putative ORF426 418603 418031 putative ORF begin stop Homology ID Species Score I% ORF427 419531 418647 Hc2 nucleoprotein L10193 Chlamydia trachomatis 1661 92 ORF428 420190 419672 [karp] gene products 1M86605 Chlamydia trachomatis 612 96 ORF429 421171 420245 aminopeptidase D17450 Mycoplasma salivarium 269 41 ORF430 421988 421518 putative L39923 Mycobacterium leprae 165 36 ORF431 422486 423043 putative ORF432 423226 425079 glycogen operon protein G1gX D90908 Synechocystis sp. 1229 ORF433 426054 425146 putative ORF434 426985 426245 Holliday junction specific D83138 Pseudomonas aeruginosa 633 53 DNA helicase ORF435 427248 427817 deoxycytidine triphosphate AE000554 Helicobacter pylori 612 63 deaminase (dcd) ORF436 429560 429886 putative ORF437 430360 429857 biotin apo-protein ligase U27182 Saccharomyces 173 38 cerevisiae ORF438 430637 430323 putative ORF439 430933 431787 putative ORF440 431658 431987 putative ORF441 432232 434475 exonuclease V alpha-subunit U29581 Escherichia coli 289 53 ORF442 436308 434620 methionyl-tRNA synthetase AB004537 Schizosaccharamyces 817 54 1 pombe ORF443 436574 436272 putative ORF444 437685 436567 RNAseH II AF005098 Lactococcus lactis 395 47 ORF445 438262 437894 ribosomal protein L19 X72627 Synechocystis sp. 287 47 ORF446 439127 438285 tRNA (guanine-N1)- U32705 Haemophilus influenzae 374 56 methyltransferase (trmD) ORF447 439339 438986 tRNA (guanine-N1)- U32705 Haemophilus influenzae 199 57 I_ methyltransferase (trmD) ORF begin stop Homology ID Species Score I% ORF448 439705 439358 ribosomal protein S16 U32705 Haemophilus influenzae 168 39 (rpS16) ORF449 441042 439699 signal recognition particle AE000347 Escherichia coli 865 protein ORF450 441911 441042 product similar to E.coli Z49782 Bacillus subtilis 314 37 PRFA2 protein ORF451 442593 441898 polypeptide chain release U32830 Haemophilus influenzae 708 62 factor 1 (prfA) ORF452 444505 446388 leader peptidase I D90904 Synechocystis sp. 268 44 ORF453 448068 446452 isoleucyl-tRNA synthetase U04953 Homo sapiens 704 49 ORF454 449575 447932 isoleucyl-tRNA synthetase U04953 Homo sapiens 1687 ORF455 450546 451076 putative ORF456 451623 451144 putative ORF457 452593 451517 putative ORF458 453195 452632 putative ORF459 453567 454868 product similar to E. coli Z97025 Bacillus subtilis 820 PhoH protein ORF460 455430 454972 CydB Z95554 Mycobacterium 105 31 tuberculosis ORF461 456047 455367 cyanide insensitive terminal Y10528 Pseudomonas aeruginosa 388 38 oxidase ORF462 457384 456047 cyanide insensitive terminal Y10528 Pseudomonas aeruginosa 537 52 oxidase ORF463 457659 458450 YbbP AB002150 Bacillus subtilis 324 42 ORF464 458508 459632 putative ORF465 459839 461203 HtrB protein X61000 Escherichia coli 77 31 ORF466 461624 461196 unknown U87792 Bacillus subtilis 114 38 ORF467 461887 462621 hypothetical protein Z75208 Bacillus subtilis 148 51 ORF468 463758 462895 putative ORF469 464048 464629 putative ORF470 464721 465848 putative ORF471 467420 466113 PET112 D90913 Synechocystis sp. 892 48 ORF begin stop Homology ID Species Score 1% ORF472 468891 467419 amidase U49269 Moraxella catarrhalis 1051 46 ORF473 469280 468906 putative ORF474 469349 469675 putative ORF475 471226 469826 putative ORF476 471624 471106 putative ORF477 471954 473267 putative 98 kDa outer U72499 Chlamydia psittaci 173 33 membrane protein ORF478 473252 473695 POMP90A precursor U65942 Chlamydia psittaci 175 39 ORF479 473982 474527 putative 98 kDa outer U72499 Chlamydia psittaci 193 38 membrane protein ORF480 475198 474602 putative ORF481 476527 475613 POMP91A U65942 Chlamydia psittaci 100 38 ORF482 478640 476517 putative 98 kDa outer U72499 Chlamydia psittaci 537 membrane protein ORF483 479084 478665 putative 98 kDa outer U72499 Chlamydia psittaci 234 membrane protein ORF484 479723 479088 putative outer membrane U72499 Chlamydia psittaci 313 protein ORF485 480012 479668 putative ORF486 481466 479895 putative 98 kDa outer U72499 Chlamydia psittaci 391 38 membrane protein ORF487 481732 481496 putative ORF488 481864 483429 POMP90A precursor U65942 Chlamydia psittaci 114 ORF489 483402 484964 putative 98 kDa outer U72499 Chlamydia psittaci 77 34 membrane protein ORF490 484898 487864 putative 98 kDa outer U72499 Chlamydia psittaci 506 39 membrane protein ORF491 485725 485222 putative ORF492 488204 489247 putative ORF493 488571 488233 putative ORF494 489440 490456 putative ORF495 492765 490507 branching enzyme M31544 Synechococcus PCC6301 1624 57 ORP begin atop Homology ID Species Score 1% ORF496 492357 492893 putative 1 ORF497 493744 492737 putative ORF498 493875 494675 YqkM D84432 Bacillus subtilis 230 44 ORF499 494573 494869 xprB M54884 Escherichia coli 245 48 ORF500 494835 495365 putative ORFS01 495174 494872 putative ORF502 495687 496634 putative ORF503 496295 497176 putative ORF504 497703 498515 putative ORF505 498280 499239 putative ORF506 499215 500732 putative ORF507 501710 500790 penicillin tolerance protein U32781 Haemophilus influenzae 702 (lytB) ORF508 502863 501808 putative ORF509 503675 502692 putative 505002 503722 hypothetical protein Z96072 Mycobacterium 102 42 tuberculosis ORF511 505739 506986 hypothetical protein in pth- AE000219 Escherichia coli 740 44 prs intergenic region ORF512 506999 507439 putative ORF513 508404 507649 fumarate hydratase AF013216 Myxococcus xanthus 611 54 ORF514 508291 508590 putative ORF515 508915 508478 fumarase D64000 Synechocystis sp. 386 57 ORF516 509600 510691 thiamine-repressed protein U32720 Haemophilus influenzae 82 31 (nmtl) ORF517 511039 511527 putative ORF518 511547 512185 hypothetical protein U67608 Methanococcus 208 39 (SP:P46851) jannaschii ORF519 512382 513092 methionine amino peptidase M15106 Escherichia coli 384 46 ORF520 514287 513055 putative ORF521 514789 515244 putative ORF522 514994 515269 putative ORF begin stop Homology ID Species Score I% ORFS23 515553 515804 putative ORF524 515808 516422 putative ORF525 516476 517171 putative ORF526 517927 517400 orfl50O gene product X!5938 Porphyromonas 340 51 gingivalis ORF527 518096 518380 30S ribosomal protein 815 D90901 Synechocystis sp. 245 52 ORF528 518403 518822 polynucleotide phosphorylase AF010578 Pisum sativum 306 '9 ORF529 518923 519516 polyribonucleotide U52048 Spinacia oleracea 387 47 phophorylase ORFP530 519577 520497 polynucleotide phosphorylase U18997 Escherichia coli 860 54 ORFP531 521986 520718 ATP-binding protein 1101376 Escherichia coli 970 49 ORF532 522131 521886 cell division protein (ftsH) U32812 Haemophilus influenzae 314 76 ORF533 523495 522143 putative ORP534 524591 523623 ORF327 gene product U38804 Porphyra purpurea 148 44 ORF535 524652 525746 putative ORFS36 525731 526078 putative ORF537 525939 526400 putative ORS38 526301 526735 putative ORF539 528323 526851 putative ORF540 528861 528292 putative ORFS41 529723 529142 phenylalanyl-tRNA synthetase X53057 Bacillus subtilis 476 52 alpha subunit ORF542 530166 529624 phenylalany-tRNA synthetase Z75208 Bacillus subtilis 164 beta subunit ORF543 530543 530223 ribosomal protein L20 (AA 1- X16188 Bacillus 230 47 119) stearothermophilus ORF544 531378 530737 unknown Z85982 Mycobacterium 452k tuberculosis ORP545 532370 533272 UDP-N- 1U86147 Synechococcus PCC7942 488 43 acetylenolpyruvylglucosamine reductase ORP begin stop Homology ID Species Score I% ORF546 533849 533244 YtqB AF008220 Bacillus subtilis 273 38 ORPSF47 534672 533944 hypothetical protein 292669 Mycobacterium 170 MTCYOBD5.03c tuberculosis ORF548 535915 534878 ribonucleoside diphosphate AE000553 Helicobacter pylori 397 33 reductase, beta subunit (nrdB) ORP549 539153 535956 ribonucleoside-diphosphate AE000581 Helicobacter pylori 1447 51 reductase 1 alpha subunit (nrdA) ORF550 539731 540519 phosphatidylserine synthase AE000614 Helicobacter pylori 226 49 (pasA) ORF551 540523 540969 putative ORF552 540906 541805 hypothetical 54.7 kD protein AE000459 Escherichia coli 82 39 in udp 3' region precursor (o475) ORF553 543255 541825 Ydr430cp; CAI: 0.15 U33007 Saccharomyces 130 48 cerevisiae ORF554 544133 543222 putative ORFP555 544565 544179 hypA gene product X86493 Clostridium perfringens 221 46 ORF556 544762 544487 orfl gene product X70951 Saccharomyces 153 38 cerevisiae ORF557 546423 544951 senine protease (htrA) AE000610 Helicobacter pylori 981 46 ORF558 547480 546584 succinyl coenzyme A U23408 Dictyostelium 869 63 synthetase alpha subunit discoideum ORF559 546789 547382 putative ORF560 547901 547476 putative succinyl-coA AJ000975 Bacillus subtilis 388 synthetase beta chain ORF561 548634 547900 succinate--CoA ligase (ADP- X54073 Thermus aquaticus 498 46 forming) flavus ORF562 548692 549459 cell division protein (ftsY) AE000588 Helicobacter pylori 330 46 ORF563 550385 549663 putative ORP begin stop Homology ID Species Score 1% ORF564 551611 550421 Tyrosine-specific transport D90832 Escherichia coli 508 protein (Tyrosine permease).

ORF565 553041 551797 tyrosine-specific transport U32730 Haemophilus influenzae 353 36 protein (tyrP) ORF566 554946 553096 L-glutamine:D-fructose-6-P U17352 Thermus aquaticus 1324 amidotransferase precursor thermophilus ORF567 556300 554927 hypothetical U32824 Haemophilus influenzae 1009 51 ORF568 556524 556904 putative ORF569 558126 557314 putative ORF570 557810 558235 putative ORF571 559215 558310 putative ORF572 561349 559196 POMP91A U65942 Chlamydia psittaci 245 39 ORF573 562931 561150 putative 98 kDa outer U72499 Chlamydia psittaci 130 38 membrane protein ORF574 564083 563121 putative PlsX protein Y13937 Bacillus subtilis 519 ORF575 563593 563943 putative ORF576 565379 566953 ORF_f495; orfF of ECMRED, U18997 Escherichia coli 874 39 uses 2nd start ORF577 567079 567966 glycerol-3-phosphate M80571 Cucumis sativus 594 acyltransferase ORF578 568021 570399 insulin-degrading enzyme M58465 Drosophila melanogaster 334 42 ORF579 571269 572021 putative ORP580 572519 572755 putative ORF581 573519 572731 unknown Z94752 Mycobacterium 203 tuberculosis ORF582 572879 573427 putative- ORF583 574160 573660 putative heat shock protein M62820 Chlamydia trachomatis 315 83 SORF; putative ORF begin stop Homology ID Species Score 1% ORF584 574426 574184 ribosomal protein S18 M62820 Chlamydia trachomatis 384 99 homolog; putative ORF585 574781 574446 ribosomal protein S6 (rps6) AE000630 Helicobacter pylori 176 39 ORF586 575243 574923 peptidyl-tRNA hydrolase U31570 Chlamydia trachomatis 358 78 ORF587 575458 575057 peptidyl-tRNA hydrolase UJ31570 Chlamydia trachomatis 393 81 ORF588 575849 575469 partial ctc gene product (AA X16518 Bacillus subtilis 94 37 1-186) ORF589 576545 578023 glycogen (starch) synthase D90899 Synechocystis sp. 695 48 ORF590 578673 578017 phosphatidylglycerophosphate U87792 Bacillus subtilis 243 48 synthase ORF591 579012 582104 glycyl-tRNA synthetase U20547 Chlamydia trachomatis 5054 99 ORF592 582697 582206 putative ORF593 583122 582811 putative ORF594 583514 583182 putative ORF595 583869 583438 putative ORF596 584435 583827 dnaG AB001896 Staphylococcus aureus 298 41 ORF597 584967 584299 DNA primase 013165 Listeria monocytogenes 339 41 ORF598 585297 585016 putative ORF599 585240 586610 DNA mismatch repair protein D90909 Synechocystis p. 673 42 ORF600 586484 587758 DNA mismatch repair protein U71154 Aquifex pyrophilus 845 ORF601 587786 589408 excinuclease ABC subunit C U32691 Haemophilus influenzae 719 46 (uvrC) ORF602 589198 589578 exinuclease ABC subunit C U29587 Rhodobacter sphaeroides 156 42 ORF begin stop Homology ID Species Score I% ORF603 590061 589630 putative ORF604 590739 591272 putative ORF605 592406 592765 homologous to E.coli rnpA X62539 Bacillus subtilis 117 34 ORF606 593145 592849 putative ORP607 593900 593121 putative OR608 594138 595637 cys-tRNA synthetase (cysS) U32693 Haemophilus influenzae 991 49 ORF609 596122 595640 lysyl-tRNA synthetase D90906 Synechocystis sp. 375 53 ORF610 596864 596154 lysine--tRNA ligase X70708 Thermus aquaticus 571 52 thermophilus ORF611 597731 597282 putative ORF612 598524 600809 putative PriA protein Y13937 Bacillus subtilis 1097 38 ORF613 601876 600734 L-alanine pimelyl CoA U51868 Bacillus subtilis 242 42 ligase ORF614 603523 601910 2- L14681 Escherichia coli 388 42 acylglycerophosphoethanolami ne acyltransferase/acyl carrier protein synthetase ORF615 603794 603531 putative ORF616 604413 603757 putative ORF617 604549 605610 3'(2'),5-diphosphonucleoside U33283 Oryza sativa 254 phosphohydrolase ORF618 606619 605582 leucine dehydrogenase X79068 Thermoactinomyces 638 49 intermedius ORF619 606843 607493 inorganic pyrophosphatase 1X57545 Arabidopsis thaliana 291 37 ORF620 609068 608031 beta-ketoacyl-ACP synthase L13242 Ricinus communis 1069 57 ORF621 609652 609296 H10034 homolog U82598 Escherichia coli 196 36 ORF622 611860 610109 putative ORF623 611812 612927 conserved hypothetical AE000579 Helicobacter pylori 780 41 protein ORP begin stop Homology ID Species Score 1% ORF624 613597 612938 trna delta(2)- Z98209 Mycobacterium 244 37 isopentenylpyrophosphate tuberculosis transferase ORF625 613952 613692 delta2- 211831 Escherichia coli 134 54 isopentenylpyrophosphate tRNA transferase ORF626 614315 615244 putative ORF627 615396 615683 unknown 274024 Mycobacterium 93 47 tuberculosis ORF628 617711 615864 D-alanine:D-alanine ligase U39788 Enterococcus hirae 555 38 ORF629 618313 617510 UDP-N-acetylmuramate-alanine U32794 Haemophilus influenzae 448 47 ligase (murC) ORF630 619338 618361 transferase, peptidoglycan U32793 Haemophilus influenzae 380 39 synthesis (murG) ORF631 620416 619247 spoVE gene product (AA 1- X51419 Bacillus subtilis 538 37 366) ORF632 619863 620261 putative ORP633 621184 620420 hypothetical protein Y14079 Bacillus subtilis 313 44 ORF634 621690 621154 murD gene product (AA 1-438) X51584 Escherichia coli 221 43 ORF635 622399 621674 MurD 295388 Mycobacterium 228 41 tuberculosis ORF636 623466 622414 ORF-Y (AA 1-360) X51584 Escherichia coli 543 ORP637 624178 623570 PROBABLE UDP-N- AB001488 Bacillus subtilis 103 43

ACETYLMURAMOYLALANYL-D-

GLUTAMYL-2, 6-DIAMINOLIGASE (EC 6.3.2.15).

ORF begin stop Homology ID Species Score I% ORF638 624918 624073 UDP-N-acetylmuramoylalanyl-D X62437 Synechocystis sp. 243 33 glutamyl-2, 6diaminopimelate--D-alanyl-Dalanine ligase ORF639 625346 626665 chaperonin 60 U56021 Thermoanaerobacter 136 31 brockii ORF640 626514 626900 putative ORF641 626954 627853 putative ORF642 627822 628124 putative ORF643 628715 628146 elongation factor P U14003 Escherichia coli 467 ORF644 628932 629801 AMP nucleosidase (EC D90837 Escherichia coli 278 47 3.2.2.4).

ORF645 630406 629804 transketolase Z73234 Bacillus subtilis 361 46 ORF646 630960 630298 transketolase 273234 Bacillus subtilis 460 47 ORF647 631799 630915 transketolase 1 (TK 1) U32783 Haemophilus influenzae 756 47 (tktA) ORF648 637488 638084 alanyl-tRNA synthetase X59956 Rhizobium leguminosarum 436 56 ORF649 638036 640207 alanyl-tRNA synthetase X95571 Thiobacillus 1121 39 ferrooxidans ORF650 640221 643472 transcription-repair U32805 Haemophilus influenzae 1426 46 coupling factor (trcF) (mfd) ORF651 640627 640220 putative ORF652 643485 644495 uroporphyrinogen M97208 Bacillus subtilis 416 decarboxylase OR653 644471 645430 putative oxygen-independent U06779 Salmonella typhimurium 638 43 coproporphyrinogen III oxidase ORF654 645394 645840 oxygen independent D90912 Synechocystis sp. 283 42 coprophorphyrinogen III oxidase ORF begin stop Homology ID Species Score 1% ORF655 645840 647111 hemY M97208 Bacillus subtilis 133 38 OR656 649676 647109 phosphoprotein L25078 Chlamydia trachomatis 2043 99 ORF657 649970 650344 Hcl M60902 Chlamydia trachomatis 603 100 ORF658 650418 651722 pCTHoml gene product M94254 Chlamydia trachomatis 1735 100 ORF659 651686 652171 putative ORF660 652516 652908 phenolhydroxylase component U32702 Haemophilus influenzae 263 41 ORF661 652799 653593 phenolhydroxylase component U32702 Haemophilus influenzae 456 51 ORF662 659884 661851 YtpT AF008220 Bacillus subtilis 709 52 ORF663 661740 662282 spoIIIEB protein M17445 Bacillus subtilis 330 43 RF664 662286 663074 yycJ D78193 Bacillus subtilis 405 38 ORF665 662951 663730 C41G7.4 Z81048 Caenorhabditis elegans 200 36 ORF666 664212 663745 hypothetical protein Z297193- Mycobacterium 194 38 MTCY180.08 tuberculosis ORF667 665619 664255 D-alanine glycine permease AE000603 Helicobacter pylori 205 34 (dagA) ORF668 666083 665727 putative ORF669 666423 665782 putative ORF670 666831 668117 putative ORF671 668121 668375 putative ORF672 668470 668174 riboflavin synthase beta U32810 Haemophilus influenzae 192 chain (ribE) ORF673 669533 668616 GTP cyclohydrolase II 3,4- AJ00053 Arabidopsis thaliana 800 51 dihydroxy-2-butanone-4phoshate synthase ORF674 669892 669485 unnamed protein product A38767 Saccharomyces 288 49 cerevisiae ORF675 670780 669998 ribG gene product L09228 Bacillus subtilis 191 42 ORF 'begin stop Homology ID Species Score I% ORF676 671241 670732 riboflavin-specific U27202 Actinobacillus 314 51 deaminase pleuropneumoniae ORF677 671182 672447 seryl-tRNA synthetase X91007 Haloarcula marismortui 736 49 ORF678 672692 673231 putative ORP679 673204 674562 ATPase L28104 Transposon Tn5422 565 41 ORF680 674612 675232 unknown Z74025 Mycobacterium 340 43 tuberculosis ORF681 675327 676463 rod-shape-determining M22857 Escherichia coli 442 37 protein ORF682 677027 676476 biotin [acetyl-CoA L02354 Paracoccus 169 49 carboxylase] ligase denitrificans ORF683 678422 677700 ORFX13 L09228 Bacillus subtilis 426 43 ORF684 678717 679508 2,3-bisphosphoglycerate M23068 Homo sapiens 494 47 ORF685 679342 680502 synthesis of [Fe-S] cluster AE000542 Helicobacter pylori 150 33 (nifS) ORF686 680579 681280 NifU AF001780 Cyanothece PCC 8801 101 31 ORF687 681539 682558 putative ORF688 682554 683087 putative ORF689 683164 684465 ORP 4 M72718 Bacillus subtilis 708 36 ORF690 684774 684418 putative ORF691 684839 686203 AgX-1 antigen [human, S73498 Homo sapiens 338 37 infertile patient, testis, Peptide, 505 aa] ORF692 686197 687204 L-glycerol 3-phosphate U00039 Escherichia coli 577 38 dehydrogenase ORF693 687341 688360 putative ORF694 688432 688193 putative ORF695 689616 688432 putative ORF696 689960 689631 putative ORF697 690487 689846 putative ORF698 690717 690463 putative- ORF699 691871 690672 putative-- ORF begin atop Homology ID Species Score I% ORF700 693837 692041 phosphoenolpyruvate M59372 Neocallimastix 1818 59 carboxykinase frontalis ORF701 694934 693837 MreB protein M96343 Bacillus subtilis 961 56 ORF702 697263 694942 SNF X98455 Bacillus cereus 1073 ORF703 698084 697170 putative ORP704 698392 697979 putative ORF705 698792 700117 trigger factor (tig) AE000591 Helicobacter pylori 84 34 OR706 700269 700895 proteosome major subunit AF013216 Myxococcus xanthus 615 59 ORF707 700912 702165 ATP-dependent protease L18867 Escherichia colil 1183 ATPase subunit ORF708 702183 703412 poly(A) polymerase L47709 Bacillus subtilis 362 38 ORF709 703522 705000 hypothetical protein D90912 Synechocystis sp. 809 41 ORF710 705011 705604 putative ORF711 706159 705704 Preprotein translocase AF022186 Cyanidium caldarium 165 44 subunit ORF712 706521 706138 secA X99401 Bacillus firmus 155 42 ORF713 708103 706496 SecA U66081 Mycobacterium smegmatis 1044 58 ORF714 708398 708078 cp-SecA; chloroplast SecA U71123 Zea mays 258 69 homolog ORF715 708610 708248 SecA U21192 Streptomyces lividans 179 42 ORF716 710278 708872 putative ORF717 711164 710262 phosphatidylserine U72715 Chlamydia trachomatis 1548 99 decarboxylase ORF718 711432 712763 homologous to E.coli 50K X62539 Bacillus subtilis 713 54 ORF719 712767 713438 ultraviolet N-glycosylase/AP U22181 Micrococcus luteus 273 lyase ORF720 714232 713651 putative ORF721 714632 714120 putative ORF722 715592 714834 putative ORF723 715854 715558 putative OR7724 716937 715921 putative ORF begin stop Homology ID Species Score I% ORF725 718357 717149 3-phosphoglycerate kinase U83197 Chlamydia trachomatis 2049 100 ORP726 718500 718862 putative ORF727 719797 718499 phosphate permease (YBR296C) U32834 Haemophilus influenzae 997 42 ORF728 720273 719782 putative ORF729 720452 720144 H. influenzae predicted U32834 Haemophilus influenzae 164 37 coding region HI1603 ORF730 720613 721575 dciAD X56678 Bacillus subtilis 722 41 ORF731 721559 722356 was dppE U00039 Escherichia coli 477 44 ORF732 723248 722397 chromosome partitioning U87804 Caulobacter crescentus 388 protein ParB ORF733 724598 723378 NifS protein. D90811 Escherichia coli 805 39 ORF734 725763 724576 hypothetical protein D64004 Synechocystis sp. 154 41 ORF735 726519 725767 Multidrug resistance protein D90811 Escherichia coli 607 54 1 (P-glycoprotein 1).

ORF736 726819 726538 ABC transporter subunit D64004 Synechocystis sp. 266 58 ORF737 727493 726753 ABC transporter subunit D64004 Synechocystis sp. 854 71 ORP738 727984 727469 ABC transporter subunit D64004 Synechocystis sp. 531 ORF739 728778 728329 putative ORF740 729346 728759 antiviral protein L36940 Saccharomyces 115 33 cerevisiae ORF741 732639 729442 penicillin-binding protein 2 U32688 Haemophilus influenzae 208 43 (pbp2) ORF742 733246 734427 major outer membrane protein M14738 Chlamydia trachomatis 2045 99 L precursor ORF743 734814 735659 ribosomal protein S2 U60196 Chlamydia trachomatis 1269 76 ORF744 735644 736504 elongation factor Ts U60196 Chlamydia trachomatis 1278 ORF745 736520 737254 UMP kinase. U60196 Chlamydia trachomatis 1153 94 ORF begin stop Homology ID Species Score I% ORF746 737254 737787 ribosome-releasing factor U60196 Chlamydia trachomatis 760 92 ORF747 737942 738679 putative ORF748 738838 739740 ORF3; putative 39 kDa U40604 Listeria monocytogenes 116 31 protein ORF749 742057 740060 XcpQ X68594 Pseudomonas aeruginosa 453 37 ORF750 742869 742045 putative ORF751 743378 742824 putative ORF752 744298 743306 unknown Z80233 Mycobacterium 137 tuberculosis ORF753 744714 744430 putative M69228 Caulobacter crescentus 117 38 ORF754 744985 744611 putative ORF755 745557 744958 putative ORF756 746412 745561 putative ORF757 746772 746416 putative ORF758 748269 746944 PscN AFO10151 Pseudomonas aeruginosa 1220 ORF759 748966 748274 putative ORF760 749426 748965 putative ORF761 749702 749433 putative ORF762 750029 749721 putative ORF763 752307 750007 putative ORF764 752913 752503 putative ORF765 754659 753616 NAD(P)H:glutamyl-transfer M57676 Bacillus subtilis 172 RNA reductase ORF766 755000 756814 DNA gyrase subunit B U35453 Clostridium 970 38 acetobutylicum ORF767 756796 758301 gyrA X92503 Mycobacterium smegmatis 409 49 ORF768 758691 758446 unknown 274024 Mycobacterium 107 34 tuberculosis ORF begin stop Homology ID Species Score 1% ORF769 759787 759338 SfhB U50134 Escherichia coli 241 48 ORF770 760242 759871 putative ORF771 760538 760188 putative ORF772 760966 761772 3-deoxy-D-manno-octulosonate U72493 Chlamydia trachomatis 1350 99 8-phosphate synthetase ORF773 761759 762142 unknown U72493 Chlamydia trachomatis 536 94 ORF774 762267 762983 ATP binding protein U72493 Chlamydia trachomatis 1197 99 ORP775 764465 763335 chlanectin coding region M17875 Chlamydia trachomatis 239 100 ORF776 764857 764438 putative ORF777 766068 764821 unknown function Z32530 Chlamydia trachomatis 1803 99 ORF778 766643 766065 unknown function Z32530 Chlamydia trachomatis 704 100 ORF779 768091 766934 RecA U16739 Chlamydia trachomatis 1753 100 ORF780 768785 768252 unknown function Z32530 Chlamydia trachomatis 904 99 ORF781 770092 768791 unknown function Z32530 Chlamydia trachomatis 2249 100 ORF782 770138 770470 putative ORF783 770661 770185 putative ORF784 770924 770634 putative ORF785 772010 771330 putative ORF786 772390 773391 unknown D26185 Bacillus subtilis 486 ORF787 774221 773427 ORFfl69 U18997 Escherichia coli 263 51 ORF788 776035 774191 DNA topoisomerase I L27797 Bacillus subtilis 1357 52 ORF789 776663 777706 putative ORF790 777195 776953 putative ORF791 779222 777732 ORFf397 U295B1 Escherichia coli 93 ORF begin stop Homology ID Species Score I% OR792 779321 781552 putative ORF793 781297 782442 putative ORP794 782447 785524 exonuclease V (AA 1-1180) X04581 Escherichia coli 557 49 ORF795 785532 786002 putative ORF796 786580 785546 MreC protein M31792 Escherichia coli 81 64 ORF797 787741 786611 aspartate aminotransferase M12105 Gallus gallus 700 42 precursor ORF798 787620 788021 putative ORF799 790124 787920 GreA U02878 Rickettsia prowazekii 84 33 ORF800 790160 790609 putative ORF801 790634 792016 NADH:ubiquinone Z237111 Vibrio alginolyticus 409 37 oxidoreductase subunit A ORF802 793084 792059 delta aminolevulinic acid L24386 Bradyrhizobium 867 52 dehydratase japonicum ORF803 793343 794056 putative ORFBO4 794046 794957 putative ORF805 795401 795144 putative ORF806 795575 796255 ompR gene product X92405 Neisseria meningitidis 103 32 ORFP807 796278 797015 glucose-i-phosphate U67553- Methanococcus 216 36 thymidylyltransferase jannaschii ORF808 796979 797365 YqiD D84432 Bacillus subtilis 184 58 ORF809 797260 797856 farnesyl diphosphate D13293 Bacillus 107 37 synthase stearothermophilus ORF810 797772 798086 putative ORF811 798426 797935 Orf39.9 X61000 Escherichia coli 290 51 ORF812 798925 798416 This ORF is homologous to a L22217 Mycoplasma-like 150 46 40.0 kd hypothetical protein organism in the htrB 3' region from E. coli, Accession Number X61000 ORF begin stop Homology ID Species Score I% ORF813 799301 799927 ribosomal protein S4 (rps4) AE000633 Helicobacter pylori 407 46 ORF814 800892 800029 apurinic/apyrimidinic U40707 Caenorhabditis elegans 397 endonuclease ORF815 801062 802129 mviB homolog U50732 Chlamydia trachomatis 1716 97 ORF816 802023 802673 mviB homolog U50732 Chlamydia trachomatis 973 97 ORF817 802851 803246 lorf2; possible membrane- U50732 Chlamydia trachomatis 280 100 bound protein ORF818 803105 804220 76 kDa protein L23921 Chlamydia pneumoniae 775 59 ORF819 804307 805356 putative ORF820 805290 806282 76 kDa protein L23921 Chlamydia pneumoniae 125 ORF821 806453 808081 putative ORF822 808026 809009 putative ORF823 810461 809079 putative ORF824 811605 810328 putative ORF825 811725 812342 putative ORF826 812329 813522 putative ORP827 813455 813772 putative ORF828 813732 814334 putative ORF829 815213 814314 putative 814878 814396 putative ORF831 815733 815428 30S ribosomal protein S20 Z67753 Odontella sinensis 150 38 ORF832 816116 817456 KIAA0336 AB002334 Homo sapiens 90 32 ORF833 817608 819320 RNA polymerase sigma-subunit J05546 Chlamydia trachomatis 2868 100 ORF834 819324 819713 putative ORF835 819704 820402 dihydropterin Y08611 Pisum sativum 310 pyrophosphokinase /dihydropteroate synthase ORF836 820375 821061 dihydropteroate synthase X68068 Neisseria meningitidis 100 48 ORF begin stop Homology ID Species Score 1% ORF837 821043 821537 dihydrofolate reductase Z84379 Streptococcus 168 pneumoniae ORFB38 821646 822239 M. jannaschii predicted U67522 Methanococcus 139 41 coding region MJ0768 jannaschii ORF839 822182 822931 putative ORF840 824355 823045 nitrogen metabolism M58480 Thiobacillus 133 58 regulator ferrooxidans ORF841 825894 824359 helicase M63176 Staphylococcus aureus 893 ORF842 826322 825879 helicase M63176 Staphylococcus aureus 282 47 ORP843 826340 827026 ipa-57d gene product X73124 Bacillus subtilis 602 52 ORF844 827014 827250 putative ORF845 827856 827230 hypothetical U32712 Haemophilus influenzae 302 ORF846 828007 829275 19/20 residue stretch (32- L19954 Bacillus subtilis 442 37 51) identical to N-terminal putative signal sequence of unknown, partly cloned B.

subtilis gene.; putative ORF847 829355 830953 heat shock protein GroEL U55047 Bradyrhizobium 418 36 japonicum ORF848 831119 831748 basl protein Z. 34917 Hordeum vulgare 516 47 ORF849 832152 831751 putative 832744 832214 putative ORF851 833446 832805 putative ORF852 833802 833368 putative ORF853 834679 833879 putative ORF854 835452 834661 putative ORF855 835778 835371 putative ORF856 836482 835775 putative ORF857 836602 837264 putative ORE begin stop Homology ID Species Score 1% ORF858 837209 838699 putative ORF859 838760 839575 putative ORF860 839942 840583 putative ORF861 840445 841713 putative ORP862 841659 842459 putative ORF863 842523 843068 putative ORF864 843495 843031 putative ORF865 843239 846196 putative ORF866 844137 843802 putative ORF867 848043 846217 putative ORF868 850123 848150 putative ORF869 851645 850230 putative ORF870 853696 851669 putative ORF871 854836 853700 putative ORF872 855525 854920 putative ORF873 856240 855437 putative ORF874 857183 856233 putative ORF875 859439 857451 putative ORF876 859946 859587 putative ORF877 859642 860640 putative ORF878 861599 860724 putative ORF879 862053 861580 putative 863540 862098 putative ORF881 863930 863571 putative ORF882 864697 863996 putative ORF883 864923 866248 DNA mismatch repair protein "U32692 Haemophilus influenzae 506 47 (mutL) ORF884 866303 866605 putative ORP885 866665 867732 YqhT D84432 Bacillus subtilis 444 39 ORF886 867810 869090 putative ORF887 869094 869357 putative ORF888 869270 871372 fimbrial assembly protein L13865 Pseudomonas aeruginosa 181 6--h 01 ORF begin stop Homology ID Species Score I% ORF889 871299 872582 xpsE gene product X59079 Xanthomonas campestris 825 56 ORF890 872429 872860 secretion protein XcpR Y09102 Acinetobacter 213 48 calcoaceticus ORF891 872773 873915 ORFo398 U18997 Escherichia coli 271 33 ORF892 873812 873360 putative -ORF893 874028 874438 putative ORF894 874778 875386 putative ORF895 875774 876382 putative ORF896 877872 877000 secretion system apparatus, X99944 Salmonella typhimurium 174 34 SsaT ORF897 878172 877876 yscS L25667 Yersinia 172 44 pseudotuberculosis ORF898 879098 878172 pathogenicity protein M64094 Xanthomonas campestris 464 46 ORF899 878883 879161 putative ORF900 879842 879105 PscL U56077 Pseudomonas aeruginosa 141 34 ORF901 880885 880052 putative ORF902 881863 880889 HrcJ U56662 Erwinia amylovora 236 43 ORF903 882904 881948 ORF YOR196c Z75104 Saccharomyces 685 44 cerevisiae ORF904 883794 882901 dihydrolipoamide L31844 Clostridium magnum 578 38 dehydrogenase ORF905 884296 883661 YqiV D84432 Bacillus subtilis 437 44 ORF906 884996 884508 putative ORF907 888777 885166 helicase of the snf2/rad54 D90916 Synechocystis sp. 824 43 family ORF908 890172 888940 sodium-coupled branched- D49784 Clostridium perfringens 230 chain amino acid carrier ORF909 891164 890325 putative Fmu protein Y13937 Bacillus subtilis 220 41 ORF910 891463 891116 putative ORP911 893278 891968 DD-carboxypeptidase M85047 Bacillus subtilis 302 39 ORP begin stop Homology ID Species Score I% ORF912 893356 893808 putative ORF913 893909 893643 putative ORF914 894276 893821 hypothetical protein D90908 Synechocystis sp. 155 39 ORF915 894778 894248 putative ORF91 895892 895050 putative ORF917 895951 896829 putative ORF918 900783 897064 DNA polymerase III alpha- AE000646 Helicobacter pylori 1974 43 subunit (dnaE) OR919 902032 900791 UhpC protein M17102 Escherichia coli 1117 52 ORF920 902659 903876 histidine--tRNA ligase 217214 Streptococcus 686 47 equisimilis ORF921 903731 903471 putative ORF922 903860 905605 aspartyl-tRNA synthetase D90910 Synechocystis sp. 1339 51 ORF923 905725 906474 mip-like protein X66126 Chlamydia trachomatis 1196 98 0RF924 906493 906945 spoU L40369 Chlamydia trachomatis 607 100 ORF925 907306 907001 trxA L39892 Chlamydia psittaci 380 76 ORF926 908101 908742 putative ORF927 908721 909194 hypothetical protein D90914 Synechocystis sp. 150 37 ORF928 909198 909584 DNA polymerase III 248003 Staphylococcus aureus 181 ORF929 909583 909951 putative ORF930 910081 910569 VdlD -U94318 Helicobacter pylori 197 43 ORF931 910615 910944 putative ORF932 910948 912261 acid-inducible gene L13845 Sinorhizobium meliloti 145 ORF933 912399 912629 putative ORF934 912595 913218 UDP-3-O-acyl-GlcNAc U67855 Pseudomonas aeruginosa 309 39 deacetylase ORF935 913203 913676 (3R)-hydroxymyristol acyl D90910 Synechocystis sp. 302 59 carrier protein dehydrase ORF begin stop Homology ID Species Score 1% ORF936 913691 914485 UDP-N-acetylglucosamine L22690 Rickettsia rickettsii 503 38 acyltransferase ORF937 914516 915136 methionyl-tRNA X63666 Escherichia coli 407 42 formyltransferase ORF938 915144 915467 putative ORF939 915629 916633 putative ORF940 916051 916539 putative ORF941 916965 917627 ribosomal protein L3 (rpL3) U32761 Haemophilus influenzae 470 48 ORF942 917612 918304 50S ribosomal protein L4 AB000111 Synechococcus sp. 210 43 OR943 918323 918655 ribosomal protein L23 Z21677 Thermotoga maritima 116 47 ORF944 918682 919533 rpl2 M74770 Mycoplasma-like 800 48 organism ORF945 919542 919829 Mycoplasma pneumoniae, AE000061 Mycoplasma pneumoniae 315 68 ribosomal protein 819; similar to GenBank Accession Number S36895, from M. bovis ORP946 919723 920157 ribosomal protein L22 Z21677 Thermotoga maritima 240 49 ORF947 920184 920840 ribosomal protein S3 (rpS3) U32761 Haemophilus influenzae 605 57 ORF948 920866 921294 ribosomal protein L16 Z21677 Thermotoga maritima 434 62 ORF949 921272 921514 ribosomal protein CtrL29e MB0325 Chlamydia trachomatis 343 99 ORF950 921510 921758 ribosomal protein S17e M80325 Chlamydia trachomatis 419 100 ORF951 921778 922143 ribosomal protein CtrL4e M80325 Chlamydia trachomatis 618 100 ORF952 922159 922491 ribosomal protein CtrL24e M80325 Chlamydia trachomatis 568 100 ORF953 922496 923035 ribosomal protein CtrL5e M80325 Chlamydia trachomatis 793 99 ORF begin stop Homology ID Species Score I% ORF954 923160 923453 ribosomal protein CtrSBe M80325 Chlamydia trachomatis 487 98 ORF955 923484 924032 ribosomal protein L6 M60652 Chlamydia trachomatis 927 100 ORF956 924048 924425 ribosonal protein CtrL18e M80325 Chlamydia trachomatis 605 99 ORF957 924443 924937 ribosomal protein CtrS5e M80325 Chlamydia trachomatis 814 99 ORF958 924933 925364 ribosomal protein CtrL15e M80325 Chlamydia trachomatis 740 99 ORF959 925390 926760 homolog L25077 Chlamydia trachomatis 2254 99 ORF960 926819 927184 ribosomal protein S13 L33834 Chlamydia trachomatis 604 100 ORF961 927209 927604 ribosomal protein S11 L33834 Chlamydia trachomatis 646 98 ORF962 927577 928155 RNA polymerase alpha-subunit L33834 Chlamydia trachomatis 847 97 ORF963 928100 928759 RNA polymerase alpha-subunit L33834 Chlamydia trachomatis 1040 98 ORF964 929222 930244 glyceraldehyde-3-phosphate U83198 Chlamydia trachomatis 1735 99 dehydrogenase ORF965 930222 930656 putative ORF966 930608 931078 putative ORF967 931367 931666 putative ORF968 931549 931959 putative ORF969 932070 932579 crossover junction U32717 Haemophilus influenzae 250 41 endodeoxyribonuclease (ruvC) ORP970 932602 933201 Holliday junction DNA U32716 Haemophilus influenzae 258, 38 helicase (ruvA) ORF971 933319 933621 nucleoside diphosphate AE000540 Helicobacter pylori 264 kinase (ndk) ORF begin stop Homology ID Species Score 1% ORF972 933522 933785 nucleoside 5'-diphosphate J05207 Myxococcus xanthus 186 64 phosphotransferase

(EC

2.7.4.6) ORF973 934546 933848 hypothetical protein U39706 Mycoplasma genitalium 156 36 (GB:U14003 297) ORF974 936377 934539 homologous to E.coli gidA X62540 Pseudomonas putida 1562 51 ORF975 938081 936666 replicative DNA helicase D26185 Bacillus subtilis 848 41 ORF976 938538 939098 phosphatidylglycerophosphate AE000610 Helicobacter pylori 120 33 synthase (pgsA) ORF977 939329 940933 adenine nucleotide Z49227 Arabidopsis thaliana 668 translocase ORF978 941031 942068 putative protease AF008220 Bacillus subtilis 265 36 OR979 942082 944685 DNA polymerase D12982 Bacillus caldotenax 1334 42 ORF980 944634 945287 TOSG5.5 Z27079 Caenorhabditis elegans 198 32 ORF981 945287 946294 'The first ATG in the open L27278 Pseudomonas fluorescens 882 68 reading frame was chosen as the initiation codon.' ORF982 946293 946676 'The first GTG in the open L27276 Deinococcus radiodurans 417 reading frame was chosen as the initiation codon.' ORF983 947105 948454 ADPglucose pyrophosphorylase M31616 Oryza sativa 755 44 ORF984 948522 949277 putative ORF985 949277 949594 Y1bH protein Z98682 Bacillus subtilis 223 41 ORF986 949849 950676 putative ORF987 950680 951330 ferrochelatase M59288 Mus musculus 260 42 0RF988 951281 951643 ferrochelatase D26106 Cucumis sativus 178 47 0F989 951788 952798 putative ORF990 953581 954264 putative ORF991 954426 955157 putative ORF begin stop Homology ID Species Score 1% ORF992 955754 957940 orf4 gene product X93084 Methanosarcina barkeri 130 41 ORF993 957837 959312 OppB gene product X56347 Bacillus subtilis 327 38 ORF994 959299 961050 dipeptide ABC transporter, AE000548 Helicobacter pylori 263 39 permease protein (dppC) ORF995 961562 961053 methylated DNA protein U67593 Methanococcus 109 39 cysteine methyltransferase jannaschii ORF996 962575 961487 putative ORF997 961979 961584 putative ORF998 964914 962545 phenylalanyl-tRNA synthetase Z75208 Bacillus subtilis 775 37 beta subunit ORF999 964941 965708 putative ORF1000 967023 966193 unknown Z48008 Saccharomyces 492 44 cerevisiae ORF1001 967444 968061 putative ORF1002 968903 968064 putative ORF1003 970685 969528 transcriptional activator of Z12154 Pseudomonas aeruginosa 849 pilA ORF1004 971806 971024 sensor protein L39904 Myxococcus xanthus 147 ORF1005 973053 972388 putative-- ORF1006 974546 973746 unknown D64126 Bacillus subtilis 500 ORF1007 975223 974558 unknown D26185 Bacillus subtilis 141 44 ORF1008 976193 975207 hypothetical protein in htrA AE000126 Escherichia coli 142 42 dapD intergenic region ORF1009 976520 976254 unknown Z49939 Saccharomyces 183 39 cerevisiae ORF1010 976588 976899 putative ORF1011 976886 977635 peptide release factor 2 X99401 Bacillus firmus 534 44 ORF1012 977661 977933 release factor 2 AF013188 Bacillus subtilis 187 52 ORF1013 977918 978433 putative ORF begin stop Homology ID Species Score I% ORF1014 978619 978984 spore coat protein CotRC D50551 Bacillus subtilis 355 52 ORF1015 978933 979331 hypothetical U32717 Haemophilus influenzae 199 ORF1016 981197 979389 putative ORF1017 979711 980112 putative ORF1018 982116 981148 putative ORF1019 982321 983598 UDP-N-acetylglucosamine U32788 Haemophilus influenzae 593 38 enolpyruvyl transferase (murZ) ORF1020 984488 983862 arginyl-tRNA-synthetase D64006 Synechocystis sp. 347 44 ORF1021 985381 984371 arginyl-tRNA-synthetase D64006 Synechocystis sp. 782 58 ORF1022 986103 985399 hypothetical protein D9091S Synechocystis sp. "224 ORF1023 986693 986046 No definition line found U00021 Mycobacterium leprae 286 ORF1024 987607 986693 0298; This 298 aa ORF is 33 AE000238 Escherichia coli 132 46 pct identical (24 gaps) to 248 residues of an approx.

256 aa protein CDSAECOLI SW; P06466 ORF1025 988119 987616 conserved hypothetical AE000627 Helicobacter pylori 343 49 protein ORF1026 988253 987936 hypothetical protein U67577 Methanococcus 110 38 (HI0920) jannaschii ORF1027 988831 989163 putative ORF1028 989693 993442 protein-export membrane D64000 Synechocystis sp. 447 38 protein SecD ORF1029 993408 993785 protein-export membrane U83136 Rhodobacter sphaeroides 240 43 protein ORF1030 993835 993416 putative ORF1031 993882 994262 putative ORF1032 994226 995656 RecJ recombination protein U41759 Chlamydia psittaci 880 66 ORF1033 996036 996611 unknown U41759 Chlamydia psittaci 533 ORFP034 QC996l88i p- -81 vd I/UYU-I U£ U .g utamyl-tRiN syntnetase homolog U41759 Chlamydia psittaci 2018 83 ORP begin stop Homology ID Species Score I% ORF1035 998962 999225 9-kDa cysteine-rich outer M35148 Chlamydia trachomatis 504 100 membrane protein ORF1036 999375 1001033 outer membrane protein 2 M23001 Chlamydia trachomatis 2857 100 ORF1037 1001211 1001516 15-kDa serine-rich outer M35148 Chlamydia trachomatis 276 94 membrane protein ORF1038 1001392 1001664 15-kDa serine-rich outer M35148 Chlamydia trachomatis 438 97 membrane protein ORF1039 1003721 1001823 ORF of prc gene (alt.) D00674 Escherichia coli 486 42 ORF1040 1004459 1004845 StrA M86701 Haemophilus influenzae 454 ORF1041 1004990 1005382 ribosomal protein S7 211567 Chlamydia trachomatis 662 99 ORF1042 1005391 1007496 translation elongation AE000625 Helicobacter pylori 2147 62 factor EF-G (fusA) ORF1043 1007486 1007821 ribosomal protein S10 221676 Spirulina platensis 350 68 ORF1044 1007802 1008698 NADPH-sulfite reducatase M23008 Escherichia coli 113 48 flavoprotein component ORF1045 1009426 1009121 unknown Z92774 Mycobacterium 102 42 tuberculosis ORF1046 1010534 1012054 serine Z38002 Bacillus subtilis 1021 hydroxymethyltransferase ORF1047 1012397 1011942 putative ORF1048 1012042 1012635 ATP-dependent Clp protease D90915 Synechocystis sp. 365 44 proteolytic subunit ORF1049 1012593 1012862 putative ORF1050 1012811 1013440 diaminopimelate epimerase U32759 Haemophilus influenzae 108 (dapF) ORF1051 1013456 1014055 putative ORF1052 1013977 1014489 putative ORF begin stop Homology ID Species Score I% ORP1053 1015224 1014529 hypothetical 28.1 kD protein AE000459 Escherichia coli 263 38 in udp-rfaH intergenic region ORF1054 1016002 1015145 putative ORF1055 1017120 1015939 conserved hypothetical AE000579 Helicobacter pylori 428 42 protein ORF1056 1017766 1017245 putative ORF1057 1018911 1017916 putative ORF1058 1019191 1018580 putative ORF1059 1020199 1019831 hemolysin AE000647 Helicobacter pylori 164 33 ORF1060 1021007 1020114 unknown Z95208 Mycobacterium 201 36 tuberculosis ORF1061 1021569 1021075 putative ORF1062 1022411 1022097 putative ORF1063 1023344 1023667 50S ribosomal subunit U18997 Escherichia coli 218 43 protein L21 ORF1064 1023701 1023949 50S ribosomal protein L27 U38804 Porphyra purpurea 251 64 ORF1065 1023976 1024776 ORF f390 U18997 Escherichia coli 603 51 ORP1066 1024704 1025045 GTP-binding protein (obg) U32769 Haemophilus influenzae 161 37 ORF1067 1025881 1024967 hypothetical protein D90903 Synechocystis sp. 439 ORF1068 1026546 1025839 YcdI AB000617 Bacillus subtilis 312 ORF1069 1027379 1026546 adhesion protein D90903 Synechocystis sp. 354 ORP1070 1030604 1027929 putative 98 kDa outer U72499 Chlamydia psittaci 95 49 membrane protein ORF1071 1033252 1030508 putative 98 kDa outer U72499 Chlamydia psittaci 75 36 membrane protein ORF1072 1031733 1032086 putative ORF1073 1037037 1033456 putative 98 kDa outer U72499 Chlamydia psittaci 160 46 membrane protein ORF1074 1035674 1035910 putative ORY begin atop Homology ID Species Score 1% 0RF1075 1036175 1036507 putative ORF begin stop Homology ID Species Score 1% ORF1076 68(con) 1036967 putative ORF1077 161 1 9 GutQ/KpsP Family Sugar-P AE001313 Chlamydia trachomatis 658 97 ORF1077 16591 16989 Isomerase ORF1078 31779 31408 putative ORF1079 56502 56834 hypothetical protein AE001309 Chlamydia trachomatis 284 ORFo108 56686 56913 hypothetical protein AE001309 Chlamydia trachomatis 303 94 hypothetical protein AE001309 Chlamydia trachomatis 501 100 ORF1081 64748 65074 (possible 357R?) Predicted OMP [leader (19) AE001308 Chlamydia trachomatis 476 100 ORF1082 73482 73195 peptide] ORP1083 78482 78736 putative ORF1084 79803 79411 hypothetical protein AE001307 Chlamydia trachomatis 583 98 ORF1085 82333 81959 Lon ATP-dependent protease AE001307 Chlamydia trachomatis 607 99 ORF1086 87313 86999 hypothetical protein AE001307 Chlamydia trachomatis 534 100 ORF1087 109929 109456 hypothetical protein AE001305 Chlamydia trachomatis 529 98 ORFOBB1088 111599 111351 putative ORF1089 112069 111734 putative ORF1090 112666 112911 hypothetical protein AE001305 Chlamydia trachomatis 395 94 ORF1091 114017 113715 putative ORF1092 120757 120464 putative ORF1093 125133 125522 predied ferredoxin AE001303 Chlamydia trachomatis 631 97 ORF1094 131888 131604 putative ORF1095 144164 144427 putative ORF1096 150698 150369 putative ORF begin stop Homology ID Species Score 1% ORF1097 164385 163948 NADH (Ubiquinone) AE001300 Chlamydia trachomatis 755 100 Dehydrogenase ORF1098 165690 166115 hypothetical protein AE001300 Chlamydia trachomatis 724 99 ORF1099 168742 168425 hypothetical protein AE001300 Chlamydia trachomatis 356 96 ORF1100D 170509 170793 hypothetical protein AE001300 Chlamydia trachomatis 489 100 AcCoA AE001299 Chlamydia trachomatis 518 99 ORFO1101 177145 177474 Carboxylase/Transferase Alpha ORF1102 188295 188023 hypothetical protein AE001298 Chiamydia trachomatis 451 100 ORF1103 188791 188330 hypothetical protein AE001298 Chlamydia trachomatis 733 97 ORF1104 190629 190336 putative ORF1105 197313 197083 putative ORF1106 210914 211384 putative ORP1107 235160 234852 Glutamate Aminomutase AE001295 Chlamydia trachomatis 507 97 ORF1108 237227 236913 putative ORF1109 249733 249446 Oligopeptide Permease AE001293 Chamydia trachomatis 512 100 ORF1110 253493 253158 hypothetical protein .AE001293 Chiamydia trachomatis 318 63 ORF1111 253701 254789 hypothetical protein AE001293 Chlamydia trachomatis 1860 99 ORF1112 271633 271932 hypothetical protein AE001291 Chlamydia trachomatis 512 100 OR1113 75666Disulfide bond AE001291 Chlamydia trachomatis 700 99 Oxidoreductase ORF1114 277931 278218 putative ORF begin stop Homology ID Species Score I% ORF1115 282741 282481 hypothetical protein AE001290 Chlamydia trachomatis 422 99 ORF1116 293178 293489 Phospholipase D Endonuclease AE001289 Chlamydia trachomatis 433 Superfamily ORF1117 303155 303469 putative ORF1118 309297 308965 hypothetical protein AE001287 Chlamydia trachomatis 422 ORF1119 312219 312536 putative ORF1120 312853 312602 hypothetical protein AE001287 Chlamydia trachomatis 338 99 ORF1121 313167 312772 hypothetical protein AE001287 Chlamydia trachomatis 616 98 ORF1122 320224 320598 hypothetical protein AE001286 Chlamydia trachomatis 628 98 ORF1123 340249 340503 Oligopeptidase AE001285 Chlamydia trachomatis 444 100 ORF1124 352839 353324 hypothetical protein AE001284 Chlamydia trachomatis 751 98 Phopholipase D Superfamily AE001282 Chlamydia trachomatis 378 100 ORF1125 373475 373699 [leader (33) peptide} ORF1126 377316 377756 hypothetical protein AE001282 Chlamydia trachomatis 764 99 ORF1127 379268 379657 hypothetical protein AE001282 Chlamydia trachomatis 535 100 ORF1128 395098 394823 putative ORF1129 401594 401142 Flagellar Secretion Protein AE001280 Chlamydia trachomatis 698 100 ORP1130 410045 410539 hypothetical protein AE001279 Chlamydia trachomatis 767 100 ORP1131 411425 411658 Coproporphyrinogen III AE001279 Chlamydia trachomatis 399 99 RF113 1 Oxidase ORF1132 414937 414416 putative ORF begin stop Homology ID Species Score I% ORF1133 422889 423212 Glycogen Hydrolase AE001278 Chlamydia trachomatis 206 100 (debranching) ORF1134 427842 428183 hypothetical protein AE001278 Chlamydia trachomatis 610 100 ORF1135 428732 429451 hypothetical protein AE001278 Chlamydia trachomatis 1010 98 ORF1136 442557 442799 hypothetical protein AE001277 Chlamydia trachomatis 649 94 ORF1137 443628 444041 L31 Ribosomal Protein AE001277 Chlamydia trachomatis 538 96 ORF1138 443678 443166 putative ORF1139 445901 446155 putative ORF1140 467981 468262 putative ORF1141 471869 472108 Putative Outer Membrane AE001361 Chlamydia trachomatis 370 100 Protein I ORF1142 488032 488337 Membrane Thiol Protease AE001360 Chlamydia trachomatis 483 96 OR1143 497179 497694 Low Calcium Response Protein AE001359 Chlamydia trachomatis 864 ORFII43 497179 497694 ORF1144 500474 500202 putative ORF1145 508968 509561 ABC transporter permease AE001358 Chlamydia trachomatis 964 100 ORF1146 510845 511264 hypothetical protein AE001358 Chlamydia trachomatis 360 89 ORF1147 526525 526848 hypothetical protein AE001356 Chlamydia trachomatis 242 81 ORF1148 531318 531863 hypothetical protein AE001356 Chlamydia trachomatis 127 100 ORF1149 556826 557224 hypothetical protein AE001354 Chlamydia trachomatis 683 99 ORF1150 564971 564537 hypothetical protein AE001353 Chlamydia trachomatis 534 100 ORF begin stop Homology ID Species Score I% ORF1151 566963 567232 Glycerol-3-P Acyltransferase AE001353 Chlamydia trachomatis 220 53 Insulinase family/Protease AE001353 Chlamydia trachomatis 925 100 ORF152 570351 570890

III

ORF1153 571072 571332 hypothetical protein AE001353 Chlamydia trachomatis 441 99 OR1154 5 5 575801 General Stress Protein AE001352 Chlamydia trachomatis 273 97 ORFll54 576025 575801 ORF 590363 590650 hypothetical protein AE001351 Chlamydia trachomatis 442 100 ORF1155 590363 590650 ORF1156 597868 598593 hypothetical protein AE001350 Chlamydia trachomatis 1176 98 ORF1157 606889 606626 putative ORF1158 608031 607786 hydrolase/phosphatase AE001349 Chlamydia trachomatis 434 99 homolog ORF1159 610110 610391 putative ORF1160 632703 633353 putative ORF1161 637213 637482 putative ORF1162 650517 649924 putative ORF1163 652317 652562 Phenolhydrolase/NADH AE001345 Chlamydia trachomatis 324 99 ubiquinone oxidoreductase ORF1164 654753 655325 putative ORF1165 661118 660810 putative ORF1166 677596 677057 hypothetical protein AE001343 Chlamydia trachomatis 864 98 ORF1167 679528 679253 putative ORF116B 732536 732210 putative ORF1169 742069 742383 putative ORF1170 759318 758782 (Pseudouridine Synthase) AE001336 Chlamydia trachomatis 909 98 ORF1171 760282 760521 putative ORF1172 771313 770894 hypothetical protein AE001335 Chlamydia trachomatis 661 96 ORF begin ORF1173 772115 ORF1174 788137 ORF1175 816302 ORF1176 846606 ORF1177 867803 ORF1178 ORF1179 ORF1180 ORF1181 ORF1182 ORF1183 ORF1184 ORF1185 ORF1186 ORF1187 ORF1188 ORF1189 ORF1190 ORF1191 ORF1192 ORF1193 ORF1194 875386 876445 884548 891859 900770 902553 908046 912313 935451 946961 953193 966199 969298 971009 972162 973119 998649 stop Homology 772408 hypothetical protein 788457 putative 815967 putative 846914 putative 868054 putative 875658 hypothetical protein 876915 hypothetical protein 884312 putative 891467 hypothetical protein 900417 putative 902269 putative 907783 putative 912567 Myristoyl GlcNac Deacetylase 935741 putative 946692 hypothetical protein 952783 hypothetical protein 965873 hypothetical protein 968765 putative 970731 2-Component Sensor 972404 putative 973508 Phosphoglycolate Phosphatase 998404 putative ID Species Score 1% AE001335 Chlamydia trachomatis 520 99 AEU01327 Chlamydia trachomatis 268 AE001327 Chlamydia trachomatis 747 99 AE001326 AE001324 AE001322 Chlamydia trachomatis Chlamydia trachomatis Chlamydia trachomatis 551 195 410 97 99 AE001322 Chlamydia trachomatis 593 100 AE001321 Chlamydia trachomatis 542 98 AE001320 AE001320 Chlamydia trachomatis Chlamydia trachomatis 467 647 97 98

P

ORF begin stop Homology ID Species Score 1% ORF1195 1004280 1003282 hypothetical protein AE001317 Chlaniydia trachoma tis 571 99 0RF1196 1010200 1009S32 hypothetical protein AE001317 Chlaxnydia trachoma tie 1.132 99 0RF1197 102914 11029482 puative TABLE 2 2 501 208 501 3 3276 505 3153 4 5068 3242 5062 6400 5126 6400 6 7977 6619 7977 7 8582 8082 8582 8 8995 8591 8995 9 9440 8979 9440 9828 10430 9828 11 10367 11254 10430 12 11245 11916 11245 13 12068 13324 12068 14 13532 14413 13538 14807 15019 14807 16 14932 15969 14977 17 15995 16501 16004 18 16467 16138 16377 19 18190 17417 18178 20521 18437 20518 21 22202 20814 22166 22 22602 22153 22509 23 22804 22478 22795 24 23183 22824 23180 23394 23110 23394 26 24569 23394 24569 27 26383 24641 26383 28 26640 27710 26640 29 28780 27725 28729 29957 28740 29957 31 30721 30032 30628 32 31281 30520 31254 33 31436 31780 31436 164 SEQID NO bg stop 7refeedt 34 33356 31800 33344 33901 33314 33874 36 34116 35027 34116 37 34988 35359 35027 38 35167 35919 35377 39 35923 36996 36031 37810 37013 37765 41 38207 39085 38252 42 39151 39927 39157 43 39923 40756 39959 44 40760 42007 40772 42175 43116 42229 46 42999 43802 43128 47 44211 45227 44217 48 46072 45275 46066 49 46340 45975 46331 46895 46506 46865 51 47955 46882 47955 52 48585 48178 48558 53 50072 48630 50012 54 50710 50099 50692 52439 50925 52430 56 53484 52348 53478 57 54536 53466 54536 58 55086 54595 55104 59 56350 55031 56350 55659 56084 55722 61 56847 58235 56931 62 58423 59181 58423 63 59185 60195 59194 64 60188 61483 60191 61496 62353 61496 66 62500 63141 62518 67 63396 63983 63396 rSEQ D NO begin Cpp prefeided gt 68 64628 64071 64580 69 64285 64656 64285 64944 64609 64938 71 65347 67269 65347 72 67656 68873 67815 73 68877 69233 68892 74 69212 69721 69323 69958 70455 69970 76 70701 71006 70725 77 73191 71086 73185 78 74900 73497 74891 79 75463 74876 75463 77124 75502 77124 81 77000 77299 77012 82 78095 77145 78095 83 79065 78154 79065 84 81971 79878 81965 82639 83271 82642 86 83792 84850 83921 87 84876 86921 84888 88 88650 87313 88383 89 87440 87805 87458 88400 88747 88409 91 88717 89265 88729 92 89355 89732 89355 93 89735 91447 89735 94 91749 91435 91749 92392 91745 92323 96 93138 92344 92874 97 98 99 94134 94637 98299 93361 94071 94628 93945 94577 98113 98715 100195 ~99 1"~ 1 I 98715 98113 101 100228 98741 166 li i linfersle^!iit red SEQ O'll begind 102 101347 100337 101323 103 102210 101323 102210 104 102485 102210 102479 105 104315 102726 104315 106 105075 104254 105075 107 105259 105894 105271 108 107429 108460 107486 109 108665 108955 108683 110 109459 109013 109456 111 110366 109704 110363 112 111330 112520 111330 113 112915 113463 112918 114 113566 113994 113566 115 114020 114604 114020 116 114720 115253 114807 117 115362 115676 115380 118 116022 119795 116040 119 119823 124010 119823 120 124065 124988 124065 121 124873 125106 124873 122 126261 125536 126243 123 126328 126930 126331 124 127138 127785 127147 125 127924 129714 127942 126 129720 131033 129720 127 131018 131629 131021 128 131834 133156 131852 129 133075 133584 133096 130 133625 133999 133628 131 133861 134508 133948 132 134638 137454 134638 133 137442 140276 137472 134 140733 140335 140727 141799 141077 141799 L

L

167 SSEQIDNO pefeedstar 136 143240 141780 143240 137 143829 143128 143820 138 143923 144393 143923 139 144548 146326 144548 140 146413 147078 146425 t 141 147140 148075 147152 142 148115 148549 148115 143 148524 149027 148524 144 149000 149305 149033 145 149187 149708 149187 146 149712 150911 149769 147 152044 151004 151966 148 152664 151999 152592 149 152900 153352 152924 150 153389 153997 153425 151 155276 153984 155228 152 156544 155231 156544 153 156806 157525 156809 154 157489 158955 157534 155 159104 159961 159104 156 159916 161220 159916 157 161183 161593 161228 158 162354 161623 162354 159 163013 162363 163013 160 163941 162994 163941 161 165505 164474 165505 162 166686 166093 166686 163 168171 166729 168171 164 169249 168848 169189 165 169586 170431 169607 166 170780 171334 170783 167 171333 172376 171390 168 172309 172722 172309 169 173048 174496 173048 170 174399 174968 174399 171 175267 175710 175267 172 175714 177009 175735 173 177423 178115 177468 174 178084 180021 178084 175 180704 180048 180635 176 181398 180631 181398 177 182594 181398 182594 178 182895 183656 182895 179 183665 184786 183665 180 186007 184796 186007 181 186848 186000 186791 182 187270 186749 187240 183 187426 187809 187429 184 189481 188798 189442 185 189693 190352 189693 186 190235 190510 190280 187 190785 191786 190824 188 191790 192464 191811 189 192392 193183 192500 190 193254 194630 193263 191 195046 194690 195037 192 195184 197031 195193 193 197018 197635 197024 194 197762 198208 197669 195 198963 197668 198954 196 199957 198962. 199945 197 200327 199941 200306 198 200685 200266 200598 199 200962 200585 200962 200 201169 202377 201184 201 203441 202380 203441 202 203998 203471 203989 203 206449 204059 206434 SEQ NO 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 207425 207506 208545 209471 210586 211332 212978 214134 214710 215143 216705 217917 217088 218364 218695 219179 219891 220499 221137 221601 222472 223423 224278 225749 225334 226654 227299 227646 228457 230001 231074 231348 233059 233801 stop prefrered start 206811 207410 208528 207506 209471 208545 210214 209471 210816 210586 210883 211293 211374 212972 212875 214134 214168 214701 214754 215128 215236 216705 216892 217911 217441 217202 218702 218364 219009 218785 219748 219260 220430 219912 221074 220505 221541 221176 222092 221616 223290 222487 223818 223423 225171 224278 225174 225749 225549 225328 225749 226654 226769 227170 227161 227646 227750 228439 228607 229854 230151 231062 233006 231366 233829 233059 234265 233801 ::SEQJID1NO 238 239 240 241 242 243 244 245 246 247 248 249 begin 234282 236300 236314 238164 238769 242022 242846 244480 245897 246877 247731 248585 234854 235227 238209 238769 240061 240313 241941 242798 244479 245924 246985 247743 preferred start 234288 236300 236314 238185 238769 242022 242846 244456 245891 246829 247725 248573 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 249420 250383 251186 252111 253088 255153 256762 257911 258780 259193 261622 264125 264741 266416 266938 267961 268320 268510 270116 270892 271191 248569 249766 250545 251095 252066 256718 257844 258690 259187 261604 264129 264742 265628 265631 266426 266942 268066 268205 268500 270095 271613 249411 250383 251174 252099 253088 255153 256774 257962 258840 259193 261622 264134 264759 266416 267946 267946 268299 268510 270116 270856 271224 271 272219 272932 272243 fI 724 EQID NO begin stop jjrcferred start 272 272884 273588 273079 273 274816 273596 274807 274 274821 275666 274953 275 277689 276103 277689 276 278268 278816 278298 277 279771 279013 279870 278 280777 279767 280762 279 281603 281295 281576 280 282104 281787 282086 281 284335 282794 284320 282 284460 284795 284550 283 284817 285674 284844 284 285637 286137 285670 285 286357 286677 286399 286 286681 287898 286852 287 288127 289227 288358 288 289744 290679 289744 289 290828 291535 291206 290 291514 292230 291514 291 292326 293048 292350 292 293330 294853 293525 293 295684 295010 295684 294 296336 295692 296294 295 297238 296243 297199 296 297791 298735 297791 297 298905 300458 298920 298 302152 300527 302131 299 304917 302071 304872 300 306157 304973 306142 301 306494 306111 306461 302 306963 306436 306963 303 308773 306977 308758 304 309881 309276 309869 305 310720 309872 310711 172 306 311570 310716 311570 307 312451 311972 312439 308 313435 314364 313462 309 314340 314738 314409 310 315526 314741 315445 311 316507 315665 316507 312 317284 316529 317284 313 317592 317338 317592 314 318470 317499 318416 315 317599 317874 317599 316 318947 318477 318887 317 319342 320142 319342 318 320544 321497 320682 319 321485 321937 321497 320 321901 322362 321943 321 322301 323140 322325 322 323144 324913 323177 323 325621 324977 325621 324 326268 325621 326262 325 326469 327203 326469 326 327281 328150 327302 327 328605 328204 328602 328 329066 328734 329066 329 329663 329292 329648 330 330666 329608 330663 331 331161 330670 331161 332 331731 331177 331731 333 332404 331721 332404 334 332779 333021 332779 335 333005 333589 333149 336 334357 333806 334321 337 334089 334361 334089 338 335142 334729 335124 339 335195 335602 335234 173 340 335673 335194 335673 341 336334 335903 336229 342 37378 336338 337378 343 339947 337347 339947 344 340507 341847 340576 345 341783 342022 341786 346 342249 342470 342249 347 342597 343370 342597 348 343361 344032 343379 349 343956 344225 343962 350 344357 345142 344357 351 345934 345161 345934 352 347102 346080 347102 353 347113 347940 347119 354 350164 348146 350113 355 350423 351283 350426 356 352207 351314 352207 357 352727 352245 352703 358 353709 353305 353709 359 354218 353670 354215 360 354721 354140 354721 361 354966 356672 354966 362 356700 357377 356700 363 357326 358093 357500 364 358035 360743 358035 365 360753 361121 360753 366 361162 361884 361162 367 361826 362746 361826 368 363859 362816 363859 369 364116 365195 364116 370 365198 365587 365198 371 365479 367320 365614 372 367341 368603 367341 373 368644 369081 368644 174

'SEQIDI

408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 :I :i l'il 400167 399778 401224 400034 401776 402021 402126 403220 403348 405180 403788 403276 405165 405920 407049 405955 409773 407056 410532 411416 411707 413410 413433 412606 413404 413952 413841 415112 414379 413978 416664 415177 417456 416740 418053 417721 418603 418031 419531 418647 420190 419672 421171 420245 421988 421518 422486 423043 423226 425079 426054 425146 426985 426245 427248 427817 429560 429886 430360 429857 430637 430323 430933 431787 431658 431987 432232 434475 400167 401209 401776 402132 403354 403785 405165 407049 409764 410532 411722 413334 413449 413991 414220 416646 417456 418044 418582 419531 420190 421171 421988 422492 423295 426021 426967 427248 429623 430360 430628 430966 431688 432238 442 436308 434620 436269 443 436574 436272 436571 444 437685 436567 437595 445 438262 437894 438256 446 439127 438285 439031 447 439339 438986 439339 448 439705 439358 439705 449 441042 439699 441042 450 441911 441042 441911 451 442593 441898 442584 452 444505 446388 444505 453 448068 446452 448029 454 449575 447932 449575 455 450546 451076 450576 456 451623 451144 451401 457 452593 451517 452575 458 453195 452632 453174 459 453567 454868 453567 460 455430 454972 455403 461 456047 455367 456047 462 457384 456047 457384 463 457659 458450 457659 464 458508 459632 458511 465 459839 461203 459839 466 461624 461196 461624 467 461887 462621 462151 468 463758 462895 463749 469 464048 464629 464063 470 464721 465848 464760 471 467420 466113 467414 472 468891 467419 468891 473 469280 468906 469226 474 469349 469675 469406 475 471226 469826 471160

178 510 505002 503722 505002 511 505739 506986 505739 512 506999 507439 507011 513 508404 507649 508302 514 508291 508590 508297 515 508915 508478 508915 516 509600 510691 509600 517 511039 511527 511147 518 511547 512185 511547 519 512382 513092 512385 520 514287 513055 514269 521 514789 515244 514792 522 514994 515269 515027 523 515553 515804 515553 524 515808 516422 515820 525 516476 517171 516605 526 517927 517400 517927 527 518096 518380 518114 528 518403 518822 518412 529 518923 519516 518923 530 519577 520497 519730 531 521986 520718 521971 532 522131 521886 522125 533 523495 522143 523483 534 524591 523623 524510 535 524652 525746 524685 536 525731 526078 525752 537 525939 526400 525999 538 526301 526735 526361 539 528323 526851 528284 540 528861 528292 528828 541 529723 529142 529645 542 530166 529624 530166 543 530543 530223 530543 179 1 1 544 531378 530737 531363 545 532370 533272 532370 546 533849 533244 533849 547 534672 533944 534615 548 535915 534878 535915 549 539153 535956 539114 550 539731 540519 539731 551 540523 540969 540526 552 540906 541805 541002 553 543255 541825 543222 554 544133 543222 544115 555 544565 544179 544532 556 544762 544487 544747 557 546423 544951 546423 558 547480 546584 547378 559 546789 547382 546900 560 547901 547476 547826 561 548634 547900 548634 562 548692 549459 548704 563 550385 549663 550376 564 551611 550421 551611 565 553041 551797 553041 566 554946 553096 554946 567 556300 554927 556300 568 556524 556904 556524 569 558126 557314 558105 570 557810 558235 557810 71 559215 558310 559215 572 561349 559196 561349 573 562931 561150 562898 574 564083 563121 564083 575 563593 563943 563644 576 565379 566953 565379 577 567079 567966 567274 689L65 18ZL69 1fLL69 119 SZ8965 t,91965 t"996S 019 £50965 0t99569 ZZI96S9 609 SE1t765 tf9969 8f~t'69 809 00£ 585 IZIE6g O06C65 L69 9017Z65 99Los 9086550 5LL069~ Z66Z'8 6L98 £69 I668s Lr98fg 5ft8 okiC,9 £08C85 801689 698EL89 109 t50r98s 85iL8s VS85 600 6089 D1998s 01785 £66 9ZS9S 9089 £698 865 1106L5S 66ZtZ89 1106tR 165 66t 59LZL5 65c"89 085 t2ZI8s 1l01LS 6911.556 11095s 66£0ZZ8 11089Z6 Z106L5So okwbas10L9 16 U985 IOL9 L9Lo06 181 SEJD NO,'ii,- 612 598524 600809 598551 613 601876 600734 601864 614 603523 601910 603520 615 603794 603531 603794 616 604413 603757 604398 617 604549 605610 604549 618 606619 605582 606619 619 606843 607493 606867 620 609068 608031 608972 621 609652 609296 609652 622 611860 610109 611830 623 611812 612927 611815 624 613597 612938 613444 625 613952 613692 613952 626 614315 615244 614441 627 615396 615683 615396 628 617711 615864 617624 629 618313 617510 618361 630 619338 618361 619338 631 620416 619247 620401 632 619863 620261 619929 633 621184 620420 621154 634 621690 621154 621678 635 622399 621674 622399 636 623466 622414 623421 637 624178 623570 624106 638 624918 624073 624918 639 625346 626665 625367 640 626514 626900 626652 641 626954 627853 626984 642 627822 628124 627873 643 628715 628146 628715 644 628932 629801 628935 645 630406 629804 630298 182 SEQD N ,preferred'sta 646 630960 630298 630915 647 631799 630915 631799 648 637488 638084 637488 649 638036 640207 638111 650 640221 643472 640236 1 640627 640220 640627 652 643485 644495 643488 653 644471 645430 644471 654 645394 645840 645538 655 645840 647111 645840 656 649676 647109 649616 657 649970 650344 649970 658 650418 651722 650433 659 651686 652171 651770 660 652516 652908 652516 661 652799 653593 652892 662 659884 661851 660136 663 661740 662282 661851 664 662286 663074 662289 665 662951 663730 663074 666 664212 663745 664194 667 665619 664255 665619 668 666083 665727 666056 669. 666423 665782 666390 670 666831 668117 667047 671 668121 668375 668139 672 668470 668174 668404 673 669533 668616 669485 674 669892 669485 669892 675 670780 669998 670765 676 671241 670732 671196 677 671182 672447 671260 678 672692 673231 672698 679 673204 674562 673204

748 738838 739740 738862 749 742057 740060 741982 750 742869 742045 742824 751 743378 742824 743348 752 744298 743306 744292 753 744714 744430 744660 754 744985 744611 744931 755 745557 744958 745548 756 746412 745561 746409 757 746772 746416 746697 758 748269 746944 748269 759 748966 748274 748954 760 749426 748965 749411 761 749702 749433 749681 762 750029 749721 750020 763 752307. 750007 752307 764 752913 752503 752901 765 754659 753616 754659 766 755000 756814 755000 767 756796 758301 756832 768 758691 758446 758688 769 759787 759338 759787 770 760242 759871 760188 771 760538 760188 760529 772 760966 761772 760966 773 761759 762142 761759 774 762267 762983 762267 775 .764465 763335 764312 776 764857 764438 764821 777 766068 764821 765972 778 766643 766065 766643 779 768091 766934 768091 780 768785 768252 768785 781 770092 768791 770062 SEQIDN stop prferedstat f 782 770138 770470 770150 783 770661 770185 770631 784 770924 770634 770894 785 772010 771330 772010 786 772390 773391 772390 787 774221 773427 774215 788 776035 774191 776035 789 776663 777706 776894 790 777195 776953 777177 791 779222 777732 779180 792 779321 781552 779360 793 781297 782442 781351 794 782447 785524 782447 795 785532 786002 785697 796 786580 785546 786580 797 787741 786611 787729 798 787620 788021 787782 799 790124 787920 790064 800 790160 790609 790178 801 790634 792016 790634 802 793084 792059 793084 803 793343 794056 793370 804 794046 794957 794079 805 795401 795144 795395 806 795575 796255 795575 807 796278 797015 796311 808 796979 797365 796979 809 797260 797856 797395 810 797772 798086 797805 811 798426 797935 798393 812 798925 798416 798916 813 799301 799927 799301 814 800892 800029 800892 815 801062 802129 801062 SEQ]DNOI~~~ efxrdsaz 816 802023 802673 802041 817 802851 803246 802920 818 803105 804220 803111 819 804307 805356 804331 820 805290 806282 805356 821 806453 808081 806498 822 808026 809009 808098 823 810461 809079 810437 824 811605 810328 811590 825 811725 812342 811824 826 812329 813522 812398 827 813455 813772 813455 828 813732 814334 813780 829 815213 814314 815207 830 814878 814396 814975 831 815733 815428 815733 832 816116 817456 816170 833 8t7608 819320 817608 834 819324 819713 819342 835 819704 820402 819713 836 820375 821061 820453 837 821043 821537 821043 838 821646 822239 821667 839 822182 822931 822221 840 824355 823045 824352 841 825894 824359 825891 842 826322 825879 826322 843 826340 827026 826340 844 827014 827250 827014 845 827856 827230 827856 846 828007 829275 828025 847 829355 830953 829358 848 831119 831748 831140 849 832152 831751 832140 SEQIDNO bein tp Jrfrd 850 832744 832214 832666 851 833446 8- 32805 833-446 852 833802 833368 833742 853 834679 833879 834661 854 835452 834661 835365 855 835778 835371 835775 856 836482 835775 836-470 857 836602 837264 836617 858 837209 838699 837209 859 838760 839575 838760 860 839942 840583 839951 861 840445 841713 840451 862 841659 842459 84-1686 863 842523 843068 842-541 864 843495 843031 843447 865 843239 846196 843335 866 844137 843802 84077 867 848043 846217 848022 868 850123 8-4-8150 850099 869 851645 850230 851504 870 853696 851669 853672 871 854836 853700 854809 872 855525 854920 855468 873 856240 855437 856240 874 857183 856233 857006 875 859439 857451 859430 877 878 879 880 1 85i9946 859642 861599 862053 863540 859587 860640 860724 861580 862098 859916 859660 861599 862038 863531 863927 864688 I

I

863930 863571 882 J 864697 863996 883 864923 866248 864923 189

SEDQI

M? frrefc'reastazt 884 885 886 887 888 889 866303 866665 867810 869094 869270 871299 866605 867732 869090 869357 871372 872582 866336 866665 867864 869094 869336 890 872429 872860 872555- 891 872773 873915 872773 892 873812 8360 873668 893 874028 874438 874067 894 874778 875386 874796 895 8757 74 876382 875843 896 877872 877000 877866 897 878172 877876 878157 898 879098 878172 879098 899 878883 879161 878886 900 879842 879105 879809 901 880885 880052 880885 902 881863 880889 881863 903 882904 881948 882901 904 883794 882901 883761 905 884296 883661 884296 906 884996 884508 884984 907 888777 885166 888771 908 890172 -88940 890172 909 891164 890325 891146 910 891463 891116 891427 911 893278 891968 893278 912 893356 893808 893386 913 893909 893643 893894 914 894276 893-821 894276 915 894778 894248 894760 916 895892 895050 895874 917 895951 896829 895963

I

SEQIDNO be~in%' flop eiicdstr 918 900783 897064 900774 919 902032 900791 902158 920 902659 903876 902659 921 903731 903471 903731 922 903860 905605 903860 923 905725 906474 905725 924 906493 906945 906493 925 907306 907001 907306 926 908101 908742 908131 927 908721 909194 908724 928 909198 909584 909201 929 909583 909951 909670 930 910081 910569 910090 931 910615 910944 910636 932 910948 912261 910951 933 912399 912629 912399 934 912595 913218 912595 935 913203 913676 913218 936 913691 914485 913691 937 914516 915136 914522 938 915144 915467 915162- 939 915629 916633 915629 940 916051 916539 916159 941 916965 917627 916965 942 917612 918304 917612 943 918323 918655 918323 944 918682 919533 918682 945 919542 919829 919542 946 919723 920157 919723 947 920184 920840 920184 948 920866 921294 920866 949 921272 921514 921272 950 921510 921758 921510 951 921778 922143 921778 SEQ ID NO betia|| prefetted start 952 922159 922491 922159 953 922496 923035 922496 954 923160 923453 923160 955 923484 924032 923484 956 924048 924425 924057 957 924443 924937 924443 958 924933 925364 924933 959 925390 926760 925390 960 926819 927184 926819 961 927209 927604 927209 962 927577 928155 927577 963 928100 928759 928127 964 929222 930244 929243 965 930222 930656 930258 966 930608 931078 930665 967 931367 931666 931406 968 931549 931959 931558 969 932070 932579 932070 970 932602 933201 932602 971 933319 933621 933319 972 933522 933785 933522 973 934546 933848 934546 974 936377 934539 936377 975 938081 936666 938081 976 938538 939098 938595 977 939329 940933 939506 978 941031 942068 941076 979 942082 944685 942082 980 944634 945287 944673 981 945287 946294 945287 982 946293 946676 946368 983 947105 948454 947132 984 948522 949277 948546 985 949277 949594 949277 SEQ, IDNxci so rf$sr 986 949849 950676 949888 987 950680 951330 950701 988 951281 951643 951290 989 951788 952798 951803 990 953581 954264 953602 991 954426 955157 954429 992 955754 957940 955766 993 957837 959312 957867 994 959299 961050. 959317 995 961562 961053 961562 996 962575 V 961487 962545 997 961979 961584 961979 998 964914 962545 964914 999 964941 965708 964956 1000 967023 966193 966984 1001 967444 968061 967459 1002 968903 968064 968792 1003 970685 969528 970685 1004 971806 971024 971785 1005 973053 972388 973026 1006 974546 973746 974546 1007 975223 974558 975214 1008 976193 975207 976193 1009 976520 976254 976511 1010 976588 976899 976588 1011 976886 977635 976934 1012 977661 977933 977682 1013 977918 978433 977933 1014 978619 978984 978619 1015 978933 979331 978987 1016 981197 979389 981197 1017 979711 980112 979753 1018 982-116 981148 982107 1019 982321 1 983598 982321 SEQ ID NO bni n atop Ba, jpidei 1020 984488 983862 984296 1021 985381 984371 985381 1022 986103 985399 986046 1023 986693 986046 986693 1024 987607 986693 987607 1025 988119 987616 987942 1026 988253 987936 988247 1027 988831 989163 988834 1028 989693 993442 989693 1029 993408 993785 993408 1030 993835 993416 993754 1031 993882 994262 993906 1032 994226 995656 994259 1033 996036 996611 996036 1034 996885 998267 996885 1035 998962 999225 998962 1036 999375 1001033 999393 1037 1001211 1001516 1001214 1038 1001392 1001664 1001443 1039 1003721 1001823 1003721 1040 1004459 1004845 1004459 1041 1004990 1005382 1004990 1042 1005391 1007496 1005391 1043 1007486 1007821 1007453 1044 1007802 1008698 1007841 1045 1009426 1009121 1009426 1046 1010534 1012054 1010534 1047 1012397 1011942 1012241 1048 1012042 1012635 1012057 1049 1012593 1012862 1012593 1050 1012811 1013440 1012829 1051 1013456 1014055 1013468 1052 1013977 1014489 1013977 1053 1015224 1014529 1015206 SEQDN bginste efar t 1054 1016002 1015145 1015963 1055 1017120 1015939 1017120 1056 1017766 1017245 1017658 1057 1018911 1017916 1018893 1058 1019191 1018580 1019110 1059 1020199 1019831 1020196 1060 1021007 1020114 1020992 1061 1021569 1021075 1021557 1062 1022411 1022097 1022402 1063 1023344 1023667 1023344 1064 1023701 1023949 1023701 1065 1023976 1024776 1023976 1066 1024704 1025045 1024704 1067 1025881 1024967 1025845 1068 1026546 1025839 1026546 1069 1027379 1026546 1027373 1070 1030604 1027929 1030328 1071 1033252 1030508 1033249 1072 1031733 1032086 1031823 11073 1037037 1033456 1037016 1074 1035674 1035910 1035674 1075 1036175 1036507 1036268 1076 68(comp) 1036967 38 1077 16591 16989 16597 1078 31779 31408 31764 1079 56502 56834 56520 1080 56686 56913 56686 1081 64748 65074 64790 1082 73482 73195 73482 1083 78482 78736 78506 1084 79803 79411 79773 1085 82333 81959 82333 1086 87313 86999 87523 1087 109929 10945 6 109716 1088 111599 111351 111599 1089 112069 111734 111988 1090 112666 112911 112666 1091 114017 113715 113978 1092 120757 120464 120757 1093 125133 125522 125133 1094 131888 131604 131837 1095 144164 144427 144191 1096 150698 150369 150635 1097 164385 163948 164385 1098 165690 166115 165408 1099 168742 168425 168742 1100 170509 170793 170509 1101 177145 177474 177145 1102 188295 188023 188295 1103 188791 188330 188791 1104 190629 190336 190626 1105 197313 197083 197307 1106 210914 211384 210956 1107 235160 234852 235160 1108 237227 236913 237188 1109 249733 249446 249904 1110 253493 253158 253493 1111 253701 254789 253701 1112 271633 271932 271633 1113 275666 276070 275666 1114 277931 278218 277976 1115 282741 282481 282738 1116 293178 293489 293181 1117 303155 303469 303185 1118 309297 308965 309297 1119 312219 312536 312246 1120 312853 312602 312844 1121 313167 312772 313167 SEQ UD NO ~begin stop prened start 1122 320224 320598 320224 1123 340249 340503 340249 1124 352839 353324 352839 1125 373475 373699 373475 1126 377316 377756 377316 1127 379268 379657 379268 1128 395098 394823 395077 1129 401594 401142 401594 1130 410045 410539 410045 1131 411425 411658 411425 1132 414937 414416 414937 1133 422889 423212 422964 1134 427842 428183 427842 1135 428732 429451 428732 1136 442557 442799 442524 1137 443628 444041 443628 1138 443678 443166 443678 1139 445901 446155 445901 1140 467981 468262 468023 1141 471869 472108 471869 1142 488032 488337 488044 1143 497179 497694 497101 1144 500474 500202 500471 1145 508968 509561 508968 1146 510845 511264 510845 1147 526525 526848 526525 1148 531318 531863 531444 1149 556826 557224 556826 1150 564971 564537 564971 1151 566963 567232 566963 1152 570351 570890 570351 1153 571072 571332 571072 1154 576025 575801 576025 1155 590363 590650 590363 'SEQiD N ~eiK~ w ~refe4 tn 1156 597868 598593 597868 1157 606889 606626 606889 1158 608031 607786 608031 1159 610110 610391 610143 1160 632703 633353 632703 1161 .637213 637482 637255 1162 650517 649924 650517 1163 652317 652562 652317 1164 654753 655325 654753 1165 661118 660810 661118 1166 677596 677057 677578 1167 679528 679253 679477 1168 732536 732210 732536 1169 742069 742383 742069 1170 759318 758782 759318 1171 760282 760521 760282 1172 771313 770894 771391 1173 772115 772408 772115 1174 788137 788457 788137 1175 816302 815967 816302- 1176 846606 846914 846612 1177 867803 868054 867806 1178 875386 875658 875395 1179 876445 876915 876445 1180 884548 884312 884548 1181 891859 891467 891859 1182 900770 900417 900728 1183 902553 902269 902529 1184 908046 907783 908007 1185 912313 912567 912313 1186 935451 935741 935451 1187 946961 946692 946940 1188 953193 952783 953145 1189 966199 965873 966184 I" ci% :tp i rdtart 1190 969298 968765 969298 1191 971009 970731 971009 1192 972162 972404 972165 1193 973119 973508 973119 1194 998649 998404 998625 1195 1004280 1003882 1004280 1196 1010200 1009532 1010200 1197 1029174 1029482 1029180 TABLE 4 ORFenset ORFoligosFd ORoRF RFligos Bd. ORFoligosp 2 1199 1198 3591 3590 3 1201 1200 3593 3592 4 1203 1202 3595 3594 1205 1204 3597 3596 6 1207 1206 3599 3598 7 1209 1208 3601 3600 8 1211 1210 3603 3602 9 1213 1212 3605 3604 1215 1214 3607 3606 11 1217 1216 3609 3608 12 1219 1218 3611 3610 13 1221 1220 3613 3612 14 1223 1222 3615 3614 1225 1224 3617 3616 16 1227 1226 3619 3618 17 1229 1228 3621 3620 18 1231 1230 3623 3622 19 1233 1232 3625 3624 1235 1234 3627 3626 21 1237 1236 3629 3628 22 1239 1238 3631 3630 23 1241 1240 3633 3632 24 1243 1242 3635 3634 1245 1244 3637 3636 26 1247 1246 3639 3638 27 1249 1248 3641 3640 28 1251 1250 3643 3642 29 1253 1252 3645 3644 1255 1254 3647 3646 31 1257 1256 3649 3648 32 1259 1258 3651 3650 33 1261 1260 3653 3652 34 1263 1262 j 3655 3654 1265 1264 j 3657 3656 36 1267 1266 3659 3658 37 1269 1268 3661 3660 38 1271 1270 3663 3662 39 1273 1272 3665 3664 1275$ 1274 3667 j 3666 i1 1277 1276 i 3669 3668 44 1283 1282 j 3675 3674 f 1285 1284 3677 3676 46 1287 1286 3679 3678 47 1289 1238 3681 3680 48 1291 1290 3683 3682 49 1293 1292 3685 3684 1295 1294 3687 3686 51 1297 1296 3689 3688 52 1299 1298 3691 3690 53 1301 1300 3693 3692 54 1303 1302 3695 3694 1305 1304 3697 3696 56 1307 1306 J 3699 3698 57 1309 1308 3701 3700 58 1311 1310 3703 3702 59 1313 1312 3705 3704 1315 1314 3707 3706 61 1317 1316 3709 3708 62 1319 1318 3711 3710 63 1321 1320 3713 3712 64 1323 1322 3715 3714 1325 1324 3717 3716 66 1327 1326 3719 3718 67 1329 1328 3721 3720 OR.nst ORFoligod MERPoligosF" 68 1331 1330 3723 3722 69 1333 1332 3725 3724 1335 1334 3727 3726 71 1337 1336 3729 3728 72 1339 1338 3731 3730 73 1341 1340 3733 3732 74 1343 1342 3735 3734 1345 1344 3737 3736 76 1347 1346 3739 3738 77 1349 1348 3741 3740 78 1351 1350 3743 3742 79 1353 1352 3745 3744 1355 1354 3747 3746 81 1357 1356 3749 3748 82 1359 1358 3751 3750 83 1361 1360 3753 3752 84 1363 1362 3755 3754 1365 1364 3757 3756 86 1367 1366 3759 3758 87 1369 1368 3761 3760 88 1371 1370 3763 3762 89 1373 1372 3765 3764 1375 1374 3767 3766 91 1377 1376 3769 3768 92 1379 1378 3771 3770 93 1381 1380 3773 3772 94 1383 1382 3775 3774 1385 1384 3777 3776 96 1387 1386 3779 3778 97 1389 1388 3781, 3780 98 1391 1390 3783 3782 99 1393 1392 3785 3784 100 1395 1394 3787 3786 101 1397 1396 3789 3788 TORFenset ORFoligosFd ORFoligosFp ORFoligisBd ORFolig 102 1399 1398 3791 3790 103 1401 1400 3793 3792 104 1403 1402 3795 3794 105 1405 1404 3797 3796 106 1407 1406 3799 3798 107 1409 1408 3801 3800 108 1411 1410 3803 3802 109 1413 1412 3805 3804 110 1415 1414 3807 3806 111 1417 1416 3809 3808 112 1419 1418 3811 3810 113 1421 1420 3813 3812 114 1423 1422 3815 3814 115 1425 1424 3817 3816 116 1427 1426 3819 3818 117 1429 1428 3821 3820 118 1431 1430 3823 3822 119 1433 1432 3825 3824 120 1435 1434 3827 3826 121 1437 1436 3829 3828 122 1439 1438 3831 3830 123 1441 1440 3833 3832 124 1443 1442 3835 3834 125 1445 1444 3837 3836 126 1447 1446 3839 3838 127 1449 1448 3841 3840 128 1451 1450 3843 3842 129 1453 1452 3845 3844 130 1455 1454 3847 3846 131 1457 1456 3849 3848 132 1459 1458 3851 3850 133 1461 1460 3853 3852 134 1463 1462 3855 3854 135 1465 1464 3857 3856 ORbGenset ORFoligosFd ORFoligo~p OP$6ligasBd ORFoigosBp 136 1467 1466 3859 3858 137 1469 1468 3861 3860 138 1471 1470 3863 3862 139 1473 1472 3865 3864 140 1475 1474 3867 3866 141 1477 1476 3869 3868 142 1479 1478 3871 3870 143 1481 1480 3873 3872 144 1483 1482 3875 3874 145 1485 1484 3877 3876 146 1487 1486 3879 3878 147 1489 1488 3881 3880 148 1491 1490 3883 3882 149 1493 1492 3885 3884 150 1495 1494 3887 3886 151 1497 1496 3889 3888 152 1499 1498 3891 3890 153 1501 1500 3893 3892 154 1503 1502 3895 3894 155 1505 1504 3897 3896 156 1507 1506 3899 3898 157 1509 1508 3901 3900 158 1511 1510 3903 3902 159 1513 1512 3905 3904 160 1515 1514 3907 3906 161 1517 1516 3909 3908 162 1519 1518 3911 3910 163 1521 1520 3913 3912 164 1523 1522 3915 3914 165 1525 1524 3917 3916 166 1527 1526 3919 3918 167 1529 1528 3921 3920 168 1531 1530 3923 3922 169 1533 1532 3925 3924 204 OR~tenst O~o~go~d~? ORFligoFp OR"oio~ ORlig01 l 170 1535 1534 3927 3926 171 1537 1536 3929 3928 172 1539 1538 3931 3930- 173 1541 1540 3933 3932 174 1543 1542 .3935 3934 175 1545 1544 3937 3936 176 1547 1546 3939 3938 177 1549 1548 3941 3940 178 1551 1550 3943 3942 179 1553 1552 3945 3944 180 1555 1554 3947 3946 181 1557 1556 3949 3948 182 1559 1558 3951 3950 183 1561 1560 3953 3952 184 1563 1562 3955 3954 185 1565 1564 3957 3956 186 1567 1566 3959 3958 187 1569 1568 1 3961 3960 188 1571 1570 3963 3962 189 1573 1572 3965 3964 190 1575 1574 3967 3966 191 1577 1576 3969 3968 192 1579 1578 3971 3970 193 1581 1580 3973 3972 194 1583 1582 3975 3974 195 1585 1584 3977 3976 196 1587 1586 3979 3978 197 1589 1588 3981 3980 198 1591 1590 3983 3982 199 1593 1592 3985 3984 200 1595 1594 3987 3986 201 1597 1596 3989 3988 202 1599 1598 3991 3990 203 1601 1600 39-93 3992 ORF~~en"set O ogsFt: ORFoio~ OH ~ig~d O4blgb 4 204 1603 1602 3995 3 994 205 1605 1604 3997 3996 206 1607 1606 3999 3998 207 1609 1608 4001 4000 208 1611 1610 4003 4002 209 1613 1612 4005 4004 210 1615 1614 4007 4006 211 1617 1616 4009 4008 212 1619 1618 4011 4010 213 1621 1620 4013 4012 214 1623 1622 4015 4014 215 1625 1624. 4017 4016 216 1627 1626 4019 4018 217 1629 1628 4021 4020 218 1631 1630 4023 4022 219 1633 1632 4025 4024 220 1635 1634 4027 4026 221 1637 1636 4029 4028 222 1639 1638 4031 4030 223 1641 1640 4033 4032 224 1643 1642 4035 4034 225 1645 1644 4037 4036 226 1647 1646 4039 4038 227 1649 1648 4041 4040, 228 1651 1650 4043 4042 229 1653 1652 4045 4044 230 1.655 1654 4047 4046 231 1657 1656 4049 4048 232 1659 1658 4051 4050 233 1661 1660 4053 4052 234 1663 1662 4055 4054 235 1665 1664 4057 4056 236 1667 1666 4059 4058 237 1669 1684061 4060 'ORFeus- O0oio~ T h ORRo I*oA", 238 1671 1670 4063 4062 239 1673 1672 4065 4064 240 1675 1674 4067 4066 241 1677 1676 4069 4068 242 1679 1678 4071 4070 243 1681 1680 4073 4072 244 1683 1682 4075 4074 245 1685 1684 4077 4076 246 1687 1686 4079 4078 247 1689 1688 4081 4080 248 1691 1690 4083 4082 291693 1692 4085 4084 250 1695 1694 4087 4086 251 1697 1696 4089 4088 252 1699 1698 4091 4090 253 1701 1700 4093 4092 254 1703 1702 4095 4094 255 1705 1704 4097 4096 256 1707 1706 4099 4098 257 1709 1708 4101 4100 258 1711 1710 4103 4102 259 1713 1712 4105 4104 260 1715 1714 4107 4106 261 1717 1716 4109 4108 262 1719 1718 4111 4110 263 1721 1720 4113 4112 264 1723 1722 4115 4114 265 1725 1724 4117 4116 266 1727 1726 4119 4118 267 1729 1728 4121 4120 268 1731 1730 4123 4122 269 1733 1732 4125 4124 270 1735 1734 4127 4126 271 1737 1736 4129 4128 ORFGaent BORFoligosd ORFoliosFp jORFoligosBd ORFoligosBp 272 1739 1738 4131 4130 273 1741 1740 4133 4132 274 1743 1742 4135 4134 275 1745 1744 4137 4136 276 1747 1746 4139 4138 277 1749 1748 4141 4140 278 1751 1750 4143 4142 279 1753 1752 4145 4144 280 1755 1754 4147 4146 281 1757 1756 4149 4148 282 1759 1758 4151 4150 283 1761 1760 4153 4152 284 1763 1762 4155 4154 285 1765 1764 4157 4156 286 1767 1766 4159 4158 287 1769 1768 4161 4160 288 1771 1770 4163 4162 289 1773 1772 4165 4164 290 1775 1774 4167 4166 291 1777 1776 4169 4168 292 1779 1778 4171 4170 293 1781 1780 4173 4172 294 1783 1782 4175 4174 295 1785 1784 4177 4176 296 1787 1786 4179 4178 297 1789 1788 4181 4180 298 1791 1790 4183 4182 299 1793 1792 4185 4184 300 1795 1794 4187 4186 301 1797 1796 4189 4188 302 1799 1798 4191 4190 303 1801 1800 4193 4192 304 1803 1802 4195 4194 305 1805 1804 4197 4196 208 ORFenset ORFoligvs$W ORFoligos p 'ORFoligbsBd' ORFbigo&Bp 306 1807 1806 4199 4198 307 1809 1808 4201 4200 308 1811 1810 4203 4202 309 1813 1812 4205 4204 310 1815 1814 4207 4206 311 1817 1816 4209 4208 312 1819 1818 4211 4210 313 1821 1820 4213 4212 314 1823 1822 4215 4214 315 1825 1824 4217 4216 316 1827 1826 4219 4218 317 1829 1828 4221 4220 318 1831 1830 4223 4222 319 1833 1832 4225 4224 320 1835 1834 4227 4226 321 1837 1836 4229 4228 322 1839 1838 4231 4230 323 1841 1840 4233 4232 324 1843 1842 4235 4234 325 1845 1844 4237 4236 326 1847 1846 4239 4238 327 1849 1848 4241 4240 328 1851 1850 4243 4242 329 1853 1852 4245 4244 330 1855 1854 4247 4246 331 1857 1856 4249 4248 332 1859 1858 4251 4250 333 1861 1860 4253 4252 334 1863 1862 4255 4254 335 1865 1864 4257 4256 336 1867 1866 4259 4258 337 1869 1868 4261 4260 338 1871 1870 4263 4262 339 1873 1872 4265 4264 340 1875 1874 4267 4266 341 1877 1876 4269 4268 342 1879 1878 4271 4270 343 1881 1880 4273 4272 344 1883 1882 4275 4274 345 1885 1884 4277 4276 346 1887 1886 4279 4278 347 1889 1888 4281 4280 348 1891 1890 4283 4282 349 1893 1892 4285 4284 350 1895 1894 4287 4286 351 1897 1896 4289 4288 352 1899 1898 4291 4290 353 1901 1900 4293 4292 354 1903 1902 4295 4294 355 1905 1904 4297 4296 356 1907 1906 4299 4298 357 1909 1908 4301 4300 358 1911 1910 4303 4302 359 1913 1912 4305 4304 360 1915 1914 4307 4306 361 1917 1916 4309 4308 362 1919 1918 4311 4310 363 1921 1920 4313 4312 364 1923 1922 4315 4314 365 1925 1924 4317 4316 366 1927 1926 4319 4318 367 1929 1928 4321 4320 368 1931 1930 4323 4322 369 1933 1932 4325 4324 370 1935 1934 4327 4326 371 1937 1936 4329 4328 372 1939 1938 4331 4330 373 1941 1940 4333 4332 ORVFThsct. OREQ i:gQSF4 ORFoligos p ORFoigosBd ORoligoslBp 374 1943 1942 4335 4334 375 1945 1944 4337 4336 376 1947 1946 4339 4338 377 1949 1948 4341 4340 378 1951 1950 4343 4342 379 1953 1952 4345 4344 380 1955 1954 4347 4346 381. 1957 1956 4349 4348 382 1959 1958 4351 4350 383 1961 1960 4353 4352 384 1963 1962 4355 4354 385 1965 1964 4357 4356 386 1967 1966 4359 4358 387 1969 1968 4361 4360 388 1971 1970 4363 4362 389 1973 1972 4365 4364 390 1975 1974 4367 4366 391 1977 1976 4369 4368 392 1979 1978 4371 4370 393 1981 1980 4373 4372 394 1983 1982 4375 4374 395 1985 1984 4377 4376 396 1987 1986 4379 4378 397 1989 1988 4381 4380 398 1991 1990 4383 4382 399 1993 1992 4385 4384 400 1995 1994 4387 4386 401 1997 1996 4389 4388 402 1999 1998 4391 4390 403 2001 2000 4393 4392 404 2003 2002 4395 4394 405 2005 2004 4397 4396 406 2007 2006 4399 4398 407 2009 2008 4401 4400 OR%3nset- O ko-isd ORoio0 ORoitd RoiI6ZBp 408 2011 2010 4403 4402 409 2013 2012 4405 4404 410 2015 2014 4407 4406 411 2017 2016 4409 4408 412 2019 2018 4411 4410 413 2021 2020 4413 4412 414 2023 2022 4415 4414 415 2025 2024 4417 4416 416 2027 2026 4419 4418 417 2029 2028 4421 4420 418 2031 2030 4423 4422 419 2033 2032 4425 4424 420 2035 2034 4427 4426 421 2037 2036 4429 4428 422 2039 2038 4431 4430 423 2041 2040 4433 4432 424 2043 2042 4435 4434 425 2045 2044 4437 4436 426 2047 2046 4439 4438 427 2049 2048 4441 4440 428 2051 2050 4443 4442 429 2053 2052 4.445 4 430 2055 2054 4447 4446 431 2057 2056 4449 4448 432 2059 2058 4451 4450 433 2061 2060 4453 4452 434 2063 2062 4455 4454 435 2065 2064 4457 4456 436 2067 2066 4459 4458 437 2069 2068 4461 4460 438 2071 2070 4463 4462 439 2073 2072 4465 4464 440 2075 2074 4467 4466 441 2017 2076 4469 4468 442 2079 2078 4471 4470 443 2081 2080 4473 4472 444 2083 2082 4475 4474 445 2085 2084 4477 4476 446 2087 2086 4479 4478 447 2089 2088 4481 4480 448 2091 2090 4483 F 4482 449 2093 2092 4485 4484 450 2095 2094 4487 4486 451 2097 2096 4489 4488 452 2099 2098 4491 4490 453 2101 2100 4493 4492 454 2103 2102 4495 4494 455 2105 2104 4497 4496 456 2107 2106 4499 4498 457 2109 2108 4501 4500 458 2111 2110 4503 4502 459 2113 2112 4505 4504 460 2115 2114 4507 4506 461 2117 2116 4509 4508 462 2119 2118 4511 4510 463 2121 2120 4513 4512 464 2123 2122 4515 4514 465 2125 2124 4517 4516 466 2127 2126 4519 4518 467 2129 212 .8 4521 4520 468 2131 2130 45-23 4522 469 2133 2132 4525 4524 470 2135 2134 4527 4526 471 2137 2136 4529 45-28 2139 2138 4531 4530 4531 4530 4 2141 2140 4533 4532 4533 I I 4532 2143 2142 4535 453 452145 2144 j 4537 t 453 4 6 476 2147 2146 4539 4538 477 2149 2148 4541 4540 478 2151 2150 4543 4542 479 2153 2152 4545 4544

AQA

481 482 483 41J.d 2157 2159 2161 2i 54 2156 2158 2160 4547 4546 484 2163 21 6 2 485 2165 2 486 2167 2166 4549 4551 4553 4555 4557 4559 4561 4563 4565 =4567 4569 2169 2168 2171 2170 489 2173 490 491 492 2175 t 2177 2179 2172 2174 2176 2178 4548 4550 4552 4554 4556 4558 4560 4562 4564 4566 4568 4570 4572 4574 4576 4578 4580 493 181 1804571 493 2181 2180 4573 494 2183 2182 4575 496 2187 2186 4579- 2189 2188 4581 A4581 211 2190 4583 4583 Aflfl t F I 2193 2192 f I 4585 2195 2194 501 2197 2196 4589 502 2199 2 19 8 4591 503 2201 2200 4593 504 2203 2202 4595 505 2205 2204 L 45977 4582 4584 4586 4588 4590 4592 4594 4596 4598 4600 4602 4604 2207 2206 4599 507 2292208 4601 508 2211 4603 4 509 2213 2212 4605 214 ORGst CQFoligosFd iiz gop RFobgo Bd ORFigBp 510 2215 2214 4607 4606 511 2217 2216 4609 4608 512 2219 2218 4611 4610 513 2221 2220 4613 4612 514 2223 2222 4615 4614 515 2225 2224 4617 4616 516 2227 2226 4619 4618 517 2229 2228 4621 4620 518 2231 2230 4623 4622 519 2233 2232 4625 4624 520 2235 2234 4627 4626 521 2237 2236 4629 4628 522 2239 2238 4631 4630 523 2241 2240 4633 4632 524 2243 2242 4635 4634 525 2245 2244 4637 4636 526 2247 2246 4639 4638 527 2249 2248 4641 4640 528 2251 2250 4643 4642 529 2253 2252 4645 4644 530 2255 2254 4647 4646 531 2257 2256 4649 4648 532 2259 2258 4651 4650 533 2261 2260 4653 4652 534 2263 2262 4655 4654 535 2265 2264 4657 4656 536 2267 2266 4659 4658 537 2269 2268 4661 4660 538 2271 2270 4663 4662 539 2273 2272 4665 4664 540 2275 2274 4667 4666 541 2277 2276 4669 4668 542 2279 2278 4671 4670 543 2281 2280 4673 4672 544 2283 2282 4675 4674 545 2285 2284 4677 4676 546 2287 2286 4679 4678 547 2289 2288 4681 4680 548 2291 2290 4683 4682 549 2293 2292 4685 4684 550 2295 2294 4687 4686 551 2297 2296 4689 4688 552 2299 2298 4691 4690 553 2301 2300 4693 4692 554 2303 2302 4695 4694 555 2305 2304 4697 4696 556 2307 2306 4699 4698 557 2309 2308 4701 4700 558 2311 2310 4703 4702 559 2313 2312 4705 4704 560 2315 2314 4707 4706 561 2317 2316 4709 4708 562 2319 2318 4711 4710 563 2321 2320 4713 4712 564 2323 2322 4715 4714 565 2325 2324 4717 4716 566 2327 2326 4719 4718 567 2329 2328 4721 4720 568 2331 2330 4723 4722 569 2333 2332 4725 4724 570 2335 2334 4727 4726 571 2337 2336 4729 4728 572 2339 2338 4731 4730 573 2341 2340 4733 4732 574 2343 2342 4735 4734 575 2345 2344 4737 4736 576 2347 2346 4739 4738 577 2349 2348 4741 4740 nn inn OIFpligosBp 578 2351 2350 4743 47 42 579 2353 2352 4745 4744 580 2355 2354 4747 4746 581 2357 2356 4749 4748 582 2359 2358 4751 4750 583 2361 2360 4753 4752 584 2363 2362 4755 4754 585 2365 2364 4757 4756 586 2367 2366 4759 4758 587 2369 2368 4761 4760 588 2371 2370 4763 4762 892373 2372 4765 4764 590 2375 2374 4767- 4766 591 2377 2376 4769 4768 592 2379 2378 4771 4770 593 2381 2380 4773 4772 594 2383 2382 4775 4774 595 2385 2384 4777 4776 596 2387 2386 4779 4778 597 2389 2388 4781 4780 598 2391 2390 4783 4782 599 2393 2392 4785 4784 600 2395 2394 4787 4786 601 2397 2396 4789 4788 602 2399 2398 4791 4790 603 2401 2400 4793 4792 604 2403 2402 4795 4794 605 2405 2404 4797 4796 606 2407 2406 4799 4798 607 2409 2408 4801 4800 608 2411 2410 4803 4802 609 2413 2412 4805 4804 610 2415 2414 4807 4806 611 2417 2416 4809 4808 Qif cest V5ogo~ 0O oORligbsp 612 2419 2418 4811 4810 613 2421 2420 4813 4812 614 2423 2422 4815 4814 615 2425 2424 4817 4816 616 2427 2426 4819 4818 617 2429 2428 4821 4820 618 2431 2430 4823 4822 619 2433 2432 4825 4824 620 2435 2434 4827 4826 621 2437 2436 4829 4828 622 2439 2438 4831 4830 623 2441 2440 4833 4832 624 2443 2442 4835 4834 625 2445 2444 4837 4836 626 2447 2446 4839 4838 627 2449 2448 4841 4840 622 2451 2450 4843 4842 629 2453 2452 4845 484 630 2455 2454 4847 4846 631 2457 2456 4849 4848 632 2459 2458 -4-85.1 4850 633 2461 2460 4853 4852 634 2463 2462 1 4855 4854 635 2465 2464 4857 4856 636 2467 2466 4859 4858 637 2469 2468 4861 4860 638 2471 2470 4863 4862 639 2473 2472 4865 4864 640 2475 2474 4867 4866 641 2477 2476 4869 4868 642 2479 2478 4871 4870 643 2481 2480 4873 4872 644 2483 2482 4875 4874 645 2485 2484 4877 4876 646 2487 2486 4879 4878 647 2489 2488 4881 4880 648 2491 2490 4883 4882 649 2493 2492 4885 4884 650 2495 2494 4887 4886 651 2497 2496 4889 4888 652 2499 2498 4891 4890 653 2501 2500 4893 4892 654 2503 2502 4895 4894 655 2505 2504 4897 4896 656 2507 2506 4899 4898 657 2509 2508 4901 4900 658 2511 2510 4903 '4902 659 2513 251-2 4905 4904 660 2515 2514 4907 4906 661 2517 2516 4909 4908 662 2519 251-8 4911 4910 663 2521 2520 4913 4912 664 2523 2522 4915 4914 665 2525 2524 4917 4916 666 2527 2526 4919 4918 667 2529 2528 4921 4920 668 2531 2530 4923 4922 669 2533 2532 4925 4924 670 2535 2534 4927 4926 671 2537 2536 4929 4928 672 2539 2538 4931 4930 673 2541 2540 4933 4932 674 2543 2542 4935 4934 675 2545 2544 4937 4936 676 2547 2546 4939 4938 677 2549 2548 4941 4940 678 2551 2550 4943 4942 679 2553 2552 4945 4944 'ORFese QRFoligosPF ORFoligoB"' 680 2555 2554 4947 4946 681 2557 2556 4949 4948 682 2559 25 58i 4951 4950 683 2561 2560 4953 4952 684 2563 2562 4955 4954 685 2565 2564 4957 4956 686 2567 2566 4959 4958 687 2569 2568 4961 4960 688 2571 2570 4963 4962 689 2573 2572 4965 4964 690 2575 2574 4967 4966 691 2577 2576 4969 4968 692 2579 2578 4914970 693 2581 2580 4973 4972 694 2583 2582 4975 4974 695 2585 2584 4977 4976 696 2587 2586 4979 4978 697 2589 2588 4981 4980 698 2591 2590 4983 4982 699 2593 2592 4985 4984 700 2595 2594 4987 4986 701 2597 2596 4989 4988 702 2599 2598 4991 4990 703 2601 2600 4993 4992 704 2603 2602 4995 4994 705 2605 2604 4997 4996 706 2607 2606 4999 4998 707 2609 2608 5001 5000 708 2611 2610 5003 5002 709 2613 2612 5005 5004 710 2615 2614 5007 5006 711 2617 2616 5009 5008 712 2619 2618 5011 5010 713 2621 2620 5013 5012 ."ORF'GcseijOUo.sd______

QFEOB

714 1 2623 2622 5015 5014 715 2625 2624 5017 5016 716 2627 2626 5019 5018 717 2629 2628 5021 5020 718 2631 2630 5023 5022 719 2633 2632 5025 5024 720 2635 2634 5027 5026 721 2637 2636 5029 5028 722' 2639 2638 5031 5030 723 2641 2640 5033 5032 724 2643 2642 5035 5034 725 2645 2644 5037 5036 726 2647 2646 5039 5038 727 2649 2648. 5041 5040 728 2651 2650 5043 5042 729 2653 2652 5045 5044 730 2655 2654 5047 5046 731 2657 2656 5049 5048 732 2659 2658 5051 5050 733 2661 2660 5053 5052 734 2663 2662 5055 5054 735 2665 2664 5057 5056 736 2667 2666 5059 5058 737 2669 2668 5061 5060 738 2671 2670 5063 5062 739 2673 2672 5065 5064 740 2675 2674 5067 5066 741 2677 2676 5069 5068 742 2679 2678 5071 5070 743 2681 2680 5073 5072 744 2683 2682 5075 5074 745 2685 2684 5077 5076 746 2687 2686 5079 5078 747 2689 2688 5015080 748 2691 2690 5083 5082 749 2693 2692 5085 5084 750 2695 2694 5087 5086 751 2697 2696 5089 5088 752 2699 2698 5091 5090 753 2701 2700 5093 5092 754 2703 2702 5095 5094 755 2705 2704 5097 5096 756 2707 2706 5099 5098 757 2709 2708 5101 5100 758 2711 2710 5103 5102 759 2713 2712 5105 5104 760 2715 2714 5107 5106 761 2717 2716 5109 5108 762 2719 2718 5111 5110 763 2721 2720 5113 5112 764 2723 2722 5115 5114 765 2725 2724 5117 5116 766 2727 2726 5119 5118 767 2729 2728 5121 5120 768 2731 2730 5123 5122 769 2733 2732 5125 5124 770 2735 2734 5127 5126 771 2737 2736 5129 5128 772 2739 2738 5131 5130 773 2741 2740 5133 5132 774 2743 2742 5135 5134 775 2745 2744 5137 5136 776 2747 2746 5139 5138 777 2749 2748 5141 5140 778 2751 2750 5143 5142 779 2753 2752 5145 5144 780 2755 2754 5147 5146 781 2757 2756 5149 5148 ORFGenset OPi olijQs:d ORFoliQesp' ORFoligsBd O..RFoligosp 782 2759 2758 5151 5150 783 2761 2760 5153 5152 784 2763 2762 5155 5154 785 2765 2764 5157 5156 786 2767 2766 5159 5158 787 2769 2768 5161 5160 788 2771 2770 5163 5162 789 2773 2772 5165 5164 790 2775 2774 5167 5166 791 2777 2776 5169 5168 792 2779 2778 5171 5170 793 2781 2780 5173 5172 794 2783 2782 5175 5174 795 2785 2784 5177 5176 796 2787 2786 5179 5178 797 2789 2788 5181 5180 798 2791 2790 5183 5182 799 2793 2792 5185 5184 800 2795 2794 5187 5186 801 2797 2796 5189 5188 802 2799 2798 5191 5190 803 2801 2800 5193 5192 804 2803 2802 5195 5194 805 2805 2804 5197 5196 806 2807 2806 5199 5198 807 2809 2808 5201 5200 808 2811 2810 5203 5202 809 2813 2812 5205 5204 810 2815 2814 5207 5206 811 2817 2816 5209 5208 812 2819 2818 5211 5210 813 2821 2820 5213 5212 814 2823 2822 5215 5214 815 2825 2824 5217 5216 ,ORF set ORFoligosFd ORFolisp ORFoligos ORFoligsBp cc.. -g 816 2827 2826 5219 5218 817 2829 2828 5221 5220 818 2831 2830 5223 5222 819 2833 2832 5225 5224 820 2835 2834 5227 5226 821 2837 2836 5229 5228 822 2839 2838 5231 5230 823 2841 2840 5233 5232 824 2843 2842 5235 5234 825 2845 2844 5237 5236 826 2847 2846 5239 5238 827 2849 2848 5241 5240 828 2851 2850 5243 5242 829 2853 2852 5245 5244 830 2855 2854 5247 5246 831 2857 2856 5249 5248 832 2859 2858 5251 5250 833 2861 2860 5253 5252 834 2863 2862 5255 5254 835 2865 2864 5257 5256 836 2867 2866 5259 5258 837 2869 2868 5261 5260 838 2871 2870 5263 5262 839 2873 2872 5265 5264 840 2875 2874 5267 5266 841 2877 2876 5269 5268 842 2879 2878 5271 5270 843 2881 2880 5273 5272 844 2883 2882 5275 5274 845 2885 2884 5277 5276 846 2887 2886 5279 5278 847 2889 2888 5281 5280 848 2891 2890 5283 5282 849 2893 2892 5285 5284 224 OR s OFo OR osp ORFligosB ORFoigosBp 850 2895 2894 5287 5286 851 2897 2896 5289 5288 852 2899 2898 5291 5290 853 2901 2900 5293 5292 854 2903 2902 5295 5294 855 2905 2904 5297 5296 856 2907 2906 5299 5298 857 2909 2908 5301 5300 858 2911 2910 5303 5302 859 2913 2912 5305 5304 860 2915 2914 5307 5306 861 2917 2916 5309 5308 862 2919 2918 5311 5310 863 2921 2920 5313 5312 864 2923 2922 5315 5314 865 2925 2924 5317 5316 866 2927 2926 5319 5318 867 2929 2928 5321 5320 868 2931 2930 5323 5322 869 2933 2932 5325 5324 870 2935 2934 5327 5326 871 2937 2936 5329 5328 872 2939 2938 5331 5330 873 2941 2940 5333 5332 874 2943 2942 5335 5334 875 2945 2944 5337 5336 876 2947 2946 5339 5338 877 2949 2948 5341 5340 878 2951 2950 5343 5342 879 2953 2952 5345 5344 880 2955 2954 5347 5346 881 2957 2956 5349 5348 882 2959 2958 5351 5350 883 2961 2960 5353 5352 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 9 14 915 916 917 2963 2965 2967 2969 2971 2973 2975 2977 2979 2981 2983 2985 2989 2991 2993 2995 2997 2999 3001 3003 3005 3007 3009- 3011 3013 3015 3017 3019 3021 3023 3025 3027 3029 QFlgsFp 2962 2964 2966 2968 2970 2972 2974 2976 2978 2980 2982 2984 2986 2988 2990 2992 2994 2996 2998 3000 3002 3004 3006 3008 3010 3012 3014 3016 3018 3020 3022 3024 3026' 3028 5 Ro355 5354~d~b 5355 5354 5357 5356' 5359 5358 5361 5360 5363 5362 5365 5366 5367 5368 5369 5368 5371 5370 5373 5372 5375 5374 53T -37 5377 5376 5379 538 5385 5380 5383 5382 5385 5384 5387 5386 53959 5395 5390 5393 5396 5399 5398 5401 5400 5403 5402 5405 5407 5406 5409 5408 5411 5410 5413 5412 5415 5414 5417 5416 5419 5418 5421 5420 :I :I set||: SRFoligoFd ORFoligosFp :ORFRigsHd ORFoli 918 3031 3030 5423 5422 919 3033 3032 5425 5424 920 3035 3034 5427 5426 921 3037 3036 5429 5428 922 3039 3038 5431 5430 923 3041 3040 5433 5432 924 3043 3042 5435 5434 925 3045 3044 5437 5436 926 3047 3046 5439 5438 927 3049 3048 5441 5440 928 3051 3050 5443 5442 929 3053 3052 5445 5444 930 3055 3054 5447 5446 931 3057 3056 5449 5448 932 3059 3058 5451 5450 933 3061 3060 5453 5452 934 3063 3062 5455 5454 935 3065 3064 5457 5456 936 3067 3066 5459 5458 937 3069 3068 5461 5460 938 3071 3070 5463 5462 939 3073 3072 5465 5464 940 3075 3074 5467 5466 941 3077 3076 5469 5468 942 3079 3078 5471 5470 943 3081 3080 5473 5472 944 3083 3082 5475 5474 945 3085 3084 5477 5476 946 3087 3086 5479 5478 947 3089 3088 5481 5480 948 3091 3090 5483 5482 949 3093 3092 5485 5484 950 3095 3094 5487 5486 951 3097 3096 5489 5488 ':ORFG=ense: ORRoia~ I""olgosf 952 3099 3098 5491 5490 953 3101 3100 5493 5492 954 3103 3102 5495 5494 955 3105 3104 5497 5496 956 3107 3106 5499 5498 957 3109 3108 5501 5500 958 3111 3110 5503 5502 959 3113 3112 5505 5504 960 3115 3114 5507 5506 961 3117 3116 5509 -5508 962 3119 3118 5511 5510 963 3121 3120 5513 5512 964 3123 3122 5515 5514 965 3125 3124 5517 5516 966 3127 3126 5519 5518 967 3129 3128 5521 5520 968 3131 3130 5523 5522 969 3133 3132 5525 5524 970 3135 3134 5527 5526 971 3137 3136 5529 5528 972 3139 3138 5531 5530 973 3141 3140 5533 5532 974 3143 3142 5535 5534 975 3145 3144 5537 5536 976 3147 3146 5539 5538 977 3149 3148 5541 5540 978 3151 3150 5543 5542 979 3153 3152 5545 5544 980 3155 3154 5547 5546 981 3157 3156 5549 5548 982 3159 3158 5551 5550 983 3161 3160 5553 5552 984 3163 3162 5555 5554 985 3165 3164 5557 5556 228 OFGnset R:o ORFol ORoligosBd. ORFoligbsBp

K

986 3167 3166 5559 5558 987 3169 3168 5561 5560 988 3171 3170 5563 5562 989 3173 3172 5565 5564 990 3175 3174 5567 5566 991 3177 3176 5569 5568 992 3179 3178 5571 5570 993 3181 3180 5573 5572 994 3183 3182 5575 5574 995 3185 3184 5577 5576 996 3187 3186 5579 5578 997 3189 3188 5581 5580 998 3191 3190 5583 5582 999 3193 3192 5585 5584 1000 3195 3194 5587 5586 1001 3197 3196 5589 5588 1002 3199 3198 5591 5590 1003 3201 3200 5593 5592 1004 3203 3202 5595 5594 1005 3205 3204 5597 5596 1006 3207 3206 5599 5598 1007 3209 3208 5601 5600 1008 3211 3210 5603 5602 1009 3213 3212 5605 5604 1010 3215 3214 5607 5606 1011 3217 3216 5609 5608 1012 3219 3218 5611 5610 1013 3221 3220 5613 5612 1014 3223 3222 5615 5614 1015 3225 3224 5617 5616 1016 3227 3226 5619 5618 1017 3229 3228 5621 5620 1018 3231 3230 5623 5622 1019 3233 3232 5625 5624 1020 3235 3234 5627 5626 1021 3237 3236 5629 5628 1022 3239 3238 5631 5630 1023 3241 3240 5633 5632 1024 3243 3242 5635 5634 1025 3245 3244 5637 5636 1026 3247 3246 5639 5638 1027 3249 3248 5641 5640 1028 3251 3250 5643 5642 1029 3253 3252 5645 5644 1030 3255 3254 5647 5646 1031 3257 32 56 5649 5648 1032 3259 3258 5651 5650 1033 3261 3260 5653 5652 1034 3263 3262 5655 5654 1035 3265 3264 5657 5656 1036 3267 3266 5659 5658 1037 3269 3268 5661 5660 1038 3271 3270 5663 5662 1039 3273 3272 5665 5664 1040 3275 3274 5667 5666 1041 3277 3276 5669 5668 1042 3279 3278 5671 5670 1043 3281 3280 5673 5672 1044 3283 3282 5675 5674 1045 3285 3284 5677 5676 1046 3287 3286 5679 5678 1047 3289 3288 5681 5680 1048 3291 3290 5683 5682 1049 3293 3292 5685 5684 1050 3295 3294 5687 5686 1051 3297 3296 5689 5688 1052 3299 3298 5691 5690 1053 3301 3300 5693 5692 OREGCDSi OR i;oFd ORoiisM RoiosBd: ORoigf~ 1054 3303 3302 5695 5694 1055 3305 3304 5697 5696 1056 3307 3306 5699 5698 1057 3309 3308 5701 5700 1058 3311 3310 5703 5702 1059 3313 3312 5705 5704 1060 3315 3314 5707 5706 1061 3317 3316 5709 5708 1062 3319 3318 5711 5710 1063 3321 3320 5713 5712 1064 3323 3322 571.5 5714 1065 3325 3324 5717 5716 1066 3327 3326 5719 5718 1067 3329 3328 $721 5720 1068 3331 3330 5723 5722 1069 3333 3332 5725 5724 1070 3335 3334 5727 5726 1071 3337 3336 5729 5728 1072 3339 3338 5731 5730 1073 3341 3340 5733 5732 1074 3343 3342 5735 5734 1075 3345 3344 5737 5736 1076 3347 3346 5739 5738 1077 3349 3348 5741 5740 1078 3351 3350 5743 5742 1079 3353 3352 5745 5744 1080 3355 3354 5747 5746 1081 3357 3356 5749 5748 1082 3359 3358 5751 5750 1083 3361 3360 5753 5752 1084 3363 3362 5755 5754 1.085 3365 3364 5757 5756 1086 3367 3366 5759 5758 1073369 3368 1761 5760 231 1088 3371 37 7356 1089 3373 3372 5765 5764 1090 3375 3374 5767 5766 1091 3377 3376 5769 5768 1092 3379 3378 5771 5770 1093 3381 3380 5773 5772 1094 3383 3382 5775 5774 1095 3385 3384 5777 5776 1096 3387 3386 5779 5778 1097 3389 3388 5781 5780 1098 3391 3390 5783 5782 1099 3393 3392 5785 5784 1100 3395 3394 5787 5786 1101 3397 3396 5789 5788 1102 3399 3398 5791 5790 1103 3401 3400 5793 5792 1104 3403 3402 5795 5794 1105 3405 3404 5797 5796 1106 3407 3406 5799 5798 1107 3409 3408 5801 5800 1108 3411 3410 5803 5802 1109 3413 3412 5805 5804 1110 3415 3414 5807 5806 1113417 3416 5809 5808 1112 34t9 3418 5811 5810 1113 3421 3420 5813 5812 1114 3423 3422 5815 5814 1115 3425 3424 5817 5816 1116 3427 3426 5819 5818 1117 3429 3428 5821 5820 1118 3431 3430 5823 5822 1119 3433 3432 5825 5824 1120 3435 3434 5827 5826 1121 3437 3436 582-9 5828 ORGset'jOfbo~<f R g6F' O R 0 OR lg s l Ij. 1122 1123 3439 3441

L

1124 3443 3438 3440 3442 5831 5833 5835 5837 1125 3445 t 3445 *1 3 4 4 4 i 'it r T 1126D 34471 3446 1127 J 3449 3448 1128 3451 3450 1129 3453 3452 1130 1131 1132 1133 1134 1135 1136 3455 3457 3459 3461 3463 3465 3467 3454 3456 3458 3460 3462 3464 3466 3468 3470 3472 3474 3476 3478 5839 5841 5843 5845 5847 5849 5851- 5853 5830 5832 5834 5836 5838 5840 5842 5844 5846 5848 5850 5852 1137 1138 1139 1140 1141 1142 3469 3471 3473 3475 3477 3479 5855 5857 5859 5861 5863 5865 5854 5856 5858 5860 5862 5864 5867 5869 1143348134805871 1143 3481 3480 5873 1144 3483 34824 5875 1145 3485 3484 5877 1147 3489 3488 5881 1148 3491 3490 5883 1149 3493 3492 5885 1150 3495 3494 58875 1151 3497 3496 5889 5 1152--- 3499 3498 5891 5 5866 5868 5870 5872 5874 5876 5878 5880 5882 5884 5886 888 890 892 894 1153 3501 3500 5893 1154 f 3503 3502 f 5895 5 5 1155 3505 3504 S897 5897 896 ORF~nt OIRFoIo~ OR oIgsp 0Joio~ ORbiBp 1156 3507 3506 5899 5898 1157 3509 3508 5901 5900 1158 3511 3510 5903 5902 1159 3513 3512 5905 5904 1160 3515 3514 5907 5906 1161 3517 3516 5909 5908 1162 3519 3518 5911 5910 1163 3521 3520 5913 5912 1164 3523 3522 5915 51 1165 3525 3524 5917 5916 1166 3527 3526 5919 5918 1167 3529 3528 5921 5920 1168 3531 3530 5923 5922 1169 3533 3532 5925 5924 1170 3535 3534 5927 5926 1171 3537 3536 5929 5928 1172 3539 3538 5931 5930 1173 3541 3540 5933 5932 1174 3543 3542 5935 5934 1175 3545 3544 5937 5936 1176 3547 3546 5939 5938 1177 3549 3548 5941 5940 1178 3551 3550 5943 5942 1179 3553 3552 5945 5944 1180 3555 3554 5947 5946 1113557 3556 5949 5948 1182 3559 3558 5951 5950 1183 3561 3560 5953 5952 1184 3563 3562 5955 5954 1185 3565 3564 5957 5956 1186 3567 3566 5959 5958 1187 3569 3568 5961 5960 1188 3571 3570 5963 5962 1189 3573 3572 5965 5964 234 O%0 ne R~io~ ligOS rjO olgBd jO oitsa 1190 3575 3574 5967 5966 1 191 3577 3576 5969 5968 1192 3579 3578 5971 5970 1193 3581 3580 5973 5972 1194 3583 3582 5975 5974 1195 3585 3584 5977 5976 1196 3587 3586 5979 5978 1197 3589 3588 5981 5980 SEQ ID Or. position 1198 F 1038449 1199 F 1036517 1200 F 250 1201 F 1036965 1202 F 3011 1203 F 1123 1204 F 4907 1205 F 2996 1206 F 6379 1207 F 4483 1208 F 7837 1209 F 5961 1210 F 8351 1211 F 6467 1212 F 18705 1213 F 6834 1214 F 9598 1215 F 7709 1216 F 10134 1217 F 8248 1218 F 10990 1219 F 9060 1220 F 11823 1221 FP9946 1222 F 13236 1223 F 11410 1224 F 14529 1225 F 112643 1226 F 14668 1227 F 12813 1228 F 15747 1229 F :13844 TABLE SEQi5--D7Or. position 2793 F 785793 2794 F 789918 2795 F 788039 2796 F 790378 2797 F 788456 2798 F 791834 2799 F 789918 2800 F 793102 2801 F 791176 2802 F 793826 2803 F 791921 2804 F 794911 2805 F 793023 2806 F 795296 2807 F 793427 2808 F 796005 2809 F 794127 2810 F 796729 2811 F 794811 2812 P 797041 2813 F 795065 2814 F 797553 2815 F 795651 2816 F 797716 2817 F 795815 2828 F 7.98197 2819 F 796285 2820 F 799004 2821 F 797173 2822 F 799785 2823 F 797910 2824 F 800789 SEQ ID Or. position 4388 B 394245 4389 B 396116 4390 B 395604 4391 B 397475 4392 B 396249 4393 B 398133 4394 B 396759 4395 B 398660 4396 B 397746 4397 2 399639 4398 B 398973 4399 B 400878 4400 B 399921 4401 B 401846 4402 B 400393 4403 B 4022B7 4404 B 401444 4405 B 403344 4406 B 402258 4407 B 404150 4408 B 403461 4409 B 405340 4410 B3 405400 4411 B 407325 4412 B 404027 4413 B 405941 4414 B 406141 4415 B 408055 4416 B 407325 4417 S 409172 4418 B 409 99 4419 1B 411893 'SEQ ID I Or. 1position SEQ ID 2825 1230 F 15903 1231 F 14019 1232 F 17198 1233 F 15298 1234 F 18218 1235 F 16263 1236 F 20595 1237 F 18692 1238 F 21932 1239 F 19969 1240 F 22259 1241 F 20E 8 1242 F 22605 1243 F 20659 1244 F 22890 1245 F 20987 1246 F 23150 1247 F 21244 1248 F 24413 1249 F 22506 1250 F 26379 1251 F 24476 1252 F 27498 1253 F 25602 1254 F 28476 1255 F 126621_ 1256 F 129785 1257 F 127860 1258 F 130276 1259 F 28363 1260 F 31184 1261 F 29287 1262 F 31574 1263 F 29650 Or.

F

position 798866-- 2826 F 801800 2827 F 799847 2828 F 802561 282.9 F 800732 2830 F 802881 2831 F 800926 2832 F 804088 2833 F 802162 2834 F 805071 2835 F '803150 2836 F 801224 2837 F 804333 2838 F 807742 2839 F 805907 2840 F 808860 2841 F 806959 2842 F 810074 2843 F 808209 2844 F 811442 2845 F 809555 2846 F 81208B 2847 F 810158 2848 F 813225 2849 F :811336 2850 F 813512 2851 F 811473 2852 F 814095 2853 F 812185 2854 F 814173 2855 F 812276 2856 F 815188 2857 F 813268 2858 F 815897 SEQ ID Or. lposition 4420 B 411645 4421 B 413542 4422 B 413693 4423 B 1415530 4424 B 413693 4425 B 415S59 4426 B 414172 4427 B3 416072 4428 B 415337 4429 B 417275.

4430 B 414599 4431 B 416499 4432 B 416887 4433 B 418821 4434 B 417700 4435 B 419585 4436 B 418274 4437 B3 420173 4438 B 418823 4439 B 1420732 4440 B 419778 4441 B 421678 4442 2 420461 4443 B 422361 444 S 421460 4445 B 423336 4446 B 422265 4447 B 424120 4448 B 423263 4449 B !425182 4450 B 425302 4451 B 427252 4452 B3 426283 4453 B 428210 SEQ ID JOr. Iposition 1264 F 33095 1265 F 31184 1266 F 33840 1267 F 31949 1268 F- 34769 1269 F 32869 1270 F 34915 1271! 32961 1272 F 35696 1273 -F 339 1274 F- 36794 1275 F 34893 1276 F 37960 1277 36085 1278 F 38924 1279 F 37017 1280 F- 39704 1281 F 37754 1282 F 40541 1283 FV 38615 1284 F 41945 1285 ~F 40054 1286 F 42779 1287 F 40859 1288 F '43991 1289 F 42061 1290 F 45056 1291 F 43155 1292 FP45755 1293 F 43821 1294 F 46272 1295 44382 1296 F 46654 SE'Q ID 2859 2860 Or.

Fr

F

position 813968 817367 2861 F 815456 2862 F 819089 2863 F 817201 2864 F 819482 2865 F 817563 2866 F 8043 2867 F 818252 2868 F 820800 2869 F 818900 2870 F 821426 2871 F 819500 2872 F 821943 2873 F 820003 2874 F 822811 2875 F 820926 2876 F 824117 2677 F 822214 2878 F 825659 2879 F 8 237T47 2880 F 826112 2881 F 824151 2882 F 826773 2883 F 824894 2884 F 826945 2885 F 825061 2886 F 827754 2887 F 825869 2888 F 829117 2889 F 827236 2890 F '830870 2891 F 828917 2892 F 831522

I

SEQ ID !or. position 4454 B 427252 4455 B 429129 4456 B 428040 4457 B 429940 4458 B 430106 4459 B 432063 4460 B 430580 4461 R 432480 4462 B 1430860 4463 B 432776 4464 B 432063 4465 B 433919 4466 B 43226 4467 R 434137 4468 B 434730 4469 B 436671 4470 B 436671 4471 B 438495 4472 B 436803 4473 B 438696.

4474 B 437953 4475 B 439850 4476 B 438490 4477 B 1440383 4478 B 439374 447.9 B 441289 4480 B 439562 4481 3 1441466 4482 B 1439976 4483 B 1441847 4484 B 441301 4485 B 443216 4486 B 442161 4487 B 444066 1297 F 144763 SEQ ID Or. Iposition 1298 F 47926 1299 F 46059 1300 F- 48403 1301 F 146485 1302 FT 149871 1303 F 147980 1304 F 150706 1305 F 148792 1306 F152129 1307 F 150199 1308 F 53247 1309 F 51346 1310 F~P 54376 1311 152462 1312 F 54790 1313 F 52890 1314 55404 1315 FP53540 1316 FP56602 1317 FT~ 54695 1318 F 58151 1319 F 56284 1320 F58965 1321 F 57039 1322 7F 59955 1323 Fj- 58032 1324 P 61247 1325 59364 1326 F 62249 1327 F 60375 1328 F63117 1329 F~Y 61247 1330 F- 63829 1331 FY 161908 SEQ ID Or. lposition 2893 F 829613 2894 F 831995 2895 F 830093 2896 F 832585 2897 F 830686 2898 F833149 2899 F 831240 2900 F833660 2901 F 831704 2902 F 834442 2903 F 832539 2904 F 825147 2905 F 833252 2906 F 835536 2907 F 833656 2908 F 836378 2909 F 834480 2910 F 836990 2911 F 835067 2912 F ;838512 2913 F 836603 2914 F 839718 2915 F 837811 2916 F 840211 2917 F 838266 2918 F 841434 2919 F 839485 2920 F 842250 2921 F 8077 2922 F 842761 2923 F 840912 2924 F 843000 2925 F 841103 2926 F 843583 SEQ ID Or. position 4488 B 442834 4489 B3 444713 4490 B 446608 4491 B 448508 4492 B 448288 44-93 B 450225 4494 B i449798 4495 B 451705 49 6 B 451345 4497 B 453199 4498 B 451891 4499 B 453768 4500 B42813 4501 _B 1454720 4502 B 453439 4503 B 455315 4504 B 455088 4505 B 1456988 4506 B 455682 4507 B 457551 4508 B 456302 4509 B 458221 4510 B 457645 4511 B 459519 4512 B 1458699 4513 B 460570 4514 B 459867 4515 B ;461758 416_G B 461464 4517 2 463337 4518 B3 461887 4519 B 463795 4520 B 462842 4521 B 464780 239 SEQ ID 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1-356- 1357 1358 1359 1360 1361 1362 1363 1364 1365 Or. position F 64066 62136 F 64369 62437 F 65124 F 63225 F 67407 F 65513 F 68652 F 166758 F 68946 F 67080 F 69660 F 67818 F 70432 F 1 68572 F 70866 F 6 8946 F73272 F 71373 F74657 F72752 F 75282 F73383 F76781 F74878 F76925 F75017 F77935 F76028 F 79611 F77-750 F82371 F 180509 SEQ I 2927 2928 2929 2930 2931 2932 2933 2934 2935 Or.

F

F

F

F

F

-F

-F

position 841683 845985 T44 098 847919 846025 850011 848109 851442 849547 SEQ ID Or.

4522 B 4523 B 4524 B 4525 B 4526

B

4527

B

4528 B 4529 3 4530 B 4531

B

4-5 32 B 4533 B 4534 B 4535 13 4536 BI 4537 -B 14 4538 B 1 4539 BF 4 4540 B (464031 (465946 14-64849 4 668 01 466078 467968 467670 469540 469208 471075 469520 414 00 169895 171798 17153.3 173363 ~71867 :73 744 :73 542 2936 2937 2938 2939 2940 2941 2942 2943 2944 2945 2946 2947 2948 2949

F

F

F

F

-F

F

-F

F.

F

F

F-

F

F

853479 851567 8 54701 852801 855197 853282 856012 85S4 111 857227 855326 859309 85-7458 '8594181 857515 2950 F 860468 2951 F858583 2952 F 861361 2953 F 859441 2954 F 861872 2955 F 859979 2956 F 863352 2957 F 861444 2958 F863777 2959 F861872 2960 F 864636 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4552 4553 4554 4555

B

Bh

B

B

B

B

B

Br 475387 473919 475824 474747 476666 475493 477373 476747 478682 478861 4803821 479311 481243 47.9943 481858-- SEQ ID -Or. position 1366 F 83502 1367 F 81655 1368 F 84657 1369 F 82740 1370 F 87093 1371 F 85186 1372 F 87188 1373 F 185320 1374 F 88179 1375 F 86281 1376 F 188486 1377 F 86598 1378 F 89077 1379 F 87236 1380 F 89495 1381 F 87578 1382 F 91202 1383 F 89232 1384 F 91526 1385 F 89598 1386 F 92085 1387 F 0203 1388 F 93104 1389 F 91239 1390 F 93833 1391 F 191938 1392 F 94392 1393 F 92508 1394 F 97894 1395 F 95984 1396 F 98502 1397 F 96620 1398 F 100117 1399 F 98215 SEQ ID 2961 2962 2963 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 2981 0:

F

F

-F

F

F

F

F

F

F

F

F

Fv

F

F

F

-F

F

Position 862792 866084 864184 8644-3 864500 867576 865673 868841 866960 86.9050 867150 871062 869138 872210 870310 872497 870597 873141 871236 873800 871909 874558 8 7264 8 875521 873612 876781 874 84 8 877657 87 5 727 877935 876044 87 8 633 876695 8788

S-FE-QID

4556 4557 4558 4559 4560 4561 4562 4564 4565 4566 4567 4568 4569 4570 4571 Fo-.

B

positilon '480257 482146

B

B

B

B

B

Br 481708 483633 481969 483871 48366'8 485559 485198 4B87094 48 8084 409985 485945 487859 489498 491367 2982 2983 2984 2985 2986 2987 2989 2990 2991 2992 2993

F

F

F

F

F

F

F

-F

4572 4573 4574 4575 4576 4577 4578 4579 4580 4581 4582 4583 4584 4585 4586 4587 4588

B

Br

B

B

1488799 4.90691 490677 492589 492994 494929 493113 495035 493985 495864 494929 496801 495090 496989 495585 497485 495436 2994 [FjI 4589 B 497304 SEQ ID Or., lposition 1400 F 101104 1401 F 99158 1402 F 101981 1403 F 100080 1404 F 102499 1405 F 100546 1406 F 104014 1407 F 102126 1408 F 105028 1409 F 103092 1410 F 107210 1411 F 105310 1412 F 108446 1413 F 106545 1414 F 108792 1415 F 106853 1416 F 109472 1417 F 107561 1418 F 1 11060 1419 F 109147 1420 F 112669 1421 F 110796- 1422 F 113335 1423 F 111435 1424 F 113733 1425 F 111882 1426 F 114479 1427 F 112580 1428 F 1115138 1429 F 1113196 1430 F 1115765 1431 F 113891 1432 F 119580 1433 F 1117660 SEQ ID Or. position 2995 F 876963 2996 F 879824 2997 F877933 2998 F 880670 2999 F 878769 3000 F 881719 3001 F 879824 3002 F 862682 3003 F 880774 3004 F 883432 3005 F 681540 3005 F 884263 3007 F 882357 3008 F 884947 3009 F 883044 3010 F 888721 3011 F 886762 3012 F 890084 3013 F 688182 3014 F 890897 3015 F 888996 3016 F 891749 3017 F 889830 3018 F 893136 3019 F 891228 3020 F 893415 3021 F891471 3022 F 893591 3023 F 891684 3024 F 894005 3025 F 892127 3026 F 894827 3027 F 892900 3028 F 895732 SEQ ID 4590 4591 4592 4595 4596 Or.

B

B

B

!Position 49 6 854 498754 497396 499316 498735 500635 499484 4597 4598 4599 4600 4601 4602 -r 4r-

B

B7

BF

101005 502852 501937 50O3 85-3 503083 4603 B 505003 4604 B 503895 4605 B 505846 4606 B 505263 4607 B 507137 4606 B 507214 4609 B 509106 4610 B 507687 4611 B 5 09559 4612 B 508632 4613 B 510534 4614 B 508863 4615 B 510730 416 B 509202 4617 B 511062 4618 B 510940 4619 B '512832 4620 B 511747 47621 R 513649 4622 B 1512446 4623 B S.4305 SEQ ID fO.[osition 1434 F 123834 1435 F 121914 1436 F 124699 1437 F 122753 1438 F 125280 1439 F 123416 1440 F 126101 1441 F 124208 1442 F 126871 1443 F 125013 1444 F 127698 1445 F 125787 1446 F 129465 1447 F 127467 1448 F 130799 1449 F 128869_ 1450 F 131615 1451 F 12971! 1452 F 132856 1453 F 130914 1454 F 133401 1455 F 131474 1456 F 133624 1457 F 131706 1458 F 134385 1459 F 132500' 1460 F 137183 1461 F 135320 1462 F 140106 SEQ ID 3029 3030 3031 3032 Or.

F.

-F

-F.

position [893 790 896823 894907 900571

SEQI

4624 Or.

po-sI tolan 3033 3034 3035 F3036 3037 3038 3039

F

F.

F

F

898639 902407 900507 903243 901346 903616 9 01726 3040 3041 3042 3043 3044 3045 3046 3047 3048 3049 3050

F

-F

F

F

F

-F

F

F

F

F

905486 9389 906234 904350 906774 904846 907868 905924 908501 906583 908975 4625 B 515212 4626 B1 514529 4627 B 1516410 4628 B 5154-66 4629 B 517354 4630 B 515496 4631 B 517389 4632 B 1516069 4633 B 517978 4634 B 516642 4635 B 518551 4636 B 517420 4637 B 519349 4638 B 518187 4639 B 520053 4640 B 518617 46 41 B 520500 4642 B 59078 4643 B 1520963 4644 P3 519736 4645 B 521636 4646 B 520719 4647 B 522655 4648 B 522221 4649 B 524115 4650 B :522354 4651 B 524287 4652 B3 523763 4653 B 1525689 4654 B 1524854 4655 B 526756 4656 B 525970 4657 B 527866 3051 3052 3--053 3054

LI

F

-r 907079 909351 907456 909835 1463 1464 1465 1466 1467

F

F7 Fr

-F

-F

1381 140-839 13-8927 141535 13 9614 3055 907957- 3056 F 910382 3057 F 908496 3058 F'T 910693 3059 F 908829 3060 F912169 3061 F 91024 13062F SEQ ID Or. position 1468 F 142909 1469 F 140952 1470 F 143684 1471 F 141782 1472 F 144309 1473 F 142375 1474 F 146178 1475 F 144294 1476 F 146894 1477 F 144997 1478 F 147858 1479 F 145960 1480 F 148277 1481 F 146347 1482 F '148781 1483 F 146846 1484 F 148947 1485 F '147021 1486 F 149424 1487 F 147592 1488 F 150769 1489 F 148884 1490 F 1151743 1491 F 149880 1492 F 152659 1493 F 150769 1494 F 153101 1495 F 151270 1496 F 153719 1497 F 151850, 1498 F 155002 1499 F 153096 1500 F 156550 1501 1F 154687 S-EQ ID Or. position 3063 F 910476 3064 F 912984 3065 F 911084 3066 F 913437 3067 F 911545 3068 F 914282 3069 F 912376 3070 F 914925 3071 F 913023 3072 F 915394 3073 F 913510 3074 F 915827 3075 F 913912 3076 F 916683 3077 F 914788 3078 F 917347 3079 F 915438 3080 F 918089 3081 F 916289 3082 F 918399 3083 F 916506 3084 F 919296 3085 F 917406 3086 F 919457 3087 F 917598 3088 F 919864 3089 F 917963 3090 F 920641 3091 F 919711 3092 F 921029 3093 F 919138B 3094 F 921239 3095 F 919366 3096 F '921526 SEQ ID Or. position 4658 B 526312 4659 B 528202 4660 B 526640 4661 B 528553 4662 B 526991 4663 B 528855 4664 B 1528553 4665 B 530443 4666 B3 529081 4667 B $30988 4668 B 529943 4669 B 531844 4670 B 530424 4671 23 532301 4672 B 530799 4673 B 532675 4674 B 531670 4675 R 533594 4676 B 533498 4-7677 B 535393 4678 2 534147 4679 B 535997 4680 B 534892 4681 2 536813 4682 B 536191 4683 B 538068 44 B 539438 4685 B 541306 4686 B 540771 4687 B 542639 4688 B '541223 4689 B 543141 4690 B 1542025 4691 B S543927 1 SEQ ID Or. position 1502 F 157206 1503 F 155353 1504 F 158818 1505 F 156924 1506 F 159676 1507 F 157795 1508 F 160957 1509 F 159063 1510 F 161319 1511 F 159504 1512 F .162131 1513 F 160240 1514 F 162775 1515 F 160865 1516 F 164236 1517 F 162345 1518 F 165837 1519 F 163923 1520 F 166508 1521 F 164605 1522 F 168612 1523 F 166683 1524 F 169367 1525 F 167436 1526 F 170556" 1527 F 168661 1528 F 171067 1529 F 169173 1530 F 172090 1531 F 170171 1532 F 172797 1533 F 170904 1534 F 174176 1535 F 172236- SEQ ID iOr. position 3097 F 919638 3098 F 921930 3099 F 919979 3100 F 922212 3101 F 920325 3102 F 922925 3103 F 921029 3104 F 923258 3105 F 1921324 3106 F 923808 3107 F 921929 3108 F 9241F5 3109 F 922311 3110 F 924680 3111 F 922764 3112 F 925111 3113 F 923258 3114 F 926538 3115 F 924638 3116 F 926972 3117 F 925072 3118 F 927351- 3119 F 925415 3120 F 927870 3121 P 925924 3122 F 928974- 3123 F 927031 3124 F 930003 3125 F 928103 3126 F 930383 3127 F 928402 3128 F 931084 3129 F 929222T 3130 F 193130 SEQ ID Or. position 4692 B 543495 46.93 B 545375 4694 B* 544367 4695 B546253 4696 B 544790 4697 B 546697 4698 B 544982 4699 B 546-850 4700 Sr 546655 4701 B 548555 4702 B 547701 4703 B 549667 4704 Bh 547609 4705 Bh 549533 4706 Bh 548121 4707 B 550040 4708 B 548878 4709 B 1550836 4710 B 549681 4711 B 551602 4712 B 550605 4713 B 5S2527 4714 B 551849 4715 B 553750 4716 B 553261 4717 B 555165 4718 BF 555176 4719 B 557075 4720 B 556590 4721 13 558489 4722 B 557130 43 B 1559024 4724 8 558346 4725 B 560246 SEQ ID Or. position 1536 F 175048 1537 F 173138 1538 F 175476 1539 F 173595 1540 F 177183 1541 F 175275 1542 F 177858 1543 F 175942 1544 F 179819 1545 F 177923 1546 F 180412 1547 F 178455 1548 F 181169 1549 F 179226 1550 F 182628 1551 F 180694 1552 F 183403 1553 F 181494 1554 F 184577 1555 F 182628 1556 F 185763 1557 F 183843 1558 F 186496 1559 F 184614 1560 F 187187 1561 F 18526-2 1562 F 188542 1563 F 186632 1564 F 189410 1565 F 187514 1566 F 190016 1567 F 188083 1568 F 190545 1569 F 188666 SEQ 113 Or. position 3131 F929397 3132 F931824 3133 F 929927 3134 F 932352 3135 F 930470 3136 F 933044 3137 F 931084 3138 F9,33303 3139 F 9313 96 3140 F 933626 3141 F 931686 3142 F 934320 3143 F~ 932412 3144 F936427 3145 F 934508 3146 F 938309 3141 936402 3148 F 939110 314.9 F 937204 3150 F940791 3151 F938889 3152 F 941806 3153 F 939906 3154 F 944314 3155 F 942412 3156 F 944987 3157 F 943090 3158 F 946072 3159 F 944166 3160 F 946877 3161 F 944986 3162 F 948258 3163 F946403 SEQ ID Or. position 4726 B 558455 4727 B 560376 4728 B3 559450 4729 B 561362 4730 B3, 561581 4731 B 563478 4732 B 563153 4733 B 565073 4734 B 564319 4735 B 566220 4736 B '564201 4737 B 566078 4738 B 1567243 4739 B 1569143 4740 B 568192 4-74.1 B 570133 4742 B 570619 4743 B 1572532 4744 B 572241 4745 B 574208 4746 B 1572994 4747 B 574916 4748 B 573744 4-Z749 B 575640 4750 B 573679 4751 B 575571 4752 B 1574398 4753 B 576288 4754 B3 574677 4755 B 576633 4756 B 575033 4757 B3 576922 4758 B 575482 4759 B 577363 3164 [1 949037 SEQ ID Or. position 1570 F 191538 1571 F 189595 1572 F 192173 1573 F 190247 1574 F 193015 1575 F 191135 1576 F 194471 1577 F 192522 1578 F 194946 1579 F 193015 1580 F 196798 1581 F 194896 1582 F 197440 1583 F 195550 1584 F 197440 1585 F 195549 1586 F 198736 1587 F 196802 1588 F 199722 1589 F 197822 1590 F 200003 1591 F 198147 1592 F 200361 1593 F 198453 1594 F 200945 1595 F 199009 1596 F 202122 1597 F 200215 1598 F 203251 1599 F 201352 1600 F 203807 1601 F 201903 1602 F 1206555 1603 F 1204669 SEQ ID Or. position 3165 F 947137 3166 F 949581 3167 F 947671 3168 F 950455 3169 F 948558 3170 F 951058 3171 F 949151 3172 F 951569 3173 F 949652 3174 F 953340 3175 F 951431 3176 F 954174 3177 F 952288 3178 F 955475 3179 F 953604 3180 F 957601 3181 F 955703 3182 F 959053 3183 F 957168 3184 F 960824 3185 F 958.932 3186 F 961268 3187 F 959368 3188 F 961365 3189 F 959465 3190 F 962324 3191 F 960423 3192 F 964706 3193 F 962822 3194 F 965974 3195 F 964074 3196 F 967210 3197 F 950 3198 F 1967808 SEQ ID Or. position 47G0 B 575699 4761 B577606 4762 B576078 4763 B577993 4764 Bh 578265 476.5 B 580143 4766 B 578948 4767 B 580848 4768 B582336 476.9 31584225 4770 S 582917 4771 B584317 4772 B 583359 4773 B585252 4774 B583734 4775 S 585634 4776 3584122 4777 5 85990 4778 B 584665 4779 B 586598 4780 B 585213 4781 B 587123 4782 B 585517 4783 B 587434 4784 B 586850 4785 B :588730 4786 B 589017 4787 B3 589878 4788 B 5839628 4789 B 591543 4790 B 589798 4791 B 591723 4792 B 590323 4793 B 592211 SEQ mD Or. position 1604 F207269 1605 F 205369 1606 F 208293 1607 F 206395 1608 F 209252 1609 F 207345 1610 F 210330 1611 F 208414 1612 F 210632 1613 F 208694 1614 F 211151 1615 F 209255 1616 F 212650 1617 F 210756 1618 F 213920 1619 F 212036 1620 F 214535 1621 F 212635 1622 F 215003 1623 F 213077 1624 F 216641 1625 F 214772 1626 F !216869 1627 F 214961 1628 F 218145 1629 F 216218 1630 F 218461 1631 F 216576 1632 F 218960 1633 F 217044 1634 F 219646 1635 F 217772 1636 F 220257 1637 jF j218379 SEQ ID (Dr. position 3199 F 965925 3200 F 969286 3201 F 967320 3202 F 970802 3203 F 968888 3204 F 972169 3205 F 970269 3206 F 973487 3207 F 971616 3208 F 974339 3209 F 972408 3210 F 974988 3211 F 973035 3212 F 976035 3213 F 974114 3214 F 976367 3215 F 974411 3216 F 976565 3217 F 974730 3218 F 977439 3219 F 975500 3220 F 977698 3221 F 975799 3222 F 978389 3223 F 976478 3224 F 97865 3225 F 976760 3226 F 979134 3227 F 977270 3228 F 97-9473 3229 F 977592 3230 F 980915 3231 F 979026 3232 F 982043 SEQ ID Or. position 4794 B 591492 4795 B 593419 4796 B 593002 4797 B 594885 4798 B 593367 4799 B 595321 4800 B 594166 4801 B 596020 4802 B 595942 4803 B 597826 4804 B 596354 4805 9 598255 4806 B 597147 4807 B 598998 4808 B 597960 4809 B 599851 4810 B 601068 4811 B 602929 4812 3 j602096 4813 B 603996 4814 B 603761 4815 B 605643 4816 B 604014 4817 B 605920 4818 B 604634 4819 B 606548 4820 B 605864 4821 B 1607736 4822 B 606903 4823 B 608742 4824 B 607722 4825 B 609674 4826 B 60.9329 4827 B 611215 SEQ ID Or. position 1638 F 220903 1639 F 218989 1640 F 221314 1641 F 219470 1642 F 222253 1643 F 220338 1644 F 223186 1645 F 221278 1646 F 223994 1647 F 222146 1648 F 224908 1649 F 1223014 1650 F 1225051 1651 F 1223131 1652 F 225510O 1653 F 223615 1654 F 226550 1655 F 224609 1656 F 226928 1657 F 225029 1658 F 1227528 1659 F 225631 1660 F 228388 1661 F 226475 1662 F 229930 1663 F 228032 1664 FP231129 1665 F 229205 1666 F 232785 1667 F 230915 1668 F 233561 1669 F 231664 1670 F 234013 1671 F 232149 SEQ ID Or. position 3233 F 980178 3234 F 983628 3235 F 981736 3236 F 984149 3237 F 982271 3238 F 985180 3239 F 983280 3240 F 985815 3241 F 983882 3242 F 986458 3243 F 984547 3244 F 987340 3245 F 985462 3246 F 987686 3247 F 985815 3248 F 988559 3249 F 986670 3250 F 989455 3251 F987558 3252 F 993122 3253 F 991289 3254 F 993186 3255 F 991297 3256 F 993650 3257 F 991727 3258 F 994007 3259 F 992107 3260 F 995743 3261 F 993915 3262 F 996663 3263 F 994763 3264 F 998586 3265 F 996755 3266 F 999153 SEQ ID Or. position] 4828 B 609916 4829 B 611866 4830 B 612090 4831 B 613998 4832 B 613166 4833 B 615091 4834 B 613838 4835 B 1615761 4836 B 614217 4837 B 616094 4838 B 615464 4839 B 617391 4840 B 615913 4841 B 617803 4842 B 617932 4843 B3 619837 4844 iB 618598 4845 B 620532 4846 B 619591 4847 B 621465 4848 B 620636 4849 B 622536 40 B 620532 4851 B 622381 4852 B 621404 4853 B 623307 4854 B 621932 4855 B 623834 4856 B 622666 4857 B 62458 4858 B 623689 45 9 B 625605 4860 S 624435 4861 1B 1626298 SEQ ID JOr. position 1672 1673 1674 1675 1676

F

F

F

F

F

234942 233061 236015 234123 237945 SEQ ID 3267 3268 3269 3270 3271 Or.

F

F

F

position 997253 1000967 999092 1001173 999246 1677 F 236045 1678 F 238482 1679 F 236599 1680 F 240094 1681 F 238190 1682 F 241713 1683 F 239820 1684 F 242569 1685 F 240653 1686 F 244253 1687 F 242360 1688 F 245693 1689 F 243796 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705

F

F

F

F

F

F

F

F

F

F

F

F

F

F

F

246762 244825 247498 245575 248343 246444 249500 247625 250315 248425 250832' 248942 251847 249939 254897 252955 3272 F 1001604 3273 F 999645 3274 F 1004159 3275 F 1002326 3276 F 1004763 3277 F 1002871 3278 F 1005160 3279 F 1003235 3280 F 1007181 3281 F 1005250 3282 F 1007561 3283 F 1005665 3284 F 1008855 3285 F 1007002 3286 F 1010205 3287 F 1008342 3288 F 1011716 3289 F 1009623 3290 F 1011812 3291 F 1009914 3292 F 1012372 3293 F 1010385 3294 F 1012567 3295 F 1010624 3296 F 1013237 3297 F 1011337 3298 7 1013690 3299 F 1011856 3300 F 11014301 SEQ ID 4862 4863 4864 4865 4866 4867 4868 4869 4870 4871 4872 4873 4874 4875 4876 4877 4878 4879 4880 4881 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 0r

E

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

B

a

B

r position 625204 627128 626885 628790 627128 629026 628073 629983 628359 630267 628976 63085C 630023 631988 630642 632526 631205 633081 632046 633969 638311 640204 640448 642328 643695 645639 640847 642769 644745 646615 645686 647558 646060 647972 SEQ ID Or. position 1706 F 256543 1707 F 254643 1708 F 257692 1709 F 255790 1710 F 258561 1711 F 256651 1712 F 258927 1713 F 257036 1714 F 261368 1715 F 259469 1716 F 263887 1717 F 262000 1718 F 264503 1719 F 262599 1720 F 265364 1721 F 231 1722 F 266202 1723 F j264277 1724 F 1266709 1725 F 264801 1726 F 267847 1727 F 1265947 1728 F 267980 1729 F 266077 1730 F '268271 1731 F 1266341 1732 F 269840 1733 F 267913 1734 F 270961 1735 F 269072 1736 F 271883 1737 F 270080 1738 F 272642 1739 F 270748 SEQ ID Or. position 3301 F 1012396 3302 F 1014926 3303 F 1013010 3304 F 1015664 3305 F 1013820- 3306 F 1017026 3307 F 1015099 3308 F 1017674 3309 F 1015786 3310 F 1018353 3311 F 1016460 3312 F 1019602 .3313 F 1017674 3314 F 1019876 3315 F 1017948 3316 F 1020853 3317 1F 1018956 3318 F 1021878 3319 F .1019972 3320 F 1023054 3321 F 1021186 3322 F '1023415 3323 F 1021579 3324 F 1023748 3325 F 1021850 3326 F 1024485 3327 F 1022574 3328 F 1024744 3329 F 1022836 3330 F 1025618 3331 F 1023720 3332 F 1026323 3333 F 1024403 3334 F 1027710 SEQ ID Or.'position 4896 B 647331 4897 B 649231 4898 B 649987 4899 B 651829 4900 13 650580 4901 S 652484 4902 B 651942 4903 B 653852 4904 B 652395 4905 D 654310 4906 B 653132 4907 B 655028 '4908 B 653827 4909 BF 655713 4910 3 1662071 4911 B !664023 4912 B 662543 4913 664403 4914 B 1663295 4915 BF 665205 4916 B 663972 4917 B 665850 491 B 664432 4919 B 666332 4920 B 665860 4921 B 667789 4922 B 666312 4923 BW 668233 4924 B 666652 4925 B 668550 4926 B 668338 4927 B 670238 4928 B 668605 4929 B 670495 SEQ ID Or. position 1740 F 273367 1741 F 271477 1742 F 274562 1743 F 272702 1744 F 275882 1745 F 273984 1746 F 278004 1747 F 276149 1748 F 278747 1749 F 276893 1750 F 279521 1751 F 277632 1752 F 281076 1753 F 279118 1754 F 281551 1755 F 279668 1756 F 282573 1757 F 280663 1758 F 284229 1759 F 282316 1760 F 284598 1761 F 282655 1762 F 285418 1763 F 283518 1764 F 286104 1765 F 284229 1766 F 286456 1767 F 284531 1768 F 287865 1769 F 286008 1770 F 289163 1771 F 287384 1772 F J290609 1773 F 1288709 SEQ ID Or. position 3335 F 1025809 3336 F 1030272 3337 F 1028389 3338 F 103 1486 3339 F 1029602 3340 F 1033215 3341 F :1031334 3342 F 1035425 3343 F 1033555 3344 F 1035956 3345 F 1034-55 3346 F 1036748 3347 F 1034844 3348 F 16372 3349 F 14463 3350 F 31184 3351 F' 29287 3352 F 56283 3353 F 54383 3354 F 56384 3355 F 54538 3356 F 64528 3357 F 62600 3358 F 72965 3359 F 71054 3360 F 78245 3361 F 76347 3362 F 79133 3363 F 772.91 3364 F 81740 3365 F 179840 3366 F 86772 3367 F 84880 3368 1F 109188T- SEQ ID Or. position 4930 B 668690 4931 B 670590 4932 B 669766 4933 B 671653 4934 B 670160 4.935 B 672109 4936 B 671000 4937 B 672900 4938 B 671470 4939 B 673412 4940 B 672685 4941 B 674567 4942 B 673461 4943 B j675365 4944 B 674786 4945 B 676682 4946 B 675456 4947 B 1677375 4948 B3 676683 4949 B 678594 49590 B 677334 4951 B 1679183 4952 B 1678726 4953 B 680596 4954 B 679729 4955 B 681628 4956 B 680747 4957 B 682668 4958 B 681500 4959 B 683406 4960 B 682779 4961 B 684716 4962 R 683320 4963 B 685249 252 SEQ ID1 Or. position 1774 F 291264 1775 F 289389 1776 F 292107 1777 F 290166 1778 F 293099 1779 F 291211 1780 F 294791 1781 F 292883 1782 F 295464 1783 F 293573 1784 F 296018 1785 F 294095 1786 F 297572 1787 F 295664 1788 F 298686 1789 F 296716 1790 F 30030$ 1791 F 2984-7 1792 F 301852 1793 F 299946 1794 F 304754 1795 F 302849 1796 F 305854 1797 F 303992 1798 F 306214 1799 F 304303 1800 F 30675-8 1801 F 304856 1802 F 309057 1803 F 307125 1804 F 309635 1805 F 307750 1806 F 310491 1807 _tF 3059 SEQ ID or. position 3369 F 107337 3370 F 111132 3371 F 109188 3372 F 111505 3373 F 109597 3374 F 112432 3375 F 110462 3376 F 113446 3377 F 111592 3378 F 120225 3379 F 118303 3380 F 124892 3381 F 123004 3382 F 131327 3383 F 129485 3384 F 143944 3385 F 142043 3386 F 150138 3387 F 148247 3388 F 163715 3389 F 161804 3390 F 165186 3391 F 163274 3392 F 168143 3393 F 166302 3394 F 170287 3395 F 168387 3396 F 176838 3397 F 174996 3398 F 187776 339.9 F 185900 3400 F 188083 3401 F 186208 F3402 F 90117 SEQ ID Or. position 4.964 B 684716 4965 B 686585 4966 B3 685010 4967 B 686897 4968 B 686423 4969 B2 688323 4970 IB 687426 4971 B 689324 4972 B 688619 4973 B 690482 4974 B 688653 4975 B 690563 4976 B 689836 4977 B 691775 4978 B 690186 4979 B 692088 4980 B 690715 4981 B 692616 4982 B 690937 4983 B 692837 4984 B 692091 4985 B 693991 4986 B 694171 4987 a 696078 4988 B 695197 4989 B 697093 4990 B3 697486 4991 B 699428 4992 B 698313 4993 B 700238 4994 S 698646 4995 B 700515 4996 B 700337 49.97 B 702249 SEQ ID Or. position 1808 F 311753 1809 F 309790 1810 F 313188 1811 F 311292 1812 F 1314121 1813 F 312194 1814 F 314489 1815 F 312539 1816 F 315431 1817 F 313526 1818 F 316309 1819 F 314380 1820 FP317102 1821 F 315214 1822 F 317271 1823 FP315343 1824 F 317380 1825 F 315480 1826 FP318256 1827 F 316352 1828 FP319047 1829 FP317181 1830 F 320325 1831 F 318338 1832 F 321228 1833 F 1319366 1834 F 321676 1835 F 319782 1836 F 322066 1837 F 320097 1838 F 1322910 1839 F 320982 1840 F 324744 1841 F 322849 SEQ ID Or. position 3403 F188168 3404 F196802 3405 F 194946 3406 F 210685 3407 F 208785 3408 F 234633 3409 F 232727 3410 F 236682 3411 F 234794 3412 F 249227 3413 F 247310 3414 F 252939 3415 F 251036 3416 F 253406 3417 F 251562 3418 F 271365 3419 F 269466 3420 F 275390 3421 F 273489 3422 F 277681 3423 F 275765 3424 F 282260 3425 F 280357 3426 F 292925 3427 F 291054 3428 F 302910 3429 F 301032 3430 F 308746 3431 F 306806 3432 F 311994 3433 F 310073 3434 F 312375 3435 F 310483 3436 F 312531 SEQ ID Or. position 4998 B701115 4999 B 703015 5000 B*W 702385 5001 B 704285 5002 B 703636 5003 B 705561 5004 B 705271 5005 B 707136 5006 B 705875 5007 B707725 5008 B 706444 5009 B 1708279 5010 B 706741 5011 1B 708673 5012 B 708324 5013 B 710226 £014 B 708673 5015 B 710518 5016 B 708876 5017 B 710791 5018 B 710498 5019 B 712447 5020 B 711435 5021 B713354 5022 B 712993 5023 B 714887 5024 B 713686 5025 B 715574 5026 B 714474 5027 B 716354 5028 B 714867 5029 B 716760 5030 S 716047 5031 B 717877 254 SEQ ID Or. position 1842 F 325392 1843 F 323445 1844 F 1326217 1845 F 1324331 1846 F 327038 1847 F 325t62 1848 F 327957 1849 F 1326079 1850 F 328458 1851 F 326612 1852 F 329032 1853 F 327173 1854 F 1329329 1855 F 1327489 1856 F 330446 1857 F 328551 1858 F 330915 1859 F 329032 1860 F 331410 1861 F 329602 1862 F 332534 1863 F 330626 1864 F 332782 1865 F 330879 1866 F 333587 1867 F 1331632 1868 F 333870 1869 F 331962 1870 F 334510 1871 F 332594 1872 F 334958 1873 F 333049 1874 F 1334958 1875 F 3049 SEQ ID O0r. position 3437 F 310647 3438 F 319923 3439 F 318009 3440 F 3 3 9991 3441 F 338104 3442 F 352535 3443 F 350653 3444 F 373218 3445 F 371320 3446 FP376994 3447 F 375085 3448 F :378954 3449 F 377011 3450 F :394604 3451 F 392704 3452 F 400915 3453 F 398972 3454 F 409744 3455 F 407904 3456 F 411155 3457 F 409253 3458 F 414197 3459 F 412281 3460 F 422638 3461 F 420770 3462 F 427595 3463 F 425701 3464 F 428453 3465 F 426553 3466 F 442272 3467 F 440364 3468 F 443303 3469 F 441380 3470 F 442939 SEQ ID Or. position 5032 B 716086 5033 B 717976 5034 B j717189 5035 B 719068 5036 B 718624 5037 B 720503 5038 B 719083 5039 B 720983 5040 B 720047 5041 B 722004 ,5042 B 720503 5043 B 722393 5044 B 720753 5045 B3 722653 5046 B 721798 5047 B 723724 5048 B 722631 5049 B 724493 5050 B 1723468 5051 B 725376 5052 B 724852 5053 B 726743 5054 B 726005 5055 B 727903 5056 B 726779 5057 B 728691 5058 B 1727058 5059 B 1728947 5060 B 727727 5061 B 729613 5062 B 728224 5063 B 730116 5064 B 729048 5065 B 730907 SEQ ID Or. position 1876 F 335655 1877 FT~ 333766 1878 F 336117 1879 F 334219 1880 F 337108 1881 335210 1882 F 340251 1883 F 338372 1884 F 341538 1885 F 339662 1886 F 341953 1887 F 399 1888 F 342348 1889 340450 1890 F 343112 1891 V 341242 1892 F 343736 1893 F 341811 1894 F 344117 1895 F 342207 1896 F 344940 1897 F 343000 1898 F 345837 1899 F 343958 1900 F 346872 1901 F 449 1902 ~*~347910 1903 F 345971 1904 F 350124 1905 F 348298 1906 F 351095 1907 F 1349167 1908 F 351996 1909 50122 SEQ ID Or. position 3471 F 441047 3472 F 445572 37473 F 443707 3474 F 467757 3475 F 465801 3476 F 471583 3477 P 4 6 971 2 3478 F 487813 3479 F 485913 3480 F 496852 3481 F 494952 3482 F 499979 3483 F 498074 3484 F 508715 3485 F 506798 3486 F 510584 3487 F 508632 3488 F 526255 3489 F 524350 3490 F 531098 3491 F 529150 3492 F 556575 3493 F !554706 3494 F 564318 3495 F ;562390 3496 F 566692 3497 F 564838 3498 F 570033 3499 F 568150 3500 F 570844 3501 F 568915 3502 F 575571 3503 F 573671 3504 F 590045 S-iEQ ID Or. position 5066 B 729566 5067 B 731468 5068 B 7!32909 5069 B 734770 5070 B 734663 5071 B 736569 5072 B 735879 5073 B 737785 5074 P 736724 5075 B 738632 5076 B 737474 5077 B 792 5078 B 738007 5079 B 739907 5080 B 738911 5081 B 740799 5082 B 739960 5083 B 741908 5084 B 742277 5085 B 744187 5086 B 743089 5087 B 744989 5088 B 743603 5089 B 745539 5090 B 744565 5091 B 746432 5092 B 744977 5093 B 746867 5094 B 745249 5095 B 747138 5096 B 174577T7 5097 B 747677 5098 B 746632 5099 2 74853 SEQ ID Or. position 1910 F 353051 1911 F 351186 1912 F 353413 1913 F 1351481 1914 F 1353908_ 1915 F 1351996 1916 F 1354723 1917 F 1352799 1918 F 356466 1919 F 354569 1920 F 357107 1921 F 1355178 1922 F 357767 1923 F 355878' 1924 F 360528 1925 F 358628 1926 F 360877 1927 F 358974 1928 F 361573 1929 F 359692 1930 F 362584 1931 F 360681 1932 F 363835 1933 F 361966 1934 F 364960 1935 F 363021 1936 F 365240 1937 F 363360 1938 F 367060 1939 F 365115 1940 F 368383 1941 F 366505 1942 F 368862 1943 F 366963 SEQ ID or. position 3505 F 588196 3506 F 597631 3507 F595698 3508 F 606387 3509 F 604507 3510 F 607566 3511 F 605637 3512 F 609842 3513 F 607958 3514 F 632472 3515 F 630572 3516 F 636994 3517 F 635071 3518 F 649681 3519 F 647800 3520 F 652059 3521 F 650101 3522 F 654522 3523 F 652562 3524 F 660587 3525 F 656691 3526 F 676785 3527 F 674938 3528 F 679031 3529 F 677133 3530 F 731967 3531 F 730091 3532 F 741797 3533 F 739935 3534 F 758555 3535 F 756641 3536 F 760010 3537 F 758082 3538 F 770670 SEQ ID Or. position 5100 B 747054 5101 B 748893 5102 B 748519 5103 2 750396 5104 B 749186 5105 B 751108 5106 B 749646 5107 B 751546 5108 B 749922 5109 B3 751824 5110 B 750260 5111 B 752151 5112 B 752527 5113 B 754427 5114 B 753169 5115 B 755064 5116 B 755004 5117 B 756843 5118 B 757034 5119 B 758991 5120 B 758532 5121 B 760452 5122 B 758911 5123 B3 760841 5124 B 760015 5125 IB 761913 5126 B 760463 5127 B 762363 5128 B 760782 5129 B j762671 5130 B 762053 5131 B 763911 5132 B :762363 513 B 1764264 SEQ ID Or. position 1944 F 370513 1945 F 368631 1946 F 370974 1947 F 369076 1948 F 372891 1949 F 1370980 1950 F 373395 1951 F 371495 1952 F- 374005 1953 F 1372033 1955 T 372572 1956 F 376509 1957 F 374624 1958 F 377630 1959 F- 375708 1960 F 378384 1961 F 376507 1962 F 378798 1963 F 1376871 1964 F 379413 1965 F 377501 1966 F~ 379890 1967 FV 377989 1968 F 381241 1969 F 379348 1970 F 382485 1971 F 380579 1972 F 383395 1973 F 381536 1974 F 383730 1975 F 381782 1976 F 384948 1977 F 383057 SEQ ID 3539 Or.

F

position 768751 3540 F 771896 3541 F769996 3542 fF 787857 3543 F 785958 3544 F 815714 3545 F 813840 3546 F 846380 3547 F 844470 3548 F 867576 3549 F 865673 3550 F 875167 3551 F- 873254 3552 F 876214 3553 F 874314 3554 F 884093 3555 F882162 3556 ~F 891248 3557 F 889348 3558 F900125 3559 F 898298 3560 F 902048 3561 F 900125 3562 F 907563 3563 F 905656 3564 F 912076 3565 F 910133 3566 F- 935157-- 3567 F 933211 3568 F 946473 3569 F 944568 3570 F 952562 3571 F 950664 3572 7 965649 SEQ ID Or. position 5134 B 763203 5135 B 765107 5136 B 764690 5137 B 766595 5138 B 765107 5139 B 766977 5140 B 766327 5141 B 768221 5142 B 766932 5143 B 768851 5144 B 768314 5145 B 770221 5146 B 769045 5147 B 770945 5148 B 770315 5149 B :772234 5150 B 770705 5151 B 772598 5152 B 770882 5153 B 772781 5154 B 771156 5155 B; 773044 5156 B 772234 5157 B 774148 5158 B 773611 5159 B 775511 5160 S 774513 5161 B 776404 5162 B 776333 5163 B 778191 5164 2 1777926 5165 B 779832 5166 S 777455 5167 B 779380 258 SEQ I-D Or. position 1978 F 385474 1979 F 383532 1980 F 385908 1981 F 384008 1982 F 386643 1983 F 384750 1984 F 387099 1985 F 385204 1986 F 387581 1987 F 385677 1988 F 388009 1989 F 386062 1990 F 388927 1991 F 387033 1992 F 389726 1993 F 387821 1994 F 391295 1995 F 389365 1996 F 392171 1997 F 390291 1998 F 393930 1999 F 392014 2000 F 395085 2001 F 393185 2002 F 395827 2003 F 393940 2004 F 396274 2005 F 394423 2006 F 397156 2007 F 1395216 2008 F 398641 2009 F 396790 2010 F 399550 SEQ 15 Or. position 3573 F963730 354 968519 3575 F 966614 3576 F .9704.97 357 968601 3578 F 971879 3579 F970043 3580 F 972888 3581 F 970962 3582 F998162 3583 F996241 3584 F 1003657 3585 F 1001756 3586 F 100.9313 3587 F 1007413 3588 F 1028954 3589 F 1027039 3590 B 730 3591 B 2645 3592 B 13521 3593 B 5431 3594 B 5295 3595 B !7188 3596 B 6740 3597 B 8652 3598 B 8240 3599 B 10138 3600 B 8959 3601 B 10816 3602 B 9285 3603 B 11160 3604 B 9689 3605 2 11591 3606 B 10679 SEQ ID Or. position 5168 B 779476 5169 B 781342 5170 B 1781774 5171 B 783686 5172 23 782667 5173 B 784562 5174 B 785748 5175 B 787658 5176 B 786222 5177 S 788126 5178 B 786803 5179 B 788703 5180 B 787998 5181 B 789876 5182 B 788279 5183 B 790255 5184 B 790369 5165 B 792247 5186 B 790862 5187 B3 792787 5188 B 792247 5189 B 794137 5190 B 793352 5191 B 795215 5192 B 794276 5193 B 796196 5194 B '795215 5195 B 7.97077 5196 B 795667 5197 B 797571 5198 B 796515 5199 B3 798382 5200 2773 5201 B 799168- 2011 397659 259 SEQ ID Or. position 2012 F 399797 2013 F397915 2014 F 401527 2015 3-9 962 3 2016 F401907 201.7 F 399960 2018 F 1403017 2019 F 401131 2020 F 403017 2021 F 401131 2022 F 40491.0 2023 F 403010 2024 F 405728 2025 F 403836 2026 F 406837 2027 F 404932 2028 F 1410291 2029 F 1408-347 2030 F 1411488 2031 F 409518 2032 F 412379 2033 F 410487 2034 F 141.3164 2035 F 411263 2036 F 413606 2037 F 411626- 2038 FP413721 2039 F 411859 2040 F 414921 2041 F 413049 2042 F 416517 2043 F 414606 2044 F 417445 2045 F 4-5557 SEQ ID Or.

3607 IB positionI SEQ ID IJOr. positijon 12568 3608 3609 3610 3611 3612

B

B

13376 12136 14038 13565 3613 3614 3615 3616 3617 3618

B

B

B

B

15450 14667 16535 15254 17183 16189 3619 B 18097 3620 B 16790 3621 B 18621 3622 Bw 16710 3623 B 18587 3624 B 18458 3625 B 20318 3626 B 20768 3627 B 22647 3628 B 22438 3629 BF 24335 3630 B 22892 3631 B 24752 3-6 3 2 B 23046 3633 B 24924 3634 B 23442 3635 B 25313 3636 B 23623 3637 BW 25528 3638 B 24822 3639 B260 3640 2 j661 520 797585 5203 B799553 5204 B798102 5205 B 799976 5206 3 1798306 5207 B 800214 5208 B3 798662 5209 B 800546 5210 B799168 5211 B3 801074 572 1 2 B3 800159 5213 B 802054 5214 B!801153 5215 B 803031 5216 B3 802363 5217 B 1804257 5218 H3 802893 5219 B 804802 5220 B 803466 5-221 B 8059366 5222 B 804440 5223 B 806374 5224 B 805576 5E22 5 B 807523 5T2 26 B 806511 5227 B 808410 5228 B 808305 5229 B 810207 53 0 B 809229 5231 B811164 53 2 B 810700 5233 B 812581 5234 B 811825 5235 B 813787 260 SEQ ID Or. position 2046 F 417812 2047 F 41.5912 2048 F 418381 2049 F 416517 2050 F 419453 2051 F 417447 2052 F 420026 2053 FP418068 2054 F 421270 2055 F 419392 2056 F 422262 2057 F 420364 2058 F 423007' 2059 F 421107 2060 F 424834 2061 F 423018 2062 F 426026 2063 P 424110 2064 F 426883 2065 FP425040 2066 F 429303 2067 F 427438 2068 F 429609 2069 F 427737 2070 F 430104- 2071 F 428191 2072 F 430622 2073 F 428814 2074 F 431439 2075 F 429537 2076 F 431968 2077 F 430108 2078 F 1434401 2079 F 1432485 SEQ ID IOr. position 3641 1B 28544 3642 B 27972 3643 B 29859 3644 B 29000 3645 B 30908 3646 B 30242 3647 B 32160 3648 B 30966 3649 B 32849 3650 B 31516 3651 B 3 3 401 3652 B 32032 3653 B 33900 3654 B 33576 3655 B 35496 3656 B 34121 3657 B '36052 3658 B 35251 3659 B 37164 3660 B 35588 3661 B 37502 3662 B 36152 3663 B 38041 3664 B 37216 3665 B 39127 3666 B 38041 3667 B 39980 3668 B 39322 3669 B3 41205 3670 9 40161.

3671 B 42074 3672 B 40985 3673 B 42887 3674 B 42284 SEQ ID Or. position 5236 B 812574 5237 B 814467 5238 B 8 13787 5239 B 815676 5240 B 1814082 5241 B 815892 .5242 B 814571 5243 B 816454 5244 B !815441 5245 B 817347 5246 B 815101 5247 B 817025 5248 B 815953 5249 B 817887 5250 B 817709 5251 B 819618 5252 B 819559 5253 B 821442 5254 B 819933 5255 B 821846 5256 B 820622 5!2 5 7 IB 822548 5-;258 B 821281 52S9 B 823181 5260 B 821778 5261 B 823666 5262 B 822494 5263 B 824387 5264 B 823155 5265 B 825057 5266 B 824589 526 B 826509 5268 B '826122 5269 B 828041 SEQ ID Or. position 2080 F 436050 2081 F 434134 2082 F 436342 2083 F 434428 2084 F 437672 2085 F 435775 2086 F 438051 2087 F 436165 2088 F 438767 2089 F 436866 2090 F 439139 F 437145 2092 F 439479 2093 F 437574 2094 F !440823 2095 F 482 2096 F 441668 2097 F 439746 2098 F 444271 2099 F 442371 2100 F 446233 2101 F 444302 2102 F 447687 2103 F 445803 2104 F 450318 2105 F 448399 2106 F 450876 2107 F 449025 2108 F 451274 2109 F 449397 2110 F 452413 2111 F 450513 2112 F 453303 2113 F 451427 SEQ ID Or.

B

posi11tion ~44lSo 3675 3676 BY 433 3677 B 45275 3678 B 44022 3679 B45927 3680 B ;45451 3681 B 47375 3682 B 46308 3683 B 48208 3684 B 46560 3685 B 48485 3686 B 47115 3687 B 49053 3688 B 48208 3689 B 50118 3690 B 48806 3691 B 50708 3692 B 150333 SEQ ID or. position 5270 B 826572 5271 B 828500 5272 B 827246 5273 B 829208 5274 B 827489 5275 B j829407 5276 B 1828274 5277 B 183017 6 5278 B 829495 5279 B 831395 5280 B 831192 5281 B 833082 5282 B 1832005 5283 B 833870 5284 B 832373 5285 B 834280 5286 B 832964 5287 B 834864 5288 B 833672 5289 B 835604 5290 B3 834022 5291 B 835945 5292 B 834907 5293 B 836803 5294 B 835683 5295 B 837593 5296 B 836018 5297 B 837902 5298 B 836714 5299 B 838602 5300 B 837484 5301 B 839424 3693 52220 3694 B50960 3695 B 52890 3696 B 52660 3697 B 54606 3698 B 53737 3699 B 55645 3700 B54'793 3701 B 56691 3702 B 55329- 3703 B 57226 3704 B56691 3705 B 58566 3706 B 56317 3707 B 58226 3708 B 58469 5302 5303

B

838950 840832 SEQ ID Or. position 2114 F 454713 2115 T 452853 2116 F 455096 2117 F 453248 2118 F 455808 2119 F 453928 2120 F 457440 2121 F 455488 2122 F 458282 213 F 456354 2124 F 459558 2125 F 457686 2126 F 460960 2127 F 459060 2128 F 461659 2129 F 459758 2130 F 462674 2131 F 460775 2132 F 463788 2133 F 461895 2134 F 464479 2135 F 462602 2136 F 465882 2137 F 463989 2138 F 467200 2139 F 465300 2140 F 468680 2141 F 466787 2142 F 469130 2143 F 467224 2144 F 469572 2145 F 467707 2146 F 1470887 1 2147 _F 146898 SEQ ID Or. position 3709 B 60363 3710 B 59406 3711 B 61301 3712 B 60450 3713 B 62316 3714 IB 61722 3715 B63603 3716 B 62585 3717 B 64473 3718 B 63362 3719 R 65285 3720 B 64203 3721 B 66103 3722 B 64850 3723 B 66749 3724 93 64899 3725 B 66776 3726 B 65164 3727 B 67067 3728 B 67514 3729 B 69390 3730 B 69097 3731 B 71033 3732 B 69470 3733 B 71354 3734 B 69961 3735 B 71898 3736 B 70707 3737 B 72579 3738 B 71249 3739 B 73134 3740 B 73458 3741 B 75376 3742 B 75121 SEQ ID Or. position 5304 B 839800 5305 B 841700 5306 B 840808 5307 B 842715 5308 B 841975 5309 B 843834 5310 B 842679 5311 B 844614 5312 B 843342 5313 B 845247 5314 B 843736 5315 B 845626 5316 B 846423 5317 B 848330 5318 B 844423 5319 B 846258 5320 B 848265 5321 B 850174 5322 B 850343 5323 B 852246 5324 B 851875 5325 B 853765 5326 B 853944 5327 R 855822 5328 B 855056 5329 B 856964 5330 B 855750 5331 B 857714 5332 B 856488 5333 B 858370 5334 B 857403 5335 B 859303 5336 B 859659 5337 B 861570 SEQ ID Or. position 2148 F 471590 2149 F 469835 2150 F 473033 2151 F 471133 2152 F 473761 2153 F 471861 2154 F 474383 2155 F 472478 2156 F 475333 2157 F 473465- 2158 F 476279 2159 F 474390 2160 F 478446 2161 F 476546 2162 F 478869 2163 F 476918 2164 F 479441 2165 F 477548 2166 F 479676 2167 F 477775 2168 F 481277 2169 F 479377 2170 F 481635 2171 F 479745 2172 F 483172 2173 F 481279 2174 F 484659 2175 F 482764 2176 F 485003 2177 F 483097 2178 1F 1487946 SEQ ID Or. position 3743 B 77020 3744 B 75741 3745 B 77608 3746 B 77447 3747 BF 79300 3748 B 77535 3749 BF 79430 3750 B 78333 3751 B 180243 3752 B 79300 3753 R*W 81197 3754 B~ 82201 3755 BF 84100 3756 B 83493 3757 BF 85405 3758 B 85075 3759 B 86973 3760 B 87141 3761 B 89086 3762 SF 88903 3763 9 90810 3764 Bh 88038 3765 B 8.9946 3766 B 88981 3767 B 90884 3768 B 89485 3769 3 91385 3770 B 89975 3771 B 91855 3772 B 91680 3773 B 93567 3774 B 92008 3775 B ;93902 3776 B 92633 SEQ ID Or. 'Position 5338 B 860166 5339 B862082 5340 B860879 5341 B 862767 5342 B 861861.

5343 B863727 5344 B 862284 5345 B864173 5346 B 863792 5347 B 865660 5348 B 864164 5349 B ;866050 5350 B864925 5351 B 866860 535-2- B 866468 5353 B 868368 5354 B 866860 5355 B 868734 5356 B 867952 5357 B 869878 5358 B 869311 5359 B 871226 5360 B 869582 5361 B 871517 5362 B !871614 5363 B 873536 5364 R 872804 5365 B 874702 56 B 873093 5367 W' 874980 5368 B 874158 5369 B 876056 5370 B 874033 5371 B i875932 2179 2180 2181

F

-7-

F

486083 487946 486093 SEQ ID Or. position 2182 F 489220 2183 F 487274 2184 F 490276 2185 F 488388 2186 F 492138 2187 F 490229 2188 F 492475 2189 F 490618 2190 F 493591 2191 F 491719 2192 F 494297 2193 F 492436 2194 F 494530 2195 F 492679 2196 F 494637 2197 F 1492753 2198 F 495467 2199 F 493559 2200 F 496076 2201 F 14941 .26 2202 F 497468 2203 F 495569 2204 F 498050 2205 F 496160 2206 F 498994 2207 F 497096 2208 F 500571 2209 F 498671 2210 F 501547 2211 F 499671 2212 F 502469 2213 F 500572 2214 F 503435 2215 F 501547 SEQ ID Or. position 3777 B94569 3778 B 93390 3779 B95288 3780 B94354 3781 S 96254 3782 1394897 3783 R 96772 3784 B98519 3785 B 100439 3786 B 98962 3787 B 100853 3788 B 100451 3789 B 102387 3790 B 101639 3791 B '103473 3792 B 102457 3793 B 104357 3794 B 102745 3795 B 104666 3796 B 104544 3797 B 106464 3798 B 105338 3799 B 107237 3800 B 106127 3801 B 108014 3802 B 108693 3803 B 110587 3804 B 109189 3805 B 111079 3806 B 109684 3807 B 111580 3808 B 110587 3809 B 112486 3810 B3 112740 SEQ ID Or. position 5372 B 874670 5373 B 876580 5374 B '875606 5375 B 877506 5376 B 1876619 5377 B3 878519 5378 B 878160 5379 B 903 5380 B 878429 5381 B 880292 5382 B 879336 5383 B 881230 5384 B 879393 5385 B 881281 5386 B 880089 5387 B 881994 5388 B 881108 5389 B 1883062 5390 B 882094 5391 B 884013 5392 B 883124 5393 B 885027 5394 B 884014 5395 B 885924 5 396 B 884530 5397 B 886432 5398 B 885226 5399 B 887139 5400 B 889010 5401 B 890900 5402 B 890421 5403 B 892310 5404 B [891438 5405 B_ 1893 1287 SEQ ID Or. position 2216 F 505469 2217 F 503545 2218 IF 1506768 2219 F 504880 2220 F 507356 2221 F 505530 2222 F 508015 2223 F 506157 2224 F 508247 2225 F 506351 2226 F 509270 2227 F 507356 2228 F 510759 2229 F 508918 2230 F 511268 2231 F 509359 2232 F 512124 2233 F 510202 2234 F 512836 2235 F 510926 2236 F 514569 2237 F 512663 2238 F 514688 2239 F 512874 2240 F 515334 2241 F 513415 2242 F 515516 2243 F 513670 2244 F 516230 2245 F 514348 2246. F 517181 2247 F 515261 2248 F 517840 2249 F 515977 SEQ ID Or. position 3811 B 1146_73 3812 B 113684 3813 B 115653 3814 B 114216 3815 B3 116158 3816 B 114836 3817 B 116732 3818 B 115473 3819 B 117380 3820 B 115898 3821 B3 117797 3822 B 120031 3823 B 121926 3824 B 124231 3825 B 126158 3826 B 125215 3827 B 127115 3828 B 125352 3829 B 127271 3830 B 126492 3831 B 128390 3832 B 127150 3833 B 129050 3834 B 128010 3835 B 129905 3836 B 129947 3837 B 131873 3838 B 131255 3839 B 133205 3840 B 131873 3841 B 133749 3842 B 133351 3843 B 135305 3844 1 B 13380 SEQ ID Or. position 5406 B 891703 5407 B 893606 5408 B 893606 5409 B 895490 5410 B 894049 5411 B 896024 5412 B 894139 5413 B 896074 5414 B 894545 5415 B 896413 5416 B 894999 5417 B 896912 5416 B 896127 5419 B 898012 5420 B 897049 5421 B 898949 5422 B 901018 5423 B 902955 5424 B 902393 5425 B 904301 5426 B 904098 5427 B3 906002 5428 B 903951 5429 B 905851 5430 B3 905825 5431 B 907725 5432 B 906700 5433 B 908669 5434 B 907174 5435 B 909066 5436 B 907579 5437' B 909480 5438 B 908962 5439 B -910922 SEQ ED Or. position 2250 F 518184 2251 F 516283 2252 F 518704 2253 F 516804 2254 F 519358 2255 F 517404 2256 F 520483 2257 F 518598 2258 F 521632 2259 F 519765 2260 F 521919 2261 F 520024 2262 F 523372 2263 F 521495 2264 F 524404 2265 F 522508 2266 F 525498 2267 F 523600 2268 F 525687 2269 F 523753 2270 F 526036 2271 F 524164 2272 F 526632 2273 F j524732 2274 F 528073 2275 F 526158 2276 F 528835 2277 F 1526999 2278 F 529393 2279 F 527504 2280 F 530004 2281 F 528082 2282 F 530518 2283 F 528594 SEQ ID Or. position 3845 B 135704 3846 B 134219 3847 B 136133 3848 B 134729 3849 B 136633 3850 B 137694 3851 B3 139583 3852 B 140496 3853 B3 142396 3854 B 140953 3855 B 142856 3856 B 142031 3857 B 143950 3858 S 143520 3859 B 145425 3860 B 144066 3861 B 145967 3862 B3 144629 3863 B 146519 3864 B 146547 3865 B 148446 3866 B 147304 3867 B 149227 3868 B 148296 3869 B 150255 3870 B 148769 3871 B 150670 3872 B 149320 3873 B 151168 3874 B 149532 3875 B 151470 3876 B 149934 3877 B 151845 3878 B 151168 SEQ ID Or. position 5440 2 909415 5441 B 911315 5442 B 909804 5443 B 911704 5444 B 910218 5445 B912075 5446 B 910834 5447 B912689 5448 B 911225 5449 B913064 5450 B 912492 5451 B 914381 5452 B 912852 5453 B914763 5454 R913438 5455 B915340 5456 B 913901 5457 B 915814 5458 B 914730 5459 B 916694 5460 B 915356 5461 B 917256 5462 B 915717 5463 B 917608 5464 B 916854 5465 B 918761 5466 B 916762 5467 9 918712 5468 B 917848 5469 B 919756 5470 B 918588 5471 B 920424 5472 B 918875 5473 B 920796 SEQ ED Or. position 2284 F 532100 2285 F 530224 2286 F 533025 2287 F 531125 2288 F 533710 2289 F 531825 2290 F 534658 2291 FP532758 2292 F 535737 2293 F 533828 2294 F 539456 2295 F 537568 2296 F 540290 2297 F 538375 2298 F 540672 2299 F 538777 2300 F 541573 2301 F 539706 2302 F 542999 2303 F 541102 2304 F 543922 2305 F 542057 2306 F 544268 2307 F 542354 2308 P 544691 2309 F 542785 2310 F 546323 2311 F 544441 2312 F 546467 2313 F 544650 2314 F 547257- 2315 FP545357 2316 F 547658 2317 F 1545781 SEQ ID 'Or. position 3879 B 153047 3880 B 152273 3881 B 154165 3882 B 152887 3883 B 154804 3884 B '153600 3885 S 155482 3886 B 154217 3887 B 156157 3888 B 155523 3889 B 157396 3890 B 156823 3891 B 158731 3892 B 157745 3893 B 159645 3894 B 159207 3895 B 161084 3896 B 160216 3897 B 162127 3898 B 161451 3899 B 1653350 3900 B 161818 3901 B 163726 3902 B 162601 3903 B 164501 3904 B 163282 3905 B 165205 3906 B 164171 3907 B 166082 3908 B 165812 3909 B 167672 3910 B3 166939 3911 B 168861 3912 B 168421 SEQ ID or. position 5474 B 919756 5475 B ;921710 5476 B 920055 5477 B 921949 5478 B 920389 5479 B3 922328 5480 B 921130 5481 B 922978 5482 B 921517 5483 B 923414 5484 B 921740 5485 B 1923646 5486 B 921979 5487 B 923926 5488 B 922396 5489 B 924327 5490 B 922729 5491 B 924611 5492 B 923256 5493 B 925216 5494 B 923673 5495 B 925589 5496 B 924297 5497 B 926176 5498 B 924645 5499 B 926555 5500" B 925216 5501 B 927117 5502 B 925589 5503 B 92748.9 5504 B 926980 5505 B3 928903 5506 B 92-7408 5507 B 1929331 SEQ ID Or. position 2318 F548406 2319 F 546466 2320 F 549443 2321 F 547527 2322 F 550193 2323 F 548288 2324 F 551554 2325 F 549665 2326 F 552877 2327 F 1550963 2328 F 554708 2329 F 552807 2330 F 556293 2331 F 554381 2332 F 557095 2333 F 555164 2334 F 557522 2335 F 555656 2336 F 558021 2337 F 556191 2338 F 558964 2339 F 557076 2340 F 560913 2341 F 559007 2342 F 562832 2343 F 561002 2344 F 563374 2345 F 561474 2346 F 565061 2347 F 563198 2348 F 566840 2349 F 564908 2350 F 567802 2351 F 565896 SEQ ID Or. position 3913, B 170322 3914 B 169503 3915 B 171369 3916 B 170715 3917 R 172587 3918 B 171554 3919 B 173512 3920 B3 172596 3921 B 174496 3922 B 173021 3923 B 174847 3924 B 174716 3925 B 176619 3926 B 175205 3927 B 177143 3928 B 175943 3929 B 177830 3930 B 177244 3931 B 1791B0 3932 B 178337-- 3933 B 180239 3934 B 180274 3935 B 182181 3936 B 180972 3937 B 182664 3938 B 181659 3939 B 183572 3940 B 182864 3941 B 184750 3942 B 183876 3943 B 185778 3944 B 185007 3945 B 186910 3946 B 186246 SEQ ID or. position 5508 B 927824 5509 B 929727 5510 B 928418 5511 B 930287 5512 B 1928979 5513 B 930879 5514 B 930474 5515 B 932367 5516 B 930879 5517 B 932776 5518 B3 1931298 59 B 933223 5520 B 931886 5521 B 933812 5522 B 932187 5523 B 934117 5524 B 932803 5525 B 934733 5526 B 933421 552 B 1935352 5528 B 933841 5529 B 935758 5530 B 934062 5531 B 935933 5532 B 934794 5533 B 936682 5534 B 936606 55T35 B 938521 55H36 B 938373 5537 R 940324 5538 B 939321 5539 B 941229 5540 B 941153 5541. B..,1943053 SEQ ID 2352 2353 2354 Or

-F

-F

571045 572300 2355 F 570362 2356 F 572512 2357 F 570612 2358 F 572627 2359 F 570753 2360 F 573416 2361 F 571539 2362 F 573964 2363 F 572065 2364 F 574221 2365 F 572303 2366 F 574704 2367 F 572781 2368 F 1574795 2369 F '572936 2370 F 575229 2371 F 573350 2372 F 576318 2373 F 574384 2374 F 577796 2375 F 575893 2376 F 578774 2377 F 576870 2378 F 1581976- 2379 F 580073 2380 F 582589 2381 F 580679 2382 F 582962 2383 F 581060 2384 F 583210 2385 F581316 S9EQ ID -Or. position 3947 Bv 188160 3948 B 187080 3949 B18901$ 3950 B 187490 3951 B189421 3952 B 188044 3953 R 189929 3954 B 189711 3955 B 191656 3956 B-190594 3957 B 192533 3958 r, 190731 3959 B 192679 3960 B 192027 3961 B 193906 3962 B 192684 3963 B 194643 3964 B 193419 3965 B 195348 3966 B 194978 3967 B 196750 3968 B 195270 3969 B 197166 3970 B 197255 3971 B 199165 3972 B 197859 3973 B3 199756 3974 B 198443 3975 B 200328 3976 B 199202 3977 B 201084 3978 B 200198 3979 B 202084 SEQ ID lOr. position 5542 B 942291 5543 B 944212 5544 B 944964 5545 B 946809 5546 B 945527 5547 B 947426 5548 B 946546 5549 B 948430 5550 B 946896 5551 B 948823 5552 B .948677 5553 B !950581 5554 B 949505 5555 B 951398 5556 B 949834 5557 B 951743 5558 B 1950897 5559 B 952796 5560 B 951550 S561 B j953534 5562 B 951870 5563 B 953763 5564 B 1953037 5565 B 954930 5566 B 954509 55967 B 956384 5568 B 955397 5569 B 957278 5570 B958191 5571 B 1960060 5572 B 959570 5573 B 961432 5574 B 1961273 555 B 1963183] I 3980 200547 SEQ ID Or. position 2386 F 583564 2387 F 581697 2388 F 584048 2389 F 582179 2390 F 584797 2391 F 582897 2392 F 584978 2393 F 583031 2394 F 586256 2395 F 584320 2396 F 587527 2397 F 585631 2398 F 1588892 2399 F 587052 2400 F 589362 2401 F 587452 2402 F 590516 2403 F 588616 2404 F i592168 2405 F 590235 2406 F 592629 2407 F 590708 2408 F 592901 2409 F 590973 2410 F 593863 2411 F 591990 2412 F 595416 2413 F 593484 2414 F 595935 2415 F 593962 2416 F 597025 2417 F 595158 2418 F 598254 2419 F 596402 SEQ ID Or. position 3981 B 202447 3982 B 200934 3983 B 202806 3984 B 201224 3985 B 203115 3986 B 202606 3987 B 204583 3988 B 203735 3989 B 205603 3990 B 204218 3991 B 206147 3992 R 206686 3993 B 208569 3994 B 207672 3995 B 209558 3996 B 208799 3997 B 210648 3998 B 209701 3999 B 211599 4000 B 210500 4001 B 212364 4002 B 211064 4003 B 212951 4004 B 211557 4005 B 213453 4006 B 213248 4007 B 215101 4008 B 214372 4009 B 216286 4010 B3 214931 4011 B 216887 4012 B 215275 4013 B 217268 4014 B 216928 SEQ ID Or. position 5576 B 961837 5577 B 963749 5578 B 962823 5579 B 964695 5580 B 962199 5581 B 964099 5582 B3 965286 5583 B 967118 5584 B 965928 5585 B 967828 5586 B 1967261 5-587 B 9691-79 5588 B 968345 558.9 B 970181 5590 B 969123 5591 B 971023 5592 B 970973 5593 B 972849 5594 B 972081 5595 B 9739233 5596 B 973279 5597 B 975173 5598 B 974803 5599 B 976683 5600 B !975459 5601 B 977346 5602 B3 976431 5603 B 978335 5604 B 976740 5605 B 978640 5606 B -977175 5607 B 979042 5608 B 977855 5609 B 979768 SEQ ID Or. position 2420 F 600515 2421 F 598575 2422, F 601691 2423 F 599745 2424 F 603291 2425 F 601376 2426 F 603538 2427 F 601638 2428 F 604263 2429 F 602388 2430 F 605359 2431 F 603425 2432 F 606622 2433 F 604721 2434 F 60772 2435 F 605908 2436 F 609039 2437 F 1607143 2438 F 1609842 2439 F 607958 2440 F 611565 2441 F 609657 2442 F 612719 2443 F 610819 2444 F 613473 2445 F j611565 2446 F 614096 2447 F 612172 2448 F 615072 2449 F 613207 2450 F 615645 2451 F 613745 2452 F 617266 2453 F 615347 SEiQ ID Or. position 4015 B 218828 4016 B 218137 4017 B 220027 4018 B 217661 4019 B 219561 4020 B 218937 4021 B3 220822 4022 B 219229 4023 B 221130 4024 B 220005 4025 B 221868 4026 B 220654 4027 B 222560 4028 2 221294 4029 B 223195 4030 B 221762 4031 B 223673 4032 B '222338 4033 B 224212 4034 B 223510 4035 B 225417 4036 B 224094 4037 B 226033 4038 B 225417 4039 B 227291 4040 B 226033 4041 B !227907 4042 B 225811 4043 R 227671 4044 B 226947 4045 B 228871 4046 B 227523 4047 B 229432 4048 -dB 227907 SEQ ID Or. position 5610 B 978153 5611 B3 980 060 5612 B 578655 5613 B 980553 5614 B 979204 5615 B 981104 5616 B 979554 561.7 B 981465 5618 B 981423 5619 B 983319 5620 B 980363 5621 B 982289 5622 B 982361 5623 B 984236 5624 B 983818 5625 B 985718 5626 B 984720 5627 23 986608 5628 B 985607 5629 B 987553 5630 B 986323 5631 B -988223 5632 B 986925 5633 B 988825 54 B 987850 5635 B 989749 5636 B 988354 57 B 990252 5638 B 988474 5639 B 990393 5640 B 989437 5641 B 991305 5642 B 993662 5643 B 1995596 SEQ ID Or. position 2454 F 618142 2455 F 616242 2456 F 619019 2457 F 617128 2458 F 619637 2459 F 617695 2460 F 620182 2461 F 618257 2462 F 620929 2463 F 619019 2464 F 621446 2465 F 619529 2466 F 622195 2467 F 620292 2468 F 623244 2469 F 621446 2470 F 623834 2471 F 621954 2472 F 625024 2473 F 623208 2474 F 626291 2475 F 624369 2476 F 626724 2477 F 1624821 2478 F 627597 2479 F 625703 2480 F 627927 2481 F 626025 2482 F 628712 2483 F 626787 2484 F 1629535 2485 F 1627685 2486 F 6055 2487 F 628178 SEQ ID Or. position 4049 B3 229784 4050 B 228692 4051 B 230578 4052 B 230253 4053 B 232157 4054 B 231299 4055 B 233194 4056 B 233226 4057 13 235130 4058 B 234073 4059 B 235950 4060 B 234510 4061 B 236399 4062 B 235094 4063 B 236993 4064 B 236552 4065 B 238440 4066 B 238440 4067 B 240381 4068 B 238989 4069 B 240917 4070 B 240294 4071 B 242181 4072 B 242260 4073 B 244157 4074 B 243066 4075 BT 245029 4076 B 244703 4077 B 246603 4078 13 246151 4079 S 248017 4080 B 247104 4081 B 248997 4082 3 248001 SEQ ID Or. 'position 5644 B 994015 5645 B 995906 5646 B 994084 5647 B 995955 5648 B 994523 5649 S 996382 5650 B 995903 5651 B 997791 5652 B 996831 5653 B 998764 5654 B 998505 5655 B 1000417 5656 B 999445 5657 B 1001345 5658 B 1001253 5659 B3 1003169 5660 B 1001751 5661 B 1003637 5662 23 1001954 5663 B 1003786 5647 B 1004003 5665 B 1005872 5666 B 1005114 5667 B 1006999 5668 B 1005620 566.9 B 1007561 5670 B 1007761 5671 B3 1009618 5672 B 11008052 5673 B '1009941 5674 B 1008954 5675 B 1010818 5676 B 1009679 5677 B 11011621 273 SEQ ID Or. position 2488 F 630672 2489 F 628789 2490 F 637125 2491 F 635224 2492 F 637807 2493 F 635913 2494 F 639960 2495 F 638102 2496 F 639960 2497 F 638012 2498 F 643252 2499 F 641355 2500 F 644146 2501 F 642204 2502 F 645175 2503 F 643275 2504 FP645519 2505 F 643652 2506 F 646869 2507 F 644983 2508 F 649714 2509 F 647800 2510 F 650199 2511 F 648260 2512 F 651421 2513 F 649536 2514 F 652285 2515 F 650397 2516 F 652562 2517 F 1650653 2518 F 659653 2519 F 657741 2520 F 661449 2521 F 1659621 SEQ ID Or. position 4083 B 249872 4084 B 248835 4085 13 250712 4086 B 249697 4087 B 251574 4088 B 250643 4089 B 252560 4090 B 251439 4091 B ;253306 4092 B 252401 4093 B 254231 4094 B 253312 4095 B 255224 4096 B 256969 4097 B 258840 4098 B3 258065 4099 B3 259964 4100 B 258945 4101 B 260826 4102 B 259428 4103 B 261313 4104 B 261845 4105 B 263746 4106 B 264350 4107 B 266263 4108 B 264963 4109 B 266887 4110 B 265848 4111 B 267749 4112 B 266644 4113 B 268546 4114 B 268188 4115 B 270091 4116 B 268188 SEQ ID Or. position £678 B 1012274 5679 B 1014193 5680 B 1012682 5681 B 1014550 5682 B 1012855 5683 B 1014755 5684 B 1013104 5685 B 1014996 5686 B 10.13698 5687 B 1015571 5688 B 1014289 5689 B 1016181 5690 B 1014730 £691 B 1016653 5692 B 1015459 £693 B3 1017377 5694 B 1016272 5695 B 1018122 .5696 B 1017377 5697 B 1019285 5698 B 1018043 5699 B 1019888 5700 B 1019146 5701 B 1021064 5702 B3 !1019421 5703 B 1021323 £704 B 1020440 5705 B 1022319 5706 B 11021269 5'707 B 1023161 5708 B 1021789 5709 B 1023722 L5710 B 1022638 5711 B 1024535 SEQ ID 2522 Or. position 662058 7 SEQ DJr position 2523 F 660167 2524 F 662726 2525 F 660831 2526 F 663526 2527 F 661591 2528 F 664035 2529 F 662134 2530 F 665504 2531 F 663591 2532 F 665530 2533 F 663663 2534 F 666606 2535 F 664705 2536 F 667901 2537 F 665987 2538 F 667953 2539 F 666037 2540 F 668397 2541 F 666496 2542 F 669235 2543 F 667366 2544 F 669763 2545 F 667879 2546 F 670513 2547 F j668612 2548 F 670963 2549 F 669058 2550 F 672473 2551 F 670573 2552 F j672985 2553 F 1671072 4117 B 270091 4118 B 268546 4119 B 270440 4120 B 268785- 4121 B 270697 4122 B 270439 4123 B 272288 4124 B 271181 4125 B 273043 4126 B 271833- 4127 B 273738 4128 2 273188 4129 B 275062 4130 B 273817 4131 B 275718 4132 B 275062- 4133 3 1277005 4134 B :275886 4135 B 277857 4136 B3 277923 4137 B 279868 4138 2 279043 4139 B 281004 4140 B 280126 4141 B 282004- 4142 B 281004 4143 B 282911 4144 B 281825 4145 B 283746 4146 B 282335 4147 B 1284236 41.48 B 284583 4149 B 286455 4150 1B 128-5055 SEQ ID 5712 57131 5714 5715 5716 Or.

B

B

B

position 1023900 1025787 1024169 1026083 5717 B 1026938 5718 B 1025295 5719 B 1027165 5720 B 1026136 5721 B 1028031 5722 B 1026823 5723 E 1028699 5724 B 1027642 5725 B3 1029524 5726 B 1030824 572 B 1032737 5728 a 1033510 5729 B 1035372 5730 B 1032306 5731 B 1034209- 5732 B 1037275 5733 R 1162 5734 B3 1036130 5735 B 1038037 5736 fl 1036727 5737 B 149 5738 B 225 5739 B 2104 5740 B 17209 5741 a 19109 5742 B 32032 5743 B 33899 5744 B 57057 5745 B3 158954 2554 2555 [F 674381 F672493 SEQ mD Or. position 2556 F 675029 2557 F 673135 2558 F 676254 2559 F 674357 2560 F 677481 2561 F 675559 2562 F 678423 2563 F 676580 2564 F 1679049 2565 F 1677156 2566 F '680360 2567 F 678423 2568 F 681257 2569 F 679420 2570 F 682281 2571 F 680435 2572 F 682870 2573 F 681012 2574 F 684147 2575 F 682281 2576 F 684582 2577 F 682664 2578 F 685978 2579 F 684033 2580 F 687121 2581 F 685186 2582 F 1687974 2583 F :686044 2584 F 688169 2585 F 686313 2586 F '689393 2587 F 687511 2588 F 689580 2589 1F 1687727_ SEQ ID 4152 Or.

p-osition 286921 SEQ ID 5746 Or.

po-sition 4152 B~f 285894 415 B 287794 4154 B 286441 4255 B 288315 4156 B 286921 4157 B 288811 4158 2 288145 4159 B 290018 4160 B 289448 4161 B 291407 4162 B 290899 4163 B 1292805- 4164 B 291814 4165 B 293655 4166 R 292489 4167 B 294373 4168 B 293317 4169 B 295183 4170 B 295073 4171 B 297037 4172 B 295932 4173 B 297846 4-174 B 296556 4175 B 298475 4176 B 297474 4177 B 299413 4178 B 298970 4179 B 300855 4180 B 300679 4181 B 302595 4182 B 327 4183 B 304272 4184 B 305137 5747 B 59033 5748 B 65406 5749 B 67210 5750 73871 5751 B 75741 5752 B 78-956 5753 B 180903 5754 B 80042 5755 B 81944 5756 B 82642 5757 B 84491 5758 B 187820 5759 B 89658 5760 B 110184 5i7 61 B 112086 5762 B 111873 576 B 113837 5764 B 112302 5765 B 1114206 5766 8 13165 5767 B 1115093 5768 BF 114270 5769 B 116158 50 B 121039 5771 B 122904 5772 B 125742 5773 B 127643 5774 B 132170 5775 B 134028 5776 B 144647 5777 B 146547 5778 B 150960 5779 1B 152837 276 SEQ ID Or. position 2590 F 690204 2591 F 688342 2592 F 690431 2593 F 688497 2594 F 691790 2595 F :689919 2596 F 693614 2597 F 691704 2598 F 694723 2599 F 692821 2600 F 696922 2601 F j695033 2602 F 697714 2603 F 695816 2604 F 698510 2605 F 696612 2606 F 700037 2607 F 698119 2608 F 1700691 2609 F 1698783 2610 F 1701885 2611 F 1699984 2612 F 1703303 2613 F 701403 2614 F 704791 2615 F 702877 2616 F 705452 2617 F 703584 2618 F 705918 2619 F 704019 2620 F 706241 2621 F 704322 2622 F 707833 2623 F 705939 SEQ ID Or. position 4185 B 307039 4186 B 306377 4187 B 308287 4188 B 306730 4189 B 308614 4190 B 307199 4191 B 309120 4192 B 309018 4193 B 310903 4194 B3 3101287- 4195 B 312001 4196 B 310966 4197 B 312899 4198 B 311790 4199 B 313705 4200 B 31-2671 4201 B 314590 4202 B 314590 4203 B 316484 4204 B 314977 4205 B 316880 4206 B 315775 4207 B 317646 4208 B 316760 4209 B 318627 4210 B 317541 4211 B 319422 4212 B 317829 4213 B 319763 4214 B 318703 4215 B 320628 4216 B 318094 4217 B3 320048 4218 B 319182 SEQ ID !Or. position 5780 B 164761 5781 B 1166686 5782 B 166362 5783 B 168305 5784 B 1168970 5785 B 170889 5786 B 171056 $787 B 173021 5788 B '177747 5789 B 179629 5790 B 188605 5791 B 190352 5792 B 189016 5793 B3 190924 5794 B 190871 5795 B 192749 5796 B 197533 5-7-97 B 199449 5798 B 1211604 579.9 B 213554 5800 B 1235455 5801. B 237385 5802 B 237448 5803 B 239387 5-804 B 250266 5805 B 252155 5806 B 253731 5807 B 255663 508 B 255115 5809 B 256969 5810 B 272158 5811 B 274093 5812 B 276317 5813 B3 278190 SEQ ID Or. position 2624 F 708029 2625 F 706086 2626 F 708653 2627 F 706753 2628 F 710042 2629 F 708142 2630 F 711185 2631 F 709291 2632 F 712521 2633 F 710641 2634 F 713432 2635 F 711506 2636 F 713901 2637 F 711987 2638 F 714557 2639 F 712708 2640 F 715339 2641 F 713437 2642 F 715702 2643 F 713761 2644 F 716892 2645 F 714970 2646 F 718240 2647 F 716381 2648 F 718240 2649 F 716380 2650 F 719563 2651 F 717658 2652 F 719916 2653 F 718025 2654 F 720346 2655 F 718429 2656 F 721306 2657 1F 1719440 SEQ ID Or. position 4219 B 321067 4220 B 320404 4221 B 322278 4222 B 321720 4223 R 323625 4224 B 322158 4225 B 324071 4226 B 322582 4227 B 1324500 4228 B3 323371 4229 B 325260 4230 B 325173 4231 2 327057 4232 B 325882 4233 B 327770 4234 B 326509 4235 8 328388 4236 B 327463 4237 B 329330 4238 B 328374 4239 B3 330270 4240 B 328850 4241 1B 1330751 4242 B3 329330 4243 B 331210 4244 B 329883 4245 B 331822 4246 B 330886 4247 B 332797 4248 B 331395 4249 B 333375 4250 B3 331990 4251 B 333884 4252 B 332669 SEQ ID Or. 'Position 5814 B 278470 5815 B 280366 5816 B 283005 5817 B 284873 5818 B 293718 5819 B 295643 5820 B 303690 5821 8 305624 5822 B 309538 5823 B 311476 5824 B 322791 5825 a 314685 5826 B 313073 5827 B3 1314977 5828 B 313506 5829 B 315343 5830 B 320823 5831 B 322730 5832 B 340723 5833 B 342638 5834 B 353562 5835 B 355444 5836 B 373944 5837 B 375838 5838 B 377997 5839 B 379877 5840 B 379877 5841 B 381778 5842 B 395318 5843 B 1397228 5844 B 1401846 5845 B 1403782 5846 B 410759 5847 B 41267 7 278 SEQ ID 'Or. position 2658 F 722 178 2659 F 720271 2660 F 723159 2661 F 721259 2662 F 724357 2663 F 1722451 2664 F 725491 2665 F 723647 2666 F 726312 2667 F 724417 2668 F 726526 2669 F 724590 2670 F 727245 2671 F 725325 2672 F 728081 2673 F 726209 2674 F 728510 2675 F 726618 2676 F 729214 2677 F 727319 2678 F 733006 2679 F 731064 2680 F 734566 2681 F 732618 2682 F 735410 2683 F 733522 2684 F 736226 2685 F 734388 2686 F 736969 2687 F 735092 2688 F 737678 2689 F 735820 2690 F 781 2691 F 761 SEQ ID 425 3 4254 4255 Or. position B 334575 2333375 B 335166 4256 B333811 4257 B335709 4258 B 334579 4259 B 336497 4260 B334590 4261 B 336497 4262 B335362 4263 B 337262 4264 B 335863 4265 B337723 4266 B 335939 4267 B 337848 4268 B 336558 4269 B 338461 4270 B 337647 4271. B 339503 4272 B 340181 4273 B 342110 4274 B 342069 4275 B 343977 4276 B 342269 4277 B 344168 4278 B 342694 4-2 79 B 344593 4280 B 343594 4281 2 345503 4282 B 344269 4283 B 346199 4284 B 344452 4285 B 346382 4286 B 1345362 j SEQ ID Or. Position 5848 B 411878 5849 B 413779 5850 B 415199 5851 B 417099 5852 B 423479 5853 B 425332 5854 B 428421 5855 B 430332 5856 B 429678 5857 B 431571 5858 B 443036 5859 19 444947 5860 B '444280 5861 B 446161 5862 B 443964 5863 B 445811 5864 B 446392 5865 B 448276 5866 B 468498 5867 B3 470382 5868 B 472328 -5869 1B 474285 5870 B 488594 5871 B 490459 5872 B 497914 5873 B 499837 5874 B 500718 5875 B 502596 5876 B 509811 5877 B 511702 5878 B 511485 5879 B 513385 5880 B 5270.90 588 B 529014 279 SEQ ID Or. position 2692 F 739841 2693 F 737941 2694 F 741797 2695 F 739895 2696 F 742583 2697 F 740705 2698 F 743087 2699 F 741169 2700 F 744211 2701 F 742277 2702 F 744391 2703 F 742492 2704 F 744739 2705 F 742813 2706 F 745342 2707 F 743438 2708 F 746197 2709 F 744273 2710 F 746725 2711 F 744784 2712 F 748041 2713 F 746142 2714 F 748723 2715 F 746795 2716 F 749171 2717 F 747310 2718 F 749475 2719 F 747568 2720 F 749761 2721 F 747855 2722 F 752284 2723 F 750384 2724 F 753397 2725 F 1751497 SEQ ID Or. position 4287 B 347262 4288 B 346199 4289 B 348069 4290 B 347326 4292. B 349228 4292 B 348165 4293 B 350060 4294 B 350399 4295 B 352288 4296 B 351503 4297 23353403 4298 B 352460 4299 S 354356 4300 B 352948 4301 B 354901 4302 B 353959 4303 B 355890 4304 B 354438 4305 B 356378 4306 B 354997 4307 B 356866 4308 B 356897 4309 B 358793 4310 B 357643 4311 B3 359499 4312 B 358323 4313 B 360222 4314 B 360972 4315 B 362863 4316 B 361348 4317 B 363263 4318 B 362109 4319 B 364008 F4320 B 362-983 SEQ ID Or. position 5882 B 532083 5883 B 533999 5884 B 557487 5885 B 559357 5886 B 565191 5887 B 1567099 5888 B 1567452 59 B 569355 5890 2 571110 5891 B 573047 5892 B 1571557 5693 B 5736 5894 B 5768 5895 B 578181 5896 B 590890 5897 B 592770 5898 B3 598813 5699 B 600714 5900 B 1607146 5901 B 1609012 5902 B 1608260 5903 B 610162 5904 B 610621 5905 B 612514 5906 P 633573 5907 B 635473 5908 B3 637702 5909 B 639603 5910 B 65075-7 5911 B 652667 5912 B 652808 5913 B 654682 5914 B 655545 L5915 B 1-657446 SEQ ID Or. position 2726 F754693 2727 F752818 2728 F 756537 2729 754648 2730 F758227 2731 F 1756276 2732 F 759119 2733 F 757196 2734 F 759639 2735 F 757745 2736 F 759957 2737 F 758069 2738 F 760675 2739 F 758798 2740 F 761489 2741 F 759589 2742 F 762033 2743 F 760133 2744 F 763116 2745 F 761215 2746 F 764209 2747 F 762315 2748 F 764602 2749 F 762702 2750 F 765834 2751 F 763904 2752 F 766671 2753 F 764806 2754 F 768033 2755 F 766063 2756 F 768572 2757 F 766671 2758 F 769873 2759 F 768006- SEQ ID Or. position 4321 BI 364867 4322 B 364110 4323 B 366002 4324 8 365415 4325 B 367338 4326 B 365807 4327 B 367733 4328 B 367607 4329 B 369440 4330 B 366881 4331 B 370788 4332 B3 369317 4333 B 371209 4334 B 370522 4335 B 372440 4336 B 371311 4337 B 373206 4338 B 373097 4339 B 374941 4340 B 373753 4341 B 375649 4342 B 374424 4343 B 376324 4344 B 374956 4345 R 376888 4346 B 376611 4347 B 378511 4348 B i37729-7 4349 B 379209 4350 B 1378960 4351 B 380880 4352 B 379309 4353 B 381180 4354 8 379667 SEQ ID O0r. position 5916 B 661392 5917 B 663292 5918 B677837 5919 B 679716 5920 B 679748 5921 B681674 5922 B 732909 5923 B 734756 5924 B 742639 59259 B 744503 5926 B 759613 5927 B 761510 5928 B 760782 5929 B3 762671 5930 B 771617 5931 B 773519 5932 B 772628 5933 S 774528 5934 B 788703 5935 B 790577 5936 B 816591 5937 B 818443 5938 B 847145 5939 B 849042 5940 B 868276 5941 B 870177 5942 B 875887 5943 S 877779 5944 B 877137 5945 B 879035 5946 B 884780 5947 B 886680 5948 B 892172 5949 B 894073 SEQ ID Or. position 2760 F 769966 2761 F 768060 2762 f 770411 2763 F 768455 2764 F 771103 2765 F 769211 2766. F 771980 2767 F 770116 2768 F 773176 2769 F 771305 2770 F 773937 2771 F 771980 2772 F 776399 2773 F 774514 2774 F 776672 2775 F 774773 2776 F 777446 2777 F 775596 2778 F 779102 2779 F 777192 2780 F ;781078 2781 F 779148 2782 F 782192 2783 F 780236 2784 F 785250 2785 F 783413 2786 F 785324 2787 F 783427 2788 F 786392 2789 F 784488 2790 F 787401 2791 F 785488 2792 _F 1787693 SEQ ID Or. position 4355 Th 381553 4356 Bh 380238 4357 B 382152 4358 B 381699 4359 8 383615 4360 B 382790 4361 B 384687 4362 B 383935 4363 B 385837 4364 B 384167 4365 S 386065 4366 B 3854179 4367 B 387365 4368 B 385730 4369 B 387635 4370 B 387115 4371 B 389019 4372 B 386903 4373 B 388753 4374 B 387595 .4375 B 389504 4376 B 388133 4377 B 390055 4378 B 388524 4379 B 390455 4380 B 389428 4381 B 391321 4382 B 390313 4383 BF 392241 4384 Bf* 391321 4385 B 393147 4386 B j392032 4387 B 1393943~ SEQ ID Or. position 5950 B 900990 5-951 B '902955 5952 B 902780 5953 B 904687 5954 B 908266 5955 8 910218 5956 B 912811 5957 B 914730 5958 B 935988 5959 B 937863 5960 B 947227 5961 B 949089 5962 B 953426 5963 B 955397 5964 B 966421 5965 B 968345 59 66 B .969548 5967 B 971477 5968 B 971390 5969 B 973279 5970 B 972661 5971 B 1974581 5972 8 973730 5973 B 975665 5974 B 998885 5975 B3 1000774 5976 IB 1004572 5977 B 1006449 5978 B 1010507 5979 B 1012353 5980 B3 1029707 5981 B 1031628 Publications Cited in the Specification Adames et al., 1985, Nature, 318:533-538.

Altschul et al., 1993, Nature Genetics, 3:266-272.

Altschul et al., 1997, Nucl. Acids Res., 25:3389-3402.

Altschul, S.F. et al., 1990,J. Mol. Biol., 215:403-410.

Ansubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY.

Arlinghaus, H.F. et al., 1997, Anal. Biochem., 69, 18, 3747-53.

Bai, M. Et al., 1993, J. Virol., 67:5198-5205.

Barany, 1911, Proc. Natl. Acad. Sci. USA, 88:189-193.

Beattie, K. et al., 1993, Clin. Chem., 39(4):719-721.

Bernoist and Chambon, 1981, Nature, 290:304-310.

Borman, 1996, Chem. Eng. News, 74(50):42-43.

Brinster et al., 1982, Nature, 296:39-42.

Buckholz, 1993, Curr. Op. Biotechnology, 4:538-542.

Burg, J.L. et al., 1996, Mol. and Cell. Probes, 10:257-271.

Casas-Ciria J. et al., 1996 Chatelier, R.C. et al., 1995, Anal. Biochem., 229, 1, 112-118.

Chee, M. et al., 1996, Science, 274:610-613.

Chu et al., 1986, Nucleic Acids Research, 14:5591-5603.

Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96.

Cote et al., 1983, PNAS USA, 80:2026-2030.

Cserzo, Wallin, Simon, I. von Heijne G and Elofsson, 1997, Prot. Eng., 10:673-676.

DeBoer et al., 1980, Scientific American, 242:74-94.

DeBoer et al., 1983, PNAS USA, 80:21-25.

Derisi, J. et al., 1996, Nature Genet., 14:457-460.

Duck, P. et al., 1990, Biotechniques, 9:142-147.

Edwards, and Aruffo, 1993, Curr. Op. Biotechnology 4:558-563.

Erlich, 1989, In PCR Technology. Principles and Applications for DNA Amplification. New York: Stockton Press.

Fanger and Drakeman, 1995, Drug News and Perspectives, 8:133-137.

Felgner, et al., 1987, Proc. Natl. Acad. Sci. USA, 84:7413.

Fodor, S.P.A. et al., 1991, Science, 251:767-771.

Fox, G. Et al., 1989, J. Gen. Virol., 70:625-637.

Fraley et al., 1980, J. Biol. Chem., 255:10431.

Gardner et al., 1981, Nucl. Acids Res. 9:2871.

Gonnet et al., Science, 256:1443-1445.

Grosschedl et al., 1984, Cell, 38:647-658.

Guateli, J.C. et al., 1990, Proc. Natl. Acad. Sci. USA, 87:1874-1878.

Hackstadt Trends Microbiol. 1996 5:288-293.

Hammer et al., 1987, Science, 235:53-58.

Hanahan, 1985, Nature, 315:115-122.

Hayashi, S. and Wu, 1992, in N.M. Hooper and AJ. Turner Lipid Modification of Proteins: A Practical Approach. Oxford University Press, New York, pp. 261-285.

Heinkoff and Heinkoff, 1993, Proteins, 17:49-61.

Herrera-Estrella et al., 1983, Nature, 303:209-213.

Herrera-Estrella, 1984, Nature, 310:115-120.

Higgins et al, 1996, Meth. Enzymol., 266:383-402.

Houbenweyl, 1974, in Meuthode der Organischen Chemie, E. Wunsch Ed., Volume 15-1 et 15-11, Thieme, Stuttgart.

Hsia, R. et al., 1997, Molecular Micorbiology, 25:351-359.

Hueck, 1998, Molec. Biology Rev., 62:379-433.

Huovinen, P. et al., 1989 Ann., Intern Med 110:612-616.

Huse et al., 1989, Science, 246:1275-1281.

Huygen, K. et al., 1996, Nature Medicine, 2(8):893-898.

Innis, M.A. et al. 1990, in PCR Protocols. A guide to Methods and Applications. San Diego Academic Press.

Inoue et al., 1987, Nucl. Acids Res., 15:6131-6148.

Inoue etal., 1987, FEBS Lett. 215:327-330.

Kabat E. Et al., 1983, Sequences of Proteins of Immunological Interest, U.S. Dept Of Health and Human Services.

Kaneda, et al., 1989, Science, 243:375.

Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA, 87:2267-2268.

Kelsey et al., 1987, Genes and Devel., 1:161-171.

Kievitis, T. et al., 1991, J. Virol. Methods, 35:273-286.

Kohler, G. et al., 1975, Nature, 256(5517):495-497.

Kollias et al., 1986, Cell, 46:89-94.

Kozbor et al., 1983, Immunol. Today, 4:72.

Krumlauf et al., 1985, Mol. Cell. Biol., 5:1639-1648.

Krone, J.R. et al., 1997, Anal. Biochem., 244, 1, 124-132.

Kwoh, D.Y. et al., 1989, Proc. Natl. Acad. Sci. USA, 86:1173-1177.

Leder et al., 1986, Cell, 45:485-495.

Lee, 1997, Trends Microbiol., 5:148-156.

Leininger, E. et al., 1991, PNAS USA, 88:345-349.

Lipshutz, R.J. et al., 1995, Biotechniques, 19(3):442-447.

Livache, T. et al., 1994, Nucleic Acids Research, 22(15):2915-2921.

Lockhart, D.J. et al., 1996, Nature Biotechnol., 14:1675-1680.

Longbottom et al., 1998, Infect Immunol., 66:1317-1324.

Luckow, VA., 1993, Curr. Op. Biotechnology, 4:564-572.

Lukacova, M. Et al., 1994, Infect. Immunol. June, 62(6):2270-2276.

Mason et al,, 1986, Science, 234:1372-1378.

Matson, R.S. et al., 1994, Anal. Biochem., 217:306-310.

Matthews, J.A. et al., 1988, Anal. Biochem., 169:1-25.

Mrel, 1994, Biofutur, 139:58.

Merrifield, 1966, J. Am. Chem. Soc., 88(21):5051-5052.

Midoux, 1993, Nucleic Acids Research, 21:871-878.

Miele, E.A. et-al., 1983, J. Mol. Biol., 171:281-295.

Mogram et al., 1985, Nature, 315:338-340.

Morrison etal., 1984, PNAS USA, 81:6851-6855.

Morrison, R.P. et al., 1995. Gene Knockout Mice Establish a Primary Protective Role for Major Histocompatibility Complex Class II-Restricted Responses in Chlamydia irachomatis. Infect. Immun.

63:4661-4668.

Nakai, K. and Kanehisa, 1991, Proteins, 11:95-110.

Nielsen, H. et al., 1997, Protein Engin., 10:1-6.

Neuberger et al., 1984, Nature, 312:604-608.

O'Donell-Maloney, 1996, Trends Biotechnol., 14:401-407.

Olins, and Lee, 1993, Recent advances in heterologous gene expression in E. coli. Curr. Op.

Biotechnology 4:520-525.

Omitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol., 50: 399-409.

Pagano et al., 1967, J. Virol., 1:891.

Pearson and Lipman, 1988, PNAS USA, 85(8):2444-2448.

Peterson, E. et al., 1988. Protective Role of Magnesium in the Neutralization by Antibodies of Chlamydia trachomatis Infectivity.

Pierschbacher and Ruoslahti, 1987, J. Biol. Chem., 262:17294-17298.

Pinkert et al., 1987, Genes and Devel., 1:268-276.

Pugsley, 1993, Microbiol. Rev., 57:50-108.

Raulston JE., Mol Microbiol 1995 15:607-616.

Rank, R.G. et al., 1988. Susceptibility to reinfection after a primary chlamydial genital infection. Infect.

Immun. 56:2243-2249.

Readhead et al., 1987, Cell, 48:703-712.

Reeves, P.R. et al., 1996, in Bacterial Polysaccharide Synthesis and Gene Nomenclature, Elsevier Science Ltd., pp. 10071-10078.

Relman, D. et al., 1990, Cell, 61:1375-1382.

Roivainen, M. Et al., 1994, Virology, 203:357-365.

Rolfs, A. et al., 1991, In PCR Topics. Usage of Polymerase Chain reaction in Genetic and Infectious Disease. Berlin: Springer-Verlag.

Sambrook, J. et al., 1989, In Molecular cloning A Laboratory Manual. Cold Spring Harbor, NY Cold Spring Harbor Laboratory Press.

Sanchez.Pescador, 1988, J. Clin. Microbiol., 26(10):1934-1938.

Salzberg et al., 1998, Nucl. Acids Res., 26:544-548.

Sani, 1985, Nature, 314:283-286.

Sarver et al., 1990, Science, 247:1222-1225.

Schachter, J. 1980. Chlarnydiae, p.357-365. In E.H. Lennette Manual of clinical microbiology, 3" ed. American Society for Microbiology, Washington, D.C.

Schnaitman, C.A. and Klena, 1993, Microbiol. Rev., 57:655-682.

Schneewind, 0. Et al., 1995, Science, 268:103-106.

Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation.

Segev 1992, in Non-radioactive Labeling and Detection of Biomolecules Kessler C. Springer Verlag, Berlin, New-York: 197-205.

Sheldon, 1993, Clin. Chem., 39(4):718-719.

Shiver, 1995, in Vaccines, eds Chanock, R.M. Brown, F. Ginsberg, H.S. Norrby, pp.95-98, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Shoemaker, D.D. et al., 1996, Nature Genet., 14:450-456.

Sosnowsky et al., 1997, Proc. Natl. Acad. Sci. USA, 94, 1119-1123.

Struyve, M. et al., 1991, J. Mol. Biol., 218:141-148.

Sundelof, et al., 1993, Scand. J. Infec. Dis., 25:259-261.

Sutcliffe, I.C. and Russell, 1995, J. Bacteriol.

177:1123- 1128.

Swift et al., 1984, Cell, 38:639-646.

Takeda et al., 1985, Nature, 314:452-454.

Tascon, R.E et al., 1996, Nature Medicine, 2(8):888-892.

Thompson et al., 1994, Nucl. Acids Res., 22(2):4673-4680.

Urdea, 1988, Nucleic Acids Research, 11:4937-4957.

Villa-Kamaroffet al., 1978, PNAS USA, 75:3727-3731.

286 Wagner et al., 1981, PNAS USA, 78:1441-1445.

Walker, G.T. et al., 1992, Nucleic Acids Research, 20:1691-1696.

Walker, G.T. et al., 1992, Proc. Natl. Acad. Sci. USA, 89:392-396.

White, B.A. et al., 1997, Methods in Molecular Biology, 67, Humana Press, Towota.

Yamamoto et al., 1980, Cell, 22:787-797.

Yershov, G. et al., 1996, Proc. Natl. Acad. Sci. USA, 93:4913-4918.

Claims (20)

1. An isolated polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia trachomatis genome, comprising: a nucleotide sequence of ORF 971; a nucleotide sequence exhibiting at least 80% identity to ORF 971; a nucleotide sequence exhibiting greater than 97% identity to ORF 971; S(d) a nucleotide sequence exhibiting at least 99.9% identity to ORF 971; cN a nucleotide sequence which is greater than 20 bases in length and hybridizes to a nucleotide sequence according to under high stringency conditions; or a fragment of any one of to which is greater than 20 bases in length, wherein a polypeptide encoded by the nucleotide sequence is not found in Chlamydia pneumoniae.

2. A polynucleotide encoding a fusion polypeptide, comprising a nucleotide of claim 1 ligated in frame to a polynucleotide encoding a heterologous polypeptide.

3. A recombinant vector that contains a polynucleotide of claim 1 or claim 2.

4. A recombinant vector that contains a polynucleotide of claim 1 or claim 2 operatively associated with a regulatory sequence that controls gene expression. A genetically engineered host cell that contains a polynucleotide according to claim 1 or claim 2.

6. A genetically engineered host cell that contains a polynucleotide of claim 1 or claim 2 operatively associated with a regulatory sequence that controls gene expression in the host cell. I\ 288 O

7. A method for producing a polypeptide, comprising: 0 culturing a genetically engineered host cell of claim 6 under conditions suitable to produce the polypeptide encoded by the polynucleotide; and recovering the polypeptide from the culture. n 8. An isolated polypeptide encoded by a polynucleotide of claim 1 or claim 2. (N

9. The polypeptide of claim 8 which immunoreacts with seropositive serum l of an individual infected with Chlamydia trachomatis. An antibody that immunospecifically binds to a polypeptide of claim 8 or claim 9.

11. A method for the detection and/or identification of Chlamydia trachomatis in a biological sample, comprising: contacting the sample with a polynucleotide primer which hybridizes to a polynucleotide sequence according to claim 1 in the presence of a polymerase enzyme and nucleotides under conditions which permit primer extension; and detecting the presence of primer extension products in the sample in which the detection of primer extension products indicates the presence of Chlamydia trachomatis in the sample, wherein the primer does not hybridize with a polynucleotide sequence of the Chlamydia pneumoniae genome.

12. A method for the detection and/or identification of Chlamydia trachomatis in a biological sample, comprising: contacting the sample with a polynucleotide probe which hybridizes to a polynucleotide sequence according to claim 1 under conditions which permit hybridization of complementary base pairs; and detecting the presence of hybridization complexes in the sample in which the detection of hybridization complexes indicates the presence of Chlamydia trachomatis in the sample, \I 289 O c wherein the probe does not hybridize with a polynucleotide sequence of the 0 Chlamydia pneumoniae genome. O (N

13. A method for the detection and/or identification of Chlamydia trachomatis in a biological sample, comprising: contacting the sample with an antibody of claim 10 under conditions tc, m suitable for the formation of immune complexes; and 0(b) detecting the presence of immune complexes in the sample, in Swhich the detection of immune complexes indicates the presence of Chlamydia trachomatis in the sample. (N

14. A method for the detection and/or identification of antibodies to Chlamydia trachomatis in a biological sample, comprising: contacting the sample with a polypeptide of claim 8 or claim 9 under conditions suitable for the formation of immune complexes; and detecting the presence of immune complexes in the sample, in which the detection of immune complexes indicates the presence of Chlamydia trachomatis in the sample. A DNA chip containing an array of polynucleotides comprising at least one of the polynucleotides of claim 1.

16. A protein chip containing an array of polypeptides comprising at least one of the polypeptides of claim 8. 17 An immunogenic composition comprising a polypeptide of claim 8 or claim 9 and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a polypeptide of claim 8 or claim 9 and a pharmaceutically acceptable carrier.

19. A method of immunizing against Chlamydia trachomatis, comprising: administering to a host an immunizing amount of an immunogenic composition of claim 17. O 290 O A DNA immunogenic composition comprising an expression vector of claim 4. O

21. The DNA composition of claim 20, wherein the DNA composition directs the expression of a neutralizing epitope of Chlamydia trachomatis. n 22. A screening assay, comprising: contacting a test compound with an isolated polynucleotide according to claim 1 or claim 2; and detecting whether binding occurs.

23. A screening assay, comprising: contacting a test compound with a polypeptide of claim 8; and detecting whether binding occurs.

24. A kit comprising a container containing an isolated polynucleotide according to claim 1 or claim 2. The kit of claim 24, wherein the polynucleotide is a primer or a probe.

26. The kit of claim 24, wherein the polynucleotide is a primer and the kit further comprises a container containing a polymerase.

27. The kit according to any one of claims 24 to 26 which further comprises a container containing deoxynucleotide triphosphates.

28. A kit comprising a container containing an antibody that immunospecifically binds to a polypeptide of claim 8. Dated this 12 th day of October 2006 Serono Genetics Institute S.A. Patent Attorneys for the Applicant: F B RICE CO